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Abstract 
Nitrogen-containing heterocycles have attracted considerable attention owing to their 
prevalence in numerous natural substances as well as their extensive applications in biology 
and pharmacology. In recent years, great efforts have been devoted to the elaboration of 
novel synthetic methodologies for the construction of N-heterocycles such as oxindoles and 
indoles.  
Reported in 2009 by the Taylor group, access to oxindole scaffolds has been successfully 
demonstrated via a copper(II)-mediated oxidative coupling approach. Following the same 
principle, the extension of this method to the formation of the more intricate bis-oxindole 
skeleton II is demonstrated via the double cyclisation of bis-anilides I using Cu(OAc)2·H2O 
as oxidant (Scheme I, Chapter 2). 
 
Scheme I. Double copper(II)-mediated oxidative coupling approach to bis-oxindoles II. 
The scope of the copper(II)-mediated cyclisation to the formation of 3H-indoles IV and 1H-
indoles V from N-aryl enamines III is also described (Scheme II, Chapter 3). 
 
Scheme II. Copper(II)-mediated oxidative coupling to 3H-indoles IV and 1H-indoles V. 
In the last part, progress towards the total synthesis of the highly complex spirooxindole 
alkaloid natural product rankinidine (VI) is presented. Towards this end, the application of 
the copper(II)-mediated cyclisation for the formation of the oxindole core of rankinidine 
(VII) is presented (Chapter 4). 
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Chapter 1. Introduction to oxindoles 
 
1.1 Formation of 3,3-disubstituted oxindoles 
 
1.1.1 Prevalence of biologically active oxindoles 
 
Studies by the US Food and Drug Administration (US FDA) revealed that 59% of small-
molecule drugs contain a nitrogen heterocycle,1 a motif considered to be the most significant 
structural component of pharmaceuticals. Among the nitrogen-containing heterocycles, 3,3’-
disubstituted oxindoles are versatile structural motifs found in a wide range of biologically 
active natural products and synthetic drugs (Figure 1.1).2 Over the last decade, there has been 
significant resurgence in the synthesis of oxindoles as these structures represent excellent 
targets in the search for new drug candidates.3 For example, oxindole 1 is a potent anti-
cancer agent, whereas the 3-substituted 3-hydroxyoxindole is a key structural feature found 
in numerous alkaloid natural products (e.g. maremycin (2)). Similarly, 3-substituted 3-
aminooxindoles such as 3, are also an important type of structure present in a number of 
pharmaceutical candidates (e.g. AG-041R (3)). 
 
 
Figure 1.1. Biologically active oxindole scaffolds. 
 
The significant biological activities observed for oxindoles emphasises the need to develop 
efficient synthetic strategies to access these scaffolds. Representing an important challenge 
for the synthetic community, numerous methods have been reported for the synthesis of 
oxindoles and reviewed by many groups,2 therefore only recent and relevant examples will 
be discussed.  
2 
1.1.2 Synthesis of oxindoles through C–N bond formation 
 
A convenient route to 3-substituted N-benzoyl oxindoles was reported by Prabhakar and co-
workers.4 The cyclisation was conducted from substrate 4, containing both N-acyl-protected 
amine and carboxylic acid moieties using N,N’-dicyclohexylcarbodiimide (DCC) as 
coupling agent (Scheme 1.1). DCC-mediated dehydration of substrates 4 gave oxindoles 5 
in moderate to good yields. 
 
 
Scheme 1.1. Prabhakar’s formation of oxindoles via DCC-dehydration. 
 
A different example of a C–N disconnection strategy5 for the formation of oxindoles was 
reported by the Hsieh group in 2012, which developed an intramolecular domino copper-
catalysed coupling reaction from ortho-bromophenyl-methylenenitrile 6 to access oxindoles 
7 (Scheme 1.2).5a The copper complex involved in the cyclisation was proposed to play two 
different roles by acting as a Lewis acid for the nitrile group and also by facilitating the C–
N bond formation. Access to a wide range of unprotected oxindoles 7 was possible, in very 
high yields, with only a few exceptions. 
 
 
Scheme 1.2. Hsieh’s copper-catalysed synthesis of oxindoles.  
3 
1.1.3 Synthesis of oxindoles through C3-C3a bond formation 
 
1.1.3.1 A palladium-catalysed cyclisation to oxindoles 
 
Recently, numerous methods have been reported for the synthesis of 3,3’-disubstituted 
oxindoles via a C3-C3a bond formation.2d The most common of these involve a palladium-
mediated cyclisation of pre-functionalised linear ortho-halide precursors of type 8. By way 
of example, the palladium-mediated cyclisation of ortho-bromoanilides 8 in the presence of 
bulky carbene ligand 10 provides access to oxindoles 9 in very good yield (Scheme 1.3).6  
 
 
Scheme 1.3. Palladium-catalysed cyclisation of ortho-bromo anilides 8 to oxindoles 9. 
 
1.1.3.2 Antonchick’s iodine-mediated cyclisation to oxindoles 
 
A variety of synthetic routes has been reported for the synthesis of oxindoles from N-
arylacrylamides.7 Recently, Antonchick et al. developed a different approach to obtain 
various oxindole derivatives by azidoarylation of alkenes.8 Azidyl radicals, generated by 
oxidation of azides in the presence of hypervalent iodine(III) reagents, can easily be trapped 
with arenes such as compounds 11 to afford oxindoles 12 in very good yield, under metal-
free reaction conditions and at ambient temperature (Scheme 1.4). Moreover, the resulting 
products with an appended azide group, can be used to create further molecular complexity 
around the privileged oxindole scaffold. 
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Scheme 1.4. Metal-free cyclisation for the synthesis of oxindoles 12. 
 
1.1.3.3 Yang’s silver-catalysed route to phosphorylated oxindoles 
 
With the same objective, Yang et al., recently published a silver-catalysed carbon 
phosphorylation of alkenes which achieved direct cyclisation to give phosphorylated 
oxindoles 14, potentially useful for insecticides or herbicides and as P,O-ligands for 
transition metal-catalysed reactions. Treatment of N-arylacrylamides 13 in the presence of 
silver(I) and Mg(NO3)2∙6H2O afforded oxindoles 14 in good yield (Scheme 1.5).9 In the case 
of the N-unprotected and mono-substituted (R2 = H) acrylamide, no conversion into 
oxindoles 14 was observed. 
 
 
Scheme 1.5. Silver-catalysed carbon phosphorylation and direct C–H functionalisation to oxindoles 14. 
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1.2 A copper(II)-mediated oxidative coupling route 
 
1.2.1 The use of copper in the construction of N-heterocyclic compounds 
 
In light of the biological importance of N-heterocycles, a range of efficient synthetic 
procedures for the formation of nitrogen-containing cyclic scaffolds have been developed. 
Recently, attention has turned to copper-mediated systems which benefit from the use of 
inexpensive, insensitive-to-air, non-toxic copper salts. The versatility of copper catalysts in 
the synthesis of five- and six-membered N-heterocycles, as well as fused-ring systems, was 
highlighted in a recent review by the Fu group.10a More recently, Zhang and co-workers 
reviewed the utility of copper in C–H functionalisation reactions for the construction of 
heterocycles.10b 
 
1.2.2 Copper-mediated oxidative functionalisation of C–H bonds 
 
A review by the Stahl group highlighted the use of copper(II) as a versatile oxidant in the 
selective oxidation of C–H bonds.11 By employing a source of copper(II) in combination 
with molecular oxygen, as a stoichiometric oxidant to regenerate the active copper(II) 
catalyst, many of these reactions can be performed catalytically. However, much work 
remains to understand the mechanism of the copper-catalysed C–H functionalisation 
reactions. Early studies highlighted the oxidative potential of copper(II) in a number of 
coupling reactions initiated by single electron transfer (SET).12 
 
1.2.3 A stoichiometric Cu(II) oxidative coupling for the construction of oxindoles 
 
A number of research groups have focused their attention on the development of improved 
methods for the synthesis of oxindoles via a direct intramolecular C–H, Ar–H coupling of 
non-prefunctionalised linear precursors. In 2009, Kündig and co-workers developed a 
copper(II) chloride-mediated cyclisation, which proceeds via the oxidative coupling of linear 
anilides 15 into oxindoles 17 in good yields (eq. a, Scheme 1.6).13 The synthesis of oxindoles 
was performed under strictly anhydrous and inert reaction conditions. Subsequently, Taylor 
and co-workers developed a similar approach in which α-ester anilides 16 were converted 
into oxindoles 17 using a stoichiometric amount of Cu(OAc)2·H2O under basic conditions 
6 
but without the need to rigorously exclude H2O and air (eq. b, Scheme 1.6).
14 These 
procedures are valuable as an ortho-halo-anilide is not required for cyclisation. 
 
 
Scheme 1.6. Copper(II)-mediated oxidative coupling routes to oxindoles from anilides. 
 
1.2.4 Proposed mechanism for the oxidative coupling route to oxindoles 
 
The proposed mechanism for this process is depicted in Scheme 1.7. In the first step, radical 
19 is formed by means of a single-electron oxidation of amide enolate 18. At this point, 
intramolecular homolytic aromatic substitution affords the radical 20, which is oxidised to 
generate the carbocation 21, and upon rearomatisation, provides the oxindole product 17. 
 
 
Scheme 1.7. Proposed mechanism for the copper(II)-mediated oxindole cyclisation. 
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In keeping with the proposed mechanism, Kundig and co-workers revealed the presence of 
a secondary isotope effect of KD/KH = 0.8, which indicated that the C–H bond cleavage in 
anilide 22 is not involved in the rate-determining step of the transformation into oxindole 23 
(Scheme 1.8).13 
 
 
Scheme 1.8. Secondary isotope effect in the copper(II) oxidative coupling. 
 
A subsequent mechanistic study was carried out by the Taylor group using an anilide 
substrate containing a cyclopropyl radical probe such as 24 (Scheme 1.9).14 Oxindole 
products were not formed, but instead, the dienyl anilide 25 was observed, resulting from 
the radical fragmentation of the cyclopropyl substituent in 26 into the radical species 27. 
This information is consistent with the suggested radical amide-enolate intermediate formed 
in the first single-electron oxidation. 
 
 
Scheme 1.9. Radical probe experiment in the copper(II) oxidative coupling reaction. 
 
Also Kündig et al. confirmed the cyclisation proceeds via a radical pathway and determined 
the homolytic aromatic substitution as the rate-limiting step in the copper mediated oxindole 
synthesis using DFT calculations.15  
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1.2.5 A catalytic Cu(II) oxidative coupling for the construction of oxindoles 
 
Subsequently, Taylor and co-workers reported a copper(II)-catalysed cyclisation of anilides 
16 to form 3,3-disubstituted oxindoles 17 using Cu(OAc)2·H2O (5 mol%) in boiling 
mesitylene under an air atmosphere (Scheme 1.10).16 Compared to the previous conditions, 
the optimised catalytic conditions required no base additives, low catalyst loading, short 
reaction times and the reaction could be run open to air. Only a catalytic amount of copper 
is required for the transformation, as oxygen acts as the stoichiometric re-oxidant of the 
copper(I) species. 
 
 
Scheme 1.10. Copper(II)-catalysed formation of 3,3-disubstituted oxindoles. 
 
1.3 Formation of spirocyclic oxindoles 
 
1.3.1 Prevalence of biologically active spirocyclic oxindoles 
 
The spirocyclic oxindole moiety is remarkably important and is prevalent in many 
biologically active natural products, most of which have been isolated from Apocynaceae 
(oleander) and Rubiacae (coffee).17 Over the last decade, there has been significant interest 
in the synthesis of spirocyclic oxindoles as these structures represent good targets in the 
search for new drug candidates.18 Some examples of natural products 28-31 that contain the 
key ring system are outlined in Figure 1.2. 
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Figure 1.2. Spirocyclic oxindole alkaloids. 
 
1.3.2 Palladium-mediated Heck cyclisation to spirocyclic oxindoles 
 
In 1998, Overman and co-workers reported the asymmetric Heck cyclisation of aryl halides 
32 to prepare enantioenriched heterocycles 33 (Scheme 1.11).19 The use of Pd2(dba)3 as a 
catalyst and (R)-BINAP (34) as a chiral ligand gave spirocyclic oxindoles 33 in good yields 
but moderate levels of enantioselectivity. The role of the additives used in the catalytic cycle 
was crucial for establishing the absolute configuration of the spirocyclic oxindole. While the 
addition of a silver salt led to the formation of the (S)-enantiomer, the use of a guanidine-
derived additive to scavenge HI, namely 1,1,2,3,3-pentaisopropylguanidine (PIG), resulted 
in the formation of the opposite enantiomer of the spirocyclic product. Thus, either 
enantiomer of the spirocyclic oxindole can be formed with good selectivity using a single 
enantiomer of a chiral diphosphine ligand. 
 
 
Scheme 1.11. Overman’s palladium-mediated synthesis of spirocyclic oxindoles 33. PIG = 1,1,2,3,3-
pentaisopropylguanidine. 
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1.3.3 An organocatalytic asymmetric cascade reaction to spirocyclic oxindoles 
 
A number of excellent examples have been reported for the preparation of chiral 
spirooxindoles via organocatalytic cascade reactions.20 In 2012, Yan et al. reported an 
organocatalytic three-component reaction of isatins 35, malononitrile (36) and 
isocyanoacetates 37 in the presence of Takemoto’s catalyst 39 which provides 3,3-
dihydropyrryl-spirooxindoles 38a-b in excellent yields and enantioselectivities (Scheme 
1.12). 
 
 
Scheme 1.12. Organocatalytic asymmetric cascade reaction to spirocyclic oxindoles. 
 
1.3.4 A copper(II)-catalysed cyclisation reaction to spirocyclic oxindoles 
 
The development of a spirooxindole cyclisation via a direct intramolecular C─H, Ar─H 
coupling methods has been studied by the Taylor group.21 This method allows the 
installation of a quaternary carbon centre at the spirocyclic junction and constitutes an 
attractive approach for the preparation of oxindole-based natural products. As described 
previously, a copper(II) catalyst (10 mol%) in mesitylene at 170 °C for 30 to 90 minutes 
enables the cyclisation of linear substrates 40 to give spirocyclic oxindoles 41 in good yields 
(Scheme 1.13). The scope of the reaction was expanded by varying the size of the lactam 
ring (4 to 7-membered) attached to the oxindole unit at the C3 position, the nature of the N-
protecting group as well as the benzene ring substitution pattern. 
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Scheme 1.13. Spirocyclic oxindole synthesis via a catalytic Cu(II)-mediated cyclisation. 
 
1.4 Project background and aims 
 
The facile entry to nitrogen-heterocycles inspired us to further demonstrate the utility of the 
copper(II) oxidative coupling into more complicated systems such as bis-oxindoles 43. It 
was envisaged that the central core could easily be varied providing access to a range of bis-
oxindoles 43 from bis-anilides 42 (Scheme 1.14). This research is discussed in Chapter 2 
 
 
Scheme 1.14. Cu(OAc)2·H2O-mediated oxidative coupling route to bis-oxindoles 43 from bis-anilides 42. 
 
This route was additionally tested for the synthesis of indole derivatives, commonly found 
in a wide range of biologically active natural and unnatural compounds. It was proposed that 
the formation of 1H- and 3H-indoles would occur from the cyclisation of N-aryl enamines 
44 to give the 3H-indoles 45 if R2 ≠ H or the 1H-indoles 46 if R2 = H (Scheme 1.15). This 
research is discussed in Chapter 3. 
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Scheme 1.15. A copper(II)-mediated synthesis of 1H- and 3H-indoles. 
 
Finally, the utility of the copper(II)-mediated oxidative coupling route was suggested as the 
potential key step for the total synthesis of the natural product rankinidine (49). Whereas the 
biological activity of rankinidine (49) has not been established yet, related natural products 
have shown potent medicinal properties. Access to the key spirooxindole 48 was envisioned 
from anilide 47, and compound 48 appeared to be a useful intermediate for the total synthesis 
of rankinidine (49) (Scheme 1.16). 
 
 
Scheme 1.16. Proposed application of the copper(II)-mediated cyclisation in the total synthesis of rankinidine 
(49). 
 
Chapters 2‒4 describe the results in each area, and each Chapter contains a more detailed 
introduction and discussion. 
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Chapter 2. The synthesis of bis-oxindole derivatives 
 
2.1 Introduction 
 
2.1.1 Chemical and biological importance of bis-oxindoles 
 
Oxindoles are privileged structural motifs that exist in many natural products and synthetic 
compounds of biological interest.3, 22 They have therefore attracted great attention from 
synthetic and medicinal chemists and as a result, a multitude of efficient methods are now 
available for the creation of the oxindole core.2 
More recently, structurally challenging bis-oxindoles have emerged as potentially useful 
scaffolds in medicinal chemistry and diversity-oriented synthesis. With regard to medicinal 
applications, the novel piperidone-containing bis-spirooxindoles (50, Ar = 2,4-Cl2C6H3, 
Figure 2.1) and (51, Ar = 1-naphthyl) were evaluated as potent and selective cholinesterase 
inhibitors, towards AChe and BuChe respectively.23 Recently discovered, the synthetic 
dispirooxindole-pyrrolidine 52 has been shown to possess significant anti-bacterial and anti-
cancer activities (againgst A549 human lung adenocarcinoma).24 Of natural complexity, 
geleganimine B (53) was extracted recently from the plant Gelsemium elegans and exhibited 
neural anti-inflammatory activity.25 
 
Figure 2.1. Spirocyclic bis-oxindoles as bioactive natural products and synthetic compounds. 
 
Non-spirocyclic bis-oxindole derivatives are also important for having potent biological 
activities. By means of example, the anti-cancer agent Natura (54, Figure 2.2) has been 
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shown to inhibit several cyclin dependent kinases (CDKs).26 Bis-oxindole 55 displayed 
considerable activity against both Gram positive and Gram negative bacteria.27 Also of 
considerable interest, bis-oxindoles such as the cyclotryptamine intermediate 56, have been 
widely used as useful synthetic intermediates in the synthesis of more complicated natural 
products.28 
 
 
Figure 2.2. Some biologically relevant synthetic compounds containing a bis-oxindole scaffold. 
 
2.1.2 Formation of spirocyclic bis-oxindoles by organocatalytic processes 
 
The significant biological activities of the bis-oxindole architecture have led to a great 
demand for efficient synthetic strategies for their construction. Rapid access to structurally 
diverse products from accessible building blocks represents a great achievement for the 
synthetic chemist. In that matter, a number of organocatalytic asymmetric cascade reactions 
have been developed for the construction of bis-spirooxindole motifs, which contain 
cyclopentane (57), thiopyrrolidine (58), and cyclopropane (59) central cores (Figure 2.3). 
Also, the formation of a tetrahydro-β-carboline moiety resulting from a Michael/Pictet-
Spengler cascade reactions between two isatin-derived substrates was successfully 
accomplished using a chiral phosphoric acid as the organocatalyst.29 The construction of a 
dihydrofuran linker was performed using a cinchona-derived alkaloid as the 
organocatalyst.30 
While the formation of spirocyclic bis-oxindoles with high level of stereocontrol was 
successfully demonstrated using organocatalytic processes, they can also be prepared by 
photochemical [2+2]-cycloadditions,31a and by multicomponent reactions (MCR).31b  
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Figure 2.3. Range of spirocyclic bis-oxindoles accessed by organocatalysis. 
 
2.1.2.1 Synthesis of spirocyclopentane bis-oxindoles 
 
Remarkable advances have been recently made on the enantioselective synthesis of the 
spirocyclopentane bis-oxindole scaffold. Initially, Barbas III et al. developed an 
organocatalytic asymmetric construction of the bis-spirooxindole motif 62 (Scheme 2.1).32 
Extraordinary levels of stereocontrol over four stereocentres were achieved from the domino 
Michael/aldol reaction between 3-substituted oxindoles 61 and methyleneindolinones 60. 
For this purpose, the cinchona-derived catalyst 63 was designed and contained a crucial 
binaphthyl primary amine, a thiourea and a tertiary amine, speculating that the thiourea 
would bond with the oxindole unit via multiple hydrogen-bonding interactions. 
Concurrently, the ketone or ester functionalities from the methyleneindolinone were 
suggested to coordinate to the tertiary amine group and the binaphthyl primary amine. 
 
 
Scheme 2.1. Barbas’ organocatalytic asymmetric domino Michael/aldol approach to spirocyclic bis-oxindoles. 
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Subsequently, Wang and co-workers reported in 2012 a different approach to the 
development of spirocyclopentane bis-oxindole skeleton 66 with three contiguous 
stereocentres via an organocatalytic domino Michael/alkylation strategy, starting from 
methyleneindolinones 64 and 3-substituted oxindoles 65 (Scheme 2.2).33 Their approach 
uses a chiral squaramide organocatalyst 67 represented in Scheme 2.2, and proceeded in 
good yields, enantioselectivities, but with moderate control over the relative configuration 
of the pentacyclic adduct 66. However, the possibility of isolating all diastereoisomers by 
column chromatography ensured the synthetic utility of this process. 
 
 
Scheme 2.2. Wang’s organocatalytic asymmetric domino Michael/alkylation approach to spirocyclic bis-
oxindoles. 
 
More recently, the same group reported an organocatalytic Michael/Michael cascade for the 
enantioselective construction of spirocyclopentane bis-oxindoles bearing four contiguous 
stereocentres.34 Better control over the diastereoselectivity of the transformation was 
achieved using a different organocatalyst, a chiral squaramide derived from quinidine. 
 
2.1.2.2 Synthesis of spirothiopyrrolidine bis-oxindoles 
 
In view of increasing the diversity in the scope of the organocatalytic asymmetric 
Michael/cyclisation reaction, a similar approach was investigated aiming for the formation 
of spirocyclic thiopyrrolidine bis-oxindoles.35 Amongst all examples, one was reported by 
Wang and co-workers in 2013, in which high conversion and level of stereocontrol was 
obtained for the synthesis of spirothiopyrrolidine bis-oxindoles 70 from the reaction between 
3-isothiocyanato oxindoles 69 and methyleneindolinones 68 using the quinine-derived 
organocatalyst 39 (Scheme 2.3).35a Looking at the extended range of spirothiopyrrolidine 
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bis-oxindoles synthesised as well as the very high yields and stereocontrol reported,35 3-
isothiocyanato oxindoles appear to represent ideal building blocks for such a process. 
 
 
Scheme 2.3. Wang’s organocatalytic approach to spirothiopyrrolidine bis-oxindoles. 
 
2.1.2.3 Synthesis of spirocyclopropane bis-oxindoles 
 
Another organocatalytic example was reported by Kanger et al. in 2013, who developed a 
one-pot asymmetric synthesis of spirocyclopropane bis-oxindoles 73 from 3-
chlorooxindoles 71 and methyleneindolinone derivatives 72 (Scheme 2.4).36 Derived from 
cinchona alkaloids, the squaramide organocatalyst 74 gave access to a wide range of bis-
spirooxindoles with excellent yields and high levels of stereocontrol. 
 
Scheme 2.4. Kanger’s organocatalytic approach towards spirocyclopropane bis-oxindoles. 
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2.1.3 Formation of non-spirocyclic bis-oxindoles 
 
As shown previously, the spirocyclic bis-oxindole motifs have gained broad attention from 
both synthetic and medicinal point of views. Non-spirocyclic bis-oxindoles have also 
attracted interest. Extensive studies by the group of Overman, in the area of natural product 
synthesis, has been undertaken, wherein the use of 3,3-linked bis-oxindole intermediates 
were involved.37 Consequently, a number of asymmetric studies for the construction of this 
motif were also investigated.  
 
2.1.3.1 Asymmetric addition of oxindoles to isatin-derived ketimines 
 
The control over the formation of enantioenriched quaternary centres is considered as one 
of the most powerful transformations in synthesis. One way to promote access to chiral 
centres is the use of organocatalysis as exemplified previously. An example was reported by 
Zhu and co-workers who developed a highly enantioselective synthesis of bis-oxindoles 77 
with two vicinal quaternary stereocentres by means of a Lewis base promoted addition of 3-
substituted oxindoles 75 to ketimines 76 (Scheme 2.5).38 A proposed organocatalyst mode 
of action relied on the activation of the 3-substituted oxindoles 75, which subsequently 
reacted with the imine 76 also stabilised by H-bonding within the chiral pocket of the 
organocatalyst 78. 
 
Scheme 2.5. Organocatalytic formation of bis-oxindoles 77 from 3-substituted oxindoles 75 and ketimines 76. 
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2.1.3.2 Asymmetric decarboxylative allylation approach to bis-oxindoles 
 
Access to enantioenriched oxindoles 80 via an asymmetric decarboxylative allylation was 
reported by the Taylor group in 2011. High conversions and levels of streocontrol were 
achieved from racemic 3,3-disubstituted oxindoles 79 using Pd2(dba)3 (2.5 mol%) and the 
commercially available anthracene-derived bis-phosphine 81 (6.5 mol%) as a ligand 
(Scheme 2.6),39 previously utilised by Trost in his work on catalytic asymmetric allylic 
alkylation of ketone enolates.40 
 
Scheme 2.6. Taylor’s asymmetric approach to enantioenriched oxindoles. 
 
Inspired by this work, Bisai and co-workers further expanded the scope of the transformation 
and reported the utility of this strategy in the formation of enantioenriched bis-oxindoles 83 
from racemic bis-oxindoles 82 (Scheme 2.7).41 (S,S)-83 has been commonly used as an 
intermediate for the formal synthesis of cyclotryptamine alkaloids.37 
 
 
Scheme 2.7. Bisai’s extension of the asymmetric decarboxylative allylation to bis-oxindoles. 
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2.1.3.3 Construction of bis-oxindoles by a double Michael reaction from dihydroisoindigo and 
application in the total synthesis of (+)-chimonanthine (87) 
 
The chimonanthines are the simplest members of the indole family of alkaloids containing a 
hexacyclic 3a,3a'-bis-pyrrolidino[2,3b]indoline unit. All three stereochemical 
chimonanthines are found in nature. Amongst them, (+)-chimonanthine (87) was isolated 
from both the skin of a Colombian frog42 and from plant sources.43 While Overman et al. 
developed a double alkylation of dihydroisoindigo to give spirocyclic bis-oxindoles as the 
key step of the total synthesis of (+)-chimonantine (87),37c the group of Kanai reported a 
catalytic and stereoselective double Michael addition from dihydroisoindigo 84 to give bis-
oxindole 86 (Scheme 2.8).44 The one-pot double Michael reaction was investigated and the 
Schiff base had only moderate reactivity towards the second Michael addition, possibly 
explained by the severe steric hindrance from the catalyst. Consequently, the yield and the 
diastereoselectivity of the reaction sequence were disappointingly low (44% yield and up to 
5:1 dr) but excellent enantioselectivity was generated. To solve this problem, they 
investigated next, a sequential Michael reaction in order to achieve a greater diastereocontrol 
in the second step. Not surprisingly, the chiral Mn(4-F-BzO)2/Schiff base catalyst 88 still 
afforded mono-alkylated bis-oxindole 85 with good enantiocontrol. Filtration on a pad of 
silica was necessary to remove the manganese catalyst. Pleasingly, treating the mono-
alkylated product 85 with Mg(OAc)2·4H2O in presence of benzoic acid considerably 
improved the conversion as well as the level of diastereoselectivity. The bis-oxindole 86 
represented an ideal and easy accessed target which was eventually intended for use in the 
total synthesis of (+)-chimonantine (87) as well as two other cyclotryptamine alkaloids. 
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Scheme 2.8. Kanai’s sequential Michael reaction to bis-oxindoles 86. 
 
2.1.3.4 Construction of bis-oxindoles by a double palladium-catalysed Heck coupling 
 
Interested in the formation of cyclotryptamine alkaloids, Overman and co-workers 
investigated several strategies to construct the hexacyclic 3a,3a'-bis-
pyrrolidino[2,3b]indoline motif. Whereas earlier the focus was set on a double alkylation 
method from dihydroisoindigo, the construction of bis-oxindoles 90 was also undertaken by 
a double palladium-catalysed Heck coupling from bis-anilides 89 (Scheme 2.9).37b Only a 
single hexacyclic bis-oxindole was formed from the coupling reaction of bis-iodinated 
substrates 89 with Pd(PPh3)2Cl2 (10 mol%) and excess of Et3N. It was suggested that when 
the cyclohexanediol was protected as an acetonide, the oxygen substituents were locked in 
a diequatorial position, and consequently set the configuration of the most favoured 
intermediate. Also, the relative stereochemistry of 90, in which the two oxindole units are 
orthogonal, was secured by single-crystal X-ray analysis. The total synthesis of (+)-
chimonanthine (87) was also reported.37b 
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Scheme 2.9. Overman’s double palladium-catalysed Heck coupling reaction to spirocyclic bis-oxindoles. 
 
To date, this example represents the only intramolecular cyclisation process to spirocyclic 
bis-oxindoles.45 While all the previous approaches relied on the synthesis of the central core 
from pre-existing oxindole units, this strategy focused on the formation of both oxindole 
motifs through a double palladium-catalysed coupling process. 
 
2.2 Synthesis of spirocyclic bis-oxindoles 
 
2.2.1 A copper(II)-mediated oxidative coupling approach to spirocyclic bis-oxindoles 
 
Interested by bis-oxindoles for their synthetic and biological profile, potential substrates 
capable of undergoing an intramolecular cyclisation under the copper(II)-mediated oxidative 
coupling were investigated. Following the reported synthesis of oxindoles,14,16 spirocyclic 
oxindoles21 and other heterocycles,46 the synthesis of more structurally complex bis-
oxindoles 91 with two stereogenic centres was conducted. Bis-anilide substrates were chosen 
as potentially amenable to perform the double C–H, Ar–H functionalisation. While Overman 
uses ortho-iodinated bis-anilide precursors as well as a palladium catalyst for the double 
cyclisation to proceed,37b the use of non-prefunctionalised bis-anilide 92 and a very 
inexpensive source of copper was proposed (Scheme 2.10). With regard to the already 
published work in the area, this work is, to the best of our knowledge, the first example 
representing the variation of the bis-oxindole central core. 
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Scheme 2.10. Expected synthesis of bis-oxindoles 91 from bis-anilide precursors 92 via a copper(II)-mediated 
double cyclisation. 
 
2.2.2 Strategy for the formation of cyclopentanone bis-anilide precursors 
 
Different approaches were explored for the formation of bis-anilide precursors. To start, 
disconnection at the α-position of the central cyclic ketone in compound 92 was investigated 
but all efforts failed to give the bis-substituted product 92 from the reaction between the 
preformed bis-enolate of ketone 94 and carbamoyl chloride 93 (pathway a, Scheme 2.11). 
Another synthetic strategy was then proposed in which compound 92 would result from the 
dialkylation of tricarbonyl intermediate 95 with non-activated dibromo-alkyl derivatives 96. 
Disappointingly, conversion of bis-anilide 95 to cyclic product 92 was never observed 
(pathway b, Scheme 2.11). 
 
 
Scheme 2.11. Disconnection strategies for the formation of bis-anilides 92. 
 
Consequently, a new approach was considered in which the formation of the bis-anilide 
substrate 92 would result from a formal carbon monoxide insertion between both amide 
moieties as depicted in the Scheme 2.12. Initial amide coupling with di-carboxylic acid 99 
and N-methylaniline (98) would provide access to bis-amide 97. Thus, the tricarbonyl bis-
anilide 92 would directly arise from a novel ring closure from compound 97. 
  
24 
 
Scheme 2. 12. Proposed route to the cyclopentanone 2,5-dicarboxamide 92. 
 
Using Mukaiyama’s peptide coupling conditions, treatment of adipic acid with a small 
excess of N-methylaniline (98), 2-chloro-1-methylpyridinium iodide (100) and Et3N in THF 
at 0 °C, gave the bis-amide 97a in 75% yield (entry 1, Table 2.1). Due to the poor solubility 
of adipic acid in DCM, THF was used as the solvent for the coupling reaction. This bis-
amide coupling can be performed conveniently on large scale to provide multigram 
quantities of precursors 97. Symmetrical substrates 97a-d as well as unsymmetrical 
substrates 97e-f were obtained in moderate to good yields.  
 
Table 2.1. Mukaiyama’s coupling approach for the synthesis of bis-amides 97. 
 
entry R/R1 R2/R3 product yield (%)a 
1 R = R1 = H R2 = R3 = Me 97a 75 
2 R = R1 = H R2 = R3 = Bn 97b 38 
3 R = R1 = 4-Me R2 = R3 = Me 97c 93 
4 R = R1 = 4-OMe R2 = R3 = Me 97d 91 
5 R = 4-Me, R1 = 4-OMe R2 = R3 = Me 97e 40b 
6 R = R1 = H R2 = Me, R3 = Bn 97f 22b 
a Yield of isolated product. b Dr. Timothy E. Hurst carried out the synthesis of both 
unsymmetrical substrates. 97e-f were synthesised using a sequential addition of anilines. 
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A novel ring closure approach was next investigated from 97a. Multiple coupling agents and 
bases were tried and the results are shown in the Table 2.2. Pleasingly, LHMDS (3 eq) in 
combination with CDI (1.5 eq) validated the feasibility of the ring closure reaction and 
afforded product 92a in a moderate 27% yield (entry 1, Table 2.2). Replacing LHMDS with 
NaH dramatically lowered the yield of the reaction with only starting material recovered 
(entry 2). The nature of the coupling agent was also studied and the combination of 
diphosgene with LHMDS did not afford the cyclopentanone-derived product 92a (entry 3). 
Finally, another set of conditions was tried involving the use of LDA as a base and 
triphosgene as the coupling agent and this gave cyclic product 92a in 38% yield. However, 
the reaction never afforded bis-anilide 92a as clean as the original conditions (entry 1). Even 
though compound 92a from conditions 4 was submitted to a series of purifications by 
column chromatography, unidentified side-products were still observed. 
 
Table 2.2. Optimisation of conditions for the synthesis of tricarbonyl bis-anilide 92a 
 
entry base (3 eq) coupling agent (1.5 eq) yield (% 92a)a 
1 LHMDS CDI 27 
2 NaH CDI 0b,c 
3 LHMDS diphosgene 0b 
4 LDA triphosgene 38d 
a Unless otherwise stated all reactions were carried out in THF (0.08 M-0.12 M) at –78 °C 
and allowed to warm to rt once quenched by addition of NH4Cl. b Only starting material 
was recovered. c The reaction was carried out at –40 °C. d The yield is not accurate as 
impurities were still present even after a series of purifications. 
 
Full characterisation by NMR and IR spectroscopy, ESI-HRMS analysis confirmed the 
structure of bis-anilide 92a obtained by the LHMDS/CDI route. The thermodynamically 
more stable trans-bis-anilide diastereoisomer 92a was the only product obtained from the 
reaction. Additionally, the relative configuration of 92a was confirmed by X-ray analysis 
(Figure 2.4). 
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Figure 2.4. Crystal structure of trans-92a (50% probability ellipsoids, CCDC 1013303). 
 
Then, the scope of the CDI-mediated cyclopentanone cyclisation was expanded to the range 
of bis-amide substrates 97a-f (Table 2.3). Tricarbonyl cyclisation precursors 92a-f were 
obtained in moderate yields. 
 
Table 2.3. Scope of the CDI-mediated cyclopentanone cyclisation. 
 
entry R/R1 R2/R3 product yield (%)a 
1 R = R1 = H R2 = R3 = Me 92a 27 
2 R = R1 = H R2 = R3 = Bn 92b 27 
3 R = R1 = 4-Me R2 = R3 = Me 92c 18 
4 R = R1 = 4-OMe R2 = R3 = Me 92d 17 
5 R = 4-Me, R1 = 4-OMe R2 = R3 = Me 92e 11b 
6 R = R1 = H R2 = Me, R3 = Bn 92f 20b 
a Yield of isolated product. b Dr. Timothy E. Hurst carried out the cyclisation of both 
unsymmetrical substrates 92e-f. 
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2.2.3 Strategies for the formation of 6- and 7-membered ring bis-anilide precursors 
 
While the CDI-mediated cyclisation afforded the cyclopentanone-derived bis-anilides in 
moderate yields, 6- and 7-membered-related structures were not accessible by the same 
route. A different strategy was investigated and relied on the disconnection of both amide 
bonds (Scheme 2.13). It was anticipated that the cyclic di-carboxylic acid 101 would react 
with aniline 98 and give access to cyclisation precursors 92g-i. 
 
 
Scheme 2.13. Second strategy to access bis-anilide with larger ring size central core. 
 
The di-carboxylic acid 101 was readily available from the reaction of cyclic ketones 94 with 
methyl magnesium carbonate47 and resulted in the formation of an inseparable mixture of 
mono- and bis-acid (Table 2.4). A one-pot treatment of the acid mixture with aniline under 
Mukaiyama’s conditions afforded bis-anilide 92g-i along with a majority of mono-
substituted anilide 102, conveniently separable by column chromatography. Rapid access to 
bis-anilides 92g-i was thus achieved from the one-pot MMC/Mukaiyama’s coupling route. 
  
28 
Table 2.4. Scope of the synthesis of bis-anilides. 
 
entry R n 
yielda 
102 92 
1 H 1 30% 102a 14% 92g 
2 t-Bu 1 38% 102b 10% 92h 
3 H 2 34% 102c 9% 92i 
a Yield of isolated products. Mono-anilides 102a-c and bis-anilides 92g-i are separable 
by column chromatography. 
 
A different strategy was developed for the formation of the 7-membered ring benzo-fused 
bis-anilide 92j, mainly because of the high cost of the ketone starting material necessary for 
the MMC/amide bond coupling sequence. Formation of tricarbonyl bis-amide 95 was 
achieved in 19% yield from the diester 103 (Scheme 2.14). Treatment of the preformed 
dienolate of 95 with dielectrophile 104 yielded the trans-bis-anilide 92j in a moderate 27% 
yield. This strategy was only possible with the structurally-rigid dielectrophile in order to 
avoid the competitive double alkylation at the same carbon atom. 
 
 
Scheme 2.14. Synthesis of bis-anilide 92j. 
 
It was assumed that the five-, six-, and seven-membered ring bis-anilides were all isolated 
as the trans-bis-anilide diastereoisomers. 
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However, no crystal structures were obtained for the six- and seven-membered examples to 
confirm this assumption. 
 
2.2.4 Preliminary studies and optimisation of the cyclisation conditions 
 
For initial investigations, the cyclopentanone 2,5-dicarboxamide 92a was chosen as the 
model substrate. The double spirocyclisation was undertaken, initially using Cu(OAc)2·H2O 
in mesitylene at 170 °C, conditions optimised for the formation of mono-oxindoles.16 After 
30 min, TLC analysis indicated the complete consumption of bis-anilide 92a but only traces 
of cyclised product 91a were observed (entry 1, Table 2.5). Decreasing the temperature and 
carrying out the reaction in toluene at 110 °C improved the cyclisation to 24% yield (entry 
2). Further reduction in temperature resulted in lower yields, even after extended reaction 
times (entry 3). A significant improvement was observed when employing the conditions 
optimised in the original study on the formation of oxindoles with stoichiometric copper.14a 
The desired spirocyclic bis-oxindole 91a was obtained in 67% yield when the reaction was 
carried out in DMF at 110 °C with addition of KOt-Bu (2.2 eq) (entry 4). In a control 
experiment carried out using KOt-Bu (2.2 eq), in the absence of copper salt, no cyclisation 
took place, leading to predominantly hydrolysed and decomposed starting materials (entry 
5). 
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Table 2.5. Optimisation of the double cyclisation reaction conditions 
 
entry base Cu source solvent time (h) yield (% 91a)a 
1 - Cu(OAc)2·H2O (1 eq) mesitylene (170 °C) 0.5 <5b 
2 - Cu(OAc)2·H2O (1 eq) toluene (100 °C) 0.5 24 
3 - Cu(OAc)2·H2O (1 eq) toluene (80 °C) 3 17 
4 KOt-Bu (2.2 eq) Cu(OAc)2·H2O (2 eq) DMF (110 °C) 0.25 67 
5 KOt-Bu (2.2 eq) - DMF (110 °C) 0.25 0c 
a Unless otherwise stated, yield of isolated products. b Yield determined from the 1H NMR spectrum 
of the crude reaction mixture. c No product was observed in the 1H NMR spectrum of the crude 
reaction mixture and only traces (<5%) of starting material were observed, while products from 
amide hydrolysis as well as decomposition were also detected. 
 
The double cyclisation proceeded with complete diastereoselectivity to give only the trans-
diastereoisomer. The novel spirocyclic bis-oxindole trans-91a was fully characterised by 
NMR spectroscopy (see Appendix I for the 1H and 13C NMR spectra), IR and ESI-HRMS 
analysis. Also, the relative configuration was confirmed by X-ray crystallographic analysis 
(Figure 2.5).  
 
Figure 2.5. Crystal structure of trans-91a (50% probability ellipsoids, CCDC 1004040).  
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Owing to the C2-symmetry of spirocyclic bis-oxindole trans-91a as well as the high 
diastereoselectivity of the double cyclisation, the interpretation of the 1H NMR spectrum 
was trivial. An expansion of the aromatic region of trans-91a is shown in Figure 2.6. Only 
4 peaks, integrating for two protons each were seen between 6.83 and 7.44 ppm. Also, two 
distinctive multiplets for each CH2 from the cyclopentanone central core and one singlet for 
both Me group appeared at lower chemical shifts (see Appendix I for full 1H and 13C NMR 
spectra of trans-91a). 
 
  
Figure 2.6. 1H NMR expansion of the aromatic signals of spirocyclic bis-oxindole trans-91a. 
 
2.2.5 Scope of the double cyclisation reaction 
 
Having established successful conditions for the double cyclisation, further investigations 
on the substrate scope of this reaction using a range of substituted bis-anilides 92 were 
undertaken. Pleasingly, changing the substitution on the nitrogen atom did not affect the 
yield of the cyclisation as bis-oxindole 91b was obtained in 57% yield (Scheme 2.15). 
Substitution of the aromatic ring in the para-position was also tolerated and both 4-Me (91c) 
and 4-OMe (91d) spirocyclic bis-oxindoles were formed in 67% and 44% yield, 
respectively. The central ring size was also varied and cyclohexanones (91g-h) as well as a 
cycloheptanone (91i-j) embedded between the two oxindole units were well-tolerated. All 
spirocyclic bis-oxindoles presented in Scheme 2.15 were obtained as single trans-
diastereoisomers, as shown by NMR spectroscopy and X-ray analysis. 
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Scheme 2.15. Spirocyclic bis-oxindole substrate scope. Unsymmetrical bis-spirooxindoles 91e-f were prepared 
by Dr. Timothy E. Hurst, with differences in either ring substitution (91e) or on the nitrogen atom (91f). 
 
For the first time, great variability in the central core is possible. While other methods 
focussed on the elaboration of the spirocyclic central unit, our route enabled the formation 
of the two oxindole motifs from bis-anilide substrates that already contained the future C3-
C3’ spirocyclic central core. As a result, the flexibility of this approach allowed introduction 
of a larger range of central cores with different ring sizes. Notably, the bis-oxindole 91g-j, 
containing 6- and 7-membered ring, are unprecedented structures. 
This method enabled the installation of two all-carbon quaternary centres at the oxindole 3-
position in a diastereoselective manner, most likely induced by the rigidity of the cyclic core 
appended to both oxindole units. 
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The optimised conditions for the synthesis of spirocyclic bis-oxindoles required very short 
reaction times. Also, an inexpensive and insensitive-to-air copper(II) salt, was used to 
perform the one-pot double cyclisation, and the reaction was run opened to the air. 
 
2.2.6 A copper(II)-mediated cyclisation to enantioenriched spirocyclic bis-oxindoles. 
 
In an effort to extend the diastereoselective properties of the copper(II)-mediated double 
cyclisation to the formation of potentially enantioenriched bis-spirooxindoles, the 
introduction of a chiral auxiliary on the nitrogen of the oxindole motif was next considered.  
Chiral auxiliaries on the ester have already been investigated by the Taylor group and a 
diastereoselective version of the oxindole cyclisation had been attempted. The use of Evans 
and Oppolzer chiral auxiliaries was studied. Unfortunately, neither produced the desired 
cyclised oxindole product. Alternatively, other chiral auxiliaries could be investigated and 
the auxiliary could be attached on the nitrogen atom instead. Preliminary studies on a radical 
cyclisation approach from ortho-bromo anilide 105 into a simple oxindole 106 was reported 
by Jones in 1989 where the use of the α-methylbenzyl group as a chiral auxiliary was 
reported to promote a moderate 39% ee after removal of the auxiliary to give enantioenriched 
oxindole 107 (Scheme 2.16).48 
 
 
Scheme 2.16. Jones’ diastereoselective formation of oxindoles. 
 
A similar approach was proposed for the diastereoselective synthesis of 3,3-disubstituted 
oxindoles as well as bis-oxindoles, with the hope to gain higher diastereoselectivities. The 
formation of 3,3-disubstituted oxindoles was first examined. The precursor 110, bearing an 
(S)-α-methylbenzyl group, was prepared via a Mukaiyama amide bond coupling between 
readily available carboxylic acid 10949 and N-benzyl aniline 10850 (Scheme 2.17). From 
anilide 110, the C–H, Ar–H coupling reaction should occur and hopefully enhance the 
resulting diastereoselectivity of the cyclisation. 
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Scheme 2.17. Proposed diastereoselective cyclisation to oxindole 111. 
 
Optimisation of the cyclisation reaction from anilide 110 into oxindole 111 was carried out 
and is presented below in the Table 2.6. Initially, the conditions developed for the formation 
of bis-oxindoles were tried (entry 1). Due to the poor yield of this reaction, the reaction 
conditions used for the transformation were reconsidered. Switching the solvent from DMF 
to toluene and carrying out the reaction at 110 °C, without base, increased the yield 
considerably (entry 2). Of greater importance, incorporation of the chiral auxiliary generated 
slight control over the diastereoselectivity of the reaction (i.e. dr 1:1.3). No consideration 
was given with respect to determining the absolute configuration of the major 
diastereoisomer 111 as all attempts at separation by column chromatography proved 
unsuccessful. However, this result provided encouragement for the potential achievement of 
greater diastereocontrol for the cyclisation of sterically more hindered spirocyclic bis-
oxindoles. 
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Table 2.6. Optimisation of the cyclisation from anilide 110 into oxindole 111. 
 
entry base (eq) solvent (temp)  time (h) yield (% 111)a drb 
1 KOt-Bu (2.2 eq) DMF (110 °C) 1 26 1:1.3 
2 - toluene (110 °C) 18 76 1:1.3 
3 - mesitylene (170 °C) 1.5 55 1:1.2 
a Yield of isolated products. b dr were calculated from the integration of the 1H NMR signal of 
both benzylic CH from the inseparable mixture of diastereoisomers after purification by 
column chromatography. 
 
With regard to the previous result, attention was focused on applying this strategy to the 
more intricate spirocyclic bis-oxindoles with the hope of attaining superior stereocontrol 
over the cyclisation process. The linear bis-anilide precursor 92k, containing the (S)-α-
methylbenzyl chiral auxiliary on both nitrogen atoms, was prepared following the double 
MMC/amide coupling reactions sequence (Scheme 2.18). Cyclisation of bis-anilide 92k 
under the optimised conditions delivered 91k in 46% yield as an inseparable mixture of 
diastereoisomers in a 1:1.3 ratio. Unfortunately, the diastereoisomeric ratio of 1:1.3 was the 
same for both mono- and bis-oxindole motifs. A screening of bulkier chiral auxiliaries would 
be the next parameter to vary for the purpose of improving the stereocontrol of such process. 
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Scheme 2.18. Cyclisation of bis-anilide 92k to give spirocyclic bis-oxindole 91k. 
 
2.3 Synthesis of bis-oxindoles with an acyclic monoketone linker 
 
To further demonstrate the scope and diversity of the double anilide cyclisation, attention 
turned to varying the cyclic ketone linker and applying this methodology to acyclic 
monoketone central core precursors. Although the linear bis-anilide would suffer from the 
lack of rigidity during the cyclisation compared to the cyclic central core precursors 
discussed earlier, a certain level of diastereocontrol during the reaction was still expected. 
 
2.3.1 General approach for the formation of bis-anilides with an acyclic monoketone 
linker 
 
For this purpose, the substrate synthesis was revised and the required cyclisation precursors 
were easily prepared in 3 steps. Readily available ester anilide 112 was treated with 
LiOH·H2O and the resulting carboxylic acid transformed into acid chloride 113 using oxalyl 
chloride in the presence of DMF (Scheme 2.19). Acid chloride 113 was synthesised on large 
scale and was sufficiently stable to allow storage at –10 °C for several months without 
degradation. Preparation of LDA, with freshly distilled diisopropylamine and a titrated 
solution of n-BuLi in hexanes was treated with 114a-b at –78 °C. The solution was stirred 
for 20 min and allowed to warm to 0 °C before lowering the temperature again to –78 °C. 
Then, the acid chloride, as a solution in THF, was slowly added and the completion of the 
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reaction monitored by TLC analysis. Following this procedure, access to 115a-b was 
achieved in good yield as a single diastereoisomer in 55% and 69% respectively. 
 
 
Scheme 2.19. Synthesis of bis-oxindoles with an acyclic monoketone linker. 
 
2.3.2 Preliminary studies and optimisations of the cyclisation conditions 
 
The efficiency of the cyclisation was tested with the symmetric precursor (115a, R = Me). 
Cyclised adduct 116a was obtained in 65% yield as a mixture of diastereoisomers which was 
determined from the 1H NMR spectrum of the crude mixture (entry 1, Table 2.7). Both trans- 
and cis-diastereomers were separable by column chromatography. However, the presence of 
a significant amount of side-product 117 complicated the purification (i.e. co-elution of the 
undesired product 117 in both diastereoisomer fractions). The contaminant 117 was 
identified as N-methyl-3-methyl-3-hydroxyoxindole, and resulted from an oxidative 
cleavage of either 115a or 116a. Pleasingly, performing the reaction without base in toluene 
minimised the formation of side-product 117 but also lowered the yield of the cyclisation 
(entry 2). Reducing the amount of time required to complete the transformation and 
consequently running the reaction in mesitylene at 170 °C for 30 min were sufficient to 
improve the yield and considerably reduce the amount of side-product 117 (entry 3). The 
small amount of 3-hydroxyoxindole 117 formed in this reaction was easily removed during 
the workup by washing with an aqueous 4.0 M NaOH solution. 
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Table 2.7. Optimisation of the double cyclisation to acyclic bis-oxindoles 116a. 
 
entry base (eq) solvent (temp)  time (h) yield (%) trans:cis-116a:117e 
1 KOt-Bu (2.2 eq) DMF (110 °C)a 1 65c 1:3:1.5 
2 - toluene (110 °C)b 18 48c 1.1:1:0.5 
3 - mesitylene (170 °C)b 0.5 58d 1:1.5:traces 
a 2 equivalents of Cu(OAc)2·H2O were used in the reaction. b 1 equivalent of Cu(OAc)2·H2O. c Yield 
after column chromatography but still contains 117. d Yield of isolated products. e Ratio was 
determined from the 1H NMR spectrum of the crude reaction mixture. 
 
The novel bis-oxindoles cis-116a and trans-116a were fully characterised by NMR, IR 
spectroscopy, and ESI-HRMS analysis. Furthermore, the relative configuration of trans-
116a was confirmed by X-ray crystallographic analysis (Figure 2.7). 
 
 
Figure 2.7. Crystal structure of trans-116a (50% probability ellipsoids, CCDC 1004039). 
 
A very noticeable difference between both diastereoisomers was observed in the 1H NMR 
spectra of the isolated products. Particular attention was given to the aromatic region 
between 6 and 8 ppm (Figure 2.8). Relying on the relative configuration determined by the 
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previous crystal structure (Figure 2.7), the assignment of both compounds with their 
respective NMR spectra was possible. The red 1H NMR spectrum (a) was attributed to cis-
116a (or meso-116a). The black 1H NMR spectrum (b) was attributed to the trans-116a, or 
optically active dl-116a. The assignment of all aromatic protons were possible with 2D-
NMR spectroscopy. A very different pattern was observed for the protons assigned as H-7 
and H-4. While H-7 and H-4 retain very similar chemical shifts in meso-116a, H-7 was found 
to be particularly shielded and H-4 deshielded in dl-116a. 
 
 
Figure 2.8. 1H NMR expansion of the aromatic signals of meso-116a (a) and dl-116a (b). 
 
2.3.3 Synthesis of an unsymmetrical bis-oxindole by double cyclisation 
 
Unsymmetrical bis-oxindole 116b was prepared in a similar manner (Scheme 2.20). 
Interestingly, changing one of the α-methyl groups in 115a to the bulkier ethyl group (115b, 
R = Et) inverted the diastereoselectivity with trans-116b identified as the major 
diastereoisomer (1.5:1 trans-116b:cis-116b). Again, both compounds were separable by 
column chromatography. 
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Scheme 2.20. Synthesis of unsymmetrical bis-oxindole 116b with a monoketone linker. 
 
The novel bis-oxindoles cis-116b and trans-116b were fully characterised by NMR, IR 
spectroscopy, and ESI-HRMS analysis. In addition, the relative configurations of cis-116b 
and trans-116b (Figure 2.9) were confirmed by X-ray crystallographic analysis. 
 
 
Figure 2.9. Crystal structures of cis-116b (left, CCDC 1004041) and trans-116b (right, CCDC 1016758) 
 
Compared to the symmetrical bis-oxindole 116a, the same trend was observed for the 
unsymmetrical cis- and trans-bis-oxindole diastereoisomers 116b with regard to their 
respective 1H NMR spectra (Figure 2.10). The red spectrum (a) shows the cis-bis-oxindole 
116b which now contains 8 aromatic peaks due to the fact that the cyclised product is no 
longer symmetrical, rendering the complete proton assignment more complex. While the 
majority of protons can be assigned for cis-116b, more difficulties were associated with the 
interpretation of the peaks in trans-116b with the exception of the shielded H-7 (black 
spectrum (b)). 
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Figure 2.10. 1H NMR expansion of the aromatic signals of cis-116b (a) and trans-116b (b). 
 
The moderate diastereoselectivities observed in the synthesis of bis-oxindoles 116a-b 
containing monoketone acyclic linker showed the importance of the more rigid cyclic core 
in spirocyclic bis-oxindoles 91a-k, which consequently lead to complete stereocontrol over 
the formation of the most favoured relative trans-configuration. 
 
2.4 Synthesis of ester-containing bis-oxindoles 
 
Finally, the nature of the electron-withdrawing group at C3 of both oxindole units was also 
varied. This specific design extended the range of linker units used for the substrate synthesis 
as the electron-withdrawing group would be separate from the linker. 
 
2.4.1 General approach for the formation of bis-anilides containing ester functionalities 
 
The one-pot synthesis of bis-anilides 118a-c started with anilide 117, which upon treatment 
with NaH generated the respective enolate. The latter was subsequently trapped with the 
requisite dibromide electrophile (Scheme 2.21). The diester bis-anilides 118a-c were 
obtained in good yield. No diastereocontrol was observed during the substrate synthesis; this 
is unconsequential as the radical mechanism involved in the C–H, Ar–H functionalisation 
cis-116b 
trans-116b 
H-7 
H-4 
H-7 H-5 H-6 
(a) 
(b) 
42 
would not retain any stereogenic information. Variety in the linker was investigated and 
pleasingly, saturated ((CH2)4, 118a), unsaturated (CH2(CH)2CH2, 118b), and benzylic 
(118c) central cores were tolerated. 
 
 
Scheme 2.21. Synthesis of ester-containing bis-anilide cyclisation precursors. All compounds were obtained 
as a 1:1 mixture of diastereoisomers. 
 
2.4.2 Scope of the double cyclisation reaction 
 
With 118a-c in hand, the double cyclisation reaction was attempted using Cu(OAc)2·H2O (1 
eq) in mesitylene at 170 °C. Pleasingly, bis-oxindole 119a was obtained in excellent yield 
and short reaction time (Scheme 2.22). Whilst bis-anilide 118a was converted into the 
corresponding bis-oxindole 119a in 30 minutes, a longer reaction time (i. e. up to 2 hours) 
was required for the conversion of bis-anilides 118b-c into bis-oxindoles 119b-c. 
Fortunately, the yield of the reaction was not affected and the cyclised product 119b-c were 
obtained in 66% and 89% yield, respectively. Unsurprisingly, all bis-oxindoles 119a-c were 
obtained as an inseparable mixture of diastereoisomers (dr 1:1), owing to the flexibily of the 
central core. 
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Scheme 2.22. Synthesis of ester-containing bis-oxindoles. 
 
2.5 Conclusion 
 
The double cyclisation of bis-anilides has been developed using a double copper(II)-
mediated C–H, Ar–H functionalisation to efficiently construct the bis-oxindole scaffold. The 
use of inexpensive and air-stable copper salts ensured the oxidative coupling proceeded in 
often good yields and with short reaction times. A variety of bis-anilides have been 
synthesised and afforded a large number of bis-oxindoles. The double copper(II)-mediated 
coupling has been shown to proceed in a diastereoselective manner for the spirocyclic bis-
oxindoles giving only the trans-products. 
A diastereoselective variant of the process has been investigated using a chiral auxiliary on 
the nitrogen atom of both oxindole units and a low level of stereoselectivity was induced. 
Whilst the rigid central core of the spirocyclic bis-oxindoles offered a great level of 
diastereocontrol, very low diastereocontrol was observed for the more flexible monoketone 
and diester-derived bis-oxindoles. 
The research described in this Chapter was recently published as a communication51 which 
was subsequently followed by a full paper.52  
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Chapter 3. The synthesis of indole derivatives 
 
3.1 Introduction to 3H-indoles 
 
3.1.1 Chemical and biological importance of indoles 
 
The indole scaffold is one of the most important heterocycles found in Nature.53 Identified 
by Hopkins and Cole in 1901, the indole-based amino acid L-tryptophan (120) is involved 
in many aspects of human nutrition and metabolism.54 Direct decarboxylation of L-
tryptophan (120) by tryptophan decarboxylase (TPD) leads to tryptamine (121) (eq. a, 
Figure 3.1), which constitutes the skeleton of a vast number of monoterpene indole alkaloids. 
L-Tryptophan (120) is also the biogenetic precursor of 5-hydroxy-L-tryptophan (122) and 
serotonin (123), with amino acid 120 first hydroxylated by a tryptophan hydroxylase (TPH) 
and further decarboxylated to afford the 5-hydroxylated tryptamine 123 (eq. b, Figure 3.1). 
 
 
Figure 3.1. Selected examples of naturally occurring indole derivatives. 
 
From the 1950s, the chemistry of indole started expanding significantly and several 
structurally diverse indoles were found to exhibit varied and potent biological activities. 
Nowadays, the indole scaffold appears to be one of the best represented heterocyclic motifs 
present in the top selling pharmaceuticals.55 Drugs such as GlaxoSmithKline’s serotonin 
receptor modulators sumatriptan (124, Imitrex) and zolmitriptan (125, Zomig) are 
representative examples (Figure 3.2). Also, plants rich in alkaloids continue to provide 
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diverse and novel indole-containing compounds. For example, criofolinine (126) was 
isolated from a Malayan Tabernaemontana species and its structure fully elucidated by Kam 
in 2014.56 
 
 
Figure 3.2. Examples of indole-containing drugs and a natural product. 
 
Among the family of indole derivatives, 3,3-disubstituted indolenine (3H-indole) scaffolds 
have attracted considerably less attention, possibly explained by their challenging indolenine 
ring, which contains a reactive imine moiety, and the presence of a quaternary carbon at C3. 
With regard to both natural product and pharmaceutical synthesis, the indolenine structure 
remains a significant challenge to access. Some structurally diverse examples include 
flustramine C57 (127, Figure 3.3), kopsifoline D58 (128) and E58 (129). Moreover, the 
synthetically interesting spiro-aziridine indolenine derivatives 130 have been shown to 
possess inherent antimicrobial activities against P. diminuta and E. coli (Gram-negative 
bacteria) and B. subtilis and B. megaterium (Gram-positive bacteria).59 Also identified as a 
promising intermediate towards the formation of indoline-type natural products, 3H-indoles 
have emerged as target substrates for the synthesis of physovenine60 (131) or 
physostigmine61 (132). 
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Figure 3.3. Examples of C3 quaternary indolenines and indoline compounds. 
 
Therefore, the development of methods for the synthesis of this privileged structure still 
remains of interest to synthetic chemist. While many routes exist for the construction of 1H-
indoles, fewer approaches enable the formation of indolenine products. Predominantly, the 
disconnection occurs via the dearomatisation of indoles but, recently cyclisation processes 
have also been reported. 
 
3.1.2 Studies on the indolenine motif 
 
3.1.2.1 Approaches to 3H-indoles by dearomatisation of indoles 
 
The nucleophilic properties of indole are attributed to the enamine moiety which provides 
nucleophilic character at the C3 position. A number of approaches have been developed to 
exploit the nucleophilic properties of indole for the synthesis of 3H-indoles.  
In 2010, You et al. developed an enantioselective method for the synthesis of 
spiroindolenines 134 via an Ir-catalysed asymmetric allylic alkylation (Scheme 3.1).62 
Readily available indoles 133 were converted into highly enantioenriched 3H-indoles 134, 
using a well-developed Ir-catalytic system involving [Ir(COD)Cl]2 and a phosphoramidite 
ligand 135, with excellent yields (88-98%) and great diastereo- and enantio-control (up to 
>99:1 dr and 97% ee).  
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Scheme 3.1. Allylic alkylation route to spiroindolenines 134. 
 
The intermolecular dearomatisation of 3-substituted indoles to give C3-quaternary 
indolenines has also been investigated with non-activated electrophiles. One of the earliest 
examples was reported in 2006 by Trost et al. who examined the formation of 
enantioenriched indolenine derivatives 137 using a palladium-catalysed C3 allylation of 3-
substituted indoles 136 (Scheme 3.2).63 The best yields and enantioselectivities were 
achieved using a Pd complex formed with Pd2dba3·CHCl3 (2.5 mol%) and Trost’s 
anthracene-derived ligand 81 (7.5 mol%), together with 9BBN-(C6H13) (1.05 eq) and allyl 
alcohol (3 eq). The boron species is tightly bound to the indole nitrogen, thus promoting 
reaction at C3 over N-allylation. The nature of the substituent R1 could vary without 
influencing the allylation results, and numerous alkyl side chains containing heteroatoms 
were tested and gave more complex indoline motifs, resulting from the intramolecular 
cyclisation of the appended nucleophile into the imine moiety. 
 
 
Scheme 3.2. Pd-catalysed C3 allylation to give 3H-indoles 137. 
 
Whereas the formation of the indolenine motif is well-precedented using indole precursors, 
only few examples exist on the cyclisation of linear substrates to 3H-indoles.  
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3.1.2.2 C–N Bond Disconnection Strategies 
 
The formation of a C–N bond constitutes one of the most established procedures in 
heterocyclic chemistry.64 Michelet and Arcadi reported in 2013 the formation of 3,3-
difluorinated 3H-indoles 149 via an intramolecular gold(I)-catalysed 5-endo dig 
aminofluorination cyclisation of 2-alkynylanilines 138 in good to excellent yields using mild 
conditions (Scheme 3.3).65 Excess of the electrophilic fluorine reagent (SelectFluor (140): 3 
eq) was found to be crucial to promote the formation of indolenine derivatives 139. 
Decreasing the amount of fluorinating agent in the reaction stopped the second fluorination 
from occurring and gave 1H-indoles exclusively. A year later, You and co-workers 
developed a very similar method and extended the formation of 3,3-difluorinated 3H-indoles 
via a silver-catalysed one-pot cyclisation/fluorination of 2-alkynylanilines.66 
 
 
Scheme 3.3. Synthesis of 3,3-difluorinated indoles 139 from 2-alkynylanilines 138. 
 
3.1.2.3 C2-C3 Bond Disconnection Strategies 
 
A C2-C3 bond disconnection approach was developed by Mukai and co-workers in their 
studies towards the formal synthesis of (±)-physostigmine (132).67 They have demonstrated 
the use of a Co2(CO)8-catalysed intramolecular aza-Pauson-Khand reaction of 
alkynecarbodiimide 141 to access the fused-indolenine adducts 142 (Scheme 3.4). A wide 
range of substitution was tolerated and afforded the 3H-indole derivatives in moderate to 
good yields. 
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Scheme 3.4. Aza-Pauson-Khand reaction of alkynecarbodiimides 141 to give indolenines 142. (TMTU = 
tetramethylthiourea) 
 
A precedented route was used to synthesise carbodiimide intermediate 141 involving the 
formation68/dehydration69 of a urea moiety from a readily available aniline precursor. The 
key aza-Pauson-Khand-type step promoted the formation of the cyclic indolenine adduct 
142 in 55% yield (Scheme 3.5). Treatment of indolenine 142 with NaCNBH3 in the presence 
of aq. HCHO resulted in the reductive methylation and formed the indoline-derived product 
143. Removal of the TMS group with TBAF gave the primary alcohol 144, which was then 
converted into the iodinated intermediate 145 in 78% yield. Final treatment with LAH 
completed the racemic total synthesis of (±)-esermethole (146), also completing the formal 
synthesis of (±)-physostigmine (132).70 
 
Scheme 3.5. Studies towards the formal synthesis of (±)-physostigmine (132).  
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3.1.2.4 C3-C3a Bond Disconnection Strategies 
 
To date, only one literature example refers to the cyclisation of linear precursors to give 3H-
indoles via C3-C3a bond formation which make this strategy very demanding. Li and co-
workers reported in 2010 an iodine-mediated oxidative coupling approach to the cyclised 
product 148 from readily available N-aryl enamines 147 in good to excellent yields (Scheme 
3.6).71 
 
 
Scheme 3.6. Iodine-mediated synthesis of 3H-indoles 148 from N-aryl enamines 147. 
 
Their mechanistic investigations suggest that the cyclisation occurs through a Friedel-Crafts 
aromatic substitution (Scheme 3.7). The iodination of enamine 147 proceeded through the 
formation of intermediate 149. Then, Friedel-Crafts aromatic substitution enabled the 
intramolecular cyclisation by means of displacement of the iodine atom and gave the 
carbocation species 150. Further rearomatisation resulted in the formation of the 3H-indole 
product 148. 
 
 
Scheme 3.7. A proposed mechanism for the formation of 3H-indole 148. 
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3.2 A copper(II)-mediated oxidative coupling approach to 3H-indoles 
 
3.2.1 Proposed synthetic route to 3H-indoles 
 
In 2009, the Taylor group reported the cyclisation of anilide precursors 16 to oxindoles 17 
via a copper(II)-catalysed C–H, Ar–H coupling (eq. a, Scheme 3.8).16 The transformation 
enabled access to highly substituted oxindoles bearing a quaternary carbon at C3.  
Following the continued interest in the development of new methods towards the formation 
of biologically relevant heterocycles, the possibility of applying the developed copper(II)-
methodology to the synthesis of indole-based molecules was investigated. It was proposed 
that N-aryl enamines 147 could be cyclised into the corresponding indolenine products 148 
(eq. b, Scheme 3.8) by means of a copper(II) oxidative coupling route. 
 
 
Scheme 3.8. Proposed route to 3H-indoles 148 from N-aryl enamines 147. 
 
3.2.2 Strategies for the formation of N-aryl enamines 
 
Prior to the iodine-mediated cyclisation to 3H-indoles, Li and co-workers proposed the 
synthesis of the enamine precursors 147 by means of a condensation reaction of anilines 151 
with β-ketoester derivatives 152 using zinc perchlorate.71 The addition of MgSO4 was 
suggested to keep the reaction mixture under anhydrous conditions. Although this reaction 
suffers from the low nucleophilicity of the aniline compounds and causes the reaction to be 
sluggish, no other method has proven more successful than the latter. So, the synthesis of N-
aryl enamines 147 using the zinc-mediated condensation between commercially available 
anilines 151 and readily available β-ketoesters 152 was conducted (Scheme 3.9). Not 
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surprisingly, condensed products 147 were obtained in poor to moderate yields ranging from 
10 to 30%. The enamine 147 was purified by column chromatography, fully characterised 
and was in agreement with the data already reported by Li and co-workers.71 Difficulties 
were observed with this route when the aromatic group at C2 was switched from a phenyl to 
a pyridine ring and at this point another method was considered. 
 
 
Scheme 3.9. Synthetic approach to N-aryl enamines following Li’s procedure. 
 
A different method using a Dean & Stark apparatus was investigated for the synthesis of 
pyridine-substituted N-aryl enamines. A significant improvement was observed in the 
condensation process between pyridine-derived β-ketoester starting materials 152 and 
substituted anilines 151 to afford the resulting enamine products 147 (Scheme 3.10). The 
reaction took place under acid catalysis and was left overnight at reflux fitted with a Dean 
& Stark apparatus under an argon atmosphere. 
 
 
Scheme 3.10. Dean and Stark method applied to the formation of pyridine-substituted enamines. 
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3.2.3 Preliminary studies and optimisations of the reaction conditions 
 
With ethyl (2Z)-2-methyl-3-phenyl-3-(phenylamino)prop-2-enoate (147a) in hand, it was 
treated with Cu(OAc)2·H2O (1 eq) in mesitylene at 170 °C. Pleasingly, the cyclised product 
148a was obtained and confirmed the feasibility of the proposed copper(II) oxidative 
coupling route to give 3H-indoles (entry 1, Table 3.1). However, only 21% yield of product 
was observed by 1H NMR spectroscopy, along with a non-negligible amount of side-product 
153, which appeared to be the result of addition of water into the reactive imine functionality, 
consistent with the ESI-HRMS data.  
This behaviour has already been observed by the group of You, who reported the formation 
of 3,3-disubstituted indolin-2-ols from indolenine substrates by addition of water in the 
reaction media.66 Also, control of the nature of the oxygenated nucleophilic agent was 
possible with the use of molecular sieves. EtOH as well as benzyl and allyl alcohol were 
tolerated and afforded the resulting indoline-type motif. 
A way to avoid the addition of water and complete the conversion of N-aryl enamine 147a 
was next investigated. Consequently, the source of copper was switched to commercially 
available Cu(2-ethylhexanoate)2, an anhydrous copper(II) salt, and the reaction condenser 
was fitted with a CaCl2 drying trap. No specific care was given to set the reaction under an 
inert atmosphere.16 Pleasingly, the cyclisation of 147a occurred in an improved 78% yield 
(entry 2). Reduction of the amount of copper in the reaction significantly reduced the yield 
of the cyclisation and showed more decomposition of starting material (entry 3). It is also 
worth noting that this protocol requires the presence of copper. Heating the enamine 
precursor in mesitylene at 170 °C without the copper oxidant resulted only in the 
decomposition of the enamine 147a. The 3H-indole 148a was purified by column 
chromatography, and fully characterised. Pleasingly, the data were consistent with those 
already reported by Li (see Appendix I for the 1H and 13C NMR spectra).71 
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Table 3.1. Optimisation of the reaction conditions for the cyclisation of enamine 147a. 
 
entry Cu-source (eq) time (h) yield (% 148a) 
1 Cu(OAc)2·H2O (1 eq) 2 21a 
2 Cu(2-ethylhexanoate)2b (1 eq) 2 78 
3 Cu(2-ethylhexanoate)2 (0.1 eq) 3 38 
4 - 3 0 (decomp.) 
a Isolated as an inseparable mixture of 148a and 153. According to 1H NMR 
spectroscopy after purification and mass recovered, the yield of 148a was determined 
to be 21% and 153 to be 14%.b Cu(2-ethylhexanoate)2 = [Me(CH2)3CH(Et)CO2]2Cu. 
 
3.2.4 Suggested mechanism for the formation of 3H-indoles 
 
Very similar to the mechanism suggested previously for the formation of oxindoles,14a the 
oxidation of N-aryl enamine 147a was suggested to give the radical intermediate 154 
(Scheme 3.11). Then, homolytic aromatic substitution occurs and promotes the formation of 
the cyclic intermediate 155. A second oxidation event generates the cyclohexadienyl cation 
156 which rearomatises to give the 3H-indole 148a. 
 
 
Scheme 3.11. Suggested mechanism for the formation of 3H-indoles.  
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3.2.5 Scope of the cyclisation process 
 
Having established successful conditions for the oxidative cyclisation on the model system 
147a, the substrate scope was then tested using a range of N-aryl enamines 147a-n (Scheme 
3.12). Varying the nature of the alkyl side-chain at C3 was well tolerated (R2 = Ph, 148b, R2 
= allyl, 148c). The oxygen-containing substrate 148d, of interest for the synthesis of 
indoline-type natural products such as physovenine (131, Figure 3.3), cyclised in a good 
63% yield. An electron-rich aniline was also tolerated (148e). The alkyl group at C3 could 
also be replaced by a second ester functionality (148f).  
 
 
Scheme 3.12. Scope of the cyclisation reaction to 3H-indoles. 
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Attention was predominantly focused on the nature of the aromatic ring at C2 which has not 
been explored by Li in the iodine-mediated cyclisation to 3H-indoles. Pleasingly, the 
cyclisation occurred and did not reduce the yield of the reaction. In fact, α-naphthyl (148g), 
4-substituted phenyl (148h-i), thiophenyl (148j), and pyridinyl (148k-n) substituents were 
well-tolerated. The oxidative copper(II)-mediated coupling route also proceeded upon 
varying the nature of the electron-withdrawing group at C3 from the ethyl ester to nitrile and 
phosphonate moieties (148l-m). It should be noted that with the exception of 148a, all 
cyclised products are novel compounds. A suitable crystal of the indolenine product 148h 
was obtained for X-ray crystallographic analysis and conclusively confirmed its structure 
(Figure 3.4). 
 
Figure 3.4. Crystal structure of 148h (50% probability ellipsoids, CCDC 1033699). 
 
3.2.6 Limitations of the cyclisation process 
 
Despite the success of the cyclisation strategy for a wide range of N-aryl enamine precursors, 
this method suffered from limitations with regard to the nature of the substituents around the 
enamine moiety. Notably, the presence of a C2 aryl substituent appeared crucial for the 
oxidative coupling reaction to proceed; starting materials were recovered for substrates 157, 
158, and 159 which had non-aromatic functional groups at C2 (Scheme 3.13). In the case of 
160, the starting material was consumed but no spirocyclic 3H-indole product was isolated. 
Steric hindrance at the spirocyclic junction may have been the problem in this specific 
example. 
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Scheme 3.13. Limitation in the scope of the cyclisation to indolenine compounds. 
 
3.2.7 Studies on the cyclisation of N-benzyl enamine 
 
Extended recently by the Taylor group, the copper(II)-mediated oxidative coupling route has 
also been applied to the synthesis of interesting scaffolds such as tetrahydroquinolines 162 
and dihydro-1H-quinolin-2-ones 163 (Scheme 3.14).46 Catalytic amounts of Cu(2-
ethylhexanoate)2 (10 mol%) along with Hünig’s base (2.2-2.4 eq) were sufficient to 
successfully convert linear and non-functionalised precursors 161 into the corresponding 
cyclic products 162-163. 
 
 
Scheme 3.14. Previous approach on copper(II)-mediated cyclisation to related 6-membered ring system. 
 
Alongside the formation of 3H-indoles, the copper(II)-mediated oxidative coupling route to 
the synthesis of 1,4-dihydroisoquinolines 165 from N-benzyl enamines 164 was envisioned. 
The investigation started with the synthesis of ethyl (2Z)-3-(benzylamino)-2-methyl-3-
phenylprop-2-enoate (164) using the Dean & Stark procedure. Treatment of the β-ketoester 
152 with N-benzylamine and p-TSA afforded the resulting condensed product 164 in 32% 
yield (Scheme 3.15). 
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Scheme 3.15. Proposed route for the synthesis of 1,4-dihydroisoquinolines 165. 
 
For initial investigations, the linear precursor 164 was treated with Cu(2-ethylhexanoate)2 (1 
eq) in mesitylene at 170 °C for 2 h. No starting material remained after 2 h by TLC and a 
new UV-active spot was detected. However, ESI-HMRS data were not consistent with the 
expected 1,4-dihydroisoquinoline 165 and indicated that the resulting product had the 
chemical formula C16H13NO. Analysis of the isolated product by 
1H NMR spectroscopy 
suggested the disappearance of the ester by the absence of any triplet around 1.30 ppm 
corresponding to the CH3 group as well as multiplet at 4.15-4.23 ppm assigned as the CH2 
of the ethyl ester functionality. Also, 1H NMR spectroscopy of the product revealed that all 
the aromatic protons from the starting material were retained and a new singlet at 2.61 ppm 
appeared which integrated for 3 protons. This singlet seemed deshielded for a methyl group, 
and suggested that this methyl should be adjacent to a heteroatom. Examination of all the 
data suggested the formation of the oxazole product 167 (Scheme 3.16). The oxazole 167 
was characterised by NMR spectroscopy and ESI-HRMS analysis and the data were 
consistent with those already reported.72 
Mechanistically, oxidation of substrate 164 at the benzylic position was suggested to occur 
first to give the enamide 166 (Scheme 3.16). A copper-catalysed aerobic oxidation from 
benzylamines was already reported by Fu, and afforded the corresponding amides in good 
yield.73 
 
 
Scheme 3.16. Proposed oxidation of N-benzyl enamine.  
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Subsequently, the formation of the oxazole was proposed to follow an oxidative coupling 
pathway, already reported by the group of Buchwald,74 and Stahl.75 They concurrently 
suggested that Cu(II) could be used as a single-electron oxidant to convert enamide 168 into 
an enamide radical cation 169 (Scheme 3.17), which then cyclised to the radical intermediate 
170. Subsequent oxidation of the radical species 170 using Cu(II) was proposed to give the 
oxazole 171. Further decarboxylation would be required, in our system, to access the oxazole 
product 167 from substrate 164. 
 
 
Scheme 3.17. Buchwald’s reported mechanism for the formation of oxazole 171. 
 
3.3 Introduction to 1H-indoles 
 
Given the success of the Cu(II)-mediated oxidative coupling route with 3H-indoles, the 
approach was extended to prepare related 1H-indoles. 
 
3.3.1 Studies on the 1H-indole motif 
 
Despite a plethora of protocols to prepare 3-substituted indoles, interest still remains in new 
practical procedures with a low environmental impact. While classical methods such as the 
Fischer indole synthesis76 (eq. a, Scheme 3.18) have been used for more than a hundred 
years, the transition metal-catalysed cyclisation of linear enamine precursors has recently 
emerged as a powerful alternative to access the indole motif (eq. b, Scheme 3.18).77 
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Scheme 3.18. a) The Fischer indole synthesis and b) Cross-Dehydrogenative Coupling (CDC) approach to 1H-
indole synthesis. 
 
3.3.2 Glorius’ approach to 1H-indoles 
 
In 2008, Glorius and co-workers reported the efficient synthesis of functionalised indoles 
173 using a palladium-catalysed, intramolecular oxidative coupling (Scheme 3.19).78 A great 
variety of substituted anilides 172 were converted into indoles in excellent yields using 
Pd(OAc)2 (5-10 mol%), Cu(OAc)2 (3 eq) as the oxidant, and K2CO3 (3 eq) as the base. 
Importantly, removing the palladium catalyst from their reactions was detrimental to the 
formation of indoles as only traces of cyclised product were then observed. 
 
 
Scheme 3.19. Glorius’ CDC approach to 1H-indole derivatives. 
 
A plausible mechanism reported by Glorius involves an initial electrophilic palladation of 
the nucleophilic enamine 172, followed by deprotonation to give intermediate A (Scheme 
3.20). Intramolecular C–H activation gives palladacycle B and subsequent reductive 
elimination generates the indole product 173 and a Pd0 complex. The stoichiometric amount 
of Cu(OAc)2 plays an essential role to oxidise the Pd
0 back to PdII completing the catalytic 
cycle.  
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Scheme 3.20. Mechanism suggested for the cross-dehydrogenative palladium-catalysed coupling reaction to 
indoles 173. 
 
3.3.3 Other routes to 1H-indoles 
 
Following Glorius’ seminal report on the CDC approach to 1H-indoles, many groups have 
studied this transformation and have extended the scope of the reaction. Cacchi and co-
workers accomplished the synthesis of indoles 173 from N-aryl enaminones 172 via an 
intramolecular copper-catalysed aryl C–H functionalisation process (Scheme 3.21).79 Zhao 
et al. disclosed a PhI(OAc)2-mediated oxidative coupling to transform N-aryl enamines 172 
into 1H-indoles 173.80 Iodine-mediated cyclisation to 1H-indoles was also studied by Chan81 
and Li.82 
Most recently, the Yoshikai group reported an expedient assembly of indole rings 173 from 
imine precursors 174 via a Pd-catalysed approach, allowing considerable broadening of the 
substrate scope (no need for substitution at C3, even though tolerated).83 Their catalytic 
system was also found to work in the cyclisation to form pyrrole derivatives.83b 
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Scheme 3.21. Other routes to 1H-indoles from N-aryl enamines or imines. 
 
3.4 A copper(II)-mediated oxidative coupling approach to 1H-indoles 
 
3.4.1 Proposed synthetic route to 1H-indoles 
 
Given the success of the Cu(II)-mediated cyclisation to 3H-indoles (eq. a, Scheme 3.22), the 
construction of related 1H-indoles was envisioned (eq. b, Scheme 3.22). The only difference 
between both reactions would reside in the nature of the N-aryl enamines involved in the 
copper(II)-mediated cyclisation process. While R2 cannot bear a hydrogen at C3 for the 
formation of 3H-indoles, it would be a requirement for the synthesis of 1H-indoles. It was 
assumed that after initial cyclisation of enamine 172, the 3H-indole intermediate 175 would 
tautomerise and give the aromatic 1H-indole 173. 
 
 
Scheme 3.22. Proposed route to 1H-indoles from N-aryl enamines.  
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3.4.2 Preliminary studies and optimisation of the reaction conditions 
 
Preliminary studies for the formation of indoles using a copper(II)-mediated oxidative 
coupling was envisioned. The readily prepared N-aryl enamine 172a was used to optimise 
the reaction. Treatment of commercially available ethyl benzoylacetate (176) with aniline 
(151) in presence of a catalytic amount of p-TSA afforded the known enamine78 172a in 
moderate yield (Scheme 3.23). 
 
 
Scheme 3.23. Synthesis of enamine 172a from aniline and ethyl benzoylacetate. 
 
With practical quantities of precursor 172a in hand, the proposed Cu(II)-mediated oxidative 
coupling approach for the synthesis of 1H-indoles was tested. The reaction of ethyl (2Z)-3-
phenyl-3-(phenylamino)prop-2-enoate (172a) with Cu(2-ethylhexanoate)2 gave the desired 
product but only in a moderate 54% yield (entry 1, Table 3.2). Varying the copper salt to 
Cu(OAc)2·H2O significantly improved the yield of the cyclisation to 69% (entry 2). As 
noticed earlier while optimising conditions of 3H-indoles, reducing the amount of copper(II) 
in the reaction significantly lowered the yield of the cyclisation product (entry 3). Pleasingly, 
when the reaction was carried out without copper salt, only decomposition of the enamine 
substrates was observed (entry 4). It should be noted that all reactions were carried out under 
air atmosphere, without a CaCl2 drying trap fitted to the reaction condenser. Indole 173a was 
purified by column chromatography and fully characterised. Pleasingly, the data were 
consistent with those reported by Glorius.78 
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Table 3.2. Optimisation of the reaction conditions for the cyclisation of enamine 172a. 
 
entry Cu-source (eq) time (h) yield (% 173a)a 
1 Cu(2-ethylhexanoate)2 (1 eq) 2 54 
2 Cu(OAc)2·H2O (1 eq) 2 69 
3 Cu(OAc)2·H2O (0.1 eq) 3 17 
4 - 2 0 (decomp.) 
a Yield of isolated product. 
 
3.4.3 Scope of the cyclisation process 
 
Having established successful conditions for the cyclisation on the model system 172a, the 
substrate scope using a variety of enamine precursors 172a-f was investigated. Cyclisation 
of electron-rich enamine 172b occurred in a moderate 34% yield (173b, Scheme 3.24). 
Different groups at C2 were also tolerated. Thus, 4-substituted phenyl (172c-d), 2-
thiophenyl (172e), and 4-pyridinyl (172f) substrates delivered the cyclised products in good 
yields. Compounds 173b, 173d-f were novel and were fully characterised. 
 
Scheme 3.24. Scope of the cyclisation reaction for the formation of 1H-indoles.  
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3.5 Conclusion 
 
An efficient oxidative coupling reaction from easily accessible N-aryl enamines has been 
clearly demonstrated and represents a facile method for the synthesis of indole-based 
heterocycles. A wide range of readily available β-ketoester and aniline components can be 
used to prepare the enamine precursors. Furthermore, this oxidative coupling method also 
has the advantage of employing a very inexpensive and air-stable copper salt. Reaction 
conditions were optimised with respect to catalyst loading, temperature, solvent and time: 
Cu(2-ethylhexanoate)2 (1 eq), mesitylene, 170 °C, 2 h, were found to be the optimal 
conditions for the cyclisation to proceed in high yields. Some limitations of this oxidative 
coupling process have been established. Notably, the design of the enamine precursor has 
been shown to require an aryl group at C2. The presence of a hindered pseudo-spirocyclic 
centre in the enamine precursor had a detrimental impact on the cyclisation. With the 
exception of 148a, all cyclised products are novel compounds and were fully characterised. 
The structure of one indolenine product was proved by X-ray analysis.  
With only minor condition changes, a range of 1H-indoles have also been prepared with 
Cu(OAc)2·H2O as the preferred reagent. Four of these compounds were novel. 
Finally, the rapid access to indole derivatives using inexpensive metal salts could be of 
relevance for further application in the synthesis of biologically active compounds. 
The work in this Chapter has recently been published.84 
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Chapter 4. Studies towards the total synthesis of rankinidine 
 
4.1 Introduction 
 
4.1.1 Gelsemium alkaloids 
 
The genus Gelsemium, which belongs to the plant family Loganiaceae, comprises three 
species: Gelsemium elegans, widespreaded over Southeast Asia, together with Gelsemium 
rankinii and Gelsemium sempervirens, both of which grow in the southeastern part of the 
United States of America. More than seventy alkaloids have been isolated from all 
Gelsemium species. These have been classified into six types according to their diverse 
chemical structures: sarpagine-, koumine-, humantenine-, gelsedine-, gelsemine-, and 
yohimbane-type alkaloids (Figure 4.1).85 In addition to either an indole subunit, e.g. in 
koumidine (177), koumine (178) and sempervirine (184), or an oxindole motif, e.g. in 
humantenine (179), rankinidine (49), gelsedine (180), gelsemicine (181), gelsevirine (182) 
and gelsemine (183), these compounds also possess highly strained polycyclic structures to 
complete their complex alkaloid skeletons. 
 
 
Figure 4.1. Representative Gelsemium alkaloid types. 
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4.1.2 Biological activity of Gelsemium alkaloids 
 
From a medicinal perspective, the Gelsemium elegans plant itself has been used in traditional 
Chinese medicine for certain kinds of skin ulcers. Recently, some pharmacological effects, 
exhibited by extracts of G. elegans, including analgesic,86 anti-inflammatory,86 and cytotoxic 
activities,87 have been reported. It has been previously proved that extracts of G. elegans 
form the basis of ‘Yakatsu’, one of the ancient medicines stored in the Shosoin repository in 
Japan.88 G. sempervirens and G. rankinii have also been used in the treatment of neuralgia 
and migraines, as well as spasmodic disorders such as asthma. However, in addition to their 
useful medicinal properties, it has been known for more than a century that these plants also 
cause death in both humans and livestock. Gelsemicine (181) (Figure 4.1) represents the first 
toxic component of the G. sempervirens extract, isolated by Chou in 1931.89 
 
4.2 Biomimetic approaches to Gelsemium alkaloids 
 
4.2.1 Biosynthesis of monoterpenoid indole alkaloids 
 
In 1979, Zenk et al. proposed a biosynthetic pathway towards monoterpenoid indole 
alkaloids 185 and 186 (Scheme 4.1). In this context, by condensation of tryptamine (121) 
with secologanin (187), two epimers at the C3 position, strictosidine (185) and vincoside 
(186), were formed.90 
 
 
Scheme 4.1. Proposed biosynthesis of strictosidine (185) and vincoside (186). 
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4.2.2 Biosynthesis of Gelsemium alkaloids 
 
In 1988, Ponglux et al. extended this biosynthetic route to most types of gelsemium alkaloids 
(Scheme 4.2).91 The intermediate strictosidine (185), previously reported by Zenk et al., 
serves as a precursor to sarpagine-type indole alkaloids, such as koumidine (177). 
Metabolism of koumidine (177) via C/D ring-opening, leads to intermediate 19-Z-
taberpsychine (188). Subsequently, transformation of indole 188 via an oxidative 
rearrangement to oxindole and N-methoxylation, gives rise to the humantenine-type 
alkaloids humantenine (179), humantenirine (189), and rankinidine (49).92 Expanding their 
research to gelsedine-type alkaloids, Ponglux et al. proposed that gelselegine (190) could be 
derived from humantenine-type alkaloids. As such, access to gelselegine (190) occurs by a 
rearrangement of C21 to the exo-position in the D ring of humantenine-type oxindole 
alkaloids. At this point, construction of gelsedine-type alkaloids is believed to proceed by 
loss of the C21 carbon present in gelselegine (190). 
 
 
Scheme 4.2. Ponglux’s proposed biosynthetic route to Gelsemium alkaloids.  
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4.2.3 First synthesis of Gelsemium alkaloids using a biomimetic approach 
 
In light of Ponglux’s proposed biosynthetic route to Gelsemium alkaloids, Takayama et al. 
reported a synthetic procedure for the conversion of the sarpagine-type indole alkaloid 191 
into the oxindole alkaloids gelselegine (190) and gelsedine (180). Gardnerine (191) was first 
transformed into 19-E-koumidine (177) by a six-step sequence in 62% overall yield (Scheme 
4.3).93 Overall, this sequence involved one structural change, namely removal of the aryl 
methyl ether to form the intermediate 192, following Fujita’s procedure.94 
 
 
Scheme 4.3. Conversion of gardnerine (191) into 19-E-koumidine (177). 
Reagents and conditions: (a) Ac2O, py., rt, 8 h, 97%; TsCl, n-Bu4NHSO4, 50% aq. KOH-benzene, rt, 3 h, 
98%; (b) AlCl3, EtSH, CH2Cl2, −18 °C, 3 h, 91%; (c) Tf2O, Et3N, CH2Cl2, −20 °C, 10 min, 97%; (d) Pd(OAc)2, 
DPPF, Et3N, HCO2H, DMF, 60 °C, 2 h, 98%; (e) LAH, THF, reflux, 6 h, 95%. 
 
19-E-Koumidine (177) was treated with 2,2,2-trichloroethyl chloroformate in the presence 
of magnesium oxide in aqueous THF to generate the ring-opened compound 193 in 94% 
yield (Scheme 4.4).95 Dihydroxylation of the exocyclic alkene and the indole C–C double 
bond in 193 with osmium tetroxide (2 eq) afforded the oxidative rearranged oxindole 195 in 
39% yield as well as indole diol 194 in 28% yield where oxidation of the indole nucleus had 
not taken place. However, partially-reacted product 194 could be further transformed to 
oxindole 195 by treatment with osmium tetroxide.  
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Scheme 4.4. The synthesis of Gelsemium alkaloids using a biomimetic route. 
 
With the diol 195 in hand, olefin 196 was obtained via a three-step sequence in 75% overall 
yield (Scheme 4.5). More specifically, treatment of diol 195 with trimethyl orthoformate and 
pyridinium p-toluenesulfonate furnished an orthoester functionality, which was then 
transformed into the humantenine-type intermediate 196 following treatment with acetic 
anhydride and aqueous potassium hydroxide. Conversion of humantenine-type structure 196 
into gelselegine (190) was achieved in eight more steps in 11% overall yield.  
 
 
Scheme 4.5. Biomimetic synthesis of Gelsemium alkaloids gelselegine (190). 
 
In keeping with the biosynthesis proposed by Ponglux et al., the C21 carbon of gelselegine 
(190) was oxidatively cleaved with sodium periodate in 64% yield and afforded gelsenicine 
(197) (Scheme 4.6). Gelsedine (180) itself was then obtained by catalytic hydrogenation of 
the imine 197 in quantitative yield. 
  
71 
 
Scheme 4.6. Biomimetic synthesis of gelsenicine (197) and gelsedine (180) from gelselegine (190). 
 
4.3 Humantenine-type Gelsemium alkaloids 
 
Present in G. elegans, G. rankinii, and G. sempervirens species, humantenine-type alkaloids 
have been the subject of many investigations over several decades. In 1989, Lin et al. 
disclosed the isolation and structural elucidation of seven new humantenine-type alkaloids 
from G. elegans (Table 4.1).96 Structurally, humantenine-type alkaloids contain a spirocyclic 
junction linking a strained tricyclic core appended to the oxindole unit, differing only in the 
substituents on the nitrogen atoms and the benzene ring. 
 
Table 4.1. Humantenine-type alkaloids from G. elegans. 
 
R1 R2 R3 Gelsemium alkaloids ref number 
H H H N-desmethoxyrankinidine 198 
OMe H H rankinidine 49 
OMe H OH 11-hydroxyrankinidine 199 
OMe Me H humantenine 179 
OMe Me OH 11-hydroxyhumantenine 200 
OMe H OMe humantenirine 189 
OMe Me OMe 11-methoxyhumantenine 201 
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4.3.1 Rankinidine (49): a humantenine-type Gelsemium alkaloid 
 
The first isolation of rankinidine (49) from the species G. rankinii was reported by Schun 
and Cordell in 1986.92 Lin et al. then isolated rankinidine (49) and humantenine (179) from 
G. elegans.96 Despite the occurrence of rankinidine (49) in both G. rankinii, and G. elegans, 
the biological profile of rankinidine (49) has not yet been established as it was found to 
decompose rapidly. 
 
4.3.2 Structure elucidation 
 
Rankinidine (49) was first isolated from the dried stem of G. rankinii as white needles.92 The 
structure of the alkaloid 49 was elucidated by comparison of spectroscopic data with other 
humantenine-type alkaloids, previously isolated from G. rankinii (Figure 4.2). The IR 
spectrum showed absorptions at 3300, 1722, 1716, 1698, 1466, 753 cm-1, and UV 
absorptions at 217 and 256 nm, characteristic of an oxindole nucleus. This spirocyclic 
oxindole 49 was assigned the molecular formula C20H24N2O3 by mass spectrometry and 
displayed a molecular ion peak at 340. Concerning the 1H NMR spectroscopic data, 
comparison of rankinidine (49) with humantenine (179) revealed similar proton signals. The 
key difference was the disappearance of the methyl group (R = H) in rankinidine (49). 
 
 
Figure 4.2. Structure elucidation of rankinidine (49). 
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4.4 Retrosynthetic analysis and strategy 
 
The strategy, chosen for the synthesis of rankinidine (49), is both novel and challenging. The 
copper(II)-mediated cyclisation was planned as the key step of the proposed strategy towards 
the total synthesis of spirocyclic oxindole 49. However, owing to the intricate nature of this 
target, an earlier stage spirooxindole cyclisation was studied. Retrosynthetically, the 
polycyclic rankinidine (49) structure will be formed by an intramolecular hemiketalisation 
of a primary alcohol with a ketone, followed by deoxygenation, removal of all protecting 
groups and N-methoxy bond formation will be envisioned from substrate 202 (Scheme 4.7). 
The bridging six-membered piperidine ring will be introduced by a radical cyclisation from 
enone 203. 
 
 
Scheme 4.7. Proposed retrosynthesis of rankinidine (49) from enone 203. 
 
The side chain used for the ring closure will be derived from the alkylation step of oxindole 
intermediate 205 using the readily available allyl bromide 204 (Scheme 4.8). An aziridine 
ring-opening will be used to introduce the alcohol-containing side-chain and the N-protected 
amine in 205 from spirooxindole 206. 
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Scheme 4.8. Proposed retrosynthesis of compound 203 from intermediate 206. 
 
Installation of the C–C double bond in enone 206 will utilise the in situ formation of an 
enolate and a subsequent Saegusa or selenium-based oxidation process (Scheme 4.9). The 
aziridine 207 could be derived from the corresponding alkene 48. 
 
 
Scheme 4.9. Proposed retrosynthesis of compound 206 from the spirocyclic oxindole 48. 
 
The key step is the formation of the oxindole 48 utilising the copper(II)-mediated C–H, Ar–
H functionalisation methodology, which is expected to proceed from anilide 47 and directly 
install the 3-oxindole quaternary stereogenic centre in spirocyclic oxindole 48 (Scheme 
4.10). The ring-closing metathesis of diene will install the key olefin functionality in 
oxindole 48. The diene intermediate will come from the installation of an allyl group in α-
position of β-keto amide 208. 
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Scheme 4.10. Proposed retrosynthesis of spirocyclic oxindole 48 from the anilide 208. 
 
Disconnection of the amide bond in anilide 208 then generates two fragments: N-protected 
aniline 98 and masked β-keto acid 209 which is expected to come from acylation of 
Meldrum’s acid (210) with the corresponding carboxylic acid 211 (Scheme 4.11). The 
convergent nature of this synthesis and the structural features of the intermediates offer the 
potential to alter the order of steps at many stages in the actual synthesis. 
 
 
Scheme 4.11. Proposed retrosynthesis of anilide 208 from the carboxylic acid 211. 
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4.5 Rankinidine model studies 
 
4.5.1 Model studies for the formation of spirocyclic oxindole 
 
The feasibility of installing the spirocyclic carbocyclic junction in different 3,3-disubstituted 
oxindole models via a copper(II)-mediated C–H, Ar–H functionalisation method was 
initially investigated. Knowing already that a series of spirolactams could be accessed using 
the cyclisation process (Scheme 1.13),21 applying the same optimised conditions for the 
cyclisation of 2-oxocarbocyclic-containing precursors to give spirooxindoles 212-214 was 
envisaged. The synthesis of spirocyclic oxindole 214 is particularly important as it is directly 
related to rankinidine (49) by the common 7-membered ring spiro-junction at C3 (Figure 
4.3). It should be noted that this methodology should also be useful for the synthesis of 
Satavaptan (215) and this research is now on going in the Taylor group. 
 
 
Figure 4.3. Proposed models for the copper(II)-mediated cyclisation. 
 
4.5.1.1 Strategy for the synthesis of the anilide cyclisation precursors 
 
A one-step MMC/amide coupling sequence was applied to the synthesis of mono-anilide 
102. As described in the previous Chapter, this strategy was also used for the formation of 
bis-anilide precursors (entries 1-3, Table 4.2). Conducting the reaction on larger scale was 
tolerated and offered sufficient amounts of anilides to test the cyclisation reactions. 
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Table 4.2. Substrate scope for the synthesis of anilide precursors. 
 
entry PG n product yield (%)a 
1 Bn 1 102d 15 
2 Me 2 102a 30 
3 Me 3 102c 34 
a Yield of isolated products. MMC = methyl magnesium carbonate. 
 
4.5.1.2 A copper(II)-mediated oxidative coupling to N-methoxyoxindoles 
 
The copper(II)-mediated C–H, Ar–H oxidative coupling reaction was next examined. 
Pleasingly, the cyclisation proceeded in good yields (entries 1-3, Table 4.3). Cu(OAc)2·H2O 
(1 eq) in toluene at 110 °C gave the best cyclisation results. The 7-membered ring cyclisation 
of rankinidine model system 102c, was investigated in more detail. Remarkably, lowering 
the temperature to 50 °C and extending the reaction time to 12 h still gave spirooxindole 214 
in 12% yield. With regard to a potential asymmetric synthesis of rankinidine (49), dropping 
the temperature of the reaction may maximise the opportunity to induce stereoselectivity 
during the copper(II)-mediated cyclisation process to the spirooxindole. Of interest for the 
formal synthesis of satavaptan (215), the cyclohexanone-containing spirocyclic oxindole 
213 was obtained in 65% yield, confirming the viability of the proposed route. 
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Table 4.3. Scope and optimisation of the oxidative cyclisation process. 
 
entry PG n product yield (%)a 
1 Bn 1 212 56 
2 Me 2 213 65 
3 Me 3 214 66b 
a Yield of isolated products. b A test reaction was carried out and lowering the 
temperature to 50 °C and extending the reaction time to 12 h still gave spirooxindole 
214 in 12% yield. 
 
Thus, access to the spirocyclic oxindole core utilising the copper(II)-mediated radical 
cyclisation methodology was successfully investigated and a number of model compounds 
were prepared successfully. 
 
4.5.2 Studies towards the N-methoxyoxindole scaffold 
 
N-Alkoxyoxindoles are versatile building blocks, found in a wide range of alkaloids such as 
gelsedine-type85 or notoamide-type.97 These scaffolds represent excellent targets in the 
search for new drug candidates. For example, N-hydroxyoxindole derivatives have been 
found to be active against sclerosis.98 They have also been studied as alternative coupling 
reagents for peptide bond formation.99 Only a few methods have been described so far for 
the synthesis of this feature.100 
 
4.5.2.1 Cyclisation processes for the formation of N-methoxyoxindoles 
 
Of particular interest, N-methoxyoxindoles 217, a key structural feature of rankinidine (49), 
were synthesised for the first time by Kikugawa et al. in 1984 via electrophilic aromatic 
substitution with a nitrenium ion generated from N-chloro-N-methoxyamides.101 Although 
this method is widely used, the outcome is strongly dependent on the substitution pattern of 
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the phenyl ring. N-Methoxyoxindole 217 can also be prepared by copper-catalysed 
intramolecular N-arylation of hydroxamates.102 In 2008, Yu et al. disclosed a C−H amination 
procedure for the preparation of β-, γ-, and δ-lactams employing Pd-catalysed C−H 
activation reactions (Scheme 4.12).103 Treatment of hydroxamates 216 with Pd(OAc)2 (10 
mol%), CuCl2 (1.5 eq) and AgOAc (2 eq) afforded N-methoxyoxindoles 217 in good yields 
(72-96%). 
 
 
Scheme 4.12. Lactamisation of aryl C–H, and N–H bonds to afford N-methoxyoxindoles. 
 
4.5.2.2 The synthesis of N-methoxyoxindoles from unprotected oxindoles 
 
Of particular relevance, Sakai et al. reported the oxidation of unprotected oxindole 218 to 
give N-methoxyoxindole 220 via intermediate 219 in a four-step sequence in 47% overall 
yield (Scheme 4.13).95b Lactam 218 was reduced with BH3∙SMe2 and the resultant amine 
219 was oxidised using a urea-hydrogen peroxide complex, in the presence of sodium 
tungstate.104 Subsequent O-methylation with diazomethane yielded the N-methoxyoxindole 
220 in 61% overall yield from indoline 219. 
 
 
Scheme 4.13. Sakai’s synthesis of N-methoxyoxindole. 
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4.5.2.3 A copper(II)-mediated cyclisation process to N-methoxyoxindoles 
 
We decided to investigate a different approach for the formation of N-methoxyoxindoles via 
a copper(II) oxidative coupling process from anilide precursors (Scheme 4.14). It was 
envisaged that N-methoxyoxindole 221 would potentially be accessed using a copper(II)-
mediated oxidative process from anilide 222. Disconnection of the anilide 222 at the amide 
functionality would lead to N-methoxyaniline 223 and the respective carboxylic acid 109. 
 
 
Scheme 4.14. Preliminary disconnection strategy to N-methoxyoxindole. 
 
4.5.2.4 Initial studies for the synthesis of anilide 222 from N-methoxyaniline 
 
Initial studies towards the preparation of oxindole 221 commenced with the synthesis of 
readily available N-methoxyaniline 223.105 The requisite 4-nitrobenzo-O-methyl 
hydroxamic acid 225 was obtained in good yield by acylation of methoxylamine with acid 
chloride 224 (Scheme 4.15). Then, a copper(I)-catalysed C−N bond formation between 
hydroxamate 225 and iodobenzene afforded 226 in 40% yield.106 The resulting N-aryl 
hydroxamate 226 was successfully converted into O-methyl-N-phenylhydroxylamine (223) 
via hydrazinolysis.  
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Scheme 4.15. Synthesis of O-methyl-N-phenylhydroxylamine (223). 
 
With compound O-methyl-N-phenylhydroxylamine (223) in hand, the amide coupling 
between aniline 223 and 3-ethoxy-2-methyl-3-oxopropanoic acid (109) was next 
investigated (Scheme 4.16). Aniline 223 was added to a mixture of acid 109 and N,N′-
dicyclohexylcarbodiimide (DCC) in dichloromethane. Disappointingly, no reaction was 
observed after 24 h. Further heating also failed to promote the reaction, and instead led to 
decomposition of the starting material. 
 
 
Scheme 4.16. Attempts towards the synthesis of anilide 222. 
 
4.5.2.5 Revised route towards the synthesis of N-methoxyanilide  
 
Given the synthetic difficulties encountered with the formation of anilide 222 discussed 
above, the focus was transferred to a different disconnection approach whereby N-
methoxyanilide 222 would result from the cross-coupling of O-alkyl hydroxamates 228 with 
aryl iodides 227a or phenylboronic acid 227b (Scheme 4.17).  
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Scheme 4.17. Retrosynthetic analysis for the synthesis of anilide 222. 
 
Hydrolysis of commercially available diethyl methylmalonate (229) and treatment of the 
resulting mono-acid with oxalyl chloride afforded the acid chloride 230 (Scheme 4.18). The 
acid chloride 230 was successfully converted into the corresponding hydroxamate 228 in 
51% yield via slow addition of acid chloride 230 into a cooled solution of methoxylamine 
(3 eq) and triethylamine (4.5 eq). Alternative conditions using DCC, T3P and Mukaiyama’s 
coupling agent were unsuccessful. 
 
 
Scheme 4.18. Synthesis of hydroxamate 228. 
 
Access to practical quantities of hydroxamate 228 was crucial in order to be able to 
thoroughly examine a number of methods for the preparation of substrate 222. Initial 
investigations examined C−N cross-coupling of hydroxamate 228 with iodobenzene (entry 
1, Table 4.4) using the procedure developed by Katkevics.102, 106 The desired anilide 222 was 
isolated in 33% yield. An alternative approach, first reported by Chan and Lam in 1998,107 
using a source of copper(II) and arylboronic acid, was next explored. However, the isolated 
yield was lowered to 23% (entry 2, Table 4.4). Reported by Tomkinson et al., the use of 
palladium(II) was found to promote C−N cross coupling in the presence of Xantphos (1.5 
mol%), with a low catalyst loading (1 mol%).108a Unfortunately, a lower yield was observed 
using Tomkinson’s procedure (entry 3, Table 4.4). CuI was also used as the C−N cross-
coupling promotor, but no improvement in yield was observed (entry 4, Table 4.4).108b 
Subsequently, a one-pot coupling reaction/cyclisation sequence, using a stoichiometric 
amount of Cu(OAc)2∙H2O, was investigated (entries 5-6, Table 4.4). By heating the reaction 
to 110 °C in DMF or 120 °C in toluene, with or without addition of base, the amide bond 
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formation and concomitant cyclisation to oxindole product 221 was unsuccessful. Traces of 
anilide 222 was observed in both cases. 
 
Table 4.4. Optimisation for the synthesis of anilide 222. 
 
entry catalyst (mol%) ligand (mol%) basee solvent (°C) yield (%)f 
1a Cu2O (10) DMEDA (20)c K2CO3 toluene (80) 33 
2b Cu(OAc)2 (100) - - DMF (60) 23 
3a Pd(OAc)2 (1) Xantphos (231) (1.5) Cs2CO3 1,4-dioxane (80) 11 
4a CuI (5) 1,10-phen (50)d Cs2CO3 DMF (80) 10 
5b Cu(OAc)2·H2O (100) - piperidine DMF (110) 8 
6b Cu(OAc)2·H2O (100) - - toluene (120) 7 
a The reaction was carried out using 1.2 to 3 eq of 227a. b The reaction was carried out using 1.2 eq 
of 227b. c DMEDA = N,N’-dimethylethylenediamine. d 1,10-phen = 1,10-phenanthroline. e An 
excess of base was used in the reaction (5 to 10 eq). f Yield of isolated product. 
 
4.5.2.6 Copper(II)-mediated cyclisation of 222 to give N-methyloxindole 221 
 
With sufficient quantities of N-methoxyanilide 222 prepared via the Cu2O method, the 
proposed cyclisation to oxindole 221 was investigated. Using a stoichiometric amount of 
Cu(OAc)2∙H2O in toluene under air at reflux, the presence of cyclised product 221 was 
detected in the 1H NMR spectrum of the unpurified reaction mixture (entry 1, Table 4.5). 
Despite all efforts, oxindole 221 was found to be inseparable from the starting material 222. 
Although, replacing the copper source by Cu(II) 2-ethylhexanoate enhanced the conversion 
of the cyclisation to completion, unfortunately the isolated yield for both catalytic (entry 2) 
or stoichiometric (entry 3) procedures, was particularly poor owing to partial decomposition. 
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Table 4.5. Attempts towards the synthesis of N-methoxyoxindole 221. 
 
entry copper source (mol%) base (eq.) yield (%)b 
1 Cu(OAc)2·H2O (100) - 20c 
2 Cu(2-ethylhexanoate)2 (10)a DIPEA (2) 15 
3 Cu(2-ethylhexanoate)2 (200) DIPEA (5) 17 
a Cu(2-ethylhexanoate)2 = [Me(CH2)3CH(Et)CO2]2Cu. b Unless otherwise stated, 
yield of isolated product. c The conversion was not complete even after 18 h, the 
yield represents the inseparable mixture of 222:221 in a 5:1 ratio, respectively. 
 
The novel oxindole 221 was fully characterised by NMR, IR spectroscopy, and ESI-HRMS 
analysis. 1H NMR spectroscopy showed a characteristic deshielded methyl group appearing 
as a singlet at 4.04 ppm, in accordance with the predicted high chemical shift nature of the 
N-OMe group. 
 
4.5.3 A new one-pot oxidation/methylation sequence to N-methoxyoxindoles 
 
4.5.3.1 Lactam oxidation of unprotected oxindoles 
 
The cyclisation reaction conditions were revised, and an alternative route to N-
methoxyoxindole 221 was proposed in which the targeted oxindole could be obtained by 
oxidation of the unprotected lactam 233 to afford the hydroxamic acid 232, followed by a 
methylation step (Scheme 4.19). Formation of protected oxindole 234 could utilise the 
Cu(II)-mediated cyclisation route from anilide 235. 
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Scheme 4.19. Revised route towards N-methoxyoxindole 221. 
 
4.5.3.2 Undheim’s oxidation of cyclic amines for the synthesis of hydroxamic acids 
 
Undheim has reported that a number of cyclic secondary amines 236 can be oxidised to the 
corresponding hydroxamic acids 238 via intermediates 237 using dimethyldioxirane as the 
sole oxidant (eq. a, Scheme 4.20).100b Indeed, dioxiranes have become well established as 
remarkable oxidants, capable of highly selective oxidations, including epoxidations and 
electrophilic O-insertion into non-activated C─H bonds.109 It was proposed that unprotected 
oxindole 233 could be oxidised with DMDO to yield the corresponding hydroxamic acid 
232 (eq. b, Scheme 4.20). Subsequent methylation of the hydroxamic acid 232 could provide 
access to the desired N-methoxyoxindole 221. More recently, Grainger et al. reported an 
iron-mediated peroxide oxidation of nitroxides to the protected N-OMe products.110 
 
 
Scheme 4.20. Undheim’s DMDO oxidation of cyclic secondary amines (eq. a). Proposed route towards N-
methoxyoxindole 221 following Undheim’s procedure (eq.b).  
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4.5.3.3 Attempted oxidation of unprotected oxindole 233 
 
Readily available N-(2,4-dimethoxybenzyl)aniline111 (239) was subjected to Mukaiyama’s 
coupling conditions and afforded anilide 235 in good yield (Scheme 4.21). Next, N-(2,4-
dimethoxybenzyl)oxindoles 234 was prepared using the copper-mediated cyclisation step to 
give N-protected oxindole 234 in moderate yield. Finally, deprotection of the oxindole, 
following Trost’s procedure,112 afforded oxindole 233 in quantitative yield. 
 
 
Scheme 4.21. Synthesis of unprotected oxindole 233. 
 
Initially, a solution of unprotected oxindole 233 in acetone was treated with a solution of 
DMDO (0.05 to 0.07 M in acetone) at 0 °C. After warming to room temperature, the reaction 
mixture was stirred for a further 18 h, but the oxidation of lactam 233 was not observed. 
However, when oxindole 233 was added to a preformed suspension of NaH in THF and 
subsequently treated with a dilute solution of DMDO at 0 °C, analysis of the unpurified 
material by 1H NMR spectroscopy, after 18 h, showed the presence of the unexpected N-
methoxyoxindole 221 (Scheme 4.22). Differentiated from oxindole 233 by the appearance 
of a shifted singlet assigned to the methoxy group at 4.04 ppm, the 1H NMR spectrum of the 
unpurified reaction mixture revealed incomplete oxidation, indicated by the presence of 
recovered starting material. Pleasingly, no evidence of decomposition was detected. Despite 
all efforts, the separation of both compounds was unsuccessful and led to the recovery of a 
mixture of starting material 233 and product 221 in a 1:1 ratio.  
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Scheme 4.22. Synthesis of N-methoxyoxindole. 
 
4.5.3.4 Proposed mechanism for the formation of N-methoxyoxindole 221 
 
The radical reactivity of dioxiranes is well-known. In 1991, Adam and co-workers reported 
the reaction of dioxiranes with a nitroxide to produce methyl radicals, readily trapped by the 
radical scavenger.113 In agreement, the group of Minisci suggested that the homolytic 
decomposition of the dioxirane occurred in the presence of an aminoxyl radical such as 
2,2,6,6-tetramethyl-1-piperidinyloxy (TEMPO). When TEMPO was used as a trapping 
agent for radicals during the oxidation of alkanes with dimethyldioxirane, no resulting 
alcohols or ketones were observed. Instead, the main reaction product arose from the 
trapping of a methyl radical.114 In their studies on the reaction of aminoxyl with dioxiranes, 
Curci et al. have also found that these radical species react readily with dioxiranes and 
indeed, promote their radical decomposition (Scheme 4.23).115 The formation of 242 could 
be envisaged by homolytic substitution between the aminoxyl 240 and the dioxirane 241 O–
O bond, affording the radical intermediate 242. Driven by the release of CO2, two methyl 
radicals can be generated and subsequently trapped by the radical scavenger 240 to give 
access to the N-methoxy product 243. 
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Scheme 4.23. Curci’s proposed radical decomposition of DMDO in presence of an aminoxyl radical. 
 
In light of Undheim’s oxidation of cyclic secondary amine to hydroxamic acid (eq. a, 
Scheme 4.20) and Curci’s rationalisation on the radical decomposition of DMDO in the 
presence of aminoxyl derivatives, a plausible mechanism for the one-pot 
oxidation/methylation sequence is proposed in Scheme 4.24. First the base is expected to 
deprotonate the lactam 233, which consequently triggers the first oxidation by DMDO and 
form the N-oxide intermediate 244 (Scheme 4.24). Oxidation of N-oxide 244 was suggested 
to give the reactive aminoxyl 245, which would promote the radical decomposition of 
DMDO and generate methyl radicals. Eventually, the aminoxyl scavenger would trap a 
methyl radical and lead to N-methoxyoxindole 221. 
 
 
Scheme 4.24. Proposed mechanism for the formation of N-methoxyoxindole. 
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4.5.3.5 Scope and optimisation of the oxidation/methylation reaction 
 
The scope and optimisation of the reaction conditions was investigated in order to gain 
deeper understanding of this promising oxidation process. Two model substrates were 
chosen for initial investigations, commercially available ε-caprolactam (246) and acetanilide 
(248). However, neither afforded their respective oxidised products 247 and 249 when 
treated with NaH/DMDO and resulted in the recovery of starting material (Scheme 4.25). 
 
 
Scheme 4.25. Attempted oxidation of model substrates 246 and 248. 
 
Attention then moved to the application of this method to the benzo-fused 7-membered 
lactam 252. The use of lactam 252 as a model system is also beneficial since the N-methoxy 
product 253 has previously been fully characterised. Following the reported procedure,116 
tetralone (250) was treated with the HCl salt of hydroxylamine in the presence of sodium 
hydroxide which afforded the oxime 251 in 93% yield (Scheme 4.26). At this point, 
Beckmann rearrangement of substrate 251 gave access to benzo-fused caprolactam 252 in 
83% yield. 
 
 
Scheme 4.26. Synthesis of the benzo-fused caprolactam model 252. 
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With practical quantities of precursor 252 in hand, optimisation of the oxidation reaction 
was next envisioned (Table 4.6). Gratifyingly, the N-methoxyoxindole product 253 was 
observed. Significant differences in yield were observed by altering the number of 
equivalents of DMDO added to the reaction (entries 1-5, Table 4.6). The use of 1.5 eq of 
dioxirane was found to give the best result (entry 3). Subsequent addition of MeOH, 15 min 
after addition of DMDO did not improve the ratio of starting material to product, suggesting 
that the methyl group is not coming from the presence of MeOH in the reaction mixture 
(entry 5). Interestingly, replacing THF with DMF did affect the reaction (entry 6) but not in 
favour of the product 253. The use of DBU as an organic base was tried but no reaction was 
observed (entry 8). However, the ratio was significantly improved using different inorganic 
bases (entries 8-9). Indeed, the use of NaHMDS in place of NaH, improved the ratio to 1.5:1 
252:253. For comparison, switching from DMDO to m-CPBA (entry 10) resulted in the 
exclusive recovery of starting material. Pleasingly, the data for compound 253 were 
consistent with those already reported by Togo.117 
Table 4.6. Optimisation of the oxidation/methylation steps by DMDO. 
 
entry base (eq) solvent eq of DMDO ratio (252:253)b 
1 NaH (2.1) THF 0.5 23:1 
2 NaH (2.3) THF 1 6:1 
3 NaH (1.3) THF 1.5 3:1c 
4 NaH (1.5) THF 2 7:1 
5 NaH (1.05) THFa 3 11:1 
6 NaH (1.05) DMF 1.5 18:1 
7 DBU (1.05) toluene 1.5 252 
8 LHMDS (2) THF 1.5 2.5:1 
9 NaHMDS (2) THF 1.5 1.5:1 
10 NaH (2.6) THF m-CPBA (1.2) 252 
a MeOH (0.5 mL) was added 15 min after DMDO was added to the reaction. b Unless 
otherwise stated, ratio of 252:253 calculated using the 1H NMR of the unpurified reaction 
mixture. c Purification by column chromatography of the separable mixture afforded the 
lactam 252 and N-methoxylactam 253, in 59% and 18% yields, respectively.  
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4.5.3.6 Suggested DMDO oxidation route to N-methoxycaprolactam 253 
 
Reported by Aue et al., peracid oxidation of an imino ether promoted the formation of the 
corresponding hydroxamic acid albeit in low yield.118 Therefore imidate 254 was prepared 
from lactam 252,119 and treated with DMDO; however, the formation of the N-methoxy 
product 253 was not observed (Scheme 4.27). 
 
 
Scheme 4.27. Proposed dimethyldioxirane oxidation of imidate 254. 
 
Analysis of the unpurified reaction mixture by 1H NMR spectroscopy showed the presence 
of lactam 252, resulting from hydrolysis, as well as another side-product. The molecular 
formula of the sodium salt was established as C12H15NNaO4 through ESI-HRMS analysis, 
suggesting that over-oxidation had taken place since three extra oxygen atoms were present. 
1D and 2D NMR spectroscopic data were consistent with the cleavage of the amide 
functionality and rationalised by the loss of the proton from the amide at 7.88 ppm. Besides, 
a new signal at 173.1 ppm in the 13C NMR spectrum suggested the presence of an ester 
functionality (an IR stretch at 1729 cm-1 was also observed). Two characteristic N–O 
stretching bands were identified respectively at 1524 and 1345 cm-1 which suggested that 
the product was ester 258. Comparison with the known methyl ester120 equivalent of 258 
confirmed the structure of the latter. Reviewed by Murray,121 dimethyldioxirane can oxidise 
primary amines to nitro compounds. Mechanistically, the process is believed to involve a 
succession of oxygen atom transfers. Although, unprecedented, it is proposed that the 
transformation of imino ether 254 to afford the ortho-nitro phenyl compound 258 took place 
using a similar pathway. The first equivalent of DMDO could oxidise the imidate nitrogen 
to give the radical intermediate 255 (Scheme 4.28). Driven by the loss of acetone and the 
excess of DMDO, the lactam ring could open and lead to intermediate 256. With an excess 
of DMDO in the reaction mixture, the nitroso functionality present in intermediate 257 could 
be oxidised further to the nitro compound 258. 
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Scheme 4.28. Proposed mechanism for the formation of the ortho-nitro ethyl ester 258. 
 
As a result of the prevalence of the N-methoxyoxindole feature in Gelsemium alkaloids, the 
development of a new methodology for the oxidation of the oxindole nucleus would be of 
considerable value. Further investigations will be required to gain more insight into the 
mechanism of the above processes. To date, this is the only method that consists of a one-
pot oxidation/methylation sequence for the synthesis of N-methoxyoxindoles, although 
further optimisation will be required to improve the transformation into a useful synthetic 
procedure. 
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4.6 Progress towards the total synthesis of rankinidine (49) 
 
4.6.1 A seven-membered ring formation by a cycloaddition route 
 
In the preliminary studies, cyclisation of the preformed cycloheptanone was used to generate 
the rankinidine core structure 214. However, formation of the required functionalised 
cycloheptanone cyclisation precursor appeared problematic. Therefore, the focus was turned 
to the formation of the requisite seven-membered ring by ring-closure of precursors already 
bearing the required functionalities. Reviewed by Enders et al. in 2013, compounds 
containing a seven-membered ring are commonly found in the cores of naturally occurring 
compounds.122 In comparison with five- or six-membered ring formation, methods available 
to construct seven-membered carbocycles are limited which makes them challenging targets 
for synthetic chemists. With respect to the structure of rankinidine (49), the challenging 
target contains a seven-membered carbocycle embedded in a tricyclic core. Two 
disconnection approaches will be presented, which consist of cycloaddition and a ring-
closing metathesis approaches. 
 
4.6.1.1 Overman’s 7-membered ring closure to (−)-aplyviolene (265)  
 
Reported by Overman et al. in the total synthesis of (−)-aplyviolene (265) in 2012,123 the 
construction of seven-membered carbocycles was accomplished by a 
cycloaddition/fragmentation reaction. Overman’s strategy started with the synthesis of 
precursor 260, obtained in seven steps from inexpensive commercially available (+)-
fenchone (259) (Scheme 4.29). Treatment of intermediate 260 with phenylisocyanate and a 
base promoted the synthesis of isoxazoline 263 via an Intramolecular Nitrile Oxide-Olefin 
Cycloaddition (INOC) reaction, proceeding through intermediates 261 and 262. 
Fragmentation of the new isoxazoline ring was performed by hydrogenation and gave access 
to the β-hydroxy ketone product 264 which was converted into the natural product 
aplyviolene (265) in 17 further steps. 
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Scheme 4.29. Overman’s strategy for the total synthesis of aplyviolene (265). 
 
4.6.1.2 Proposed retrosynthetic pathway for the formation of spirooxindole 205 
 
It was anticipated that a similar approach could be used to prepare spirocyclic oxindole 205, 
potentially a key intermediate in the synthesis of rankinidine (49). Retrosynthetically, enone 
formation and fragmentation of the isoxazoline motif in intermediate 266 would give access 
to spirooxindole 205. Cycloadduct 266 would arise from nitrile oxide 267 which itself could 
be achieved by treatment of aldehyde 268 with hydroxylamine as depicted in Scheme 4.30. 
Our copper(II) chemistry would be employed to prepare oxindole 268. 
 
 
Scheme 4.30. Proposed retrosynthetic pathway to afford spirooxindole 205. 
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4.6.1.3 Synthesis of 3,3-disubstituted oxindole 273 
 
The synthesis of 1,3-dipolar cycloaddition precursor 268 was first required. Anilide 270 was 
prepared by amide coupling between aniline 98 and the carboxylic acid 269 in 73% yield 
using N,N’-dicyclohexylcarbodiimide as the coupling agent (Scheme 4.31). Pleasingly, 
insertion of a 2-carbon containing side chain was achieved via alkylation of substrate 270 
with alkyl iodide 272 in good yield. Oxindole formation from anilide 271 using a copper(II)-
mediated oxidative coupling process led to the cyclised product 273 in 62% yield. 
 
 
Scheme 4.31. Synthesis of oxindole 273. 
 
4.6.1.4 Attempted synthesis of INOC precursor 268 
 
With oxindole 273 in hand, the installation of the keto alkene side chain present in compound 
268 was explored by transformation of the ester functionality. Initial investigation of ester 
hydrolysis to form the corresponding carboxylic acid 274, using sodium hydroxide afforded 
a complex mixture of products (Figure 4.4). Using milder conditions, the hydrolysis of ester 
273, followed by in situ addition of oxalyl chloride to form acid chloride 275 was attempted 
(suitable for a Grignard addition in a later stage). However, conversion into oxindole 275 
was not observed but decomposition of starting material was detected by 1H NMR 
spectroscopic analysis. Reduction of the ester 273 to the corresponding alcohol 276 with 
DIBAL-H was also attempted. However, both the amide and ester functionalities were 
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reduced to the known indole 277 in low yield. 1H NMR spectroscopic data were consistent 
with those already published.124 
 
 
Figure 4.4. Attempted synthesis of oxindoles 274-276. Synthesis of indole 277. 
 
4.6.2 An alternative strategy for the synthesis of oxindole 268 
 
4.6.2.1 Synthesis of oxindole 283 
 
It became apparent that the ester functionality in oxindole 273 had to be replaced. The 
synthesis was adapted by changing the ester with the requisite keto alkene side chain. In this 
context, the synthesis began with the functionalisation of methyl acetoacetate (278). 
Alkylation of the preformed β-keto ester dianionic species with allyl bromide furnished 
compound 279 in 65% yield (Scheme 4.32).125 Basic hydrolysis to give the carboxylic acid 
280, followed by amide coupling using Mukaiyama’s procedure led to anilide 281. 
Alkylation of β-keto amide 281 with tert-butyl(2-iodoethoxy)dimethylsilane (272) provided 
access to the cyclisation precursor 282 in 60% yield. Finally, the copper(II)-mediated 
cyclisation proceeded with moderate efficiency. 3,3-Disubstituted oxindole 283 was fully 
characterised by IR, NMR spectroscopy and ESI-HRMS analysis. 
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Scheme 4.32. Synthesis of 3,3-disubstituted oxindole 283. 
 
4.6.2.2 Attempted access to aldehyde intermediate 268 
 
Desilylation/oxidation of protected alcohol 283 was required next. For initial investigations, 
oxindole 283 was treated with a solution of tetrabutylammonium fluoride. As expected, 
deprotection of the silyl alcohol took place, however ESI-HRMS data were not consistent 
with the expected product 284, supporting a molecular formula of C22H23NNaO4, 16 units 
(also an atom of oxygen) higher than the expected oxindole 284. Analysis of the isolated 
product by 13C NMR spectroscopy showed an absence of a signal corresponding to a ketone 
at ~ 200 ppm and a new signal in the ester region at 172.8 ppm was observed. The presence 
of a quaternary carbon at 75.2 ppm suggested that the product should still be a di-substituted 
oxindole, but the value had shifted 9 ppm downfield compared to the starting material 
(quaternary carbon at 66.2 ppm). A broad IR stretch at 3369 cm-1 suggested the presence of 
a hydroxyl group. The spectroscopic data were consistent with the structure 286. 
Mechanistically, formation of the primary alcohol 284 promoted the direct rearrangement to 
the anionic intermediate 285 which by means of aerial oxidation gave the 3-substituted-3-
hydroxy-2-oxindole 286 with high efficiency (Scheme 4.33). 
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Scheme 4.33. Proposed mechanism for the formation of di-substituted oxindole 286. 
 
Conclusive evidence for the structure was obtained by single crystal X-ray diffraction 
analysis of the product 286 (Figure 4.5). 
 
 
Figure 4.5. Crystal structure of 286 (50% probability ellipsoids, CCDC 1049570). 
 
Support for this mechanism is provided by the report of Buckley et al., who developed a 
method of hydroxylation at the C3 position of mono-substituted oxindoles using aerial 
oxidation in combination with TBAF.126 In their case, the formation of 3-hydroxy-oxindole 
291 is reported to proceed via the catalytic cycle shown in the Scheme 4.34. Treatment of 
oxindole 287 with TBAF afforded the tetrabutylammonium enolate 288. Addition of O2 
promoted the peroxide anion 289 formation. Recombination with a molecule of HF gave 
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peroxide 290 and regenerated TBAF, able to re-enter a new catalytic cycle. Then, they 
proposed the cleavage of the O–O bond by addition of a second enolate 288 which led to 
two molecules of the hydroxylated product 291. 
 
 
Scheme 4.34. Buckley’s proposed catalytic cycle for the formation of 3-hydroxyoxindole 291. 
 
4.6.3 Proposed access to cycloaddition adduct 266 from nitro alkene precursor 
 
In light of these results and in search of a more efficient method for preparing the 
cycloaddition precursor 267, the use of an alternative method was next investigated as shown 
in Scheme 4.35. The nickel-catalysed Michael addition of β-dicarbonyls developed by 
Nelson et al. in 1980 inspired an attempt to perform the conjugate addition of β-keto amide 
281 into nitroethylene.127 The nitrile oxide precursor 267 can be formed directly from the 
nitro group present in oxindole 292 as shown previously by Overman in the synthesis of 
aplyviolene (265) (Scheme 4.29). 
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Scheme 4.35. Proposed retrosynthetic pathway to cycloadduct 266. 
 
4.6.3.1 Synthesis of nitro alkene precursor 292 
 
Nitroethylene was formed by distillation of a mixture of 2-nitroethanol and phthalic 
anhydride heated at 180 °C (DrySyn heating block) under vacuum (106-107 mm Hg). The 
distillate was dried over CaCl2 and could be stored in the freezer for a reasonable period of 
time. Addition of nitroethylene to a premixed solution of 281 with a catalytic amount of 
Ni(acac)2 afforded product 293 in moderate yield (Scheme 4.36). Copper(II)-mediated 
cyclisation of anilide substrate 293 gave access to the desired INOC precursor 292 in 40% 
yield, which was fully characterised. 
 
 
Scheme 4.36. Synthesis of the cycloaddition precursor 292. 
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4.6.3.2 Attempted INOC cycloaddition 
 
With oxindole 292 in hand, the cycloaddition reaction to form the tetracyclic spirooxindole 
266 was attempted. Initially, Overman’s procedure, shown previously in Scheme 4.29, was 
applied, however, decomposition of the starting material was observed (entry 1, Table 4.7). 
Dehydration of the nitro group in oxindole 292 was next envisioned using phosphorus 
oxychloride, and triethylamine.128 Disappointingly, decomposition of starting material was 
also observed (entry 2). Reported by Basel and Hassner in 1997,129 the dehydration 
conditions using (Boc)2O in the presence of DMAP appeared to offer a milder alternative to 
other methods because of the innocuous nature of the side-products (t-BuOH and CO2). 
Applying these conditions to nitro-containing oxindole 292 did not afford the corresponding 
cyclised product 266. Instead, unreacted starting material was recovered after purification 
(entry 3). 
 
Table 4.7. Attempted INOC cyclisation from nitro-containing oxindole 292. 
 
entry dehydrating agent (eq) base (eq) solvent (°C) time (h) yield (% 266) 
1 PhNCO (3) Et3N (5) toluene (110) 1 0a 
2 POCl3 (3) Et3N (5) CHCl3 (rt) 1 0a 
3 Boc2O (2.5) DMAP (0.1) toluene (90) 18 0b 
a Only decomposition was observed. b Decomposition was observed, however some starting 
material was also recovered. 
 
4.6.3.3 Investigation of the INOC reaction with a different substrate 
 
The synthesis of a simpler substrate was envisaged, in order to further investigate the 
cycloaddition reaction. Reported in the total synthesis of gelsemoxonine by Carreira et al. in 
2013,130 intermediate 294 was treated with Boc2O in the presence of DMAP and delivered 
isoxazoline 297. Alcohol activation followed by elimination to give intermediate 295, 
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formation of nitrile oxide 296, and intramolecular dipolar cycloaddition was proposed to 
give access to tricyclic product 297 (Scheme 4.37). 
 
 
Scheme 4.37. Carreira’s INOC reaction strategy. 
 
An alternative INOC precursor 298 was synthesised using the previous strategy. Readily 
available β-keto ester 279 was alkylated by 1,4-conjugate addition into nitroethylene in the 
presence of nickel(II) to give intermediate 298 in 53% yield (Scheme 4.38). Subjecting the 
precursor 298 to Carreira’s cycloaddition reaction conditions were unsuccessful. 
Unfortunately, 1H NMR spectroscopy of the unpurified reaction mixture did not show the 
desired bicyclic product 299, but instead, decomposition was observed. Dehydration of 
substrate 298 was attempted with phenyl isocyanate, but decomposition was again detected. 
 
 
Scheme 4.38. Synthesis of compound nitro-alkene derivative 298. 
 
4.6.4 Suggested 7-membered ring closure by epoxide ring-opening 
 
With the cycloaddition reaction proving problematic, an approach consisting of epoxide 
ring-opening of oxindole 301 towards the key intermediate 300 was investigated (Scheme 
4.39). It was anticipated that upon deprotonation of the alpha position of the nitro group, the 
anion would directly undergo epoxide ring-opening to give the seven-membered 
spirooxindole 300. Oxirane 301 should be available from the epoxidation of the terminal 
alkene present in the INOC precursor 292.  
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Scheme 4.39. Proposed synthetic route to spirocyclic oxindole 300. 
 
4.6.4.1 Attempted synthesis of spirocyclic oxindole 300 
 
Alkene 292 was treated with DMDO to give the terminal oxirane 301 in good yield as an 
inseparable mixture of diastereoisomers in a 1:1 ratio (Scheme 4.40). Formation of the 7-
membered ring was then investigated. Surprisingly, when DBU was used as base, loss of 
nitroethylene was observed by ESI-HRMS analysis. The 1D and 2D NMR spectroscopic 
data of the product were consistent with this observation and suggested the presence of three 
CH2 and one CH left as found in the undesired cyclised product 303. Considering literature 
precedent on THF ring formation by epoxide ring-opening via enolate formation, the enolate 
regioselectivity can be explained based on stereoelectronic effects.131, 132 Indeed, formation 
of a five-membered ring by carbon alkylation of an enolate is unfavourable as the approach 
of the electrophile will take place perpendicularly to the plane of the enolate 302. 
Accordingly, reaction at the enolate oxygen is preferred. It also appeared that the cyclisation 
resulted in the oxirane ring-opening at the sterically more hindered central carbon, liberating 
primary alcohol 303 over the six-membered secondary alcohol. The geometry of the 
exocyclic double bond was not confirmed (the formation of both E-131 and Z-isomers132 have 
been reported). 
 
 
Scheme 4.40. Proposed formation of 3-methyleneoxindole 303.  
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4.6.4.2 Reduction of the ketone functionality in oxindole 292 
 
In response to these unexpected results, reduction of the ketone with NaBH4 was attempted 
to suppress this unwanted side reaction (Scheme 4.41). Unfortunately, loss of the keto-alkene 
side chain was suggested by ESI-HRMS analysis. The molecular formula of the sodium salt 
of the product was established as C17H16N2NaO3. The 
1H and 13C NMR spectroscopic data 
showed an absence of a ketone at ~ 200 ppm and a new CH signal at 72.5 ppm identified as 
a doublet of doublets (J = 8.4, 5.3 Hz) at 3.63 ppm in the 1H NMR spectrum. Two 
characteristic N–O stretching bands were identified respectively at 1550 and 1345 cm-1 
which suggested that the product is oxindole 305. Mechanistically, hydride reduction to give 
the secondary alcohol 304, followed by a retro-aldol-type reaction affords the 3-substituted 
oxindole 305 in good yield. 
 
 
Scheme 4.41. Formation of the unexpected mono-substituted oxindole 305. 
 
4.6.4.3 Acetal protection of the ketone functionality in oxindole 292 
 
To overcome the formation of the product 305, attention was turned to the acetal protection 
of the ketone 292 (Scheme 4.42). Analysis of the unpurified material by 1H NMR 
spectroscopy after treatment of ketone 292 with an excess of ethylene glycol in the presence 
of p-toluenesulfonic acid showed no trace of the desired oxindole 306 but only recovery of 
starting material 292. 
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Scheme 4.42. Attempted acetal protection of the ketone 292. 
 
After unsuccessful attempts to promote seven-membered ring-closing using a range of 
approaches, attention turned to an alternative disconnection strategy, wherein the cyclisation 
of the carbocyclic ring system would take place via Grubbs ring-closing metathesis. 
 
4.6.5 Ring-closing metathesis strategy  
 
4.6.5.1 Snider’s 7-membered ring-closing metathesis towards guanacastepene A (311) 
 
Whilst attention had initially focused on a cycloaddition disconnection, ring-closing 
metathesis was proposed as a new approach to construct the seven-membered carbocyclic 
system. The metathesis reaction has been reported to be an excellent method to promote the 
formation of medium sized ring systems.122 In the formal synthesis of (±)-guanacastepene A 
(311), Snider et al. reported the construction of the central seven-membered ring by ring-
closing metathesis using the first generation Grubbs catalyst (Scheme 4.43).133 Precursor 
308 was completed in a seven-step sequence from iodo alkene 307. To complete the formal 
synthesis of advanced intermediate 310,134 eleven more steps were required from compound 
309. 
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Scheme 4.43. Snider’s formal synthesis of guanacastepene A (311). 
 
4.6.5.2 Proposed retrosynthetic pathway to cycloadduct 312 
 
It was envisaged that cycloadduct 312, containing an alkene for further functionalisation, 
could be prepared from diene 313. Alkylation of β-keto amide 281, followed by the 
copper(II)-mediated oxidative coupling would give access to the metathesis precursor 313 
(Scheme 4.44). 
 
 
Scheme 4.44. Retrosynthetic analysis for the formation of spirocyclic oxindole 312. 
 
4.6.5.3 Synthesis of spirocyclic oxindole 312 
 
Having prepared substrate 281 on large scale, alkylation with allyl bromide afforded anilide 
314 in 83% yield (Scheme 4.45). The following key copper(II)-mediated oxidative coupling 
step proceeded to give the oxindole 313 in moderate yield. Pleasingly, subjecting oxindole 
313 to diene metathesis produced the desired spirofused tricyclic product 312 in 61% yield. 
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Scheme 4.45. Synthesis of spirocyclic oxindole 312 via ring-closing metathesis. 
 
4.6.5.4 Meldrum’s acid variant 
 
Next, the synthetic route was shortened and a more easily removed N-protecting group was 
employed. Acylation of Meldrum’s acid (210) with commercially available and inexpensive 
carboxylic acid 315 using DCC as the coupling agent gave access to the masked β-keto acid 
316 in good yield (Scheme 4.46).135 Heating compound 316 to reflux in 1,4-dioxane, with 
N-protected aniline afforded the corresponding amide 317 in excellent yield. The synthesis 
was pursued using the same route developed previously and through a three-step sequence 
afforded the advanced oxindole precursor 319. Epoxide 320 was also prepared as a potential 
cyclisation precursor. 
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Scheme 4.46. Optimised synthesis of cyclisation precursors 319 and 320. 
 
The formation of oxindoles was then investigated (Scheme 4.47). However, both substrates 
319 and 320 suffered from the issue of anilide hydrolysis. Consequently, the temperature of 
the reaction was decreased to 100 °C and afforded spirocyclic oxindoles 321 and 322, in 
55% and 62% yield, respectively. Both compounds were fully characterised and the 1H NMR 
data for the alkene/epoxide were diagnostic (321, δ 5.68-5.66 ppm; 322, δ 3.01-317 ppm). 
 
 
Scheme 4.47. Synthesis of spirocyclic oxindoles 321 and 322. 
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4.6.6 Preliminary functionalisation around the alkene functionality 
 
4.6.6.1 Retrosynthetic studies towards spirocyclic oxindole 323 
 
The reactivity of the seven-membered ring in spirooxindole 322 was tested in preliminary 
studies, but unfortunately both enone formation and epoxide ring-opening have not been 
successful. Consequently, introduction of a functionalised alkene at an earlier stage was 
investigated. To this end, the synthesis of the seven-membered ring spirocyclic oxindole 323 
was proposed (Scheme 4.48). Initially, the spirocyclic oxindole could be formed from β-keto 
ester 324 via an ester hydrolysis, amide bond formation and copper(II)-mediated cyclisation 
sequence. The formation of ester 324 could be achieved from metathesis of the respective 
diene, which in turn could be synthesised via a double alkylation process between ethyl 
acetoacetate (325) and two different allyl bromide building blocks 326 and 327. 
 
Scheme 4.48. Retrosynthetic pathway to spirocyclic oxindole 323. 
 
4.6.6.2 Attempted synthesis of spirocyclic oxindole 323 
 
The synthesis of allyl bromide 326 began following a well-established protocol.136 
Specifically, Baylis-Hillman reaction between methyl acrylate (328) and paraformaldehyde, 
followed by primary alcohol protection afforded α,β-unsaturated methyl ester 329 in 31% 
over two steps (Scheme 4.49). DIBAL-H reduction of the ester 329 gave the primary alcohol 
330, the treatment of the alcohol with triphenylphosphine and tetrabromomethane gave the 
bromo alkyl product 326. 
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Scheme 4.49. Synthesis of allyl bromide building block 326. 
 
With allyl bromide 326 in hand, alkylation of ethyl acetoacetate (325) was carried out in 
moderate yield using LDA (2 eq) and gave access to β-keto ester 331 (Scheme 4.50). Diene 
332 was obtained via a second alkylation procedure with allyl bromide and yielded 
metathesis precursor 332 as a mixture of keto-enol tautomers in a 1.5:1 ratio, respectively. 
The ring-closing metathesis was performed using the second generation Grubbs catalyst and 
gave the expected seven-membered ring product 324 as a 1.3:1 mixture of keto-enol 
tautomers, respectively. Ester hydrolysis and amide coupling followed by a key copper(II)-
mediated cyclisation step would potentially afford the advanced intermediate 323. 
Unfortunately, at this stage investigation had to be stopped due to lack of time. 
 
 
Scheme 4.50. Synthesis of β-keto ester 324. 
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4.7 Conclusion 
 
An efficient synthetic route to the complex natural product rankinidine (49), which utilises 
the copper(II)-mediated radical cyclisation methodology has been investigated. The 
synthesis of model substrates was successfully undertaken. Disappointingly, when the 
oxidative coupling was applied to the synthesis of N-methoxyoxindole, the cyclisation 
proved more difficult, mainly due to decomposition. An alternative approach, based on 
dioxirane-mediated oxidation of unprotected oxindole proved to be a more successful route 
to access the N-methoxyoxindole scaffold. Unfortunately, this transformation proved 
difficult to optimise. 
An intramolecular cycloaddition approach to more advanced rankinidine precursors proved 
unsuccessful but a reliable and readily scalable route to spirooxindole 322 was undertaken. 
Further studies (cycloheptenone 324) were also successful. These result should form the 
basis for future studies towards the synthesis of rankinidine (49). 
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Chapter 5. Final conclusions and future work 
 
5.1 The synthesis of bis-oxindole derivatives 
 
In light of the work developed by the Taylor group in the area of copper(II)-mediated 
cyclisations to oxindoles, the extension of this method to the synthesis of the structurally 
more challenging bis-oxindoles has been successfully demonstrated. A great diversity has 
been observed in the nature of the central core between both oxindole units, going from a 
rigid system containing cyclic ketones to a more flexible system containing linear mono-
ketone, and di-ester linkers (Figure 5.1). Whereas complete diastereocontrol was observed 
for the formation of the spirocyclic bis-oxindoles, the introduction of more flexible moieties 
in the linker has been shown to be detrimental in maintaining the diastereoselectivity. 
 
 
Figure 5.1. Substrate scope in the copper(II)-mediated formation of bis-oxindoles. 
 
Asymmetric studies, relying on the introduction of a chiral auxiliary on the nitrogen of the 
spirocyclic bis-oxindole precursors 92k has been investigated (Scheme 5.1), but further 
research is needed in this area. 
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Scheme 5.1. Asymmetric studies in the formation of spirocyclic bis-oxindoles. 
 
Future work in this area will focus on the introduction of bulkier chiral auxiliaries on the 
nitrogen and study the impact on the copper(II)-mediated double cyclisation of spirocyclic 
bis-oxindole substrates. A range of α-chiral amines could be tested in order to gain higher 
diastereocontrol (Figure 5.2). 
 
 
Figure 5.2. Examples of α-chiral amines. 
 
5.2 The synthesis of indole derivatives 
 
The extension of the copper(II)-mediated oxidative coupling has been successfully applied 
to the synthesis of indole derivatives. The construction of 3H-indoles 148 and 1H-indoles 
173 has been undertaken through the cyclisation of simple and readily available N-aryl 
enamines (Scheme 5.2). A wide range of cyclised products has been obtained using a copper 
salt as oxidant. 
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Scheme 5.2. A copper(II)-mediated synthesis of 3H- and 1H-indoles. 
 
The extension of the substrate scope to simpler N-aryl enamines could be tested. Also, imine 
precursors instead of enamines will potentially give access to a larger range of indole 
derivatives. The total synthesis of biologically potent indoline natural products would 
present an opportunity to apply this copper(II)-mediated methodology. 
 
5.3 Studies towards the total synthesis of rankinidine (49) 
 
Application of the copper(II)-mediated oxidative coupling to underpin a synthetic approach 
to the spirocyclic oxindole rankinidine (49) has been studied. Access to spirocyclic ketone 
oxindoles containing 5-, 6-, and 7-membered rings has shown promising results for the 
viability of the proposed application. Further investigations on the asymmetric synthesis of 
spirocyclic ketone oxindoles could be also envisioned. 
 
 
Scheme 5.3. Synthesis of spirocarbocyclic oxindoles via a copper(II) oxidative coupling route. 
 
Concerning the formation of N-methoxyoxindoles, a one-pot oxidation/methylation 
sequence using DMDO as oxidant showed great promise (Scheme 5.4). However, the poor 
conversion of this transformation needs to be improved to make it synthetically useful. 
Having already screened a number of different conditions for this reaction, the nature of the 
oxidant could next be investigated. To gain deeper understanding of the mechanism, either 
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the influence of a deuterium labelled dioxirane oxidant or the addition of a radical promotor 
could be investigated. 
 
 
Scheme 5.4. Optimisation of the transformation of unprotected oxindole 333 to N-methoxyoxindole 334. 
 
A possible synthetic route to the natural product rankinidine (49) is proposed in Scheme 5.5 
and the preparation of the functionalised 7-membered ring compound 324 will hopefully 
pave the way to complete the synthesis of rankinidine (49) in future studies. 
The formation of compound 324 was achieved in 3 steps. Ester hydrolysis, amide coupling 
with N-4-methoxybenzylaniline, copper(II) cyclisation, enone formation, followed by N-
protected aziridine formation and opening will provide an alternative key intermediate 341. 
From intermediate 341, the amino functionality is expected to react with E-1-bromo-2-
iodobut-2-ene in a SN2 manner and afford the iodoalkene 342 on treatment with base. 
Intramolecular radical cyclisation will then directly generate the tetracyclic structure 343. 
Finally, deprotection of the primary alcohol in spirooxindole 343 will result in 
intramolecular hemiketalisation, whereas reduction of the ensuing hemiketal, followed by 
oxindole deprotection, DMDO oxidation/methylation sequence and nitrogen protecting 
group removal will provide the natural product rankinidine (49). 
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Scheme 5.5. Forward synthesis towards rankinidine (49). 
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Chapter 6. Experimental 
 
6.1 General experimental 
 
All reactions were performed under an atmosphere of argon unless specified otherwise. 
Acetonitrile, dichloromethane, tetrahydrofuran, diethyl ether and toluene were dried on an 
Innovative Technology Pure Solv solvent purification system. Anhydrous tetrahydrofuran 
(THF) was obtained by distillation over sodium benzophenone ketyl. All other reagents and 
solvents were from commercial sources and used without further purification. Aqueous 
solutions are saturated unless specified otherwise. Thin layer chromatography (TLC) was 
carried out on Merck plastic-backed plates (Fluka Kieselgel 60 F254) and visualised by ultra-
violet irradiation (254 nm) and by staining with aqueous acidic ceric ammonium 
molybdate(IV) or potassium permanganate solutions as appropriate. Aldrich silica gel (60, 
0.040-0.063 mm) was used for flash column chromatography. All melting points were taken 
on a Gallenkamp apparatus. 1H NMR spectra were recorded on a Jeol ECX-400 MHz or Jeol 
ECS-400 MHz spectrometer and are reported as follows: chemical shift δ (ppm) (number of 
protons, multiplicity, coupling constant J (Hz), assignment). The coupling constants are 
quoted to the nearest 0.1 Hz (s = singlet, d = doublet, t = triplet, q = quartet, pent = pentet, 
m = multiplet, br = broad) and are reported as measured splittings on each individual 
resonance. The residual protic solvent CHCl3 (δH = 7.26 ppm) signal was used as an internal 
standard. 13C NMR spectra were recorded at 100 MHz on a Jeol ECX-400 MHz or Jeol ECS-
400 MHz spectrometer. The central reference of CDCl3 (δC = 77.0 ppm, t) was used as 
reference. 13C spectra were verified using DEPT experiments. Chemical shifts are reported 
in parts per million (ppm) to the nearest 0.01 ppm for 1H NMR and the nearest 0.1 ppm for 
13C NMR. Structural assignment was aided by the use of DEPT, COSY, HSQC and HMBC 
spectroscopy. High Resolution Mass Spectra were recorded using a Bruker MicrOTOF 
spectrometer and errors are reported in ppm. IR spectra were recorded on a Jasco FT/IR-
4100 spectrometer. Samples were prepared as a neat film. All numbering of the structures 
below is for characterisation purposes and does not conform to IUPAC rules. 
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6.2 The synthesis of bis-oxindole derivatives 
 
6.2.1 General procedure A: Double Mukaiyama’s amide bond coupling 
 
N,N’-Dimethyl-N,N’-diphenyladipamide (97a) 
 
To a stirred solution of adipic acid (1.01 g, 6.84 mmol) in THF (100 mL) was added N-
methylaniline (1.85 mL, 17.1 mmol), 2-chloro-1-methylpyridinium iodide (5.24 g, 20.5 
mmol), and Et3N (9.52 mL, 68.4 mmol) at 0 °C. The reaction mixture was stirred at 0 °C for 
1 h, warmed to room temperature and stirred overnight. Then, a solution of aq. HCl (10%, 
100 mL) was added. The aqueous phase was extracted with EtOAc (2 × 80 mL), washed 
with water (2 × 80 mL) and brine (2 × 80 mL), dried (MgSO4), filtered, and concentrated 
in vacuo. The crude yellow oil was then purified by column chromatography (SiO2, 
Hexane/EtOAc, 1:4) to give the title compound 97a (1.66 g, 75%) as a yellow solid; mp. 68-
70 °C; Rf 0.34 (EtOAc); νmax (cm-1) 2948, 1650, 1592, 1494, 1454, 1417, 1385, 1325, 1288, 
1266, 1113, 1039, 776, 699, 566; δH (400 MHz; CDCl3) 7.35 (4 H, t, J = 7.4 Hz, H-2), 7.28 
(2 H, t, J = 7.4 Hz, H-1), 7.08 (4 H, d, J = 7.4 Hz, H-3), 3.18 (6 H, s, H-5), 1.94 (4 H, br s, 
H-7), 1.42 (4 H, br s, H-8); δC (100 MHz; CDCl3) 172.9 (C-6), 144.2 (C-4), 129.8 (C-2), 
127.8 (C-1), 127.4 (C-3), 37.3 (C-5), 33.9 (C-7), 25.2 (C-8); Found (ESI): [MNa]+ 347.1731; 
C20H24N2NaO2 requires [MNa]
+ 347.1730, 0.2 ppm. 
Lab-book No PD/8/44. 
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N,N’-Dibenzyl, N,N’-diphenyladipamide (97b) 
 
Adipic acid (0.508 g, 3.47 mmol), N-benzylaniline (1.61 g, 8.78 mmol), 2-chloro-1-
methylpyridinium iodide (2.66 g, 10.4 mmol), and Et3N (4.83 mL, 34.7 mmol) in THF (50 
mL) were subjected to general procedure A. The residue was purified by column 
chromatography (SiO2, Hexane/EtOAc, 4:1 to Hexane/EtOAc, 2:1) to give the title 
compound 97b (0.630 g, 38%) as a colourless solid; mp. 64-66 °C; Rf 0.15 (Hexane/EtOAc, 
2:1); νmax (cm-1) 1655, 1595, 1495, 1454, 1398, 1259, 1203, 1079, 1017, 700; δH (400 MHz; 
CDCl3) 7.31 – 7.26 (6 H, m, HAr), 7.24 – 7.20 (6 H, m, HAr), 7.18 – 7.13 (4 H, m, HAr), 6.90 
(4 H, dd, J = 6.4, 3.1 Hz, HAr), 4.83 (4 H, s, H-5), 1.98 (4 H, br s, H-11), 1.50 (4 H, br s, H-
12); δC (100 MHz; CDCl3) 172.7 (C-10), 142.4 (CAr), 137.7 (CAr), 129.6 (CHAr), 128.9 
(CHAr), 128.5 (CHAr), 128.4 (CHAr), 128.0 (CHAr), 127.4 (CHAr), 53.0 (C-5), 34.2 (C-11), 
25.1 (C-12); Found (ESI): [MNa]+ 499.2337; C32H32N2NaO2 requires [MNa]
+ 499.2356, 3.8 
ppm. 
Lab-book No PD/9/39. 
 
N,N’-Dimethyl-N,N’-di-4-tolyladipamide (97c) 
 
Adipic acid (0.503 g, 3.44 mmol), N-methyl-p-toluidine (1.09 mL, 8.60 mmol), 2-chloro-1-
methylpyridinium iodide (2.63 g, 10.3 mmol), and Et3N (4.79 mL, 34.4 mmol) in THF (50 
mL) were subjected to general procedure A. The residue was purified by column 
chromatography (SiO2, Hexane/EtOAc, 1:3) to give the title compound 97c (1.13 g, 93%) 
as a pale yellow solid; mp. 81-83 °C; Rf 0.23 (Hexane/EtOAc, 1:4); νmax (cm-1) 1650, 1612, 
1513, 1418, 1382, 1290, 1119, 1021, 826, 724, 559; δH (400 MHz; CDCl3) 7.17 (4 H, d, J = 
8.1 Hz, H-3), 6.98 (4 H, d, J = 8.1 Hz, H-4), 3.18 (6 H, s, H-6), 2.36 (6 H, s, H-1), 1.96 (4 
H, br s, H-8), 1.43 (4 H, br s, H-9); δC (100 MHz; CDCl3) 173.1 (C-7), 141.6 (C-5), 137.7 
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(C-2), 130.4 (C-3), 127.1 (C-4), 37.4 (C-6), 33.9 (C-8), 25.2 (C-9), 21.2 (C-1); Found (ESI): 
[MNa]+ 375.2033; C22H28N2NaO2 requires [MNa]
+ 375.2043, 2.8 ppm. 
Lab-book No PD/9/27. 
 
N,N’-Dimethyl-N,N’-di-4-methoxyphenyladipamide (97d) 
 
Adipic acid (0.503 g, 3.44 mmol), 4-methoxy-N-methylaniline (1.19 g, 8.67 mmol), 2-
chloro-1-methylpyridinium iodide (2.63 g, 10.3 mmol), and Et3N (4.79 mL, 34.4 mmol) in 
THF (50 mL) were subjected to general procedure A. The residue was purified by column 
chromatography (SiO2, Hexane/EtOAc, 1:4) to give the title compound 97d (1.20 g, 91%) 
as a colourless solid; mp. 85-87 °C; Rf 0.21 (Hexane/EtOAc, 1:4); νmax (cm-1) 1646, 1584, 
1508, 1443, 1383, 1291, 1243, 1170, 1106, 1119, 1029, 837, 734; δH (400 MHz; CDCl3) 
6.99 (4 H, d, J = 8.9 Hz, H-4), 6.85 (4 H, d, J = 8.9 Hz, H-3), 3.78 (6 H, s, H-1), 3.14 (6 H, 
s, H-6), 1.92 (4 H, t, J = 6.1 Hz, H-8), 1.44 – 1.38 (4 H, m, H-9); δC (100 MHz; CDCl3) 
173.2 (C-7), 158.8 (C-2), 137.0 (C-5), 128.4 (C-4), 114.9 (C-3), 55.5 (C-1), 37.4 (C-6), 33.8 
(C-8), 25.2 (C-9); Found (ESI): [MNa]+ 407.1937; C22H28N2NaO4 requires [MNa]
+ 
407.1941, 1.0 ppm. 
Lab-book No PD/9/40. 
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6.2.2 General procedure B: CDI-mediated cyclisation 
 
trans-bis(N-Methyl-N-phenyl)-2-oxo-cyclopentane-1,3-dicarboxamide (92a) 
 
To a stirred solution of N,N’-dimethyl-N,N’-diphenyladipamide (0.502 g, 1.54 mmol) in 
THF (20 mL) was added LiHMDS (1.0 M in THF, 4.62 mL, 4.62 mmol) at −78 °C. The 
reaction mixture was stirred for 15 min and a solution of CDI (0.376 g, 2.31 mmol) in THF 
(20 mL) was then added slowly at −78 °C. The reaction mixture was stirred at −78 °C for 1 
h and a sat. aq. solution of NH4Cl (20 mL) was added. The reaction mixture was allowed to 
warm to room temperature. The aqueous phase was extracted with EtOAc (2 × 10 mL). The 
combined organic portions were washed with water (2 × 10 mL) and brine (2 × 10 mL), 
dried (MgSO4), filtered, and concentrated in vacuo. The brown crude residue was purified 
by column chromatography (SiO2, Hexane/EtOAc, 1:1) to give the title compound 92a 
(0.148 g, 27%) as a colourless solid; mp. 130-132 °C; Rf 0.42 (Hexane/EtOAc, 1:4); νmax 
(cm-1) 1804, 1740, 1655, 1633, 1593, 1496, 1454, 1386, 1299, 1191, 1122, 1093, 930, 892, 
773, 699, 562; δH (400 MHz; CDCl3) 7.42 – 7.36 (4 H, m, H-2), 7.36 – 7.30 (2 H, m, H-1), 
7.26 (4 H, d, J = 7.1 Hz, H-3), 3.23 (6 H, s, H-5), 3.23 – 3.19 (2 H, m, H-7), 2.18 – 2.05 (4 
H, m, H-8); δC (100 MHz; CDCl3) 209.9 (C-9), 169.3 (C-6), 143.4 (C-4), 130.1 (C-2), 128.4 
(C-1), 127.4 (C-3), 53.2 (C-7), 37.7 (C-5), 26.4 (C-8); Found (ESI): [MNa]+ 373.1529; 
C21H22N2NaO3 requires [MNa]
+ 373.1523, 1.6 ppm. CCDC 1013303 contains the 
supplementary crystallographic data for this compound. These data can be obtained free of 
charge from The Cambridge Crystallographic Data Centre via 
www.ccdc.cam.ac.uk/data_request/cif. 
Crystals suitable for X-ray diffraction were obtained by slow evaporation from hexane in 
which a few drops of dichloromethane were added. 
Lab-book No PD/8/48. 
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trans-bis(N-Benzyl-N-phenyl)-2-oxo-cyclopentane-1,3-dicarboxamide (92b) 
 
N,N’-Dibenzyl-N,N’-diphenyladipamide (0.416 g, 0.873 mmol), LiHMDS (1.0 M in THF, 
2.62 mL, 2.62 mmol), and CDI (0.212 g, 1.31 mmol) in THF (20 mL + 5 mL) were subjected 
to general procedure B. Purification by column chromatography (SiO2, Hexane/EtOAc, 4:1 
to 2:1) afforded the title compound 92b (0.120 g, 27%) as a colourless solid; mp. 115-117 
°C; Rf 0.16 (Hexane/EtOAc, 2:1); νmax (cm-1) 1744, 1651, 1595, 1495, 1398, 1265, 1109, 
1019, 732, 699; δH (400 MHz; CDCl3) 7.33 – 7.28 (6 H, m, HAr), 7.26 – 7.21 (6 H, m, HAr), 
7.16 (4 H, dd, J = 7.5, 1.7 Hz, HAr), 7.07 (4 H, br s, HAr), 4.90 (2 H, d, J = 14.4 Hz, H-5a), 
4.83 (2 H, d, J = 14.4 Hz, H-5b), 3.27 – 3.19 (2 H, m, H-11), 2.21 – 2.12 (4 H, m, H-13); δC 
(100 MHz; CDCl3) 209.5 (C-12), 169.6 (C-10), 141.7 (CAr), 137.0 (CAr), 129.8 (CHAr), 128.7 
(CHAr), 128.6 (CHAr), 128.5 (CHAr), 128.4 (CHAr), 127.5 (CHAr), 53.4 (C-11), 53.3 (C-5), 
26.5 (C-13); Found (ESI): [MNa]+ 525.2157; C33H30N2NaO3 requires [MNa]
+ 525.2149, 1.6 
ppm. 
Lab-book No PD/9/22. 
 
trans-bis(N-Methyl-N-4-tolyl)-2-oxo-cyclopentane-1,3-dicarboxamide (92c) 
 
N,N’-Dimethyl-N,N’-di-4-tolyladipamide (0.468 g, 1.33 mmol), LiHMDS (1.0 M in THF, 
3.99 mL, 3.99 mmol), and CDI (0.325 g, 2.00 mmol) in THF (20 mL + 5 mL) were subjected 
to general procedure B. Purification by column chromatography (SiO2, Hexane/EtOAc, 1:1) 
afforded the title compound 92c (0.092 g, 18%) as a colourless solid; mp. 133-135 °C; Rf 
0.48 (Hexane/EtOAc, 1:4); νmax (cm-1) 1745, 1646, 1614, 1514, 1420, 1380, 1303, 1268, 
1107, 912, 824, 722, 560; δH (400 MHz; CDCl3) 7.21 – 7.08 (8 H, m, H-3, H-4), 3.25 – 3.21 
(2 H, m, H-8), 3.20 (6 H, s, H-6), 2.34 (6 H, s, H-1), 2.16 – 2.04 (4 H, m, H-10); δC (100 
MHz; CDCl3) 209.9 (C-9), 169.4 (C-7), 140.9 (C-5), 138.3 (C-2), 130.6 (C-3), 127.1 (C-4), 
123 
53.1 (C-8), 37.7 (C-6), 26.3 (C-10), 21.2 (C-1); Found (ESI): [MNa]+ 401.1828; 
C23H26N2NaO3 requires [MNa]
+ 401.1836, 1.8 ppm. 
Lab-book No PD/9/29. 
 
trans-bis(N-Methyl-N-4-methoxyphenyl)-2-oxo-cyclopentane-1,3-dicarboxamide (92d) 
 
N,N’-Dimethyl-N,N’-di-4-methoxyphenyladipamide (0.535 g, 1.39 mmol), LiHMDS (1.0 M 
in THF, 4.17 mL, 4.17 mmol), and CDI (0.340 g, 2.10 mmol) in THF (20 mL + 5 mL) were 
subjected to general procedure B. Purification by column chromatography (SiO2, 
Hexane/EtOAc, 1:1) afforded the title compound 92d (0.095 g, 17%) as a colourless solid; 
mp. 132-134 °C; Rf 0.42 (Hexane/EtOAc, 1:4); νmax (cm-1) 1743, 1645, 1583, 1509, 1443, 
1381, 1292, 1245, 1170, 1030, 838, 732; δH (400 MHz; CDCl3) 7.16 (4 H, br d, J = 5.7 Hz, 
HAr), 6.87 (4 H, dd, J = 7.5, 1.5 Hz, HAr), 3.80 (6 H, s, H-1), 3.26 – 3.21 (2 H, m, H-8), 3.20 
(6 H, s, H-6), 2.17 – 2.03 (4 H, m, H-10); δC (100 MHz; CDCl3) 210.0 (C-9), 169.6 (C-7), 
159.3 (C-2), 136.2 (C-5), 128.5 (CHAr), 115.1 (CHAr), 55.6 (C-1), 53.1 (C-8), 37.8 (C-6), 
26.3 (C-10); Found (ESI): [MNa]+ 433.1741; C23H26N2NaO5 requires [MNa]
+ 433.1734, 1.6 
ppm. 
Lab-book No PD/9/41. 
 
6.2.3 General procedure C: Double MMC carboxylation/Mukaiyama’s coupling 
 
trans-bis(N-Methyl-N-phenyl)-2-oxo-cyclohexane-1,3-dicarboxamide (92g) 
 
Cyclohexanone (0.210 mL, 2.04 mmol) was added to a solution of methyl magnesium 
carbonate (2.0 M in DMF, 8.15 mL, 16.3 mmol). The reaction mixture was stirred for 6 h at 
130 °C. The reaction was allowed to cool to room temperature and HCl (10% solution in 
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water) was added slowly until the pH media became acidic. The aqueous phase was extracted 
with Et2O (3 × 10 mL). The combined organic phases were washed with water (4 × 10 mL) 
and brine (2 × 10 mL), dried (MgSO4), filtered and concentrated in vacuo to give a mixture 
of mono- and bis-acids. To a stirred solution of the crude acid mixture (0.175 g, 0.938 mmol) 
in CH2Cl2 (17 mL) was added N-methylaniline (0.254 mL, 2.34 mmol), 2-chloro-1-
methylpyridinium iodide (0.720 g, 2.82 mmol) and Et3N (1.31 mL, 9.38 mmol) at 0 °C. The 
reaction mixture was allowed to warm to room temperature and stirred overnight. HCl (10% 
solution in water, 10 mL) was added to the reaction mixture and the aqueous phase was 
extracted with CH2Cl2 (2 × 10 mL). The combined organic phases were washed with water 
(20 mL) and brine (20 mL), dried (MgSO4), filtered and concentrated in vacuo to give a 
mixture of mono- and bis-anilides. Purification by column chromatography (SiO2, 
Hexane/EtOAc, 3:1 to Hexane/EtOAc, 1:4) afforded the monoanilide product 102a (0.065 
g, 30%) as a yellow oil and the title compound 92g (0.048 g, 14%) as a colourless solid; mp. 
158-160 °C; Rf 0.19 (Hexane/EtOAc, 1:4); νmax (cm-1) 1713, 1651, 1595, 1495, 1451, 1422, 
1381, 1304, 1074, 920, 774, 729, 701; δH (400 MHz; CDCl3) 7.33 – 7.29 (6 H, m, H-1, H-
2), 7.06 – 7.02 (4 H, m, H-3), 3.25 (6 H, s, H-5), 2.94 (2 H, dd, J = 13.2, 5.5 Hz, H-7), 2.33 
– 2.18 (2 H, m, H-9a), 1.91 (2 H, dd, J = 13.2, 2.7 Hz, H-9b), 1.86 – 1.79 (1 H, m, H-10a), 
1.37 – 1.22 (1 H, m, H-10b); δC (100 MHz; CDCl3) 201.9 (C-8), 168.6 (C-6), 143.8 (C-4), 
129.8 (C-2), 127.9 (C-1), 127.1 (C-3), 54.8 (C-7), 37.7 (C-5), 30.0 (C-9), 22.9 (C-10); Found 
(ESI): [MNa]+ 387.1682; C22H24N2NaO3 requires [MNa]
+ 387.1679, 0.8 ppm. 
Lab-book No PD/9/20. 
 
5-tert-Butyl-trans-bis(N-methyl-N-phenyl)-2-oxo-cyclohexane-1,3-dicarboxamide (92h) 
 
4-tert-Butylcyclohexanone (0.216 g, 1.40 mmol) and methyl magnesium carbonate (2.0 M 
in DMF, 5.6 mL, 11.2 mmol) were subjected to general procedure C. The mixture of crude 
mono- and bis-acids was subsequently treated with N-methylaniline (0.320 mL, 2.99 mmol), 
2-chloro-1-methylpyridinium iodide (0.917 g, 3.60 mmol) and Et3N (1.67 mL, 12.0 mmol) 
following general procedure C. Purification by column chromatography (SiO2, 
Hexane/EtOAc, 2:1) afforded the monoanilide product 102b (0.131 g, 38%) as a brown oil 
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and the title compound 92h (0.051 g, 10%) as a foamy colourless solid; mp. 81-83 °C; Rf 
0.42 (Hexane/EtOAc, 1:2); νmax (cm-1) 1716, 1658, 1596, 1495, 1386, 1124, 1073, 775, 702; 
δH (400 MHz; CDCl3) 7.32 – 7.29 (6 H, m, H-1, H-2), 7.06 – 7.02 (4 H, m, H-3), 3.24 (6 H, 
s, H-5), 2.97 (2 H, dd, J = 12.7, 5.4 Hz, H-7), 2.15 – 2.02 (2 H, m, H-9a), 1.96 – 1.86 (2 H, 
m, H-9b), 1.27 – 1.16 (1 H, m, H-10), 0.83 (9 H, s, H-12); δC (100 MHz; CDCl3) 202.3 (C-
8), 168.8 (C-6), 143.7 (C-4), 129.8 (C-2), 127.9 (C-1), 127.1 (C-3), 54.3 (C-7), 44.3 (C-10), 
37.8 (C-5), 32.8 (C-11), 31.3 (C-9), 27.6 (C-12); Found (ESI): [MNa]+ 443.2293; 
C26H32N2NaO3 requires [MNa]
+ 443.2305, 2.8 ppm. 
Lab-book No PD/9/37. 
 
trans-bis(N-Methyl-N-phenyl)-2-oxo-cycloheptane-1,3-dicarboxamide (92i) 
 
Cycloheptanone (0.190 g, 1.70 mmol) and methyl magnesium carbonate (2.0 M in DMF, 6.8 
mL, 13.6 mmol) were subjected to general procedure C. The mixture of crude mono- and 
bis-acids was subsequently treated with N-methylaniline (0.240 mL, 2.19 mmol), 2-chloro-
1-methylpyridinium iodide (0.670 g, 2.62 mmol) and Et3N (1.22 mL, 8.75 mmol) in CH2Cl2 
(20 mL) following general procedure C. Purification by column chromatography (SiO2, 
Hexane/EtOAc, 2:1 to Hexane/EtOAc, 1:2) afforded the monoanilide product 102c (0.073 
g, 34%) as a yellow oil and the title compound 92i (0.029 g, 9%) as a yellow oil; Rf 0.22 
(Hexane/EtOAc, 1:2); νmax (cm-1) 1709, 1650, 1595, 1495, 1452, 1419, 1381, 1118, 774, 
729, 701; δH (400 MHz; CDCl3) 7.30 – 7.25 (2 H, m, H-1), 7.22 (4 H, t, J = 7.4 Hz, H-2), 
6.96 (4 H, d, J = 7.4 Hz, H-3), 3.21 (6 H, s, H-5), 3.16 (2 H, dd, J = 6.7, 4.0 Hz, H-7), 2.00 
– 1.89 (2 H, m, H-10a), 1.88 – 1.77 (2 H, m, H-9a), 1.60 – 1.47 (2 H, m, H-9b), 1.46 – 1.32 
(2 H, m, H-10b); δC (100 MHz; CDCl3) 204.5 (C-8), 169.7 (C-6), 143.9 (C-4), 129.9 (C-2), 
128.1 (C-1), 127.6 (C-3), 54.9 (C-7), 37.6 (C-5), 28.2 (C-9), 27.1 (C-10); Found (ESI): 
[MNa]+ 401.1847; C23H26N2NaO3 requires [MNa]
+ 401.1836, 2.8 ppm. 
Lab-book No PD/9/25. 
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N,N’-Dimethyl-3-oxo-N,N’-diphenylpentanediamide (95) 
 
To a stirred solution of dimethyl 1,3-acetonedicarboxylate (1.00 mL, 6.93 mmol) in toluene 
(100 mL) was added N-methylaniline (2.25 mL, 20.8 mmol), and 4-(dimethylamino)pyridine 
(0.085 g, 0.693 mmol). The reaction mixture was stirred overnight at 110 °C and allowed to 
cool to room temperature. Toluene was removed in vacuo and the residue was purified by 
column chromatography (SiO2, Hexane/EtOAc, 1:1) and give the monoanilide product 
(0.932 g, 54%) as a brown oil and the title compound 95 (0.429 g, 19%) as a brown solid; 
mp. 74-76 °C; Rf 0.24 (Hexane/EtOAc, 1:2); νmax (cm-1) 1724, 1651, 1594, 1495, 1379, 1347, 
1120, 774, 700; δH (400 MHz; CDCl3) 7.43 – 7.37 (4 H, m, HAr), 7.36 – 7.29 (2 H, m, HAr), 
7.20 – 7.14 (4 H, m, HAr), 3.33 (4 H, s, H-7), 3.24 (6 H, s, H-5); δC (100 MHz; CDCl3) 199.1 
(C-8), 166.7 (C-6), 143.5 (C-4), 130.0 (CHAr), 128.3 (CHAr), 127.3 (CHAr), 49.2 (C-7), 37.4 
(C-5); Found (ESI): [MNa]+ 347.1350; C19H20N2NaO3 requires [MNa]
+ 347.1366, 4.7 ppm. 
Lab-book No PD/7/48. 
 
trans-6-N,8-N-Dimethyl-7-oxo-6-N,8-N-diphenyl-6,7,8,9-tetrahydro-5H-
benzo[7]annulene-6,8-dicarboxamide (92j) 
 
To a stirred solution of diisopropylamine (0.104 mL, 0.740 mmol) in THF (10 mL) at 0 °C 
was added n-BuLi (2.5 M in hexanes, 0.310 mL, 0.775 mmol). The reaction mixture was 
stirred at 0 °C for 15 min and cooled to –78 °C. A solution of N,N’-dimethyl-3-oxo-N,N’-
diphenylpentanediamide (0.229 g, 0.705 mmol) in THF (2 mL) was added and the reaction 
mixture was stirred for 30 min, allowed to warm to room temperature and stirred for a further 
30 min. It was then cooled to –78 °C and a solution of α,α’-dibromo-o-xylene (0.198 g, 0.751 
mmol) in THF (2 mL) was slowly added at –78 °C. The reaction was warmed to room 
temperature and stirred for 1 h then cooled to 0 °C and NaH (0.031 g, 0.775 mmol) was 
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added. The reaction was allowed to warm to room temperature and stirred overnight. The 
reaction mixture was quenched by addition of NH4Cl (20 mL). The two phases were 
separated and the resulting aqueous layer was extracted with EtOAc (2 × 20 mL). The 
combined organic phases were washed with water (20 mL) and brine (20 mL), dried 
(MgSO4), filtered and concentrated in vacuo. Purification by column chromatography (SiO2, 
Hexane/EtOAc, 2:1) afforded the title compound 92j (0.080 g, 27%) as a foamy colourless 
solid; mp. 60-62 °C; Rf 0.48 (Hexane/EtOAc, 1:2); νmax (cm-1) 1699, 1650, 1595, 1494, 1380, 
1117, 911, 772, 727, 699; δH (400 MHz; CDCl3) 7.40 (4 H, t, J = 7.5 Hz, H-2), 7.32 (2 H, t, 
J = 7.5 Hz, H-1), 7.14 (4 H, d, J = 7.5 Hz, H-3), 7.10 (4 H, br s, H-11, H-12), 4.07 (2 H, dd, 
J = 8.1, 5.2 Hz, H-7), 3.16 (6 H, s, H-5), 3.11 (2 H, dd, J = 14.8, 8.1 Hz, H-9a), 2.97 (2 H, 
dd, J = 14.8, 5.2 Hz, H-9b); δC (100 MHz; CDCl3) 204.0 (C-8), 168.9 (C-6), 143.3 (C-4), 
137.5 (C-10), 130.0 (C-2), 129.5 (CHAr), 128.2 (C-1), 127.5 (C-3), 127.4 (CHAr), 55.4 (C-
7), 37.8 (C-5), 34.1 (C-9); Found (ESI): [MNa]+ 449.1829; C27H26N2NaO3 requires [MNa]
+ 
449.1836, 1.5 ppm. 
Lab-book No PD/9/85. 
 
6.2.4 General procedure D: Spirocyclisation reaction 
 
trans-1,1''-Dimethyl-1,1'',2,2''-tetrahydrodispiro[indole-3,1'-cyclopentane-3',3''-indole]-
2,2',2''-trione (91a) 
  
To a stirred solution of bis-anilide 92a (0.027 g, 0.078 mmol) in DMF (3 mL) was added 
Cu(OAc)2∙H2O (0.032 g, 0.161 mmol) and KOt-Bu (0.019 g, 0.168 mmol). The reaction 
mixture was stirred at 110 °C for 15 min and allowed to cool to room temperature. An aq. 
solution of 10% NH4OH (2 × 5 mL) was added and the aqueous phase was extracted with 
EtOAc (2 × 5 mL). The combined organic phases were washed with water (4 × 5 mL), and 
brine (5 mL), dried (MgSO4), filtered and concentrated in vacuo. 
1H NMR of the crude 
128 
reaction mixture showed only the trans-diastereoisomer 91a. The residue was purified by 
column chromatography (SiO2, Hexane/EtOAc, 4:1) to give the title compound 91a (0.018 
g, 67%) as a colourless solid; mp. 184-186 °C; Rf 0.42 (Hexane/EtOAc, 1:1); νmax (cm-1) 
1751, 1704, 1612, 1493, 1471, 1370, 1347, 1266, 1070, 885, 752; δH (400 MHz; CDCl3) 
7.43 (2 H, dd, J = 7.6, 1.2 Hz, H-8), 7.31 (2 H, td, J = 7.6, 1.2 Hz, H-2), 7.10 (2 H, td, J = 
7.6, 1.2 Hz, H-1), 6.84 (2 H, d, J = 7.6 Hz, H-3), 3.21 (6 H, s, H-9), 3.15 – 3.10 (2 H, m, H-
11a), 2.78 – 2.72 (2 H, m, H-11b); δC (100 MHz; CDCl3) 208.0 (C-10), 175.0 (C-5), 144.4 
(C-4), 129.8 (C-7), 129.1 (C-2), 124.3 (C-8), 123.6 (C-1), 108.4 (C-3), 63.7 (C-6), 32.4 (C-
11), 26.6 (C-9); Found (ESI): [MNa]+ 369.1213; C21H18N2NaO3 requires [MNa]
+ 369.1210, 
0.8 ppm. CCDC 1004040 contains the supplementary crystallographic data for this 
compound. These data can be obtained free of charge from The Cambridge Crystallographic 
Data Centre via www.ccdc.cam.ac.uk/data_request/cif. 
Crystals suitable for X-ray diffraction were obtained by slow evaporation from hexane in 
which a few drops of dichloromethane were added. 
Lab-book No PD/8/88. 
 
trans-1,1''-Dibenzyl-1,1'',2,2''-tetrahydrodispiro[indole-3,1'-cyclopentane-3',3''-indole]-
2,2',2''-trione (91b) 
 
Bis-anilide 92b (0.015 g, 0.029 mmol), Cu(OAc)2∙H2O (0.012 g, 0.058 mmol) and KOt-Bu 
(0.007 g, 0.064 mmol) in DMF (1.5 mL) were subjected to general procedure D. The residue 
was purified by column chromatography (SiO2, Hexane/EtOAc, 4:1) to give the title 
compound 91b (0.008 g, 57%) as a pale yellow solid; mp. 115-117 °C; Rf 0.50 
(Hexane/EtOAc, 2:1); νmax (cm-1) 1740, 1703, 1612, 1488, 1467, 1455, 1359, 1311, 1178, 
873, 752, 734; δH (400 MHz; CDCl3) 7.48 (2 H, dd, J = 7.6, 1.0 Hz, H-8), 7.34 – 7.30 (4 H, 
m, HAr), 7.30 – 7.27 (6 H, m, HAr), 7.19 (2 H, td, J = 7.6, 1.0 Hz, H-2), 7.07 (2 H, td, J = 7.6, 
1.0 Hz, H-1), 6.70 (2 H, d, J = 7.6 Hz, H-3), 5.02 (2 H, d, J = 15.9 Hz, H-9a), 4.83 (2 H, d, 
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J = 15.9 Hz, H-9b), 3.26 – 3.15 (2 H, m, H-15a), 2.93 – 2.81 (2 H, m, H-15b); δC (100 MHz; 
CDCl3) 208.0 (C-14), 175.2 (C-5), 143.5 (C-4), 135.3 (C-10), 129.8 (C-7), 129.1 (C-2), 
129.0 (CHAr), 127.8 (CHAr), 127.1 (CHAr), 124.4 (C-8), 123.7 (C-1), 109.5 (C-3), 63.8 (C-
6), 43.9 (C-9), 32.5 (C-15); Found (ESI): [MNa]+ 521.1825; C33H26N2NaO3 requires [MNa]
+ 
521.1836, 2.0 ppm. 
Lab-book No PD/9/24. 
 
trans-1,1'',5,5''-Tetramethyl-1,1'',2,2''-tetrahydrodispiro[indole-3,1'-cyclopentane-3',3''-
indole]-2,2',2''-trione (91c) 
 
Bis-anilide 92c (0.040 g, 0.105 mmol), Cu(OAc)2∙H2O (0.044 g, 0.219 mmol) and KOt-Bu 
(0.026 g, 0.230 mmol) in DMF (4 mL) were subjected to general procedure D. The residue 
was purified by column chromatography (SiO2, Hexane/EtOAc, 4:1) to give the title 
compound 91c (0.026 g, 67%) as a colourless solid; mp. 197-199 °C; Rf 0.60 
(Hexane/EtOAc, 1:2); νmax (cm-1) 1751, 1701, 1624, 1602, 1499, 1349, 1271, 1069, 918, 
811; δH (400 MHz; CDCl3) 7.24 (2 H, dd, J = 1.3, 0.6 Hz, H-9), 7.10 (2 H, ddd, J = 7.9, 1.3, 
0.6 Hz, H-3), 6.72 (2 H, d, J = 7.9 Hz, H-4), 3.19 (6 H, s, H-10), 3.17 – 3.04 (2 H, m, H-
12a), 2.77 – 2.64 (2 H, m, H-12b), 2.33 (6 H, s, H-1); δC (100 MHz; CDCl3) 208.4 (C-11), 
175.0 (C-6), 142.1 (C-5), 133.3 (C-2), 129.8 (C-8), 129.3 (C-3), 125.1 (C-9), 108.1 (C-4), 
63.8 (C-7), 32.5 (C-12), 26.6 (C-10), 21.2 (C-1); Found (ESI): [MNa]+ 397.1506; 
C23H22N2NaO3 requires [MNa]
+ 397.1523, 4.1 ppm. 
Lab-book No PD/9/36. 
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trans-5,5''-Dimethoxy-1,1''-dimethyl-1,1'',2,2''-tetrahydrodispiro[indole-3,1'-cyclopentane-
3',3''-indole]-2,2',2''-trione (91d) 
 
Bis-anilide 92d (0.042 g, 0.102 mmol), Cu(OAc)2∙H2O (0.041 g, 0.206 mmol) and KOt-Bu 
(0.026 g, 0.228 mmol) in DMF (4 mL) were subjected to general procedure D. The residue 
was purified by column chromatography (SiO2, Hexane/EtOAc, 4:1 to Hexane/EtOAc, 2:1) 
to give the title compound 91d (0.018 g, 44%) as a colourless solid; mp. 180-182 °C; Rf 0.46 
(Hexane/EtOAc, 1:2); νmax (cm-1) 1749, 1701, 1600, 1497, 1469, 1435, 1354, 1288, 1039, 
811; δH (400 MHz; CDCl3) 7.07 (2 H, d, J = 2.6 Hz, H-9), 6.83 (2 H, dd, J = 8.4, 2.6 Hz, H-
3), 6.74 (2 H, d, J = 8.4 Hz, H-4), 3.79 (6 H, s, H-1), 3.18 (6 H, s, H-10), 3.15 – 3.03 (2 H, 
m, H-12a), 2.79 – 2.67 (2 H, m, H-12b); δC (100 MHz; CDCl3) 207.9 (C-11), 174.7 (C-6), 
156.7 (C-2), 137.9 (C-5), 130.8 (C-8), 114.1 (C-3), 111.1 (C-9), 108.8 (C-4), 64.1 (C-7), 
56.0 (C-1), 32.5 (C-12), 26.6 (C-10); Found (ESI): [MNa]+ 429.1433; C23H22N2NaO5 
requires [MNa]+ 429.1421, 2.9 ppm. 
Lab-book No PD/9/45. 
 
trans-1,1''-Dimethyl-1,1'',2,2''-tetrahydrodispiro[indole-3,1'-cyclohexane-3',3''-indole]-
2,2',2''-trione (91g) 
 
Bis-anilide 92g (0.033 g, 0.091 mmol), Cu(OAc)2∙H2O (0.037 g, 0.187 mmol) and KOt-Bu 
(0.023 g, 0.202 mmol) in DMF (3 mL) were subjected to general procedure D. The residue 
was purified by column chromatography (SiO2, Hexane/EtOAc, 4:1) to give the title 
compound 91g (0.014 g, 43%) as a colourless solid; mp. 210-212 °C; Rf 0.64 
(Hexane/EtOAc, 1:4); νmax (cm-1) 1705, 1688, 1610, 1494, 1471, 1372, 1348, 1266, 1105, 
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753; δH (400 MHz; CDCl3) 7.57 (2 H, dd, J = 7.4, 1.2 Hz, H-8), 7.28 (2 H, td, J = 7.4, 1.2 
Hz, H-2), 7.07 (2 H, td, J = 7.4, 1.2 Hz, H-1), 6.79 (2 H, d, J = 7.4 Hz, H-3), 3.17 (6 H, s, 
H-9), 2.50 (6 H, br s, H-11, H-12); δC (100 MHz; CDCl3) 203.2 (C-10), 175.8 (C-5), 143.9 
(C-4), 132.9 (C-7), 128.7 (C-2), 124.4 (C-8), 123.4 (C-1), 108.3 (C-3), 62.3 (C-6), 33.5 (C-
11), 26.6 (C-9), 17.1 (C-12); Found (ESI): [MNa]+ 383.1370; C22H20N2NaO3 requires 
[MNa]+ 383.1366, 0.9 ppm. 
Lab-book No PD/9/21. 
 
5-tert-Butyl-trans-1,1''-dimethyl-1,1'',2,2''-tetrahydrodispiro[indole-3,1'-cyclohexane-3',3''-
indole]-2,2',2''-trione (91h) 
 
Bis-anilide 92h (0.045 g, 0.108 mmol), Cu(OAc)2∙H2O (0.044 g, 0.219 mmol) and KOt-Bu 
(0.026 g, 0.228 mmol) in DMF (4.5 mL) were subjected to general procedure D. The residue 
was purified by column chromatography (SiO2, Hexane/EtOAc, 4:1) to give the title 
compound 91h (0.024 g, 54%) as a colourless solid; mp. 152-154 °C; Rf 0.48 
(Hexane/EtOAc, 1:2); νmax (cm-1) 1707, 1690, 1651, 1610, 1494, 1470, 1371, 1346, 1263, 
753; δH (400 MHz; CDCl3) 7.86 (1 H, dd, J = 7.6, 1.2 Hz, H-8a), 7.34 (1 H, dd, J = 7.6, 1.2 
Hz, H-8b), 7.28 (1 H, td, J = 7.6, 1.2 Hz, H-2a), 7.28 (1 H, td, J = 7.6, 1.2 Hz, H-2b), 7.08 
(1 H, td, J = 7.6, 1.2 Hz, H-1a), 7.07 (1 H, td, J = 7.6, 1.2 Hz, H-1b), 6.81 (1 H, d, J = 7.6 
Hz, H-3a), 6.78 (1 H, d, J = 7.6 Hz, H-3b), 3.19 (3 H, s, H-9a), 3.14 (3 H, s, H-9b), 3.05 – 
2.95 (1 H, m, H-12), 2.48 (1 H, t, J = 13.1 Hz, H-11a), 2.34 (2 H, d, J = 8.8 Hz, H-11b), 2.19 
(1 H, d, J = 14.9 Hz, H-11a), 0.96 (9 H, s, H-14); δC (100 MHz; CDCl3) 203.9 (C-10), 176.4 
(C-5a), 175.5 (C-5b), 143.9 (C-4a), 143.8 (C-4b), 133.9 (C-7a), 132.7 (C-7b), 128.8 (C-2a), 
128.6 (C-2b), 124.7 (C-8a), 124.0 (C-8b), 123.5 (C-1a), 123.3 (C-1b), 108.4 (C-3a), 108.2 
(C-3b), 63.3 (C-6a), 61.9 (C-6b), 37.5 (C-12), 35.8 (C-11a), 35.6 (C-11b), 32.6 (C-13), 27.3 
(C-14), 26.7 (C-9a), 26.5 (C-9b); Found (ESI): [MNa]+ 439.2011; C26H28N2NaO3 requires 
[MNa]+ 439.1992, 4.2 ppm. 
Lab-book No PD/9/42.  
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trans-1,1''-Dimethyl-1,1'',2,2''-tetrahydrodispiro[indole-3,1'-cycloheptane-3',3''-indole]-
2,2',2''-trione (91i) 
 
Bis-anilide 92i (0.025 g, 0.065 mmol), Cu(OAc)2∙H2O (0.028 g, 0.138 mmol) and KOt-Bu 
(0.016 g, 0.146 mmol) in DMF (2.5 mL) were subjected to general procedure D. The residue 
was purified by column chromatography (SiO2, Hexane/EtOAc, 4:1) to give the title 
compound 91i (0.019 g, 77%) as a colourless solid; mp. 196-198 °C; Rf 0.69 
(Hexane/EtOAc, 1:2); νmax (cm-1) 1701, 1682, 1608, 1493, 1470, 1373, 1347, 1260, 1126, 
1079, 947, 753, 729; δH (400 MHz; CDCl3) 7.36 (2 H, d, J = 7.6 Hz, H-8), 7.23 (2 H, td, J = 
7.6, 1.2 Hz, H-2), 7.02 (2 H, td, J = 7.6, 1.2 Hz, H-1), 6.76 (2 H, d, J = 7.6 Hz, H-3), 3.20 (6 
H, s, H-9), 2.85 (2 H, br s, H-11a), 2.43 (2 H, br t, J = 9.0 Hz, H-12a), 2.07 – 1.94 (4 H, m, 
H-11b, H-12b); δC (100 MHz; CDCl3) 174.9 (C-5), 142.8 (C-4), 132.0 (C-7), 128.5 (C-2), 
125.3 (C-8), 122.9 (C-1), 108.2 (C-3), 67.9 (C-6), 33.9 (C-11), 26.5 (C-9), 24.2 (C-12); 
Found (ESI): [MNa]+ 397.1510; C23H22N2NaO3 requires [MNa]
+ 397.1523, 3.1 ppm. 
Lab-book No PD/9/33. 
 
trans-1,1’’-Dimethyl-1,1’’,2,2’’,7’,9’-hexahydro-5’H-dispiro[indole-3,6’-
benzo[7]annulene-8’,3’’-indole]2,2’’,7’-trione (91j) 
 
Bis-anilide 92j (0.031 g, 0.073 mmol), Cu(OAc)2∙H2O (0.030 g, 0.151 mmol) and KOt-Bu 
(0.019 g, 0.170 mmol) in DMF (2 mL) were subjected to general procedure D. The residue 
was purified by column chromatography (SiO2, Hexane/EtOAc, 4:1) to give the title 
compound 91j (0.014 g, 46%) as a yellow solid; mp. 214-216 °C; Rf 0.50 (Hexane/EtOAc, 
1:1); νmax (cm-1) 1710, 1678, 1609, 1493, 1471, 1370, 1347, 1261, 1077, 1023, 910, 798, 
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752; δH (400 MHz; CDCl3) 7.33 (2 H, dd, J = 5.4, 3.3 Hz, H-14), 7.26 (2 H, td, J = 7.6, 1.2 
Hz, H-2), 7.16 (2 H, dd, J = 5.4, 3.3 Hz, H-13), 7.04 (2 H, d, J = 7.6 Hz, H-8), 6.98 (2 H, td, 
J = 7.6, 1.2 Hz, H-1), 6.81 (2 H, d, J = 7.6 Hz, H-3), 3.65 (2 H, d, J = 14.7 Hz, H-11a), 3.46 
(2 H, d, J = 14.7 Hz, H-11b), 3.17 (6 H, s, H-9); δC (100 MHz; CDCl3) 205.2 (C-10), 174.9 
(C-5), 143.9 (C-4), 135.9 (C-12), 132.5 (C-7), 130.8 (C-13), 128.8 (C-2), 127.7 (C-14), 125.0 
(C-8), 123.1 (C-1), 108.3 (C-3), 65.7 (C-6), 38.0 (C-11), 26.5 (C-9); Found (ESI): [MNa]+ 
445.1527; C27H22N2NaO3 requires [MNa]
+ 445.1523, 1.1 ppm. 
Lab-book No PD/9/87. 
 
N-[(1S)-1-phenylethyl]aniline50 (108) 
 
A mixture of iodobenzene (1.12 mL, 10.0 mmol), (S)-phenylethylamine (1.29 mL, 10.0 
mmol), K2CO3 (2.77 g, 20.0 mmol), CuI (0.190 g, 1.00 mmol) and L-proline (0.234 g, 2.03 
mmol) in DMSO (10 mL) was heated at 60 °C for 18 h. The cooled mixture was partitioned 
between water (10 mL) and EtOAc (10 mL). The organic layer was separated, and the 
aqueous layer was extracted with EtOAc (2 × 10 mL). The combined organic layers were 
washed with brine (10 mL), dried (MgSO4), filtered and concentrated in vacuo. The residual 
oil was purified by column chromatography (SiO2, Hexane/EtOAc, 49:1) to afford the title 
compound (S)-108 (0.432 g, 22%) as a clear oil; Rf 0.54 (Hexane/EtOAc, 4:1); δH (400 MHz; 
CDCl3) 7.36 (2 H, d, J = 7.4 Hz, CHAr), 7.31 (2 H, t, J = 7.4 Hz, CHAr), 7.22 (1 H, tt, J = 7.4, 
1.0 Hz, CHAr), 7.09 (1 H, d, J = 7.4 Hz, CHAr), 7.07 (1 H, d, J = 7.4 Hz, CHAr), 6.63 (1 H, 
tt, J = 7.4, 1.0 Hz, CHAr), 6.50 (2 H, dd, J = 8.6, 1.0 Hz, CHAr), 4.48 (1 H, q, J = 6.7 Hz, H-
6), 4.01 (1 H, br s, H-5), 1.51 (3 H, d, J = 6.7 Hz, H-7). 
Data are consistent with literature values.50 
Lab-book No PD/10/61. 
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3-Ethoxy-2-methyl-3-oxopropanoic acid137 (109) 
 
Diethyl methylmalonate (4.00 g, 23.0 mmol) was dissolved in a mixture of THF:H2O (1:10, 
880 mL). The reaction mixture was cooled to 0 °C, then NaOH (0.25 M in water, 120 mL) 
was added. The reaction mixture was stirred for 1 h, acidified with an aq. sol. of HCl (10%, 
5 mL) to bring the pH to 2. The solution was saturated with brine (10 g), extracted with 
EtOAc (50 mL), dried (MgSO4), filtered, and concentrated in vacuo to give the title 
compound 109 (3.02 g, quant.), which was used in the next step without further purification; 
Rf 0.4 (Petrol/EtOAc, 1:1); δH (400 MHz; CDCl3) 10.19 (1 H, br s, H-1), 4.21 (2 H, q, J = 
7.1 Hz, H-5), 3.47 (1 H, q, J = 7.3 Hz, H-3), 1.45 (3 H, d, J = 7.3 Hz, H-7), 1.27 (3 H, t, J = 
7.1 Hz, H-6). 
Analytical data are consistent with literature values.137 
Lab-book No PD/5/14. 
 
Ethyl 2-methyl-2{phenyl[(1S)-1-phenylethyl]carbamoyl}acetate (110) 
 
To a stirred solution of N-[(1S)-1-phenylethyl]aniline (108) (0.101 g, 0.514 mmol) in CH2Cl2 
(2 mL) was added at 0 °C the readily available 3-ethoxy-2-methyl-3-oxopropanoic acid 
(109) (0.066 g, 0.453 mmol), 2-chloro-1-methylpyridinium iodide (0.167 g, 0.654 mmol) 
and Et3N (0.298 mL, 2.14 mmol). The resulting yellow mixture was stirred at 0 °C for 1 h 
and allowed to warm to room temperature and stirred for a further 1 h. HCl (10% solution 
in water, 5 mL) was added, the organic layer was separated, and the aqueous layer was 
extracted with EtOAc (2 × 10 mL). The combined organic layers were washed with brine 
(10 mL), dried (MgSO4), filtered, and concentrated in vacuo. The residual oil was purified 
by column chromatography (SiO2, Hexane/EtOAc, 8:1) to afford the title compound 110 
(0.148 g, 68%) as a thick colourless oil in a 1:1.5 110/110’ ratio of inseparable 
diastereoisomers; Rf 0.22 (Hexane/EtOAc, 6:1); νmax (cm-1) 2981, 2939, 1741, 1652, 1594, 
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1495, 1451, 1391, 1341, 1311, 1233, 1190, 1081, 1030, 779, 699, 572; δH (400 MHz; CDCl3) 
7.39 (1 H, t, J = 7.4 Hz, CHAr), 7.29 (1.6 H, td, J = 7.4, 0.7 Hz, CHAr), 7.26 – 7.23 (4 H, m, 
CHAr), 7.16 (0.6 H, d, J = 7.4 Hz, CHAr), 7.14 (0.4 H, d, J = 7.4 Hz, CHAr), 7.11 (0.8 H, d, J 
= 8.1 Hz, CHAr), 7.07 (0.6 H, d, J = 7.4 Hz, CHAr), 6.36 (0.6 H, q, J = 7.2 Hz, H-11’), 6.36 
– 6.30 (0.6 H, m, CHAr), 6.30 (0.4 H, q, J = 7.2 Hz, H-11), 6.23 (0.4 H, d, J = 7.4 Hz, CHAr), 
4.12 (0.4 H, q, J = 7.1 Hz, H-8), 4.12 (0.4 H, q, J = 7.1 Hz, H-8), 4.05 (0.6 H, dd, J = 10.8, 
7.1 Hz, H-8’), 3.99 (0.6 H, dd, J = 10.8, 7.1 Hz, H-8’), 3.15 (1 H, pent, J = 7.1 Hz, H-6), 
1.44 (1.2 H, d, J = 7.2 Hz, H-12), 1.39 (1.8 H, d, J = 7.2 Hz, H-12’), 1.32 (1.8 H, d, J = 7.1 
Hz, H-10’), 1.25 (1.2 H, d, J = 7.1 Hz, H-10), 1.25 (1.2 H, t, J = 7.1 Hz, H-9), 1.15 (1.8 H, 
t, J = 7.1 Hz, H-9’); δC (100 MHz; CDCl3) 171.0 and 170.9 (C-7), 169.92 and 169.89 (C-5), 
141.0 and 140.9 (C-13), 138.0 and 137.9 (C-4), 130.6 (CHAr), 129.0 (CHAr), 128.60 and 
128.56 (CHAr), 128.23 and 128.16 (CHAr), 128.1 (CHAr), 127.62 and 127.57 (CHAr), 61.2 
and 61.1 (C-8), 52.5 and 52.0 (C-11), 44.6 and 44.5 (C-6), 17.1 and 16.9 (C-12), 14.21 and 
14.17 (C-9 or C-10), 14.12 and 14.07 (C-9 or C-10); Found (ESI): [MNa]+ 348.1562; 
C20H23NNaO3 requires [MNa]
+ 348.1570, 2.5 ppm. 
Lab-book No PD/10/36. 
 
Ethyl 3-methyl-2-oxo-1-[(1S)-1-phenylethyl]-2,3-dihydro-1H-indole-3-carboxylate (111) 
 
To a stirred solution of anilide 110 (0.028 g, 0.085 mmol) in toluene (2 mL) was added 
Cu(OAc)2∙H2O (0.018 g, 0.089 mmol). The reaction mixture was stirred at 110 °C for 18 h 
and allowed to cool to room temperature. The copper salt was removed by addition of an aq. 
sol. of NH4OH (5 mL). The aqueous phase was extracted with EtOAc (2 × 5 mL). The 
combined organic extracts were washed with water (5 mL), and brine (5 mL), dried 
(MgSO4), filtered and concentrated in vacuo. The crude product was purified by column 
chromatography (SiO2, Hexane/EtOAc, 9:1) to give the title compound 111 (0.021 g, 76%) 
as a yellow oil in a 1:1.3 111/111’ mixture of diastereoisomers, inseparable by column 
chromatography; Rf 0.23 (Hexane/EtOAc, 6:1); νmax (cm-1) 2982, 2936, 1741, 1714, 1607, 
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1484, 1467, 1350, 1237, 1190, 1112, 1019, 752, 698; δH (400 MHz; CDCl3) 7.41 – 7.37 (1 
H, m, HAr), 7.35 – 7.26 (4 H, m, HAr), 7.23 (0.45 H, d, J = 7.4 Hz, H-8), 7.22 (0.55 H, d, J = 
7.4 Hz, H-8’), 7.08 – 7.01 (1 H, m, HAr), 6.96 (0.45 H, td, J = 7.6, 1.0 Hz, H-1), 6.96 (0.55 
H, td, J = 7.6, 1.0 Hz, H-1’), 6.49 (0.45 H, d, J = 7.6 Hz, H-3), 6.45 (0.55 H, d, J = 7.6 Hz, 
H-3’), 5.92 (0.55 H, q, J = 7.2 Hz, H-9’), 5.83 (0.45 H, q, J = 7.2 Hz, H-9), 4.24 – 4.13 (1.1 
H, m, H-17’), 4.12 – 4.02 (0.9 H, m, H-17), 1.85 (1.35 H, d, J = 7.2 Hz, H-10), 1.82 (1.65 
H, d, J = 7.2 Hz, H-10’), 1.72 (1.35 H, s, H-15), 1.71 (1.65 H, s, H-15’), 1.20 (1.65 H, t, J = 
7.1 Hz, H-18’), 1.15 (1.35 H, t, J = 7.1 Hz, H-18); δC (100 MHz; CDCl3) 175.5 and 175.4 
(C-5), 171.4 and 170.0 (C-16), 141.7 and 141.5 (C-4), 139.1 and 139.0 (C-11), 130.6 and 
130.5 (C-7), 128.8 and 128.7 (CHAr), 128.56 and 128.55 (C-2), 127.54 and 127.45 (CHAr), 
126.7 and 126.6 (CHAr), 123.01 and 122.97 (C-8), 122.52 and 122.50 (C-1), 111.4 and 111.1 
(C-3), 62.1 and 62.0 (C-17), 55.01 and 54.99 (C-6), 49.5 and 48.8 (C-9), 20.0 and 19.7 (C-
15), 16.2 and 16.1 (C-10), 13.94 and 13.92 (C-18); Found (ESI): [MNa]+ 346.1406; 
C20H21NNaO3 requires [MNa]
+ 346.1414, 2.1 ppm. 
Lab-book No PD/10/65. 
 
trans-2-Oxo-1-N,3-N-diphenyl-1-N,3-N-bis[(1S)-1-phenylethyl]cyclopentane-1,3-
dicarboxamide (92k) 
 
Cyclopentanone (0.44 mL, 5.00 mmol) was added to a solution of methyl magnesium 
carbonate (2.0 M in DMF, 20.0 mL, 40.0 mmol). The reaction mixture was stirred for 6 h at 
130 °C and was allowed to cool to room temperature and HCl (10% solution in water) was 
added slowly until the pH media became acidic. The aqueous was extracted with Et2O (3 × 
10 mL). The combined organic phases were washed with water (4 × 10 mL) and brine, dried 
(MgSO4), filtered and concentrated in vacuo to give a mixture of mono- and bis-acids. To a 
stirred solution of the crude acid mixture (0.124 g, 0.722 mmol) in CH2Cl2 (7 mL) was added 
N-[(1S)-1-phenylethyl]aniline (108) (0.308 g, 1.56 mmol), 2-chloro-1-methylpyridinium 
iodide (0.553 g, 2.17 mmol) and Et3N (1.00 mL, 7.22 mmol) at 0 °C. The reaction mixture 
was allowed to warm to room temperature and stirred overnight. HCl (10% in water, 20 mL) 
was added to the reaction mixture and the aqueous phase was extracted with CH2Cl2 (2 × 10 
mL). The combined organic phases were washed with water (10 mL) and brine (10 mL), 
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dried (MgSO4), filtered and concentrated in vacuo to give a mixture of mono- and bis-
anilides. Purification by column chromatography (SiO2, Hexane/EtOAc, 6:1 to 2:1) afforded 
the monoanilide product (0.121 g, 55%) as a clear oil and the title compound 92k (0.062 g, 
16%) as a foamy colourless solid and 1:1 mixture of inseparable diastereoisomers; mp. 47-
49 °C; Rf 0.30 (Hexane/EtOAc, 1:1); νmax (cm-1) 2973, 1741, 1642, 1594, 1494, 1451, 1392, 
1345, 1230, 1085, 778, 700; δH (400 MHz; CDCl3) 7.34 – 7.11 (18 H, m, HAr), 6.52 (1 H, d, 
J = 7.5 Hz, HAr), 6.20 (1 H, q, J = 7.2 Hz, H-5a), 6.17-6.13 (1 H, m, HAr), 6.16 (1 H, q, J = 
7.2 Hz, H-5b), 3.02 – 2.95 (2 H, m, H-12), 2.12 – 2.08 (2 H, m, H-14a), 2.07 – 1.96 (2 H, m, 
H-14b), 1.42 (3 H, d, J = 7.2 Hz, H-6a), 1.38 (3 H, d, J = 7.2 Hz, H-6b); δC (100 MHz; 
CDCl3) 209.8 and 208.8 (C-13), 169.5 and 169.3 (C-11), 140.9 and 140.5 (C-7), 137.9 and 
137.7 (C-4), 131.4 and 131.1 (CHAr), 129.9 and 129.5 (CHAr), 128.74 and 128.67 (CHAr), 
128.19 and 128.14 (CHAr), 128.1 (2 × CHAr), 127.6 and 127.5 (CHAr), 54.1 and 54.0 (C-12), 
52.7 and 52.5 (C-5), 26.6 and 26.5 (C-14), 17.3 and 17.2 (C-6); Found (ESI): [MNa]+ 
553.2468; C35H34N2NaO3 requires [MNa]
+ 553.2462, 1.2 ppm. 
Lab-book No PD/10/62. 
 
trans-1,1’’-bis[(1S)-1-Phenylethyl]-1,1’’,2,2’’-tetrahydrodispiro[indole-3,1’-cyclopentane-
3’,3’’-indole]-2,2’,2’’-trione (91k) 
 
To a stirred solution of bis-anilide 92k (0.036 g, 0.068 mmol) in DMF (2 mL) was added 
Cu(OAc)2∙H2O (0.028 g, 0.139 mmol) and KOt-Bu (0.017 g, 0.149 mmol). The reaction 
mixture was stirred at 110 °C for 15 min and allowed to cool to room temperature. An aq. 
solution of 10% NH4OH (2 × 5 mL) was added and the aqueous phase was extracted with 
EtOAc (2 × 5 mL). The combined organic phases were washed with water (4 × 5 mL), and 
brine (5 mL), dried (MgSO4), filtered and concentrated in vacuo. The residue was purified 
by column chromatography (SiO2, Hexane/EtOAc, 8:1) to give the title compound 91k 
(0.016 g, 46%) as a colourless solid, in a 1:1.3 91k/91k’ mixture of diastereoisomers, 
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inseparable by column chromatography; mp. 66-68 °C; Rf 0.31 (Hexane/EtOAc, 4:1); νmax 
(cm-1) 2981, 1755, 1700, 1608, 1484, 1466, 1348, 1310, 1254, 1052, 850, 752, 697; δH (400 
MHz; CDCl3) 7.50 – 7.45 (2 H, m, CHAr), 7.36 – 7.26 (10 H, m, CHAr), 7.10 – 7.00 (4 H, m, 
CHAr), 6.51 (1.1 H, d, J = 7.1 Hz, H-3’), 6.44 (0.9 H, dd, J = 7.1, 0.7 Hz, H-3), 5.78 (1 H, 
pent, J = 7.1 Hz, H-9), 3.26 – 3.16 (2 H, m, H-16a), 2.94 – 2.83 (2 H, m, H-16b), 1.84 (3 H, 
d, J = 7.2 Hz, H-10a), 1.84 (3 H, d, J = 7.2 Hz, H-10b); δC (100 MHz; CDCl3) 208.1 and 
208.0 (C-15), 175.2 and 175.1 (C-5), 142.5 and 142.4 (C-4), 139.0 and 138.6 (C-11), 130.2 
and 130.1 (C-7), 128.8 (CHAr), 128.6 (C-2), 127.6 and 127.5 (CHAr), 126.6 (CHAr), 124.4 
and 124.3 (C-8), 123.24 and 123.19 (C-1), 111.2 and 111.0 (C-3), 63.8 and 63.6 (C-6), 49.6 
and 49.2 (C-9), 32.7 and 32.3 (C-16), 16.5 and 16.3 (C-10); Found (ESI): [MNa]+ 549.2162; 
C35H30N2NaO3 requires [MNa]
+ 549.2149, 2.4 ppm. 
Lab-book No PD/10/73. 
 
Ethyl 2-methyl-3-(methyl(phenyl)amino)-3-oxopropanoate14a (112) 
 
To a stirred solution of 3-ethoxy-2-methyl-3-oxopropanoic acid (109) (2.41 g, 16.4 mmol) 
in CH2Cl2 (100 mL) was added at 0 °C, N-methylaniline (1.94 mL, 18.0 mmol), 2-chloro-1-
methylpyridinium iodide (6.23 g, 24.5 mmol), and Et3N (11.3 mL, 0.726 mmol). The 
reaction mixture was stirred at 0 °C for 30 min and allowed slowly to warm to room 
temperature and stirred for a further 2 h. A solution of HCl (10% in water, 75 mL) was added 
and the organic phase was extracted with CH2Cl2 (2 × 75 mL). The combined organic 
portions were washed with water (2 × 75 mL) and brine (2 × 75 mL), dried (MgSO4), filtered 
and concentrated in vacuo. The crude yellow oil was then purified by column 
chromatography (SiO2, Hexane/EtOAc, 6:1) to give the title compound 112 (3.26 g, 77%) 
as a yellow oil; Rf 0.42 (Hexane/EtOAc, 3:1); δH (400 MHz; CDCl3) 7.44 – 7.39 (2 H, m, H-
2), 7.38 – 7.33 (1 H, m, H-1), 7.23 (2 H, m, H-3), 4.09 (1 H, dq, J = 14.0, 7.1 Hz, H-10a), 
4.08 (1 H, dq, J = 14.0, 7.1 Hz, H-10b), 3.38 (1 H, q, J = 7.1 Hz, H-7), 3.28 (3 H, s, H-5), 
1.28 (3 H, d, J = 7.1 Hz, H-8), 1.21 (3 H, t, J = 7.1 Hz, H-11). 
Data are consistent with literature values.14a 
Lab-book No PD/4/59. 
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2-Methyl-3-(methyl(phenyl)amino)-3-oxopropanoyl chloride (113) 
 
To a stirred solution of ethyl 2-methyl-3-(methyl(phenyl)amino)-3-oxopropanoate (112) 
(3.26 g, 13.8 mmol) in THF (50 mL) was added a solution of LiOH∙H2O (2.32 g, 55.2 mmol) 
in water (10 mL). The reaction mixture was stirred overnight at room temperature, then a 
solution of HCl was added until acidic (pH ~ 2-3). The aqueous phase was extracted with 
EtOAc (2 × 50 mL), washed with water (2 × 50 mL) and brine (2 × 50 mL), dried (MgSO4), 
filtered and concentrated in vacuo. 
The crude acid (2.84 g, 13.7 mmol) was dissolved in CH2Cl2 (50 mL). The solution was 
cooled to 0 °C and (COCl)2 (1.17 mL, 13.8 mmol) and cat. DMF were added. The reaction 
mixture was stirred for 30 min and allowed to warm to room temperature and stirred for a 
further 3 h. Then, the reaction mixture was quenched with NH4Cl (50 mL), extracted with 
CH2Cl2 (2 × 50 mL), washed with brine (2 × 50 mL), dried (MgSO4), filtered, and 
concentrated in vacuo to give the title acid chloride 113 (2.75 g, 89%) as a green solid. The 
acid chloride was stored in the freezer and stable when kept at –10 °C for several months; 
δH (400 MHz; CDCl3) 7.51 – 7.45 (2 H, m, H-2), 7.44 – 7.39 (1 H, m, H-1), 7.28 (2 H, d, J 
= 7.3 Hz, H-3), 3.84 (1 H, q, J = 6.9 Hz, H-7), 3.33 (3 H, s, H-5), 1.37 (3 H, d, J = 6.9 Hz, 
H-8). 
Lab-book No PD/8/49. 
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N-Methyl-N-phenylpropionamide138 (114a) 
 
To a stirred solution of N-methylaniline (1.19 mL, 11.0 mmol) in EtOAc (20 mL) at 0 °C 
was added propionyl chloride (1.00 mL, 11.5 mmol) and Et3N (1.68 mL, 12.1 mmol). The 
reaction mixture was stirred for 1 h at 0 °C, warmed to room temperature and stirred for a 
further 2 h. A solution of aq. HCl (10%, 20 mL) was added and the organic phase was 
extracted with EtOAc (2 × 20 mL), washed with water (2 × 20 mL) and brine (2 × 20 mL), 
dried (MgSO4), filtered, and concentrated in vacuo to afford the title compound 114a (1.48 
g, 82%) as an off-white crystalline solid; mp. 54-56 °C (lit.138 57-59 °C); Rf 0.54 
(Hexane/EtOAc, 1:1); δH (400 MHz; CDCl3) 7.40 (2 H, t, J = 7.4 Hz, H-2), 7.32 (1 H, t, J = 
7.4 Hz, H-1), 7.19 – 7.14 (2 H, m, H-3), 3.25 (3 H, s, H-5), 2.07 (2 H, q, J = 7.5 Hz, H-7), 
1.03 (3 H, t, J = 7.5 Hz, H-8). 
Data are consistent with literature values.138 
Lab-book No PD/4/49. 
 
N-Methyl-N-phenylbutyramide139 (114b) 
 
To a stirred solution of N-methylaniline (0.542 mL, 5.00 mmol) in EtOAc (10 mL) at 0 °C 
was added butyryl chloride (0.545 mL, 5.25 mmol) and Et3N (0.765 mL, 5.50 mmol). The 
reaction mixture was stirred for 1 h at 0 °C, warmed to room temperature and stirred for a 
further 2 h. A solution of aq. HCl (10%, 20 mL) was added and the organic phase was 
extracted with EtOAc (2 × 10 mL), washed with water (2 × 10 mL) and brine (2 × 10 mL), 
dried (MgSO4), filtered, and concentrated in vacuo to afford the title compound 114b (0.633 
g, 71%) as an orange oil; Rf 0.53 (Hexane/EtOAc, 1:1); δH (400 MHz; CDCl3) 7.42 – 7.34 
(2 H, m, H-2), 7.34 – 7.25 (1 H, m, H-1), 7.18 – 7.09 (2 H, m, H-3), 3.23 (3 H, s, H-5), 2.00 
(2 H, t, J = 6.5 Hz, H-7), 1.55 (2 H, dd, J = 13.0, 6.5 Hz, H-8), 0.79 (3 H, t, J = 6.5 Hz, H-
9). 
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Data are consistent with literature values.139 
Lab-book No PD/8/64B. 
 
bis(N-Methyl-N-phenyl) 1,3-dimethyl-1,3-acetonedicarboxamide (115a) 
 
To a stirred solution of freshly distilled diisopropylamine (0.083 mL, 0.589 mmol) in THF 
(4 mL) at −10 °C was added n-BuLi (2.28 M in hexanes, 0.258 mL, 0.589 mmol). The 
reaction mixture was stirred for 15 min and cooled to −78 °C. A solution of anilide 114a 
(0.087 g, 0.535 mmol) in THF (1 mL) was added at −78 °C, stirred for 20 min and allowed 
to warm to 0 °C. The reaction mixture was cooled to −78 °C and a solution of acid chloride 
113 (0.134 g, 0.589 mmol) in THF (1 mL) was added. The resulting yellow mixture was 
stirred for 2 h at −78 °C, allowed to warm to room temperature and stirred for a further 1 h. 
The reaction solution was quenched with NH4Cl (5 mL). The aqueous phase was extracted 
with EtOAc (2 × 5 mL). The combined organic portions were washed with water (2 × 5 
mL) and brine (2 × 5 mL), dried (MgSO4), filtered, and concentrated in vacuo. The brown 
crude residue was purified by column chromatography (SiO2, Hexane/EtOAc, 1:1) to give 
the title compound 115a (0.103 g, 55%) as a colourless solid; mp. 80-82 °C; Rf 0.22 
(Hexane/EtOAc, 1:1); νmax (cm-1) 1707, 1655, 1594, 1495, 1452, 1416, 1383, 1262, 1124, 
1097, 1073, 1003, 785, 771, 698, 568, 530; δH (400 MHz; CDCl3) 7.36 (4 H, t, J = 7.4 Hz, 
H-2), 7.29 (2 H, t, J = 7.4 Hz, H-1), 7.23 (4 H, d, J = 7.4 Hz, H-3), 3.46 (2 H, q, J = 7.0 Hz, 
H-7), 3.22 (6 H, s, H-5), 0.97 (6 H, d, J = 7.0 Hz, H-8); δC (100 MHz; CDCl3) 203.5 (C-9), 
170.7 (C-6), 143.5 (C-4), 130.0 (C-2), 128.2 (C-1), 127.6 (C-3), 49.0 (C-7), 37.8 (C-5), 14.3 
(C-8); Found (ESI): [MNa]+ 375.1676; C21H24N2NaO3 requires [MNa]
+ 375.1679, 0.9 ppm. 
Anal. Calcd. for C21H24N2O3: C, 71.57; H, 6.86; N, 7.95. Found: C, 71.38; H, 6.96; N, 8.06. 
Lab-book No PD/8/94. 
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bis(N-Methyl-N-phenyl) 1-methyl,3-ethyl-1,3-acetonedicarboxamide (115b) 
 
To a stirred solution of freshly distilled diisopropylamine (0.060 mL, 0.429 mmol) in THF 
(2 mL) at −10 °C was added n-BuLi (2.5 M in hexanes, 0.180 mL, 0.450 mmol). The reaction 
mixture was stirred for 15 min and cooled to −78 °C. A solution of anilide 114b (0.073 g, 
0.409 mmol) in THF (1 mL) was added at −78 °C, the reaction stirred for 20 min and allowed 
to warm to 0 °C. The reaction mixture was cooled to −78 °C and a solution of 2-methyl-3-
(methyl(phenyl)amino)-3-oxopropanoyl chloride (113) (0.113 g, 0.501 mmol) in THF (1 
mL) was added. The resulting yellow mixture was stirred for 2 h at −78 °C, allowed to warm 
to room temperature and stirred for a further 1 h. The reaction solution was quenched with 
NH4Cl (5 mL). The aqueous phase was extracted with EtOAc (2 × 5 mL). The combined 
organic portions were washed with water (2 × 5 mL) and brine (2 × 5 mL), dried (MgSO4), 
filtered, and concentrated in vacuo. The brown crude residue was purified by column 
chromatography (SiO2, Hexane/EtOAc, 1:1) to give the title compound 115b (0.104 g, 69%) 
as an orange oil; Rf 0.54 (Hexane/EtOAc, 1:1); νmax (cm-1) 1717, 1649, 1594, 1495, 1454, 
1381, 1297, 1123, 774, 701; δH (400 MHz; CDCl3) 7.44 – 7.38 (6 H, m, HAr), 7.32 (4 H, t, J 
= 8.2 Hz, HAr), 3.69 (1 H, q, J = 7.0 Hz, H-11), 3.33 (1 H, dd, J = 8.0, 5.9 Hz, H-7), 3.27 (3 
H, s, H-5 or H-14), 3.24 (3 H, s, H-5 or H-14), 1.72 – 1.60 (1 H, m, H-8a), 1.43 – 1.35 (1 H, 
m, H-8b), 0.99 (3 H, d, J = 7.0 Hz, H-12), 0.69 (3 H, t, J = 7.4 Hz, H-9); δC (100 MHz; 
CDCl3) 203.1 (C-10), 170.9 (C-6 or C-13), 169.5 (C-6 or C-13), 143.7 (C-4 or C-15), 143.5 
(C-4 or C-15), 129.9 (CHAr), 128.1 (CHAr), 127.81 and 127.78 (CHAr), 57.1 (C-7), 48.2 (C-
11), 37.8 (C-5), 23.4 (C-8), 13.9 (C-12), 12.3 (C-9); Found (ESI): [MNa]+ 389.1843; 
C22H26N2NaO3 requires [MNa]
+ 389.1836, 2.0 ppm. 
Lab-book No PD/8/86. 
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dl-3-(1,3-Diethyl-2-oxo-2,3-dihydro-1H-indole-3-carbonyl)-1,3-dimethyl-2,3-dihydro-1H-
indol-2-one (dl-116a) 
 
To a stirred solution of bis-anilide 115a (0.036 g, 0.101 mmol) in mesitylene (3.5 mL) was 
added Cu(OAc)2∙H2O (0.021 g, 0.105 mmol). The reaction mixture was stirred for 30 min at 
reflux. Mesitylene was removed in vacuo. The resulting brown residue was diluted with 
EtOAc (5 mL) and washed twice with a 10% aq. solution of NH4OH (2 × 5 mL) and 4.0 M 
solution of NaOH (3 × 5 mL). The 1H NMR of the unpurified reaction mixture showed a 
mixture of diastereoisomers in a ratio of 1:1.5 dl-116a:meso-116a. Purification by column 
chromatography (SiO2, Hexane/EtOAc, 4:1) gave first the title diastereoisomer dl-116a 
(0.010 g, 27%) as a colourless solid; mp. 262-264 °C; Rf 0.42 (Hexane/EtOAc, 1:1); νmax 
(cm-1) 1728, 1706, 1611, 1492, 1469, 1374, 1345, 1120, 1028, 768, 752; δH (400 MHz; 
CDCl3) 7.10 (2 H, td, J = 7.6, 1.1 Hz, H-2), 7.06 (2 H, dd, J = 7.6, 1.1 Hz, H-8), 6.98 (2 H, 
td, J = 7.6, 1.1 Hz, H-1), 6.31 (2 H, d, J = 7.6 Hz, H-3), 2.78 (6 H, s, H-9), 1.48 (6 H, s, H-
11); δC (100 MHz; CDCl3) 196.3 (C-10), 174.1 (C-5), 144.1 (C-4), 129.0 (C-2), 127.8 (C-
7), 125.5 (C-8), 122.2 (C-1), 107.9 (C-3), 62.1 (C-6), 26.3 (C-9), 22.7 (C-11); Found (ESI): 
[MNa]+ 371.1350; C21H20N2NaO3 requires [MNa]
+ 371.1366, 4.3 ppm. CCDC 1004039 
contains the supplementary crystallographic data for this paper. These data can be obtained 
free of charge from The Cambridge Crystallographic Data Centre via 
www.ccdc.cam.ac.uk/data_request/cif. 
Crystals suitable for X-ray diffraction were obtained by slow evaporation from hexane in 
which a few drops of dichloromethane were added. 
Lab-book No PD/8/97A/2A. 
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meso-3-(1,3-Dimethyl-2-oxo-2,3-dihydro-1H-indole-3-carbonyl)-1,3-dimethyl-2,3-
dihydro-1H-indol-2-one (meso-116a) 
 
The diastereoisomer meso-116a (0.011 g, 31%) was then isolated by column 
chromatography (SiO2, Hexane/EtOAc, 4:1) as a colourless solid; mp. 170-172 °C; Rf 0.25 
(Hexane/EtOAc, 1:1); νmax (cm-1) 1731, 1717, 1608, 1490, 1468, 1374, 1344, 1120, 1032, 
761, 542; δH (400 MHz; CDCl3) 7.20 (2 H, td, J = 7.6, 1.2 Hz, H-2), 6.76 (2 H, td, J = 7.6, 
1.2 Hz, H-1), 6.63 (2 H, d, J = 7.6 Hz, H-3), 6.55 (2 H, dd, J = 7.6, 1.2 Hz, H-8), 2.91 (6 H, 
s, H-9), 1.50 (6 H, s, H-11); δC (100 MHz; CDCl3) 197.9 (C-10), 174.2 (C-5), 144.4 (C-4), 
129.1 (C-2), 128.6 (C-7), 123.9 (C-8), 122.3 (C-1), 108.3 (C-3), 61.3 (C-6), 26.4 (C-9), 22.9 
(C-11); Found (ESI): [MNa]+ 371.1372; C21H20N2NaO3 requires [MNa]
+ 371.1366, 1.6 ppm. 
Lab-book No PD/8/97A/2C. 
 
trans-3-(3-Ethyl-1-methyl-2-oxo-2,3-dihydro-1H-indole-3-carbonyl)-1,3-dimethyl-2,3-
dihydro-1H-indol-2-one (trans-116b) 
 
To a stirred solution of bis-anilide 115b (0.051 g, 0.140 mmol) in mesitylene (4 mL) was 
added Cu(OAc)2∙H2O (0.028 g, 0.140 mmol). The reaction mixture was stirred for 30 min at 
170 °C (Drysyn heating block). Mesitylene was removed in vacuo. The resulting brown 
residue was diluted with EtOAc (5 mL) and washed twice with a 10% aq. solution of NH4OH 
(2 × 5 mL) and 4.0 M solution of NaOH (3 × 5 mL). 1H NMR of the crude reaction showed 
a mixture of diastereoisomers in a ratio of 1.5:1 trans-116b:cis-116b. Purification by column 
chromatography (SiO2, Hexane/EtOAc, 4:1 to 1:1) gave first the title diastereoisomer trans-
116b (0.021 g, 41%) as a colourless solid; mp. 200-202 °C; Rf 0.42 (Hexane/EtOAc, 1:1); 
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νmax (cm-1) 1724, 1701, 1609, 1489, 1461, 1369, 1346, 1259, 1160, 1101, 765; δH (400 MHz; 
CDCl3) 7.11 – 7.05 (3 H, m, HAr), 7.03 (1 H, dd, J = 7.6, 1.2 Hz, HAr), 7.01 – 6.93 (2 H, m, 
HAr), 6.29 (2 H, d, J = 7.6 Hz, H-3, H-3’), 2.80 (3 H, s, H-9’), 2.79 (3 H, s, H-9), 2.21 (1 H, 
dq, J = 14.8, 7.4 Hz, H-11a), 2.10 (1 H, dq, J = 14.8, 7.4 Hz, H-11b), 1.47 (3 H, s, H-13), 
0.42 (3 H, t, J = 7.4 Hz, H-12); δC (100 MHz; CDCl3) 196.1 (C-10), 174.2 (C-5), 173.2 (C-
5’), 144.9 (C-4’), 144.0 (C-4), 129.0 (C-2 or C-2’), 128.9 (C-2 or C-2’), 127.9 (C-7’), 126.0 
(C-8 or C-8’), 125.4 (C-7), 125.2 (C-8 or C-8’), 122.1 (C-1 or C-1’), 121.9 (C-1 or C-1’), 
107.9 (C-3 or C-3’), 107.7 (C-3 or C-3’), 67.2 (C-6), 62.3 (C-6’), 29.1 (C-11), 26.4 (C-9 or 
C-9’), 26.2 (C-9 or C-9’), 22.8 (C-13), 7.8 (C-12); Found (ESI): [MNa]+ 385.1525; 
C22H22N2NaO3 requires [MNa]
+ 385.1523, 0.7 ppm. CCDC 1016758 contains the 
supplementary crystallographic data for this compound. These data can be obtained free of 
charge from The Cambridge Crystallographic Data Centre via 
www.ccdc.cam.ac.uk/data_request/cif. 
Crystals suitable for X-ray diffraction were obtained by slow evaporation from hexane in 
which a few drops of dichloromethane were added. 
Lab-book No PD/8/93/2A. 
 
cis-3-(3-Ethyl-1-methyl-2-oxo-2,3-dihydro-1H-indole-3-carbonyl)-1,3-dimethyl-2,3-
dihydro-1H-indol-2-one (cis-116b) 
 
The diastereoisomer cis-116b (0.013 g, 26%) was then isolated by column chromatography 
(SiO2, Hexane/EtOAc, 1:1) as a colourless solid; mp. 155-157 °C; Rf 0.23 (Hexane/EtOAc, 
1:1); νmax (cm-1) 1727, 1712, 1611, 1493, 1470, 1372, 1347, 1259, 1161, 1102, 755; δH (400 
MHz; CDCl3) 7.20 (1 H, td, J = 7.6, 1.2 Hz, H-2 or H-2’), 7.19 (1 H, td, J = 7.6, 1.2 Hz, H-
2 or H-2’), 6.78 (1 H, td, J = 7.6, 1.2 Hz, H-1), 6.73 (1 H, td, J = 7.6, 1.2 Hz, H-1’), 6.65 (1 
H, d, J = 7.6 Hz, H-3’), 6.60 (1 H, d, J = 7.6 Hz, H-3), 6.57 (1 H, dd, J = 7.6, 1.2 Hz, H-8), 
6.48 (1 H, dd, J = 7.6, 1.2 Hz, H-8’), 2.94 (3 H, s, H-9’), 2.85 (3 H, s, H-9), 2.18 (1 H, dq, J 
= 14.8, 7.4 Hz, H-11a), 2.09 (1 H, dq, J = 14.8, 7.4 Hz, H-11b), 1.48 (3 H, s, H-13), 0.47 (3 
H, t, J = 7.4 Hz, H-12); δC (100 MHz; CDCl3) 197.7 (C-10), 174.2 (C-5), 173.3 (C-5’), 145.0 
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(C-4’), 144.6 (C-4), 129.1 (C-2 or C-2’), 129.1 (C-2 or C-2’), 128.6 (C-7’), 126.6 (C-7), 
124.3 (C-8 or C-8’), 123.7 (C-8 or C-8’), 122.2 (C-1, C-1’), 108.4 (C-3 or C-3’), 108.1 (C-
3 or C-3’), 66.2 (C-6), 61.6 (C-6’), 29.6 (C-11), 26.5 (C-9 or C-9’), 26.2 (C-9 or C-9’), 22.9 
(C-13), 7.7 (C-12); Found (ESI): [MNa]+ 385.1518; C22H22N2NaO3 requires [MNa]
+ 
385.1523, 1.3 ppm. CCDC 1004041 contains the supplementary crystallographic data for 
this compound. These data can be obtained free of charge from The Cambridge 
Crystallographic Data Centre via www.ccdc.cam.ac.uk/data_request/cif. 
Crystals suitable for X-ray diffraction were obtained by slow evaporation from hexane in 
which a few drops of dichloromethane were added. 
Lab-book No PD/8/93/2C. 
 
Ethyl 3-(N-methyl-N-phenylamino)-3-oxopropionate140 (117) 
 
To a stirred solution of commercially available 3-ethoxy-3-oxopropanoic acid in CH2Cl2 
(100 mL) at 0 °C, was added N-methylaniline (6.50 mL, 60.1 mmol), 2-chloro-1-
methylpyridinium iodide (20.8 g, 81.9 mmol), and Et3N (38.0 mL, 273 mmol). The reaction 
mixture was stirred at 0 °C for 1 h and allowed to warm to room temperature and stirred for 
a further 2 h. A solution of HCl (10% in water, 100 mL) was added and the organic phase 
was extracted with CH2Cl2 (2 × 100 mL). The combined organic portions were washed with 
water (2 × 100 mL) and brine (2 × 100 mL), dried (MgSO4), filtered and concentrated in 
vacuo. The crude yellow oil was then purified by column chromatography (SiO2, 
Hexane/EtOAc, 1:1) to give the title compound 117 (12.0 g, 99%) as a yellow oil; Rf 0.37 
(Hexane/EtOAc, 1:1); δH (400 MHz; CDCl3) 7.41 (2 H, t, J = 7.3 Hz, H-2), 7.35 (1 H, t, J = 
7.3 Hz, H-1), 7.22 (2 H, d, J = 7.3 Hz, H-3), 4.11 (2 H, q, J = 7.1 Hz, H-8), 3.29 (3 H, s, H-
10), 3.19 (2 H, s, H-6), 1.21 (3 H, t, J = 7.1 Hz, H-9). 
Data are consistent with literature values.140 
Lab-book No PD/4/58. 
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6.2.4 General procedure E: dialkylation reaction 
 
dl/meso-1,8-Diethyl 2,7-bis[N-methyl(N-phenyl)carbamoyl]octanedioate (dl/meso-118a) 
 
To a stirred suspension of NaH (60% in mineral oil, 0.107 g, 2.66 mmol) in DMF (20 mL) 
was added ethyl 3-(N-methyl-N-phenylamino)-3-oxopropionate (117) (0.490 g, 2.22 mmol) 
at 0 °C. The reaction mixture was stirred for 15 min at 0 °C and 1,4-dibromobutane (0.131 
mL, 1.11 mmol) was then added at 0 °C. The reaction was stirred at room temperature 
overnight. The reaction mixture was quenched by addition of an aq. sol. of NH4Cl (20 mL). 
The aqueous phase was extracted with EtOAc (2 × 20 mL). The combined organic portions 
were washed with water (4 × 20 mL) and brine (20 mL), dried (MgSO4), filtered, and 
concentrated in vacuo. The crude residue was purified by column chromatography (SiO2, 
Hexane/EtOAc, 2:1) to give the title compound dl/meso-118a (0.298 g, 54%) as a colourless 
oil in a 1:1 mixture of diastereoisomers, inseparable by column chromatography; Rf 0.25 
(Hexane/EtOAc, 1:2); νmax (cm-1) 1733, 1655, 1595, 1496, 1382, 1181, 1116, 1026, 919, 
774, 729, 700; δH (400 MHz; CDCl3) 7.42 – 7.36 (4 H, m, H-2), 7.36 – 7.29 (2 H, m, H-1), 
7.21 – 7.16 (4 H, m, H-3), 4.14 – 4.00 (4 H, m, H-8), 3.27 (3 H, s, H-10a), 3.26 (3 H, s, H-
10b), 3.23 (1 H, t, J = 5.7 Hz, H-6a), 3.21 (1 H, t, J = 5.7 Hz, H-6b), 1.85 – 1.67 (4 H, m, H-
11), 1.20 (6 H, t, J = 7.1 Hz, H-9), 1.16 – 0.96 (4 H, m, H-12); δC (100 MHz; CDCl3) 170.1 
(C-7), 169.2 and 169.1 (C-5), 143.5 (C-4), 129.9 (C-2), 128.3 (C-1), 127.8 (C-3), 61.2 (C-
8), 49.1 (C-6), 37.7 (C-10), 29.4 and 29.3 (C-11), 27.41 and 27.40 (C-12), 14.2 (C-9); Found 
(ESI): [MNa]+ 519.2461; C28H36N2NaO6 requires [MNa]
+ 519.2466, 0.8 ppm. 
Lab-book No PD/9/66. 
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dl/meso-1,8-Diethyl (4E)-2,7-bis[methyl(phenyl)carbamoyl]oct-4-enedioate (dl/meso-
118b) 
 
NaH (60% in mineral oil, 0.110 g, 2.75 mmol), 3-(N-methyl-N-phenylamino)-3-
oxopropionate (117) (0.491 g, 2.22 mmol), and trans-1,4-dibromo-2-butene (0.234 g, 1.09 
mmol) in DMF (20 mL) were subjected to general procedure E. The residue was purified by 
column chromatography (SiO2, Hexane/EtOAc, 2:1) to give the title compound dl/meso-
118b (0.434 g, 79%) as a colourless waxy oil in a 1:1 mixture of diastereoisomers, 
inseparable by column chromatography; Rf 0.18 (Hexane/EtOAc, 1:1); νmax (cm-1) 1734, 
1655, 1595, 1496, 1382, 1255, 1183, 1156, 1116, 1027, 774, 729, 700; δH (400 MHz; CDCl3) 
7.41 – 7.34 (4 H, m, H-2), 7.33 – 7.27 (2 H, m, H-1), 7.21 – 7.12 (4 H, m, H-3), 5.23 – 5.19 
(2 H, m, H-12), 4.10 – 4.00 (4 H, m, H-8), 3.30 (1 H, dd, J = 5.9, 3.1 Hz, H-6a), 3.28 (1 H, 
dd, J = 5.9, 3.1 Hz, H-6b), 3.24 (3 H, s, H-10a), 3.21 (3 H, s, H-10b), 2.58 – 2.35 (4 H, m, 
H-11), 1.18 (3 H, t, J = 7.1 Hz, H-9a), 1.18 (3 H, t, J = 7.1 Hz, H-9b); δC (100 MHz; CDCl3) 
169.61 and 169.55 (C-7), 168.6 and 168.5 (C-5), 143.5 and 143.4 (C-4), 129.9 (C-2), 129.1 
and 129.0 (C-12), 128.2 (C-1), 127.9 and 127.8 (C-3), 61.2 (C-8), 49.0 and 48.9 (C-6), 37.72 
and 37.66 (C-10), 32.5 (C-11), 14.1 (C-9); Found (ESI): [MNa]+ 517.2310; C28H34N2NaO6 
requires [MNa]+ 517.2309, 0.3 ppm. 
Lab-book No PD/9/71. 
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dl/meso-Ethyl 2-[(2-{3-ethoxy-2-[methyl(phenyl)carbamoyl]-3-
oxopropyl}phenyl)methyl]-2-[methyl(phenyl)carbamoyl]acetate (dl/meso-118c) 
 
NaH (60% in mineral oil, 0.111 g, 2.70 mmol), 3-(N-methyl-N-phenylamino)-3-
oxopropionate (117) (0.499 g, 2.25 mmol), and dibromo-o-xylene (0.300 g, 1.13 mmol) in 
DMF (20 mL) were subjected to general procedure E. The residue was purified by column 
chromatography (SiO2, Hexane/EtOAc, 2:1) to give the title compound dl/meso-118c (0.406 
g, 66%) as a white solid in a 1:1 mixture of diastereoisomers, inseparable by column 
chromatography; mp. 86-88 °C; Rf 0.23 (Hexane/EtOAc, 1:1); νmax (cm-1) 1740, 1654, 1595, 
1495, 1382, 1259, 1183, 1116, 1026, 728, 700; δH (400 MHz; CDCl3) 7.23 – 7.13 (7 H, m, 
HAr), 7.12 – 7.05 (3 H, m, HAr), 7.01 – 6.95 (1 H, m, HAr), 6.60 (3 H, br s, HAr), 4.14 – 4.03 
(4 H, m, H-8), 3.43 (1 H, dd, J = 8.9, 6.1 Hz, H-6a), 3.38 (1 H, dd, J = 11.4, 4.1 Hz, H-6b), 
3.10 (3 H, s, H-10a), 3.08 (3 H, s, H-10b), 2.87 (1 H, d, J = 6.1 Hz, H-11a), 2.86 (1 H, d, J 
= 8.9 Hz, H-11a’), 2.80 (1 H, dd, J = 13.6, 11.4 Hz, H-11b), 2.51 (1 H, dd, J = 13.6, 4.1 Hz, 
H-11b’), 1.21 (6 H, t, J = 7.1 Hz, H-9); δC (100 MHz; CDCl3) 169.4 and 169.2 (C-7), 168.5 
(C-5), 143.1 and 142.9 (C-4), 136.9 and 136.7 (C-12), 130.8 and 130.6 (CHAr), 129.58 and 
129.55 (CHAr), 128.2 and 128.1 (CHAr), 127.6 and 127.4 (CHAr), 127.1 and 126.8 (CHAr), 
61.40 and 61.36 (C-8), 50.0 and 49.2 (C-6), 37.5 and 37.3 (C-10), 31.6 and 31.5 (C-11), 
14.12 and 14.07 (C-9); Found (ESI): [MNa]+ 567.2475; C32H36N2NaO6 requires [MNa]
+ 
567.2466, 1.6 ppm. Anal. Calcd. for C32H36N2O6: C, 70.57; H, 6.66; N, 5.14. Found: C, 
70.03; H, 6.58; N, 4.88. 
Lab-book No PD/9/70. 
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6.2.5 General procedure F: double cyclisation of di-ester containing bis-oxindoles 
 
dl/meso-Ethyl 3-{4-[3-(ethoxycarbonyl-1-methyl-2-oxo-2,3-dihydro-1H-indol-3-yl]butyl}-
1-methyl-2-oxo-2,3-dihydro-1H-indole-3-carboxylate (dl/meso-119a) 
 
To a stirred solution of bis-anilide dl/meso-118a (0.060 g, 0.121 mmol) in mesitylene (2 mL) 
was added Cu(OAc)2∙H2O (0.024 g, 0.121 mmol). The reaction mixture was stirred for 30 
min at 170 °C and allowed to cool to room temperature. Mesitylene was removed and the 
residue was diluted with EtOAc (5 mL), and washed with an aq. sol. of NH4OH (5 mL). The 
aqueous phase was extracted with EtOAc (2 × 5 mL). The combined organic extracts were 
washed with water (5 mL), and brine (5 mL), dried (MgSO4), filtered and concentrated in 
vacuo. The crude product was purified by column chromatography (SiO2, Hexane/EtOAc, 
3:1) to give the title compound dl/meso-119a (0.054 g, 90%) as a yellow solid in a 1:1 
mixture of diastereoisomers, inseparable by column chromatography; mp. 145-147 °C; Rf 
0.35 (Hexane/EtOAc, 1:2); νmax (cm-1) 1736, 1709, 1609, 1492, 1470, 1372, 1346, 1223, 
1081, 1020, 750, 727; δH (400 MHz; CDCl3) 7.29 (1 H, td, J = 7.4, 1.2 Hz, H-2a), 7.28 (1 
H, td, J = 7.4, 1.2 Hz, H-2b), 7.16 (1 H, dd, J = 7.4, 1.2 Hz, H-8a), 7.15 (1 H, dd, J = 7.4, 
1.2 Hz, H-8b), 7.04 (1 H, td, J = 7.4, 1.2 Hz, H-1a), 7.02 (1 H, td, J = 7.4, 1.2 Hz, H-1b), 
6.80 (2 H, t, J = 8.3 Hz, H-3), 4.13 – 4.02 (4 H, m, H-11), 3.20 (3 H, s, H-9a), 3.18 (3 H, s, 
H-9b), 2.15 – 2.00 (4 H, m, H-13), 1.12 (3 H, t, J = 7.1 Hz, H-12a), 1.10 (3 H, t, J = 7.1 Hz, 
H-12b), 0.99 – 0.73 (4 H, m, H-14); δC (100 MHz; CDCl3) 174.3 and 174.2 (C-5), 169.4 (C-
10), 144.1 (C-4), 129.1 and 129.0 (C-2), 128.1 and 128.0 (C-7), 123.37 and 123.36 (C-8), 
123.0 and 122.8 (C-1), 108.3 (C-3), 61.9 (C-11), 59.5 and 59.4 (C-6), 34.0 and 33.9 (C-13), 
26.47 and 26.45 (C-9), 23.63 and 23.55 (C-14), 13.99 and 13.98 (C-12); Found (ESI): 
[MNa]+ 515.2153; C28H32N2NaO6 requires [MNa]
+ 515.2153, 0.1 ppm. 
Lab-book No PD/9/69B. 
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dl/meso-Ethyl 3-[(2E)-4-[3-(ethoxycarbonyl)-1-methyl-2-oxo-2,3-dihydro-1H-indol-3-
yl]but-2-en-1-yl]-1-methyl-2-oxo-2,3-dihydro-1H-indole-3-carboxylate (dl/meso-119b) 
 
Bis-anilide dl/meso-118b (0.049 g, 0.100 mmol), and Cu(OAc)2∙H2O (0.020 g, 0.100 mmol) 
in mesitylene (2 mL) were subjected to general procedure F. The reaction mixture was stirred 
at 170 °C for 2 h. The residue was purified by column chromatography (SiO2, 
Hexane/EtOAc, 2:1) to give the title compound dl/meso-119b (0.032 g, 66%) as a yellow 
solid in a 1:1 mixture of diastereoisomers, inseparable by column chromatography; mp. 130-
132 °C; Rf 0.35 (Hexane/EtOAc, 1:1); νmax (cm-1) 1736, 1711, 1609, 1493, 1470, 1372, 1347, 
1223, 1086, 1021, 750, 729; δH (400 MHz; CDCl3) 7.28 (2 H, td, J = 7.6, 1.1 Hz, H-2), 7.14 
– 7.09 (2 H, m, H-8), 7.04 – 6.98 (2 H, m, H-1), 6.79 (2 H, d, J = 7.6 Hz, H-3), 5.02 (1 H, 
dd, J = 4.4, 3.6 Hz, H-14a), 4.94 (1 H, d, J = 3.6 Hz, H-14b), 4.11 – 4.00 (4 H, m, H-11), 
3.21 (3 H, s, H-9a), 3.14 (3 H, s, H-9b), 2.80 (2 H, td, J = 14.1, 3.2 Hz, H-13a), 2.69 – 2.55 
(2 H, m, H-13b), 1.10 (3 H, t, J = 7.1 Hz, H-12a), 1.09 (3 H, t, J = 7.1 Hz, H-12b); δC (100 
MHz; CDCl3) 173.6 and 173.5 (C-5), 169.0 and 168.9 (C-10), 144.2 and 144.1 (C-4), 129.0 
(C-2), 127.9 and 127.61 (C-14), 127.56 and 127.49 (C-7), 123.7 and 123.5 (C-8), 122.8 and 
122.7 (C-1), 108.5 and 108.3 (C-3), 61.9 (C-11), 59.3 and 59.1 (C-6), 37.20 and 37.16 (C-
13), 26.6 and 26.5 (C-9), 14.0 (C-12); Found (ESI): [MNa]+ 513.1997; C28H30N2NaO6 
requires [MNa]+ 513.1996, 0.1 ppm. 
Lab-book No PD/9/78. 
  
152 
dl/meso-Ethyl 3-[(2-{[ethoxycarbonyl)-1-methyl-2-oxo-2,3-dihydro-1H-indol-3-
yl]methyl}phenyl)methyl]-1-methyl-2-oxo-2,3-dihydro-1H-indole-3-carboxylate (dl/meso-
119c) 
 
Bis-anilide dl/meso-118c (0.060 g, 0.111 mmol), and Cu(OAc)2∙H2O (0.024 g, 0.120 mmol) 
in mesitylene (3 mL) were subjected to general procedure F. The reaction mixture was stirred 
at 170 °C for 2 h. The residue was purified by column chromatography (SiO2, 
Hexane/EtOAc, 2:1) to give the title compound dl/meso-119c (0.048 g, 89%) as a colourless 
solid in a 1:1 mixture of diastereoisomers, inseparable by column chromatography; mp. 113-
115 °C; Rf 0.42 (Hexane/EtOAc, 1:2); νmax (cm-1) 1735, 1710, 1609, 1492, 1470, 1372, 1351, 
1222, 1095, 1060, 1021, 751, 728; δH (400 MHz; CDCl3) 7.24 (1 H, d, J = 7.4 Hz, H-8a), 
7.18 (1 H, t, J = 7.4 Hz, H-2a), 7.14 (1 H, t, J = 7.4 Hz, H-2b), 7.08 (1 H, d, J = 7.4 Hz, H-
8b), 6.98 (1 H, t, J = 7.4 Hz, H-1a), 6.95 (1 H, t, J = 7.4 Hz, H-1b), 6.74 – 6.68 (2 H, m, H-
16), 6.68 – 6.63 (2 H, m, H-15), 6.54 (1 H, d, J = 7.4 Hz, H-3a), 6.50 (1 H, d, J = 7.4 Hz, H-
3b), 4.15 (4 H, dq, J = 14.4, 7.2 Hz, H-11), 3.64 (1 H, d, J = 14.2 Hz, H-13a), 3.39 (1 H, d, 
J = 14.2 Hz, H-13a’), 3.33 (1 H, d, J = 14.2 Hz, H-13b), 3.18 (1 H, d, J = 14.2 Hz, H-13b’), 
2.93 (3 H, s, H-9a), 2.91 (3 H, s, H-9b), 1.17 (3 H, t, J = 7.1 Hz, H-12a), 1.15 (3 H, t, J = 7.1 
Hz, H-12b); δC (100 MHz; CDCl3) 173.8 and 173.7 (C-5), 169.3 and 169.2 (C-10), 144.0 
and 143.4 (C-4), 134.1 and 133.8 (C-14), 129.9 and 129.7 (C-15), 129.1 and 129.0 (C-2), 
127.4 and 127.1 (C-7), 126.1 and 126.0 (C-16), 124.4 and 124.2 (C-8), 122.4 and 122.3 (C-
1), 108.03 and 108.01 (C-3), 62.1 and 62.0 (C-11), 61.0 and 60.9 (C-6), 35.94 and 35.87 (C-
13), 26.2 (C-9), 14.0 (C-12); Found (ESI): [MNa]+ 563.2163; C32H32N2NaO6 requires 
[MNa]+ 563.2153, 1.9 ppm. Anal. Calcd. for C32H32N2O6: C, 71.09; H, 5.97; N, 5.18. Found: 
C, 70.73; H, 6.02; N, 5.06. 
Lab-book No PD/9/86. 
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6.3 The synthesis of indole derivatives 
 
6.3.1 General procedure G: alkylation step 
 
Ethyl 2-methyl-3-oxo-3-phenylpropanoate71 (152a) 
 
To a stirred solution of ethyl benzoylacetate (0.866 mL, 5.00 mmol) in DMF (5 mL) was 
added K2CO3 (1.04 g, 7.50 mmol) and iodomethane (0.343 mL, 5.50 mmol). The reaction 
mixture was heated at 60 °C for 3 h and allowed to cool to room temperature. The resulting 
yellow suspension was quenched with water (50 mL) and the aqueous phase was extracted 
with EtOAc (2 × 50 mL). The combined organic extracts were washed with water (3 × 50 
mL) and brine (50 mL), dried (MgSO4), filtered, and concentrated in vacuo. The residue was 
purified by column chromatography (SiO2, Hexane/EtOAc, 8:1) and afforded the title 
compound 152a (1.03 g, 99%) as a yellow oil; Rf 0.27 (Hexane/EtOAc, 9:1); δH (400 MHz; 
CDCl3) 7.99 – 7.94 (2 H, m, H-3), 7.60 – 7.54 (1 H, m, H-1), 7.50 – 7.43 (2 H, m, H-2), 4.36 
(1 H, q, J = 7.1 Hz, H-6), 4.13 (2 H, q, J = 7.1 Hz, H-8), 1.48 (3 H, d, J = 7.1 Hz, H-10), 
1.15 (3 H, t, J = 7.1 Hz, H-9). 
Data are consistent with literature values.71 
Lab-book No PD/7/78. 
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6.3.2 General procedure H: Zn-mediated condensation approach to N-aryl enamines 
 
Ethyl (2Z)-2-methyl-3-phenyl-3-(phenylamino)prop-2-enoate71 (147a) 
 
To a stirred solution of ethyl 2-methyl-3-oxo-3-phenylpropanoate (152a) (1.03 g, 4.99 
mmol) in 1,2-dichloroethane (2.5 mL) was added aniline (0.910 mL, 9.99 mmol), 
Zn(ClO4)2·6H2O (0.093 g, 0.250 mmol) and MgSO4 (0.184 g, 1.53 mmol). The reaction 
mixture was stirred at 60 °C for 18 h and allowed to cool to room temperature. The solvent 
was removed in vacuo and the residue was purified by column chromatography (SiO2, 
Hexane/EtOAc, 8:1) to give the title compound 147a (0.418 g, 30%) as a pale yellow solid; 
mp. 67-69 °C; Rf 0.58 (Hexane/EtOAc, 6:1); νmax (cm-1) 3224, 2991, 1638, 1568, 1497, 1247, 
1137, 1029, 777, 709; δH (400 MHz; CDCl3) 10.92 (1 H, br s, H-5), 7.34 – 7.31 (3 H, m, 
HAr), 7.25 – 7.22 (2 H, m, HAr), 7.03 – 6.94 (2 H, m, H-2), 6.79 (1 H, t, J = 7.4 Hz, H-1), 
6.52 (2 H, d, J = 7.8 Hz, H-3), 4.24 (2 H, q, J = 7.1 Hz, H-14), 1.68 (3 H, s, H-12), 1.34 (3 
H, t, J = 7.1 Hz, H-15); Found (ESI): [MH]+ 282.1483; C18H20NO2 requires [MH]
+ 282.1489, 
2.0 ppm. 
Data are consistent with literature values (no reported melting point).71 
Lab-book No PD/7/82. 
 
Ethyl 3-oxo-2,3-diphenylpropanoate141 (152b) 
 
To a stirred solution of diisopropylamine (0.924 mL, 6.59 mmol) in THF (20 mL) was added 
n-BuLi (2.5 M in hexanes, 2.76 mL, 6.90 mmol) at 0 °C. The reaction mixture was stirred at 
0 °C for 15 min and cooled to –78 °C, then ethyl phenylacetate (1.00 mL, 6.27 mmol) was 
added and the reaction mixture was stirred at –78 °C for 30 min. Benzoyl chloride (0.765 
155 
mL, 6.59 mmol) was then added at –78 °C and the reaction was allowed to warm to room 
temperature and stirred for 18 h. The resulting yellow solution was quenched with sat. aq. 
NH4Cl (20 mL). The aqueous phase was extracted with EtOAc (2 × 20 mL). The combined 
organic extracts were washed with water (20 mL) and brine (20 mL), dried (MgSO4), 
filtered, and concentrated in vacuo to afford a yellow oil which was purified by column 
chromatography (SiO2, Hexane/EtOAc, 49:1 to 9:1) to give the title compound 152b (1.40 
g, 83%) as a colourless solid; mp. 63-65 °C (Lit.142 89-90 °C); Rf 0.36 (Hexane/EtOAc, 4:1); 
δH (400 MHz; CDCl3) 7.95 (2 H, dd, J = 8.3, 1.2 Hz, HAr), 7.55 – 7.49 (1 H, m, HAr), 7.45 – 
7.38 (4 H, m, HAr), 7.37 – 7.32 (2 H, m, HAr), 7.32 – 7.26 (1 H, m, HAr), 5.60 (1 H, s, H-6), 
4.21 (1 H, q, J = 7.1 Hz, H-8a), 4.21 (1 H, q, J = 7.1 Hz, H-8b), 1.23 (3 H, t, J = 7.1 Hz, H-
9). 
Data are consistent with literature values.141, 142 
Lab-book No PD/9/91. 
 
Ethyl (2Z)-2,3-diphenyl-3-(phenylamino)prop-2-enoate (147b) 
 
Ethyl 3-oxo-2,3-diphenylpropanoate (152b) (0.168 g, 0.625 mmol), aniline (0.114 mL, 1.25 
mmol), Zn(ClO4)2·6H2O (0.012 g, 0.031 mmol) and MgSO4 (0.023 g, 0.187 mmol) in 1,2-
dichloroethane (1.5 mL) were subjected to general procedure H. The residue was purified 
by column chromatography (SiO2, Hexane/EtOAc, 19:1) to give the title compound 147b 
(0.056 g, 26%) as a pale yellow oil; Rf 0.69 (Hexane/EtOAc, 4:1); νmax (cm-1) 3197, 2987, 
1645, 1590, 1566, 1415, 1256, 1205, 1129, 1025, 793, 696, 571; δH (400 MHz; CDCl3) 11.33 
(1 H, br s, H-5), 7.09 – 6.97 (12 H, m, HAr), 6.87 (1 H, td, J = 7.4, 1.0 Hz, H-1), 6.62 (2 H, 
d, J = 7.8 Hz, H-3), 4.21 (2 H, q, J = 7.1 Hz, H-17), 1.24 (3 H, t, J = 7.1 Hz, H-18); δC (100 
MHz; CDCl3)
 170.6 (C-16), 158.1 (C-6), 140.5 (C-4), 137.3 (C-12), 134.8 (C-7), 133.0 
(CHAr), 130.4 (CHAr), 128.6 (CHAr), 128.2 (CHAr), 127.8 (CHAr), 127.1 (CHAr), 125.5 
(CHAr), 123.0 (C-1), 122.6 (C-3), 102.9 (C-11), 60.0 (C-17), 14.6 (C-18); Found (ESI): 
[MNa]+ 366.1462; C23H21NNaO2 requires [MNa]
+ 366.1465, 0.8 ppm. 
Lab-book No PD/9/95.  
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Ethyl 2-benzoylpent-4-enoate143 (152c) 
 
Ethyl benzoylacetate (1.22 mL, 7.00 mmol), allyl bromide (0.666 mL, 7.70 mmol), and 
K2CO3 (1.45 g, 10.5 mmol) in DMF (10 mL) were subjected to general procedure G. The 
residue was purified by column chromatography (SiO2, Hexane/EtOAc, 9:1) to give the title 
compound 152c (0.803 g, 49%) as a colourless oil; Rf 0.50 (Hexane/EtOAc, 4:1); δH (400 
MHz; CDCl3) 7.98 (2 H, d, J = 7.5 Hz, H-3), 7.60 – 7.54 (1 H, m, H-1), 7.49 – 7.42 (2 H, m, 
H-2), 5.86 – 5.73 (1 H, m, H-11), 5.10 (1 H, dd, J = 17.1, 1.2 Hz, H-12a), 5.02 (1 H, dd, J = 
10.2, 1.2 Hz, H-12b), 4.38 (1 H, t, J = 7.2 Hz, H-6), 4.12 (2 H, q, J = 7.1 Hz, H-8), 2.76 – 
2.71 (2 H, m, H-10), 1.14 (3 H, td, J = 7.1, 1.2 Hz, H-9). 
Data are consistent with literature values.143 
Lab-book No PD/10/48. 
 
Ethyl (2Z)-2-[phenyl(phenylamino)methylidene]pent-4-enoate (147c) 
 
Ethyl 2-benzoylpent-4-enoate (152c) (0.261 g, 1.12 mmol), aniline (0.205 mL, 2.25 mmol), 
Zn(ClO4)2·6H2O (0.057 g, 0.152 mmol) and MgSO4 (0.040 g, 0.336 mmol) in 1,2-
dichloroethane (2 mL) were subjected to general procedure H. The residue was purified by 
column chromatography (SiO2, Hexane/EtOAc, 49:1) to give the title compound 147c (0.049 
g, 14%) as a colourless oil; Rf 0.6 (Hexane/EtOAc, 4:1); νmax (cm-1) 3073, 2977, 1648, 1610, 
1593, 1572, 1358, 1265, 1204, 1171, 1126, 1025, 910, 778, 692; δH (400 MHz; CDCl3) 11.13 
(1 H, br s, H-5), 7.33 – 7.29 (3 H, m, H-9 and H-10), 7.29 – 7.21 (2 H, m, H-8), 6.99 (2 H, 
t, J = 7.9 Hz, H-2), 6.82 (1 H, t, J = 7.3 Hz, H-1), 6.54 (2 H, d, J = 8.0 Hz, H-3), 5.81 (1 H, 
ddt, J = 16.8, 10.1, 5.8 Hz, H-13), 4.89 (1 H, dd, J = 10.1, 1.4 Hz, H-14a), 4.82 (1 H, dd, J 
= 16.8, 1.4 Hz, H-14b), 4.25 (2 H, q, J = 7.1 Hz, H-16), 2.80 (2 H, d, J = 5.8 Hz, H-12), 1.32 
(3 H, t, J = 7.1 Hz, H-17); δC (100 MHz; CDCl3) 171.2 (C-15), 157.7 (C-6), 140.8 (C-4), 
157 
138.9 (C-13), 135.1 (C-7), 129.2 (C-8), 128.8 (C-10), 128.6 (C-2), 128.4 (C-9), 122.6 (C-1), 
122.1 (C-3), 113.8 (C-14), 96.7 (C-11), 59.7 (C-16), 32.2 (C-12), 14.6 (C-17); Found (ESI): 
[MH]+ 308.1641; C20H22NO2 requires [MH]
+ 308.1645, 1.5 ppm. 
Lab-book No PD/10/52. 
 
Ethyl 2-benzoyl-4[(tert-butyldimethylsilyl)oxy]butanoate (152d) 
 
Ethyl benzoylacetate (0.866 mL, 5.00 mmol), tert-butyl(2-iodoethoxy)dimethylsilane (1.54 
mL, 5.38 mmol), and K2CO3 (1.04 g, 7.50 mmol) in DMF (10 mL) were subjected to general 
procedure G. The residue was purified by column chromatography (SiO2, Hexane/EtOAc, 
19:1) to give the title compound 152d (0.901 g, 51%) as a colourless oil; Rf 0.56 
(Hexane/EtOAc, 4:1); νmax (cm-1) 2951, 2931, 2862, 1740, 1687, 1253, 1195, 1159, 1096, 
1002, 948, 833, 775, 690; δH (400 MHz; CDCl3) 8.06 – 7.99 (2 H, m, H-3), 7.60 – 7.53 (1 
H, m, H-1), 7.50 – 7.43 (2 H, m, H-2), 4.66 (1 H, dd, J = 7.3, 6.5 Hz, H-6), 4.15 (2 H, q, J = 
7.1 Hz, H-8), 3.67 (2 H, t, J = 5.8 Hz, H-11), 2.27 – 2.13 (2 H, m, H-10), 1.17 (3 H, t, J = 
7.1 Hz, H-9), 0.87 (9 H, s, H-14), 0.01 (3 H, s, H-12a), –0.02 (3 H, s, H-12b); δC (100 MHz; 
CDCl3) 195.9 (C-5), 170.1 (C-7), 136.2 (C-4), 133.5 (C-1), 128.9 (C-2 or C-3), 128.7 (C-2 
or C-3), 61.4 (C-8), 60.5 (C-11), 50.3 (C-6), 32.1 (C-10), 26.0 (C-14), 18.3 (C-13), 14.1 (C-
9), –5.4 (C-12a), –5.5 (C-12b); Found (ESI): [MNa]+ 373.1791; C19H30NaO4Si requires 
[MNa]+ 373.1806, 3.8 ppm. 
Lab-book No PD/9/94. 
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Ethyl (2Z)-4-[(tert-butyldimethylsilyl)oxy]-2-[phenyl(phenylamino)methylidene]butanoate 
(147d) 
 
Ethyl 2-benzoyl-4[(tert-butyldimethylsilyl)oxy]butanoate (152d) (0.344 g, 0.981 mmol), 
aniline (0.179 mL, 1.96 mmol), Zn(ClO4)2·6H2O (0.030 g, 0.081 mmol) and MgSO4 (0.040 
g, 0.332 mmol) in 1,2-dichloroethane (3 mL) were subjected to general procedure H. The 
residue was purified by column chromatography (SiO2, Hexane/EtOAc, 49:1 to 19:1) to give 
the title compound 147d (0.044 g, 10%) as a yellow oil along with the by-product 172a 
(0.021 g, 8%) inseparable by column chromatography; Rf 0.66 (Hexane/EtOAc, 4:1); νmax 
(cm-1) 2959, 2927, 2854, 1653, 1612, 1594, 1573, 1503, 1267, 1210, 1171, 1132, 1086, 1025, 
1038, 835, 774, 749, 699; δH (400 MHz; CDCl3) 11.19 (1 H, br s, H-5), 7.34 – 7.31 (3 H, m, 
HAr), 7.28 – 7.24 (2 H, m, HAr), 7.00 – 6.95 (2 H, m, H-2), 6.82 (1 H, t, J = 7.4 Hz, H-1), 
6.51 (2 H, d, J = 7.7 Hz, H-3), 4.26 (2 H, q, J = 7.1 Hz, H-18), 3.57 – 3.47 (2 H, m, H-13), 
2.39 – 2.32 (2 H, m, H-12), 1.35 (3 H, t, J = 7.1 Hz, H-19), 0.83 (9 H, s, H-16), −0.07 (6 H, 
s, H-14); δC (100 MHz; CDCl3) 171.3 (C-17), 158.6 (C-6), 140.6 (C-4), 135.0 (C-7), 129.4 
(CHAr), 128.7 (CHAr), 128.3 (CHAr), 122.7 (CHAr), 122.3 (CHAr), 122.2 (CHAr), 94.5 (C-11), 
63.6 (C-13), 59.7 (C-18), 31.3 (C-12), 26.1 (C-16), 18.5 (C-15), 14.7 (C-19), −5.2 (C-14); 
Found (ESI): [MNa]+ 448.2288; C25H35NNaO3Si requires [MNa]
+ 448.2278, 2.1 ppm. 
Lab-book No PD/9/97. 
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Ethyl (2Z)-3[(2,4-dimethoxyphenyl)amino]-2-methyl-3-phenylprop-2-enoate (147e) 
 
Ethyl 2-methyl-3-oxo-3-phenylpropanoate (152a) (0.431 g, 2.09 mmol), 2,4-
dimethoxyaniline (0.642 mL, 4.19 mmol), Zn(ClO4)2·6H2O (0.039 g, 0.104 mmol) and 
MgSO4 (0.083 g, 0.691 mmol) in 1,2-dichloroethane (3 mL) were subjected to general 
procedure H. The residue was purified by column chromatography (SiO2, Hexane/EtOAc, 
19:1) to give the title compound 147e (0.151 g, 21%) as a light brown solid; mp. 75-77 °C; 
Rf 0.38 (Hexane/EtOAc, 4:1); νmax (cm-1) 2935, 1648, 1608, 1572, 1512, 1249, 1205, 1122, 
1034, 832, 776, 703; δH (400 MHz; CDCl3) 10.65 (1 H, br s, H-9), 7.30 – 7.26 (3 H, m, HAr), 
7.22 – 7.18 (2 H, m, HAr), 6.34 (1 H, d, J = 2.7 Hz, H-7), 6.10 (1 H, d, J = 8.8 Hz, H-3), 5.99 
(1 H, dd, J = 8.8, 2.7 Hz, H-2), 4.24 (2 H, q, J = 7.1 Hz, H-18), 3.81 (3 H, s, H-6 or H-8), 
3.64 (3 H, s, H-6 or H-8), 1.65 (3 H, s, H-16), 1.33 (3 H, t, J = 7.1 Hz, H-19); δC (100 MHz; 
CDCl3) 171.5 (C-17), 157.1 (C-10), 156.1 (C-1 or C-5), 152.6 (C-1 or C-5), 136.0 (C-11), 
129.3 (C-12 or C-13), 128.4 (C-14), 128.2 (C-12 or C-13), 123.8 (C-4), 123.4 (C-3), 103.2 
(C-2), 98.7 (C-7), 92.9 (C-15), 59.5 (C-18), 55.8 (C-6 or C-8), 55.4 (C-6 or C-8), 14.7 (C-
19), 14.4 (C-16); Found (ESI): [MNa]+ 364.1522; C20H23NNaO4 requires [MNa]
+ 364.1519, 
0.6 ppm. 
Lab-book No PD/9/96. 
 
N-(Diphenylmethylidene)hydroxylamine144 
 
To a stirred solution of benzophenone (1.82 g, 10.0 mmol) in MeOH (15 mL) was added 
NH2OH·HCl (1.11 g, 16.0 mmol) and NaOAc (1.64 g, 20.0 mmol) in water (20 mL). The 
reaction mixture was stirred at reflux overnight and allowed to cool to room temperature. 
Water (20 mL) was added, the aqueous phase was extracted with EtOAc (20 mL) and 
separated. The organic layer was dried (MgSO4), filtered, and concentrated in vacuo. 
Purification by column chromatography (SiO2, Hexane/EtOAc, 6:1) afforded the title 
compound (0.976 g, 50%) as a colourless solid; mp. 139-141 °C (Lit.144 140 °C); Rf 0.52 
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(Hexane/EtOAc, 1:1); δH (400 MHz; CDCl3) 8.63 (1 H, br s, H-6), 7.48 – 7.39 (7 H, m, HAr), 
7.38 – 7.29 (3 H, m, HAr). 
Data are consistent with literature values.144 
Lab-book No PD/11/5. 
 
1,3-Di-tert-butyl 2-[phenyl(phenylamino)methylidene]propanedioate (147f) 
 
To a stirred solution of benzophenone oxime (0.099 g, 0.500 mmol) in toluene (6 mL) was 
added Et3N (0.070 mL, 0.500 mmol) and triflic anhydride (0.126 mL, 0.750 mmol) at –78 
°C. The reaction mixture was stirred at –78 °C for 5 min and the preformed di-tert-butyl 
malonate sodium salt (1.50 mmol) in THF (2 mL) was introduced via cannula at –78 °C. The 
reaction mixture, that turned instantly yellow, was allowed to warm to room temperature, 
and stirred for 1 h. NH4OH (10 mL) was added and the aqueous phase was extracted with 
EtOAc (2 × 10 mL). The combined organic phases were washed with brine (10 mL), dried 
(MgSO4), filtered, and concentrated in vacuo. Purification by column chromatography 
(SiO2, Hexane/EtOAc, 19:1) afforded the title compound 147f (0.100 g, 51%) as a colourless 
oil; Rf 0.52 (Hexane/EtOAc, 4:1); νmax (cm-1) 2977, 2932, 1717, 1652, 1594, 1572, 1501, 
1366, 1280, 1253, 1164, 1133, 851, 698; δH (400 MHz; CDCl3) 10.87 (1 H, br s, H-5), 7.42 
– 7.17 (5 H, m, H-8, H-9, H-10), 7.11 – 6.93 (2 H, m, H-2), 6.88 (1 H, t, J = 7.5 Hz, H-1), 
6.61 (2 H, d, J = 7.8 Hz, H-3), 1.52 (9 H, s, H-14a), 1.18 (9 H, s, H-14b); δC (100 MHz; 
CDCl3) 167.9 (C-12a), 166.6 (C-12b), 158.6 (C-6), 139.5 (C-4), 134.0 (C-7), 129.3 (C-10), 
129.1 (C-8 or C-9), 128.6 (C-2), 128.3 (C-8 or C-9), 123.8 (C-1), 123.2 (C-3), 101.5 (C-11), 
80.6 (C-13a), 80.2 (C-13b), 28.6 (C-14a), 27.6 (C-14b); Found (ESI): [MH]+ 396.2156; 
C24H30NO4 requires [MH]
+ 396.2169, 3.4 ppm. 
Lab-book No PD/11/8. 
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6.3.3 General procedure I: Formation of β-ketoester 
 
Ethyl 3-(naphthalen-2-yl)-3-oxopropanoate145 
 
To a stirred suspension of NaH (60% in dispersion in oil, 1.20 g, 50.8 mmol) in THF (10 
mL) was added diethylcarbonate (4.85 mL, 40.0 mmol) and the reaction mixture was brought 
to reflux. Then, 2-acetonaphthone (1.70 g, 10.0 mmol) was added dropwise. The suspension 
was stirred for 3 h, and allowed to cool to room temperature. Glacial acetic acid (1 mL), 
followed by aq. sol. of HCl (10%, 20 mL) were added to the reaction mixture. The aqueous 
phase was extracted with EtOAc (2 × 10 mL). The combined organic phases were washed 
with aq. sol. of NaHCO3 (10 mL), H2O (10 mL), and brine (10 mL), dried (MgSO4), filtered, 
and concentrated in vacuo to give a brown oil, which was purified by column 
chromatography (SiO2, Hexane/EtOAc, 8:1) to afford the title compound (2.23 g, 92%) as a 
yellow oil; Rf 0.45 (Hexane/EtOAc, 4:1); δH (400 MHz; CDCl3) 8.43 (1 H, d, J = 1.3 Hz, 
HAr), 8.00 (1 H, dd, J = 8.6, 1.8 Hz, HAr), 7.95 (1 H, d, J = 7.8 Hz, HAr), 7.88 (2 H, d, J = 8.8 
Hz, HAr), 7.60 (1 H, ddd, J = 8.2, 7.0, 1.4 Hz, HAr), 7.55 (1 H, ddd, J = 8.2, 7.0, 1.4 Hz, HAr), 
4.22 (2 H, q, J = 7.1 Hz, H-14), 4.10 (2 H, s, H-12), 1.25 (3 H, t, J = 7.1 Hz, H-15). 
Data are consistent with literature values.145 
Lab-book No PD/11/19. 
 
Ethyl 2-methyl-3-(naphthalen-2-yl)-3-oxopropanoate146 (152g) 
 
Ethyl 3-(naphthalen-2-yl)-3-oxopropanoate (1.01 g, 4.17 mmol), iodomethane (0.285 mL, 
4.59 mmol), and K2CO3 (0.868 g, 6.28 mmol) in DMF (10 mL) were subjected to general 
procedure G. The residue was purified by column chromatography (SiO2, Hexane/EtOAc, 
19:1) to give the title compound 152g (0.833 g, 78%) as a pale yellow oil; Rf 0.38 
(Hexane/EtOAc, 4:1); δH (400 MHz; CDCl3) 8.50 (1 H, s, HAr), 8.02 (1 H, dd, J = 8.8, 1.8 
Hz, HAr), 7.96 (1 H, d, J = 8.3 Hz, HAr), 7.89 (1 H, d, J = 8.8 Hz, HAr), 7.86 (1 H, d, J = 8.3 
Hz, HAr), 7.60 (1 H, ddd, J = 8.1, 7.0, 1.5 Hz, HAr), 7.55 (1 H, ddd, J = 8.1, 7.0, 1.5 Hz, HAr), 
162 
4.53 (1 H, q, J = 7.0 Hz, H-12), 4.15 (1 H, q, J = 7.1 Hz, H-14a), 4.14 (1 H, q, J = 7.1 Hz, 
H-14b), 1.54 (3 H, d, J = 7.0 Hz, H-16), 1.15 (3 H, t, J = 7.1 Hz, H-15); δC (100 MHz; 
CDCl3) 195.9 (C-11), 171.1 (C-13), 135.8 (CAr), 133.3 (CAr), 132.6 (CAr), 130.5 (CHAr), 
129.8 (CHAr), 128.8 (CHAr), 128.7 (CHAr), 127.9 (CHAr), 127.0 (CHAr), 124.2 (CHAr), 61.5 
(C-14), 48.5 (C-12), 14.1 (C-15 or C-16), 14.0 (C-15 or C-16). 
Data are consistent with literature values.146 
Lab-book No PD/11/22. 
 
Ethyl (2Z)-2-methyl-3-(naphthalen-2-yl)-3-(phenylamino)prop-2-enoate (147g) 
 
Ethyl 2-methyl-3-(naphthalen-2-yl)-3-oxopropanoate (152g) (0.198 g, 0.773 mmol), aniline 
(0.141 mL, 1.55 mmol), Zn(ClO4)2·6H2O (0.029 g, 0.077 mmol) and MgSO4 (0.028 g, 0.232 
mmol) in 1,2-dichloroethane (2 mL) were subjected to general procedure H. The residue was 
purified by column chromatography (SiO2, Hexane/EtOAc, 49:1) to give the title compound 
147g (0.032 g, 13%) as a colourless solid; mp. 80-82 °C; Rf 0.60 (Hexane/EtOAc, 4:1); νmax 
(cm-1) 3228, 2979, 1649, 1592, 1576, 1499, 1256, 1238, 1137, 1112, 822, 748; δH (400 MHz; 
CDCl3) 11.01 (1 H, br s, H-5), 7.89 – 7.74 (4 H, m, HAr), 7.58 – 7.45 (2 H, m, HAr), 7.35 (1 
H, dd, J = 8.4, 1.7 Hz, HAr), 6.97 – 6.88 (2 H, m, H-2), 6.75 (1 H, t, J = 7.4 Hz, H-1), 6.57 
(2 H, d, J = 7.6 Hz, H-3), 4.27 (2 H, q, J = 7.1 Hz, H-20), 1.72 (3 H, s, H-18), 1.36 (3 H, t, J 
= 7.1 Hz, H-21); δC (100 MHz; CDCl3) 171.6 (C-19), 155.9 (C-6), 141.2 (C-4), 133.1 (C-9, 
C-14), 133.0 (C-7), 129.1 (CHAr), 128.6 (C-2), 128.4 (CHAr), 128.2 (CHAr), 127.9 (CHAr), 
127.0 (CHAr), 126.8 (CHAr), 126.4 (CHAr), 122.2 (C-1), 121.6 (C-3), 95.2 (C-17), 59.8 (C-
20), 14.7 (C-21), 14.4 (C-18); Found (ESI): [MH]+ 332.1644; C22H22NO2 requires [MH]
+ 
332.1645, 0.3 ppm. 
Lab-book No PD/11/26. 
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Ethyl 3-(4-methylphenyl)-3-oxopropanoate145 
 
4-Methylacetophenone (1.34 mL, 10.0 mmol), diethylcarbonate (4.85 mL, 40.0 mmol) and 
NaH (60% in dispersion in oil, 1.21 g, 50.4 mmol) in THF (10 mL) were subjected to general 
procedure I. The residue was purified by column chromatography (SiO2, Hexane/EtOAc, 
19:1) to give the title compound (1.84 g, 89%) as a yellow oil in a 4:1 mixture of keto-enol 
tautomers; Rf 0.33 (Hexane/EtOAc, 6:1); δH (400 MHz; CDCl3, Keto) 7.82 (2 H, dd, J = 8.2, 
2.0 Hz, HAr), 7.25 (2 H, dd, J = 8.2, 2.0 Hz, HAr), 4.19 (2 H, qd, J = 7.1, 2.0 Hz, H-9), 3.95 
(2 H, d, J = 1.9 Hz, H-7), 2.40 (3 H, d, J = 2.4 Hz, H-1), 1.24 (3 H, td, J = 7.1, 2.0 Hz, H-
10); δH (400 MHz; CDCl3, Enol) 12.58 (1 H, s, OH), 7.65 (2 H, dd, J = 8.3, 2.0 Hz, HAr), 
7.20 (2 H, dd, J = 8.3, 2.0 Hz, HAr), 5.61 (1 H, d, J = 1.7 Hz, H-7), 4.24 (2 H, qd, J = 7.1, 
2.0 Hz, H-9), 2.37 (3 H, d, J = 2.3 Hz, H-1), 1.31 (3 H, td, J = 7.2, 2.1 Hz, H-10). 
Data are consistent with literature values.145 
Lab-book No PD/10/49. 
 
Ethyl 2-methyl-3-(4-methylphenyl)-3-oxopropanoate146 (152h) 
 
Ethyl 3-(4-methylphenyl)-3-oxopropanoate (1.19 g, 5.77 mmol), iodomethane (0.395 mL, 
6.35 mmol), and K2CO3 (1.20 g, 8.65 mmol) in DMF (10 mL) were subjected to general 
procedure G. The residue was purified by column chromatography (SiO2, Hexane/EtOAc, 
19:1) to give the title compound 152h (0.906 g, 71%) as a colourless oil; Rf 0.33 
(Hexane/EtOAc, 6:1); δH (400 MHz; CDCl3) 7.86 (2 H, d, J = 8.0 Hz, HAr), 7.24 (2 H, d, J 
= 8.0 Hz, HAr), 4.33 (1 H, q, J = 7.1 Hz, H-7), 4.12 (2 H, q, J = 7.1 Hz, H-9), 2.39 (3 H, s, 
H-1), 1.46 (3 H, dd, J = 7.1, 1.1 Hz, H-11), 1.15 (3 H, td, J = 7.1, 1.1 Hz, H-10). 
Data are consistent with literature values.146 
Lab-book No PD/10/53. 
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Ethyl (2Z)-2-methyl-3-(4-methylphenyl)-3-(phenylamino)prop-2-enoate (147h) 
 
Ethyl 2-methyl-3-(4-methylphenyl)-3-oxopropanoate (152h) (0.296 g, 1.34 mmol), aniline 
(0.245 mL, 2.68 mmol), Zn(ClO4)2·6H2O (0.053 g, 0.141 mmol) and MgSO4 (0.054 g, 0.444 
mmol) in 1,2-dichloroethane (2 mL) were subjected to general procedure H. The residue was 
purified by column chromatography (SiO2, Hexane/EtOAc, 49:1) to give the title compound 
147h (0.045 g, 11%) as a colourless oil; Rf 0.6 (Hexane/EtOAc, 6:1); νmax (cm-1) 3218, 2979, 
1649, 1594, 1578, 1498, 1250, 1171, 1128, 1034, 1015, 826, 780, 733, 692; δH (400 MHz; 
CDCl3) 10.92 (1 H, br s, H-5), 7.13 (4 H, s, H-8 and H-9), 7.02 – 6.96 (2 H, m, H-2), 6.80 
(1 H, t, J = 7.4 Hz, H-1), 6.54 (2 H, d, J = 7.6 Hz, H-3), 4.24 (2 H, q, J = 7.1 Hz, H-15), 2.34 
(3 H, s, H-11), 1.70 (3 H, s, H-13), 1.34 (3 H, t, J = 7.1 Hz, H-16); δC (100 MHz; CDCl3) 
171.6 (C-14), 156.3 (C-6), 141.3 (C-4), 138.6 (C-10), 132.6 (C-7), 129.4 (C-8 or C-9), 129.2 
(C-8 or C-9), 128.5 (C-2), 122.1 (C-1), 121.6 (C-3), 94.5 (C-12), 59.7 (C-15), 21.5 (C-11), 
14.7 (C-16), 14.3 (C-13); Found (ESI): [MH]+ 296.1640; C19H22NO2 requires [MH]
+ 
296.1645, 1.7 ppm. 
Lab-book No PD/10/56. 
 
Ethyl 3-(4-chlorophenyl)-3-oxopropanoate147 
 
4-Chloroacetophenone (1.30 mL, 10.0 mmol), diethylcarbonate (4.85 mL, 40.0 mmol) and 
NaH (60% in dispersion in oil, 1.22 g, 50.8 mmol) in THF (10 mL) were subjected to general 
procedure I. The residue was purified by column chromatography (SiO2, Hexane/EtOAc, 
19:1) to give the title compound (2.03 g, 90%) as a yellow oil in a 3:1 mixture of keto-enol 
tautomers; Rf 0.38 (Hexane/EtOAc, 6:1); δH (400 MHz; CDCl3, Keto) 7.93 – 7.80 (2 H, m, 
HAr), 7.54 – 7.40 (2 H, m, HAr), 4.21 – 4.14 (2 H, m, H-8), 3.96 – 3.91 (2 H, m, H-6), 1.26 – 
1.18 (3 H, m, H-9); δH (400 MHz; CDCl3, Enol) 12.84 – 12.31 (1 H, m, OH), 7.71 – 7.65 (2 
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H, m, HAr), 7.39 – 7.33 (2 H, m, HAr), 5.87 – 5.46 (1 H, m, H-6), 4.28 – 4.22 (2 H, m, H-8), 
1.34 – 1.28 (3 H, m, H-9). 
Data are consistent with literature values.147 
Lab-book No PD/10/50. 
 
Ethyl 3-(4-chlorophenyl)-2-methyl-3-oxopropanoate148 (152i) 
 
Ethyl 3-(4-chlorophenyl)-3-oxopropanoate (1.71 g, 7.54 mmol), iodomethane (0.517 mL, 
8.30 mmol), and K2CO3 (1.56 g, 11.3 mmol) in DMF (15 mL) were subjected to general 
procedure G. The residue was purified by column chromatography (SiO2, Hexane/EtOAc, 
19:1) to give the title compound 152i (1.45 g, 80%) as a colourless oil; Rf 0.29 
(Hexane/EtOAc, 6:1); δH (400 MHz; CDCl3) 7.94 – 7.87 (2 H, m, HAr), 7.47 – 7.40 (2 H, m, 
HAr), 4.30 (1 H, qd, J = 7.0, 1.4 Hz, H-6), 4.17 – 4.08 (2 H, m, H-8), 1.49 – 1.43 (3 H, m, H-
10), 1.18 – 1.12 (3 H, m, H-9); δC (100 MHz; CDCl3) 194.7 (C-5), 170.7 (C-7), 140.0 (C-4), 
134.3 (C-1), 130.1 (CHAr), 129.1 (CHAr), 61.6 (C-8), 48.5 (C-6), 14.0 (C-9 or C-10), 13.7 
(C-9 or C-10). 
Data are consistent with literature values.148 
Lab-book No PD/10/54. 
 
Ethyl (2Z)-3-(4-chlorophenyl)-2-methyl-3-(phenylamino)prop-2-enoate (147i) 
 
Ethyl 3-(4-chlorophenyl)-3-oxopropanoate (152i) (0.334 g, 1.39 mmol), aniline (0.253 mL, 
2.77 mmol), Zn(ClO4)2·6H2O (0.058 g, 0.155 mmol) and MgSO4 (0.062 g, 0.518 mmol) in 
1,2-dichloroethane (2 mL) were subjected to general procedure H. The residue was purified 
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by column chromatography (SiO2, Hexane/EtOAc, 49:1) to give the title compound 147i 
(0.086 g, 20%) as a colourless oil; Rf 0.64 (Hexane/EtOAc, 6:1); νmax (cm-1) 3228, 2980, 
1651, 1592, 1578, 1498, 1477, 1250, 1132, 1090, 1012, 835, 781, 750, 693; δH (400 MHz; 
CDCl3) 10.83 (1 H, br s, H-5), 7.30 (2 H, d, J = 8.3 Hz, H-9), 7.19 (2 H, d, J = 8.3 Hz, H-8), 
7.05 – 6.99 (2 H, m, H-2), 6.83 (1 H, t, J = 7.4 Hz, H-1), 6.54 (2 H, d, J = 7.5 Hz, H-3), 4.24 
(2 H, q, J = 7.1 Hz, H-14), 1.68 (3 H, s, H-12), 1.34 (3 H, t, J = 7.1 Hz, H-15); δC (100 MHz; 
CDCl3) 171.4 (C-13), 154.8 (C-6), 140.9 (C-4), 134.6 (C-10), 134.1 (C-7), 131.0 (C-8), 
128.8 (C-2 or C-9), 128.7 (C-2 or C-9), 122.5 (C-1), 122.0 (C-3), 95.2 (C-11), 59.9 (C-14), 
14.6 (C-15), 14.3 (C-12); Found (ESI): [MNa]+ 338.0901; C18H18ClNNaO2 requires [MNa]
+ 
338.0918, 5.0 ppm. 
Lab-book No PD/10/57. 
 
Ethyl 3-oxo-3-(thiophen-2-yl)propanoate149 
 
To a stirred solution of thiophene-2-carboxylic acid (1.28 g, 10.0 mmol) in CH2Cl2 (15 mL) 
was added 2,2-dimethyl-1,3-dioxane-4,6-dione (1.73 g, 12.0 mmol), DMAP (2.46 g, 20.1 
mmol) and DCC (2.27 g, 11.0 mmol) at 0 °C. The reaction mixture was stirred at room 
temperature for 2 h. The dicyclohexylurea was then filtered off, and washed with CH2Cl2 
(20 mL). The filtrate was concentrated in vacuo and the residue was dissolved in absolute 
EtOH (60 mL). The solution was then treated with a solution of p-TSA (4.67 g, 24.5 mmol) 
in absolute EtOH (15 mL) and heated at reflux for 1 h. EtOH was removed in vacuo and the 
residue was dissolved with EtOAc (50 mL). The organic extracts were washed with water 
(50 mL), aq. sat. NaHCO3 (50 mL), aq. HCl (10%, 50 mL), and brine (50 mL). The organic 
phase was dried (MgSO4), filtered and concentrated in vacuo. The residue was filtered 
through a pad of silica (SiO2, Hexane/EtOAc, 9:1) to give the title compound (1.81 g, 91%) 
as an orange oil; Rf 0.31 (Hexane/EtOAc, 4:1); δH (400 MHz; CDCl3) 7.72 (1 H, dd, J = 3.8, 
1.0 Hz, H-3), 7.68 (1 H, dd, J = 4.9, 1.0 Hz, H-1), 7.13 (1 H, dd, J = 4.9, 3.8 Hz, H-2), 4.19 
(2 H, q, J = 7.2 Hz, H-8), 3.90 (2 H, s, H-6), 1.24 (3 H, t, J = 7.2 Hz, H-9). 
Data are consistent with literature values.149 
Lab-book No PD/10/6. 
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Ethyl 2-methyl-3-oxo-3-(thiophen-2-yl)propanoate150 (152j) 
 
To a stirred suspension of NaH (60% in dispersion in oil, 0.117 g, 2.94 mmol) in DMF (25 
mL) was added ethyl 3-oxo-3-(thiophen-2-yl)propanoate (0.530 g, 2.67 mmol) at 0 °C. The 
reaction mixture was stirred at 0 °C for 30 min and iodomethane (0.183 mL, 2.94 mmol) 
was slowly added. The reaction mixture was stirred at 0 °C for 1 h and allowed to warm to 
room temperature and stirred for a further 1 h, then quenched by slow addition of water (30 
mL) at 0 °C. The aqueous phase was extracted with EtOAc (2 × 30 mL). The combined 
organic extracts were washed with water (4 × 20 mL) and brine (30 mL), dried (MgSO4), 
filtered and concentrated in vacuo to give a crude yellow oil which was purified by column 
chromatography (SiO2, Hexane/EtOAc, 8:1) and afforded the title compound 152j (0.282 g, 
53%) as a colourless oil; Rf 0.32 (Hexane/EtOAc, 4:1); δH (400 MHz; CDCl3) 7.77 (1 H, dd, 
J = 3.9, 1.1 Hz, H-3), 7.67 (1 H, dd, J = 4.9, 1.1 Hz, H-1), 7.13 (1 H, dd, J = 4.9, 3.9 Hz, H-
2), 4.21 (1 H, q, J = 7.1 Hz, H-6), 4.15 (2 H, q, J = 7.1 Hz, H-8), 1.49 (3 H, d, J = 7.1 Hz, 
H-10), 1.19 (3 H, t, J = 7.1 Hz, H-9). 
Data are consistent with literature values.150 
Lab-book No PD/10/8. 
 
Ethyl (2Z)-2-methyl-3-(phenylamino)-3-(thiophen-2-yl)prop-2-enoate (147j) 
 
To a stirred solution of ethyl 2-methyl-3-oxo-3-(thiophen-2-yl)propanoate (152j) (0.194 g, 
0.914 mmol) in AcOH (0.262 mL, 4.57 mmol) was added an excess of aniline (0.416 mL, 
4.57 mmol). The reaction mixture was stirred at 80 °C for 5 h and allowed to cool to room 
temperature. Water (10 mL) was added and the aqueous phase was extracted with CH2Cl2 
(2 × 10 mL). The combined organic phases were washed with water (10 mL) and brine (10 
mL), dried (MgSO4), filtered, and concentrated in vacuo. The residue was purified by 
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column chromatography (SiO2, Hexane/EtOAc, 99:1 to 19:1) and afforded the title 
compound 147j (0.029 g, 11%) as a yellow oil; Rf 0.25 (Hexane/EtOAc, 8:1); νmax (cm-1) 
2982, 1735, 1654, 1612, 1594, 1498, 1250, 1215, 1116, 853, 779, 757, 711, 696; δH (400 
MHz; CDCl3) 10.61 (1 H, br s, H-5), 7.43 (1 H, dd, J = 5.0, 0.7 Hz, H-10), 7.40 (1 H, dd, J 
= 3.7, 0.7 Hz, H-8), 7.05 (2 H, t, J = 7.8 Hz, H-2), 7.00 (1 H, dd, J = 5.0, 3.7 Hz, H-9), 6.85 
(1 H, t, J = 7.8 Hz, H-1), 6.63 (2 H, d, J = 7.8 Hz, H-3), 4.23 (2 H, q, J = 7.1 Hz, H-14), 1.87 
(3 H, s, H-12), 1.33 (3 H, t, J = 7.1 Hz, H-15); δC (100 MHz; CDCl3) 171.9 (C-13), 149.8 
(C-6), 143.1 (C-7), 141.7 (C-4), 129.2 (CHAr), 128.7 (CHAr), 127.8 (CHAr), 126.9 (C-9), 
122.4 (C-1), 121.3 (C-3), 98.1 (C-11), 60.0 (C-14), 14.6 (C-12 or C-15), 14.2 (C-12 or C-
15); Found (ESI): [MH]+ 288.1048; C16H18NO2S requires [MH]
+ 288.1053, 1.5 ppm. 
Lab-book No PD/10/13. 
 
6.3.4 General procedure J: Formation of α-substituted β-ketoesters 
 
Ethyl 2-methyl-3-oxo-3-(pyridin-4-yl)propanoate (152k) 
 
To a stirred solution of 4-ethyl picolinate (0.749 mL, 5.00 mmol) in THF (15 mL) was added 
ethyl propionate (1.15 mL, 10.0 mmol) at –40 °C. A solution of LHMDS (1.0 M in THF, 
10.5 mL, 10.5 mmol) was quickly added. The reaction mixture was stirred at –40 °C for 30 
min and allowed to warm to room temperature and stirred for 20 min. Then acetic acid (1 
mL) was slowly added at 0 °C and the reaction mixture precipitated. NaHCO3 (15 mL) was 
then added to the flask. The aqueous phase was extracted with EtOAc (2 × 20 mL). The 
combined organic phases were washed with brine (20 mL), dried (MgSO4), filtered, and 
concentrated in vacuo. The crude yellow oil was purified by column chromatography (SiO2, 
Hexane/EtOAc, 4:1 to 2:1) to give the title compound 152k (0.966 g, 93%) as a yellow oil; 
Rf 0.08 (Hexane/EtOAc, 4:1); νmax (cm-1) 2985, 2942, 1732, 1698, 1595, 1556, 1454, 1408, 
1376, 1338, 1222, 1180, 1073, 1036, 967, 838, 658; δH (400 MHz; CDCl3) 8.76 (2 H, d, J = 
6.0 Hz, H-1), 7.69 (2 H, d, J = 6.0 Hz, H-2), 4.26 (1 H, q, J = 7.0 Hz, H-5), 4.09 (2 H, q, J = 
7.1 Hz, H-7), 1.44 (3 H, d, J = 7.0 Hz, H-9), 1.10 (3 H, t, J = 7.1 Hz, H-8); δC (100 MHz; 
CDCl3) 195.4 (C-4), 170.1 (C-6), 151.1 (C-1), 142.0 (C-3), 121.4 (C-2), 61.8 (C-7), 48.7 (C-
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5), 14.0 (C-8 or C-9), 13.3 (C-8 or C-9); Found (ESI): [MNa]+ 230.0786; C11H13NNaO3 
requires [MNa]+ 230.0788, 0.8 ppm. 
Lab-book No PD/11/35. 
 
6.3.5 General procedure K: Dean and Stark approach to enamine precursors 
 
Ethyl (2Z)-2-methyl-3-(phenylamino)-3-(pyridin-4-yl)prop-2-enoate (147k) 
 
To a stirred solution of ethyl 2-methyl-3-oxo-3-(pyridin-4-yl)propanoate (152k) (0.186 g, 
0.898 mmol) in toluene (8 mL) was added aniline (0.082 mL, 0.898 mmol) and p-TSA (0.017 
g, 0.090 mmol). The flask was fitted with a Dean & Stark apparatus, and stirred overnight at 
110 °C. The resulting yellow reaction mixture was cooled to room temperature and toluene 
was removed. The residue was purified by column chromatography (SiO2, Hexane/EtOAc, 
8:1) to give the title compound 147k (0.130 g, 51%) as a colourless solid; mp. 58-60 °C; Rf 
0.36 (Hexane/EtOAc, 2:1); νmax (cm-1) 3242, 2980, 1653, 1591, 1577, 1499, 1257, 1145, 
1034, 833; δH (400 MHz; CDCl3) 10.75 (1 H, br s, H-5), 8.57 (2 H, dd, J = 4.4, 1.6 Hz, H-
9), 7.17 (2 H, dd, J = 4.4, 1.6 Hz, H-8), 7.07 – 6.96 (2 H, m, H-2), 6.84 (1 H, t, J = 7.4 Hz, 
H-1), 6.56 (2 H, d, J = 7.8 Hz, H-3), 4.23 (2 H, q, J = 7.1 Hz, H-13), 1.67 (3 H, s, H-11), 
1.32 (3 H, t, J = 7.1 Hz, H-14); δC (100 MHz; CDCl3) 171.2 (C-12), 153.0 (C-6), 150.1 (C-
9), 143.8 (C-7), 140.4 (C-4), 128.8 (C-2), 124.5 (C-8), 123.1 (C-1), 122.4 (C-3), 95.7 (C-
10), 60.1 (C-13), 14.6 (C-14), 14.2 (C-11); Found (ESI): [MH]+ 283.1435; C17H19N2O2 
requires [MH]+ 283.1441, 2.0 ppm. 
Lab-book No PD/11/38. 
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Diethyl [1-oxo-1-(pyridin-4-yl)propan-2-yl]phosphonate (152l) 
 
4-Ethyl picolinate (0.375 mL, 2.50 mmol), diethyl ethylphosphonate (0.811 mL, 5.00 
mmol), LHMDS (1.0 M in THF, 5.25 mL, 5.25 mmol) in THF (10 mL) were subjected to 
general procedure J. The residue was purified by column chromatography (SiO2, 
CH2Cl2/MeOH, 49:1) to give the title compound 152l (0.585 g, 86%) as a yellow oil; Rf 0.27 
(CH2Cl2/MeOH, 24:1); νmax (cm-1) 3474, 2984, 2942, 1693, 1409, 1234, 1049, 1021, 796; δH 
(400 MHz; CDCl3) 8.78 (2 H, br s, H-1), 7.87 – 7.63 (2 H, m, H-2), 4.16 – 3.99 (5 H, m, H-
5 and H-6), 1.56 – 1.44 (3 H, m, H-8), 1.30 – 1.23 (3 H, m, H-7a), 1.19 – 1.13 (3 H, m, H-
7b); δC (100 MHz; CDCl3) 196.1 (d, J(C-P) = 5.4 Hz, C-4), 150.8 (C-1), 142.9 (C-3), 121.7 
(C-2), 63.0 (d, J(C-P) = 7.4 Hz, C-6a), 62.9 (d, J(C-P) = 6.9 Hz, C-6b), 42.1 (d, J(C-P) = 
128.6 Hz, C-5), 16.4 (d, J(C-P) = 5.9 Hz, C-7a), 16.2 (d, J(C-P) = 5.9 Hz, C-7b), 11.8 (d, 
J(C-P) = 6.8 Hz, C-8); Found (ESI): [MH]+ 272.1045; C12H19NO4P requires [MH]
+ 
272.1046, 0.4 ppm. 
Lab-book No PD/11/41. 
 
Diethyl [(1Z)-1-(phenylamino)-1-(pyridin-4-yl)prop-1-en-2-yl]phosphonate (147l) 
 
Diethyl [1-oxo-1-(pyridin-4-yl)propan-2-yl]phosphonate (152l) (0.231 g, 0.852 mmol), 
aniline (0.078 mL, 0.852 mmol), and p-TSA (0.016 g, 0.085 mmol) in toluene (8 mL) were 
subjected to general procedure K. The residue was purified by column chromatography 
(SiO2, Hexane/EtOAc, 2:1 to 1:2) to give the title compound 147l (0.045 g, 15%) as a 
colourless solid; mp. 84-86 °C; Rf 0.35 (Hexane/EtOAc, 2:1); νmax (cm-1) 3253, 2982, 1593, 
1582, 1497, 1361, 1049, 1020, 959, 872, 837, 798, 750; δH (400 MHz; CDCl3) 9.50 (1 H, br 
s, H-5), 8.57 (2 H, dd, J = 4.4, 1.6 Hz, H-9), 7.21 (2 H, dd, J = 4.4, 1.6 Hz, H-8), 7.02 – 6.90 
(2 H, m, H-2), 6.78 (1 H, t, J = 7.4 Hz, H-1), 6.51 (2 H, d, J = 7.7 Hz, H-3), 4.18 – 4.03 (4 
H, m, H-12), 1.63 (3 H, d, J(H-P) = 14.0 Hz, H-11), 1.35 (6 H, t, J = 7.1 Hz, H-13); δC (100 
171 
MHz; CDCl3) 153.4 (d, J(C-P) = 10.7 Hz, C-6), 150.1 (C-9), 144.0 (d, J(C-P) = 19.1 Hz, C-
7), 141.5 (C-4), 128.7 (C-2), 124.5 (C-8), 122.1 (C-1), 121.3 (C-3), 91.7 (d, J(C-P) = 178.2 
Hz, C-10), 61.7 (C-12a), 61.6 (C-12b), 16.5 (C-13a), 16.4 (C-13b), 14.6 (d, J(C-P) = 7.4 Hz, 
C-11); Found (ESI): [MNa]+ 369.1342; C18H23N2NaO3P requires [MNa]
+ 369.1339, 0.9 
ppm. 
Lab-book No PD/11/43. 
 
2-(Pyridine-4-carbonyl)butanenitrile (152m) 
 
4-Ethyl picolinate (0.375 mL, 2.50 mmol), butyronitrile (0.435 mL, 5.00 mmol), LHMDS 
(1.0 M in THF, 5.25 mL, 5.25 mmol) in THF (10 mL) were subjected to general procedure 
J. The residue was purified by column chromatography (SiO2, Hexane/EtOAc, 2:1 to 1:2) to 
give the title compound 152m (0.427 g, 98%) as a thick yellow oil; Rf 0.20 (Hexane/EtOAc, 
1:1); νmax (cm-1) 2975, 2939, 2203, 1707, 1603, 1559, 1460, 1411, 1342, 1233, 1159, 1066, 
1003, 829, 685; δH (400 MHz; CDCl3) 8.87 (2 H, dd, J = 4.4, 1.6 Hz, H-1), 7.74 (2 H, dd, J 
= 4.4, 1.6 Hz, H-2), 4.22 (1 H, dd, J = 8.1, 5.6 Hz, H-5), 2.09 – 2.00 (2 H, m, H-7), 1.17 (3 
H, t, J = 7.4 Hz, H-8); δC (100 MHz; CDCl3) 190.6 (C-4), 151.4 (C-1), 140.1 (C-3), 121.4 
(C-2), 116.4 (C-6), 41.9 (C-5), 23.2 (C-7), 11.5 (C-8); Found (ESI): [MH]+ 175.0864; 
C10H11N2O requires [MH]
+ 175.0866, 0.9 ppm. 
Lab-book No PD/11/44. 
 
(2Z)-2-[(Phenylamino)(pyridin-4-yl)methylidene]butanenitrile (147m) 
 
2-(Pyridine-4-carbonyl)butanenitrile (152m) (0.453 g, 2.60 mmol), aniline (0.237 mL, 2.60 
mmol), and p-TSA (0.053 g, 0.280 mmol) in toluene (10 mL) were subjected to general 
procedure K. The residue was purified by column chromatography (SiO2, Hexane/EtOAc, 
2:1) to give the title compound 147m (0.343 g, 53%) as a colourless solid; mp. 100-102 °C; 
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Rf 0.35 (Hexane/EtOAc, 1:1); νmax (cm-1) 3303, 2972, 2194, 1593, 1583, 1546, 1496, 1363, 
1246, 909, 834, 747, 729, 692; δH (400 MHz; CDCl3) 8.55 (2 H, dd, J = 4.5, 1.7 Hz, H-9), 
7.37 (2 H, dd, J = 4.5, 1.7 Hz, H-8), 7.11 – 7.05 (2 H, m, H-2), 6.91 (1 H, t, J = 7.4 Hz, H-
1), 6.59 (2 H, d, J = 7.7 Hz, H-3), 6.46 (1 H, br s, H-5), 2.34 (2 H, q, J = 7.5 Hz, H-11), 1.25 
(3 H, t, J = 7.5 Hz, H-12); δC (100 MHz; CDCl3) 150.6 (C-6), 150.1 (C-9), 142.5 (C-7), 
140.1 (C-4), 129.2 (C-2), 124.3 (C-8), 123.4 (C-1), 121.0 (C-3), 120.8 (C-13), 93.3 (C-10), 
22.2 (C-11), 12.6 (C-12); Found (ESI): [MH]+ 250.1340; C16H16N3 requires [MH]
+ 
250.1339, 0.5 ppm. 
Lab-book No PD/11/45. 
 
Ethyl (2Z)-3-[(2,4-dimethoxyphenyl)amino]-2-methyl-3-(pyridin-4-yl)prop-2-enoate 
(147n) 
 
Ethyl 2-methyl-3-oxo-3-(pyridin-4-yl)propanoate (152k) (0.258 g, 1.24 mmol), 2,4-
dimethoxyaniline (0.190 g, 1.24 mmol), and p-TSA (0.024 g, 0.124 mmol) in toluene (10 
mL) were subjected to general procedure K. The residue was purified by column 
chromatography (SiO2, Hexane/EtOAc, 4:1) to give the title compound 147n (0.240 g, 57%) 
as an orange solid; mp. 88-90 °C; Rf 0.12 (Hexane/EtOAc, 2:1); νmax (cm-1) 3243, 2980, 
2939, 1731, 1704, 1652, 1609, 1577, 1513, 1254, 1208, 1135, 1034, 832, 780; δH (400 MHz; 
CDCl3) 10.37 (1 H, br s, H-9), 8.51 (2 H, dd, J = 4.4, 1.6 Hz, H-13), 7.10 (2 H, dd, J = 4.4, 
1.6 Hz, H-12), 6.28 (1 H, d, J = 2.6 Hz, H-7), 6.26 (1 H, d, J = 8.7 Hz, H-3), 6.03 (1 H, dd, 
J = 8.7, 2.6 Hz, H-2), 4.22 (2 H, q, J = 7.1 Hz, H-17), 3.76 (3 H, s, H-6 or H-8), 3.64 (3 H, 
s, H-6 or H-8), 1.60 (3 H, s, H-15), 1.31 (3 H, t, J = 7.1 Hz, H-18); δC (100 MHz; CDCl3) 
171.3 (C-16), 157.1 (C-1 or C-5), 154.7 (C-10), 153.4 (C-1 or C-5), 149.8 (C-13), 144.2 (C-
11), 125.2 (C-7), 124.2 (C-12), 122.8 (C-4), 103.3 (C-2), 98.9 (C-3), 93.3 (C-14), 59.8 (C-
17), 55.6 (C-6 or C-8), 55.4 (C-6 or C-8), 14.7 (C-15 or C-18), 14.3 (C-15 or C-18); Found 
(ESI): [MNa]+ 365.1473; C19H22N2NaO4 requires [MNa]
+ 365.1472, 0.4 ppm. 
Lab-book No PD/11/63. 
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6.3.6 General procedure L: Cu(II)-mediated cyclisation to 3H-indoles 
 
Ethyl 3-methyl-2-phenyl-3H-indole-3-carboxylate (148a) 
 
To a stirred solution of ethyl (2Z)-2-methyl-3-phenyl-3-(phenylamino)prop-2-enoate (147a) 
(0.053 g, 0.187 mmol) in mesitylene (5 mL) was added Cu(2-ethylhexanoate)2 (0.066 g, 
0.187 mmol). The flask was fitted with a condenser and a CaCl2 drying trap. The reaction 
was stirred and heated at 170 °C (Drysyn heating block) for 2 h. The resulting green solution 
was allowed to cool to room temperature. NH4OH (10 mL) was added, the aqueous phase 
was extracted twice with EtOAc (2 × 10 mL). The combined organic extracts were washed 
with water (10 mL) and brine (10 mL), dried (MgSO4), filtered and concentrated in vacuo. 
The brown residue was purified by column chromatography (SiO2, Hexane/EtOAc, 99:1) to 
give the title compound 148a (0.041 g, 78%) as a colourless oil; Rf 0.28 (Hexane/EtOAc, 
9:1); νmax (cm-1) 2983, 2935, 1728, 1531, 1444, 1236, 1221, 1101, 1012, 1004, 754, 728, 
513; δH (400 MHz; CDCl3) 7.98 – 7.94 (2 H, m, H-10), 7.71 (1 H, dd, J = 7.6, 1.0 Hz, H-3), 
7.49 – 7.45 (3 H, m, H-11 and H-12), 7.42 (1 H, td, J = 7.6, 1.0 Hz, H-2), 7.40 – 7.37 (1 H, 
m, H-8), 7.26 (1 H, td, J = 7.6, 1.0 Hz, H-1), 4.12 (1 H, dq, J = 10.8, 7.1 Hz, H-15a), 3.97 (1 
H, dq, J = 10.8, 7.1 Hz, H-15b), 1.71 (3 H, s, H-13), 0.97 (3 H, t, J = 7.1 Hz, H-16); δC (100 
MHz; CDCl3) 178.1 (C-5), 171.6 (C-14), 154.9 (C-4), 141.8 (C-7), 132.0 (C-9), 131.2 (C-
12), 129.1 (C-2), 128.9 (C-11), 128.4 (C-10), 126.4 (C-1), 121.4 (C-3 or C-8), 121.2 (C-3 or 
C-8), 62.2 (C-6), 61.9 (C-15), 21.1 (C-13), 13.8 (C-16); Found (ESI): [MNa]+ 302.1153; 
C18H17NNaO2 requires [MNa]
+ 302.1151, 0.5 ppm. 
Data are consistent with literature values.71 
Lab-book No PD/9/9. 
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Ethyl 2,3-diphenyl-3H-indole-3-carboxylate (148b) 
 
Ethyl (2Z)-2,3-diphenyl-3-(phenylamino)prop-2-enoate (147b) (0.052 g, 0.152 mmol), 
Cu(2-ethylhexanoate)2 (0.054 g, 0.155 mmol) in mesitylene (5 mL) were subjected to 
general procedure L at 170 °C for 2 h. Purification by column chromatography (SiO2, 
Hexane/EtOAc, 19:1) afforded the title compound 148b (0.042 g, 80%) as a colourless oil; 
Rf 0.40 (Hexane/EtOAc, 4:1); νmax (cm-1) 3068, 2983, 1732, 1534, 1495, 1456, 1445, 1264, 
1229, 1192, 1026, 765, 745, 693; δH (400 MHz; CDCl3) 7.92 (2 H, dd, J = 8.4, 1.4 Hz, H-
10), 7.73 (1 H, d, J = 7.6 Hz, H-3), 7.42 – 7.30 (7 H, m, HAr), 7.26 – 7.19 (4 H, m, HAr), 4.17 
(1 H, dq, J = 10.8, 7.1 Hz, H-18a), 4.04 (1 H, dq, J = 10.8, 7.1 Hz, H-18b), 0.99 (3 H, t, J = 
7.1 Hz, H-19); δC (100 MHz; CDCl3) 177.3 (C-5), 169.3 (C-17), 154.8 (C-4), 142.5 (C-7), 
136.8 (CAr), 132.7 (CAr), 130.9 (CHAr), 129.2 (CHAr), 129.1 (CHAr), 128.9 (CHAr), 128.3 
(CHAr), 127.8 (CHAr), 127.4 (CHAr), 126.8 (CHAr), 123.4 (CHAr), 121.3 (C-3), 71.6 (C-6), 
62.1 (C-18), 13.8 (C-19); Found (ESI): [MNa]+ 364.1306; C23H19NNaO2 requires [MNa]
+ 
364.1308, 0.5 ppm. 
Lab-book No PD/9/98. 
 
Ethyl 2-phenyl-3-(prop-2-en-1-yl)-3H-indole-3-carboxylate (148c) 
 
Ethyl (2Z)-2-[phenyl(phenylamino)methylidene]pent-4-enoate (147c) (0.047 g, 0.154 
mmol), Cu(2-ethylhexanoate)2 (0.054 g, 0.153 mmol) in mesitylene (2 mL) were subjected 
to general procedure L at 170 °C for 2 h. Purification by column chromatography (SiO2, 
Hexane/EtOAc, 49:1) afforded the title compound 148c (0.029 g, 61%) as a yellow oil; Rf 
0.38 (Hexane/EtOAc, 6:1); νmax (cm-1) 3064, 2980, 1726, 1532, 1445, 1266, 1224, 1075, 
1032, 1020, 922, 756, 692; δH (400 MHz; CDCl3) 7.97 – 7.92 (2 H, m, H-10), 7.69 (1 H, d, 
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J = 7.6 Hz, H-3), 7.49 – 7.44 (3 H, m, H-11 and H-12), 7.42 (1 H, td, J = 7.6, 1.2 Hz, H-2), 
7.38 (1 H, d, J = 7.6 Hz, H-8), 7.27 (1 H, td, J = 7.6, 1.0 Hz, H-1), 5.02 – 4.83 (1 H, m, H-
14), 4.73 – 4.56 (2 H, m, H-15), 4.13 (1 H, dq, J = 10.8, 7.1 Hz, H-17a), 3.99 (1 H, dq, J = 
10.8, 7.1 Hz, H-17b), 3.27 (1 H, ddt, J = 14.0, 6.8, 1.1 Hz, H-13a), 3.06 (1 H, dd, J = 14.0, 
7.6 Hz, H-13b), 0.98 (3 H, t, J = 7.1 Hz, H-18); δC (100 MHz; CDCl3) 176.4 (C-5), 171.1 
(C-16), 155.8 (C-4), 139.4 (C-7), 132.6 (C-9), 131.1 (C-12), 130.2 (C-14), 129.2 (C-2), 128.8 
(C-11), 128.2 (C-10), 126.3 (C-1), 121.7 (C-8), 121.1 (C-3), 119.2 (C-15), 66.3 (C-6), 61.9 
(C-17), 38.7 (C-13), 13.8 (C-18); Found (ESI): [MH]+ 306.1485; C20H20NO2 requires [MH]
+ 
306.1489, 1.2 ppm. 
Lab-book No PD/10/55. 
 
Ethyl 3-{2-[(tert-butyldimethylsilyl)oxy]ethyl}-2-phenyl-3H-indole-3-carboxylate (148d) 
 
The contaminated mixture (0.061 g of a mixture of ethyl (2Z)-4-[(tert-
butyldimethylsilyl)oxy]-2-[phenyl(phenylamino)methylidene]butanoate (147d) and 172a) 
that contained 147d (0.041 g, 0.095 mmol), Cu(2-ethylhexanoate)2 (0.050 g, 0.142 mmol) 
in mesitylene (5 mL) were subjected to general procedure L at 170 °C for 2 h. Purification 
by column chromatography (SiO2, Hexane/EtOAc, 49:1 to 8:1) afforded the title compound 
148d (0.025 g, 63%) as a yellow oil; Rf 0.54 (Hexane/EtOAc, 4:1); νmax (cm-1) 2955, 2930, 
2857, 1729, 1533, 1464, 1445, 1253, 1224, 1108, 1091, 1013, 835, 764, 692; δH (400 MHz; 
CDCl3) 7.97 – 7.93 (2 H, m, H-10), 7.69 (1 H, d, J = 7.6 Hz, H-3), 7.47 – 7.44 (3 H, m, H-
11 and H-12), 7.41 (1 H, td, J = 7.6, 1.0 Hz, H-2), 7.37 (1 H, d, J = 7.6 Hz, H-8), 7.25 (1 H, 
td, J = 7.6, 1.0 Hz, H-1), 4.10 (1 H, dq, J = 10.8, 7.1 Hz, H-19a), 3.96 (1 H, dq, J = 10.8, 7.1 
Hz, H-19b), 2.99 (1 H, ddd, J = 10.3, 9.0, 6.8 Hz, H-14a), 2.93 (1 H, ddd, J = 10.3, 9.0, 5.0 
Hz, H-14b), 2.80 (1 H, ddd, J = 13.8, 8.8, 5.0 Hz, H-13a), 2.68 (1 H, ddd, J = 13.8, 8.8, 6.8 
Hz, H-13b), 0.95 (3 H, t, J = 7.1 Hz, H-20), 0.63 (9 H, s, H-17), –0.31 (3 H, s, H-15a), –0.33 
(3 H, s, H-15b); δC (100 MHz; CDCl3) 176.9 (C-5), 171.1 (C-18), 155.7 (C-4), 139.2 (C-7), 
132.7 (C-9), 131.1 (C-12), 129.2 (C-2), 128.8 (C-11), 128.2 (C-10), 126.3 (C-1), 121.7 (C-
8), 121.2 (C-3), 64.9 (C-6), 61.9 (C-19), 58.3 (C-14), 37.2 (C-13), 25.8 (C-17), 18.2 (C-16), 
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13.8 (C-20), −5.72 (C-15); Found (ESI): [MH]+ 424.2305; C25H34NO3Si requires [MH]+ 
424.2302, 0.5 ppm. 
Lab-book No PD/10/4. 
 
Ethyl 5,7-dimethoxy-3-methyl-2-phenyl-3H-indole-3-carboxylate (148e) 
 
Ethyl (2Z)-3[(2,4-dimethoxyphenyl)amino]-2-methyl-3-phenylprop-2-enoate (147e) (0.151 
g, 0.443 mmol), Cu(2-ethylhexanoate)2 (0.155 g, 0.443 mmol) in mesitylene (10 mL) were 
subjected to general procedure L at 170 °C for 2 h. Purification by column chromatography 
(SiO2, Hexane/EtOAc, 8:1 to 6:1) afforded the title compound 148e (0.081 g, 54%) as a thick 
colourless oil; Rf 0.21 (Hexane/EtOAc, 4:1); νmax (cm-1) 2937, 1727, 1597, 1526, 1433, 1453, 
1377, 1320, 1231, 1200, 1100, 1048, 831, 773, 694; δH (400 MHz; CDCl3) 7.95 – 7.91 (2 H, 
m, H-12), 7.41 – 7.37 (3 H, m, H-13 and H-14), 6.53 (1 H, d, J = 2.2 Hz, H-8), 6.50 (1 H, d, 
J = 2.2 Hz, H-2), 4.11 (1 H, dq, J = 10.8, 7.1 Hz, H-17a), 4.00 (3 H, s, H-9 or H-10), 3.94 (1 
H, dq, J = 10.8, 7.1 Hz, H-17b), 3.81 (3 H, s, H-9 or H-10), 1.67 (3 H, s, H-15), 0.95 (3 H, 
t, J = 7.1 Hz, H-18); δC (100 MHz; CDCl3) 174.3 (C-5), 171.7 (C-16), 160.3 (C-1 or C-3), 
152.3 (C-1 or C-3), 144.8 (C-7), 137.0 (C-4), 132.3 (C-11), 130.4 (C-14), 128.6 (C-13), 
128.0 (C-12), 99.4 (C-2), 98.4 (C-8), 62.5 (C-6), 61.8 (C-17), 56.3 (C-9 or C-10), 55.9 (C-9 
or C-10), 21.5 (C-15), 13.8 (C-18); Found (ESI): [MH]+ 340.1540; C20H22NO4 requires 
[MH]+ 340.1543, 1.0 ppm. 
Lab-book No PD/9/100. 
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3,3-Di-tert-butyl 2-phenyl-3H-indole-3,3-dicarboxylate (148f) 
 
1,3-Di-tert-butyl 2-[phenyl(phenylamino)methylidene] propanedioate (147f) (0.047 g, 
0.120 mmol), Cu(2-ethylhexanoate)2 (0.043 g, 0.122 mmol) in mesitylene (3 mL) were 
subjected to general procedure L at 170 °C for 2 h. Purification by column chromatography 
(SiO2, Hexane/EtOAc, 19:1) afforded the title compound 148f (0.020 g, 42%) as a colourless 
solid; mp. 95-97 °C; Rf 0.41 (Hexane/EtOAc, 4:1); νmax (cm-1) 2978, 2934, 1724, 1457, 1369, 
1247, 1142, 835, 767, 690; δH (400 MHz; CDCl3) 8.10 (2 H, dd, J = 7.8, 1.4 Hz, H-10), 7.66 
(1 H, d, J = 7.7 Hz, H-3), 7.63 (1 H, d, J = 7.7 Hz, H-8), 7.46 – 7.40 (4 H, m, H-2, H-11, and 
H-12), 7.28 (1 H, td, J = 7.7, 1.1 Hz, H-1), 1.29 (18 H, s, H-15); δC (100 MHz; CDCl3) 172.6 
(C-5), 164.8 (C-13), 155.7 (C-4), 136.1 (C-7), 133.1 (C-9), 130.9 (C-12), 129.6 (C-2), 129.4 
(C-10) 128.1 (C-11), 126.6 (C-1), 123.6 (C-8), 121.1 (C-3), 83.5 (C-14), 75.5 (C-6), 27.6 
(C-15); Found (ESI): [MNa]+ 416.1819; C24H27NNaO4 requires [MNa]
+ 416.1832, 3.1 ppm; 
Anal. Calcd. for C24H27NO4: C, 73.26; H, 6.92; N, 3.56. Found: C, 73.37; H, 6.90; N, 3.23. 
Lab-book No PD/11/14. 
 
Ethyl 3-methyl-2-(naphthalen-2-yl)-3H-indole-3-carboxylate (148g) 
 
Ethyl (2Z)-2-methyl-3-(naphthalen-2-yl)-3-(phenylamino)prop-2-enoate (147g) (0.025 g, 
0.076 mmol), Cu(2-ethylhexanoate)2 (0.027 g, 0.077 mmol) in mesitylene (2 mL) were 
subjected to general procedure L at 170 °C for 2 h. Purification by column chromatography 
(SiO2, Hexane/EtOAc, 19:1) afforded the title compound 148g (0.012 g, 48%) as a yellow 
oil; Rf 0.48 (Hexane/EtOAc, 4:1); νmax (cm-1) 2981, 1729, 1531, 1457, 1241, 1221, 1102, 
1013, 861, 767, 751; δH (400 MHz; CDCl3) 8.27 (1 H, d, J = 1.6 Hz, HAr), 8.22 (1 H, dd, J 
= 8.5, 1.6 Hz, HAr), 7.93 (2 H, d, J = 8.5 Hz, HAr), 7.89 – 7.84 (1 H, m, HAr), 7.75 (1 H, d, J 
= 7.6 Hz, H-3), 7.58 – 7.54 (1 H, m, HAr), 7.54 – 7.50 (1 H, m, HAr), 7.44 (1 H, td, J = 7.6, 
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1.1 Hz, H-2), 7.42 (1 H, dd, J = 7.6, 1.1 Hz, H-8), 7.28 (1 H, td, J = 7.6, 1.1 Hz, H-1), 4.14 
(1 H, dq, J = 10.8, 7.1 Hz, H-21a), 3.98 (1 H, dq, J = 10.8, 7.1 Hz, H-21b), 1.79 (3 H, s, H-
19), 0.96 (3 H, t, J = 7.1 Hz, H-22); δC (100 MHz; CDCl3) 178.1 (C-5), 171.8 (C-20), 155.1 
(C-4), 142.0 (C-7), 134.6 (CAr), 133.1 (CAr), 129.6 (CAr), 129.1 (2 × CHAr), 129.0 (CHAr), 
128.6 (CHAr), 127.84 (CHAr), 127.77 (CHAr), 126.8 (CHAr), 126.5 (C-1), 125.1 (CHAr), 121.4 
(C-8), 121.3 (C-3), 62.2 (C-6), 61.9 (C-21), 21.4 (C-19), 13.9 (C-22); Found (ESI): [MH]+ 
330.1473; C22H20NO2 requires [MH]
+ 330.1489, 4.8 ppm. 
Lab-book No PD/11/33. 
 
Ethyl 3-methyl-2-(4-methylphenyl)-3H-indole-3-carboxylate (148h) 
 
Ethyl (2Z)-2-methyl-3-(4-methylphenyl)-3-(phenylamino)prop-2-enoate (147h) (0.042 g, 
0.142 mmol), Cu(2-ethylhexanoate)2 (0.050 g, 0.144 mmol) in mesitylene (2 mL) were 
subjected to general procedure L at 170 °C for 2 h. Purification by column chromatography 
(SiO2, Hexane/EtOAc, 49:1) afforded the title compound 148h (0.030 g, 70%) as a yellow 
solid; mp. 75-77 °C; Rf 0.41 (Hexane/EtOAc, 6:1); νmax (cm-1) 2982, 2936, 1730, 1530, 1510, 
1466, 1377, 1238, 1222, 1102, 826, 768, 754; δH (400 MHz; CDCl3) 7.85 (2 H, d, J = 8.3 
Hz, H-10), 7.69 (1 H, d, J = 7.6 Hz, H-3), 7.41 (1 H, td, J = 7.6, 1.2 Hz, H-2), 7.37 (1 H, d, 
J = 7.6 Hz, H-8), 7.27 (2 H, d, J = 8.3 Hz, H-11), 7.23 (1 H, td, J = 7.6, 1.2 Hz, H-1), 4.11 
(1 H, dq, J = 10.8, 7.1 Hz, H-16a), 3.97 (1 H, dq, J = 10.8, 7.1 Hz, H-16b), 2.41 (3 H, s, H-
13), 1.70 (3 H, s, H-14), 0.97 (3 H, t, J = 7.1 Hz, H-17); δC (100 MHz; CDCl3) 178.1 (C-5), 
171.8 (C-15), 155.1 (C-4), 141.8 (C-7 or C-9), 141.7 (C-7 or C-9), 129.6 (C-11), 129.4 (C-
12), 129.0 (C-2), 128.4 (C-10), 126.1 (C-1), 121.3 (C-8), 121.0 (C-3), 62.1 (C-6), 61.8 (C-
16), 21.6 (C-13), 21.2 (C-14), 13.8 (C-17); Found (ESI): [MH]+ 294.1501; C19H20NO2 
requires [MH]+ 294.1489, 4.1 ppm. CCDC 1033699 contains the supplementary 
crystallographic data for this compound. These data can be obtained free of charge from The 
Cambridge Crystallographic Data Centre via www.ccdc.cam.ac.uk/data_request/cif. 
Crystals suitable for X-ray diffraction were obtained by slow evaporation from hexane in 
which a few drops of dichloromethane were added. 
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Lab-book No PD/10/59. 
 
Ethyl 2-(4-chlorophenyl)-3-methyl-3H-indole-3-carboxylate (148i) 
 
Ethyl (2Z)-3-(4-chlorophenyl)-2-methyl-3-(phenylamino)prop-2-enoate (147i) (0.064 g, 
0.202 mmol), Cu(2-ethylhexanoate)2 (0.071 g, 0.202 mmol) in mesitylene (2 mL) were 
subjected to general procedure L at 170 °C for 2 h. Purification by column chromatography 
(SiO2, Hexane/EtOAc, 49:1) afforded the title compound 148i (0.045 g, 70%) as a yellow 
oil; Rf 0.38 (Hexane/EtOAc, 6:1); νmax (cm-1) 2982, 2936, 1729, 1591, 1529, 1491, 1402, 
1267, 1236, 1220, 1092, 1013, 995, 840, 755, 725; δH (400 MHz; CDCl3) 7.90 (2 H, d, J = 
8.6 Hz, H-10), 7.70 (1 H, d, J = 7.6 Hz, H-3), 7.44 (2 H, d, J = 8.6 Hz, H-11), 7.42 (1 H, td, 
J = 7.6, 1.2 Hz, H-2), 7.38 (1 H, d, J = 7.6 Hz, H-8), 7.29 – 7.25 (1 H, m, H-1), 4.11 (1 H, 
dq, J = 10.7, 7.1 Hz, H-15a), 3.97 (1 H, dq, J = 10.7, 7.1 Hz, H-15b), 1.69 (3 H, s, H-13), 
0.98 (3 H, t, J = 7.1 Hz, H-16); δC (100 MHz; CDCl3) 176.9 (C-5), 171.4 (C-14), 154.8 (C-
4), 141.8 (C-7), 137.4 (C-9 or C-12), 130.6 (C-9 or C-12), 129.6 (C-10), 129.2 (C-2 and C-
11), 126.6 (C-1), 121.4 (C-3 or C-8), 121.3 (C-3 or C-8), 62.1 (C-6), 62.0 (C-15), 21.0 (C-
13), 13.9 (C-16); Found (ESI): [MH]+ 314.0931; C18H17ClNO2 requires [MH]
+ 314.0942, 
1.2 ppm. 
Lab-book No PD/10/60. 
 
Ethyl 3-methyl-2-(thiophen-2-yl)-3H-indole-3-carboxylate (148j) 
 
Ethyl (2Z)-2-methyl-3-(phenylamino)-3-(thiophen-2-yl)prop-2-enoate (147j) (0.019 g, 
0.068 mmol), Cu(2-ethylhexanoate)2 (0.025 g, 0.070 mmol) in mesitylene (2 mL) were 
subjected to general procedure L at 170 °C for 2 h. Purification by column chromatography 
(SiO2, Hexane/EtOAc, 9:1) afforded the title compound 148j (0.010 g, 51%) as a yellow oil; 
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Rf 0.14 (Hexane/EtOAc, 8:1); νmax (cm-1) 2982, 2934, 1730, 1687, 1545, 1509, 1465, 1427, 
1240, 1223, 1105, 1013, 855, 768, 754, 716; δH (400 MHz; CDCl3) 7.67 (1 H, d, J = 7.6 Hz, 
H-3), 7.53 (1 H, dd, J = 5.0, 0.7 Hz, H-12), 7.44 (1 H, dd, J = 3.8, 0.7 Hz, H-10), 7.40 (1 H, 
td, J = 7.6, 1.0 Hz, H-2), 7.36 (1 H, dd, J = 7.6, 1.0 Hz, H-8), 7.24 (1 H, td, J = 7.6, 1.0 Hz, 
H-1), 7.13 (1 H, dd, J = 5.0, 3.8 Hz, H-11), 4.11 (1 H, dq, J = 10.8, 7.1 Hz, H-15a), 3.99 (1 
H, dq, J = 10.8, 7.1 Hz, H-15b), 1.75 (3 H, s, H-13), 1.00 (3 H, t, J = 7.1 Hz, H-16); δC (100 
MHz; CDCl3) 172.8 (C-5), 171.2 (C-14), 155.1 (C-4), 141.4 (C-7), 137.2 (C-9), 130.5 (C-
12), 129.8 (C-10), 129.1 (C-2), 128.3 (C-11), 126.2 (C-1), 121.5 (C-8), 121.0 (C-3), 62.6 (C-
6), 62.0 (C-15), 22.0 (C-13), 13.9 (C-16); Found (ESI): [MH]+ 286.0905; C16H16NO2S 
requires [MH]+ 286.0896, 3.2 ppm. 
Lab-book No PD/10/14. 
 
Ethyl 3-methyl-2-(pyridin-4-yl)-3H-indole-3-carboxylate (148k) 
 
Ethyl (2Z)-2-methyl-3-(phenylamino)-3-(pyridin-4-yl)prop-2-enoate (147k) (0.059 g, 0.207 
mmol), Cu(2-ethylhexanoate)2 (0.073 g, 0.208 mmol) in mesitylene (3 mL) were subjected 
to general procedure L at 170 °C for 2 h. Purification by column chromatography (SiO2, 
Hexane/EtOAc, 2:1) afforded the title compound 148k (0.046 g, 80%) as a yellow oil; Rf 
0.11 (Hexane/EtOAc, 2:1); νmax (cm-1) 2983, 2936, 1730, 1595, 1524, 1238, 1223, 1102, 
1012, 829, 771, 757; δH (400 MHz; CDCl3) 8.74 (2 H, br s, H-11), 7.77 (2 H, dd, J = 4.8, 1.3 
Hz, H-10), 7.74 (1 H, d, J = 7.6 Hz, H-3), 7.44 (1 H, td, J = 7.6, 1.1 Hz, H-2), 7.41 (1 H, d, 
J = 7.6 Hz, H-8), 7.31 (1 H, td, J = 7.6, 1.1 Hz, H-1), 4.10 (1 H, dq, J = 10.9, 7.1 Hz, H-14a), 
3.97 (1 H, dq, J = 10.9, 7.1 Hz, H-14b), 1.69 (3 H, s, H-12), 0.97 (3 H, t, J = 7.1 Hz, H-15); 
δC (100 MHz; CDCl3) 176.0 (C-5), 170.9 (C-13), 154.4 (C-4), 150.6 (C-11), 141.8 (C-7), 
139.0 (C-9), 129.3 (C-2), 127.5 (C-1), 122.0 (C-3, C-8, or C-10), 121.9 (C-3, C-8, or C-10), 
121.6 (C-3, C-8, or C-10), 62.2 (C-6), 62.1 (C-14), 20.5 (C-12), 13.8 (C-15); Found (ESI): 
[MH]+ 281.1280; C17H17N2O2 requires [MH]
+ 281.1285, 1.6 ppm. 
Lab-book No PD/11/40. 
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Diethyl [3-methyl-2-(pyridin-4-yl)-3H-indol-3-yl]phosphonate (148l) 
 
Diethyl [(1Z)-1-(phenylamino)-1-(pyridin-4-yl)prop-1-en-2-yl]phosphonate (147l) (0.026 g, 
0.074 mmol), Cu(2-ethylhexanoate)2 (0.027 g, 0.077 mmol) in mesitylene (2 mL) were 
subjected to general procedure L at 170 °C for 2 h. Purification by column chromatography 
(SiO2, CH2Cl2/MeOH, 99:1 to 24:1) afforded the title compound 148l (0.014 g, 55%) as a 
yellow oil; Rf 0.11 (CH2Cl2/MeOH, 49:1); νmax (cm-1) 2981, 2933, 1595, 1247, 1043, 1019, 
971, 773; δH (400 MHz; CDCl3) 8.77 (2 H, br s, H-11), 8.21 (2 H, br s, H-10), 7.76 (1 H, d, 
J = 7.6 Hz, H-3), 7.68 (1 H, d, J = 7.6 Hz, H-8), 7.46 (1 H, t, J = 7.6 Hz, H-2), 7.36 (1 H, t, 
J = 7.6 Hz, H-1), 4.00 – 3.62 (4 H, m, H-13a and H-13b), 1.92 (3 H, d, J(H-P) = 17.8 Hz, H-
12), 1.11 (3 H, t, J = 7.1 Hz, H-14a), 0.99 (3 H, t, J = 7.1 Hz, H-14b); δC (100 MHz; CDCl3) 
175.0 (C-5), 154.6 (d, J(C-P) = 6.6 Hz, C-4), 150.2 (d, J(C-P) = 4.7 Hz, C-11), 150.1 (d, 
J(C-P) = 5.4 Hz, C-7), 139.7 (d, J(C-P) = 5.7 Hz, C-9), 129.2 (d, J(C-P) = 1.5 Hz, C-2), 
127.6 (d, J(C-P) = 5.6 Hz, C-10), 127.1 (d, J(C-P) = 2.3 Hz, C-1), 124.6 (d, J(C-P) = 2.7 Hz, 
C-8), 121.8 (C-3), 63.9 (d, J(C-P) = 7.5 Hz, C-13a), 63.5 (d, J(C-P) = 7.4 Hz, C-13b), 59.7 
(d, J(C-P) = 129.2 Hz, C-6), 18.7 (d, J(C-P) = 6.4 Hz, C-12), 16.3 (d, J(C-P) = 5.6 Hz, C-
14a), 16.1 (d, J(C-P) = 6.3 Hz, C-14b); Found (ESI): [MH]+ 345.1360; C18H22N2O3P requires 
[MH]+ 345.1363, 0.8 ppm. 
Lab-book No PD/11/46. 
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3-Ethyl-2-(pyridin-4-yl)-3H-indole-3-carbonitrile (148m) 
 
(2Z)-2-[(Phenylamino)(pyridin-4-yl)methylidene]butanenitrile (147m) (0.041 g, 0.166 
mmol), Cu(2-ethylhexanoate)2 (0.058 g, 0.164 mmol) in mesitylene (5 mL) were subjected 
to general procedure L at 170 °C for 2 h. Purification by column chromatography (SiO2, 
Hexane/EtOAc, 2:1) afforded the title compound 148m (0.019 g, 47%) as a yellow oil; Rf 
0.19 (Hexane/EtOAc, 1:1); νmax (cm-1) 3039, 2972, 2933, 2237, 2223, 1686, 1595, 1529, 
1458, 1410, 1266, 827, 750, 767; δH (400 MHz; CDCl3) 8.83 (2 H, br s, H-11), 8.07 (2 H, 
dd, J = 4.8, 1.3 Hz, H-10), 7.77 (1 H, d, J = 7.7 Hz, H-3), 7.62 (1 H, d, J = 7.5 Hz, H-8), 7.54 
(1 H, td, J = 7.7, 1.2 Hz, H-2), 7.44 (1 H, td, J = 7.5, 1.2 Hz, H-1), 2.48 (1 H, dq, J = 14.8, 
7.4 Hz, H-12a), 2.13 (1 H, dq, J = 14.8, 7.4 Hz, H-12b), 0.67 (3 H, t, J = 7.4 Hz, H-13); δC 
(100 MHz; CDCl3) 170.4 (C-5), 154.4 (C-4), 151.0 (C-11), 138.0 (C-9), 136.7 (C-7), 130.6 
(C-2), 128.4 (C-1), 122.9 (C-8), 122.7 (C-3), 121.7 (C-10), 118.0 (C-14), 52.6 (C-6), 30.9 
(C-12), 7.9 (C-13); Found (ESI): [MH]+ 248.1177; C16H14N3 requires [MH]
+ 248.1182, 2.1 
ppm. 
Lab-book No PD/11/48. 
 
Ethyl 5,7-dimethoxy-3-methyl-2-(pyridin-4-yl)-3H-indole-3-carboxylate (148n) 
 
Ethyl (2Z)-3-[(2,4-dimethoxyphenyl)amino]-2-methyl-3-(pyridin-4-yl)prop-2-enoate 
(147n) (0.063 g, 0.183 mmol), Cu(2-ethylhexanoate)2 (0.064 g, 0.183 mmol) in mesitylene 
(5 mL) were subjected to general procedure L at 170 °C for 2 h. Purification by column 
chromatography (SiO2, Hexane/EtOAc, 1:1) afforded the title compound 148n (0.028 g, 
45%) as an orange oil; Rf 0.08 (Hexane/EtOAc, 1:1); νmax (cm-1) 2937, 1731, 1592, 1456, 
1317, 1235, 1153, 1049, 829; δH (400 MHz; CDCl3) 8.68 (2 H, br s, H-13), 7.77 (2 H, dd, J 
= 4.8, 1.3 Hz, H-12), 6.55 (1 H, d, J = 2.2 Hz, H-8), 6.51 (1 H, d, J = 2.2 Hz, H-2), 4.13 (1 
H, dq, J = 10.8, 7.1 Hz, H-16a), 4.02 (3 H, s, H-9 or H-10), 3.96 (1 H, dq, J = 10.8, 7.1 Hz, 
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H-16b), 3.84 (3 H, s, H-9 or H-10), 1.68 (3 H, s, H-14), 0.98 (3 H, t, J = 7.1 Hz, H-17); δC 
(100 MHz; CDCl3) 171.9 (C-5), 171.1 (C-15), 161.4 (C-1 or C-3), 153.0 (C-1 or C-3), 150.5 
(C-13), 145.1 (C-7), 139.1 (C-11), 136.6 (C-4), 121.5 (C-12), 99.5 (C-2), 98.6 (C-8), 62.5 
(C-6), 62.2 (C-16), 56.4 (C-9 or C-10), 56.0 (C-9 or C-10), 21.0 (C-14), 13.9 (C-17); Found 
(ESI): [MH]+ 341.1488; C19H21N2O4 requires [MH]
+ 341.1496, 2.4 ppm. 
Lab-book No PD/11/65. 
 
Ethyl (2Z)-2-methyl-3-(phenylamino)but-2-enoate151 (157) 
 
A mixture of ethyl 2-methylacetoacetate (2.83 mL, 20.0 mmol), aniline (1.82 mL, 20.0 
mmol), and cerium ammonium nitrate (0.552 g, 1.00 mmol) in EtOH (20 mL) was stirred at 
room temperature overnight. Water was added to the reaction mixture and the aqueous phase 
was extracted with CH2Cl2 (20 mL). The organic phase was washed with water (20 mL), 
dried (MgSO4), filtered, and concentrated in vacuo. The residue was purified by column 
chromatography (SiO2, Hexane/EtOAc, 99:1) to give the title compound 157 (0.832 g, 19%) 
as an orange oil; Rf 0.56 (Hexane/EtOAc, 1:1); δH (400 MHz; CDCl3) 10.93 (1 H, br s, H-
5), 7.29 (2 H, t, J = 7.9 Hz, H-2), 7.09 (1 H, t, J = 7.4 Hz, H-1), 7.01 (2 H, d, J = 7.4 Hz, H-
3), 4.17 (2 H, q, J = 7.1 Hz, H-11), 2.02 (3 H, s, H-7 or H-9), 1.85 (3 H, s, H-7 or H-9), 1.30 
(3 H, t, J = 7.1 Hz, H-12). 
Data are consistent with literature values.151 
Lab-book No PD/9/82. 
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Ethyl (2Z)-2-methyl-3-(phenylamino)prop-2-enoate (158) 
 
To a stirred solution of ethyl 2-methyl-3-oxopropanoate (1.01 g, 7.76 mmol) in EtOH (60 
mL) was added aniline (0.547 g, 6.00 mmol). The reaction mixture was stirred at 80 °C for 
1 h and allowed to cool to room temperature. EtOH was removed in vacuo and the residue 
was purified by column chromatography (SiO2, Hexane/EtOAc, 9:1) to give the title 
compound 158 (0.510 g, 41%) as a colourless oil; Rf 0.28 (Hexane/EtOAc, 4:1); νmax (cm-1) 
3317, 2982, 1731, 1683, 1643, 1600, 1497, 1239, 1109, 750, 691; δH (400 MHz; CDCl3) 
7.91 (1 H, dd, J = 13.3, 1.2 Hz, H-7), 7.31 – 7.21 (2 H, m, H-2), 6.98 – 6.89 (3 H, m, H-1 
and H-3), 4.19 (2 H, q, J = 7.1 Hz, H-11), 1.84 (3 H, d, J = 1.0 Hz, H-9), 1.29 (3 H, t, J = 
7.1 Hz, H-12); δC (100 MHz; CDCl3) 169.3 (C-10), 141.3 (C-4), 137.4 (C-6), 129.7 (C-2), 
122.0 (C-1), 115.2 (C-3), 99.5 (C-8), 59.9 (C-11), 14.7 (C-12), 9.9 (C-9); Found (ESI): 
[MNa]+ 228.0997; C12H15NNaO2 requires [MNa]
+ 228.0995, 1.0 ppm. 
Lab-book No PD/10/95. 
 
2-Methyl-3-(phenylamino)cyclopent-2-en-1-one (159) 
 
To a stirred solution of 2-methyl-1,3-cyclopentanedione (0.507 g, 4.52 mmol) in toluene (50 
mL) was added aniline (0.407 mL, 4.46 mmol) and p-TSA (0.025 g, 0.131 mmol). The 
condenser was fitted with a Dean & Stark apparatus and the reaction mixture was heated at 
110 °C for 18 h. The reaction mixture was neutralised by addition of solid K2CO3, filtered 
and concentrated in vacuo. Purification by column chromatography (SiO2, CH2Cl2/MeOH, 
19:1) afforded the title compound 159 (0.754 g, 89%) as a light brown solid; mp. 180-182 
°C; Rf 0.36 (CH2Cl2/MeOH, 19:1); νmax (cm-1) 3178, 3032, 2925, 1707, 1607, 1593, 1543, 
1396, 1276, 1065, 770; δH (400 MHz; CDCl3) 7.40 – 7.32 (2 H, m, H-2), 7.18 (1 H, t, J = 
7.5 Hz, H-1), 7.15 – 7.12 (2 H, m, H-3), 6.68 (1 H, br s, H-5), 2.72 – 2.63 (2 H, m, H-10), 
2.45 – 2.34 (2 H, m, H-11), 1.69 (3 H, t, J = 1.4 Hz, H-8); δC (100 MHz; CDCl3) 203.6 (C-
185 
9), 169.8 (C-6), 138.9 (C-4), 129.5 (C-2), 125.3 (C-1), 123.0 (C-3), 111.5 (C-7), 33.3 (C-
11), 26.2 (C-10), 6.8 (C-8); Found (ESI): [MH]+ 188.1069; C12H14NO requires [MH]
+ 
188.1070, 0.7 ppm. 
Lab-book No PD/9/12. 
 
3-Benzoyl-1-methylpyrrolidin-2-one152 
 
To a stirred solution of N-methyl-2-pyrrolidinone (0.500 mL, 5.19 mmol) in THF (40 mL) 
was added at −78 °C, benzoyl chloride (0.630 mL, 5.44 mmol) and LHMDS (1.0 M in THF, 
10.6 mL, 10.6 mmol). The reaction mixture, which immediately turned yellow, was stirred 
for 1 h at −78 °C. Then, the reaction mixture was quenched by addition of an aq. sol. of HCl 
(10%, 20 mL) and allowed to warm to room temperature. The aqueous phase was extracted 
with EtOAc (2 × 40 mL). The combined organic phases were washed with water (40 mL) 
and brine (40 mL), dried (MgSO4), filtered, and concentrated in vacuo. Purification by 
column chromatography (SiO2, Hexane/EtOAc, 1:1) afforded the title compound (0.980 g, 
93%) as a yellow oil; Rf 0.21 (Hexane/EtOAc, 1:1); δH (400 MHz; CDCl3) 8.15 – 8.05 (2 H, 
m, H-3), 7.61 – 7.52 (1 H, m, H-1), 7.49 – 7.43 (2 H, m, H-2), 4.54 – 4.38 (1 H, m, H-6), 
3.66 – 3.49 (1 H, m, H-9a or H-10a), 3.42 – 3.34 (1 H, m, H-9a or H-10a), 2.88 – 2.79 (3 H, 
m, H-8), 2.66 – 2.52 (1 H, m, H-9b or H-10b), 2.32 – 2.14 (1 H, m, H-9b or H-10b). 
Data are consistent with literature values.152 
Lab-book No PD/11/8. 
 
(3Z)-1-Methyl-3-[phenyl(phenylamino)methylidene]pyrrolidin-2-one (160) 
 
3-Benzoyl-1-methylpyrrolidin-2-one (0.508 g, 2.50 mmol), aniline (0.228 mL, 2.50 mmol), 
and p-TSA (0.036 g, 0.189 mmol) in toluene (50 mL) were subjected to general procedure 
K. The residue was purified by column chromatography (SiO2, Hexane/EtOAc, 3:1) to give 
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the title compound 160 (0.355 g, 51%) as a yellow solid; mp. 99-101 °C; Rf 0.57 
(Hexane/EtOAc, 1:2); νmax (cm-1) 3200, 2930, 2871, 1639, 1596, 1494, 1427, 1398, 1281, 
1245, 1084, 1073, 751, 701; δH (400 MHz; CDCl3) 10.31 (1 H, br s, H-5), 7.38 – 7.27 (5 H, 
m, HAr), 7.03 – 6.92 (2 H, m, H-2), 6.74 (1 H, t, J = 7.4 Hz, H-1), 6.52 (2 H, d, J = 7.6 Hz, 
H-3), 3.37 – 3.24 (2 H, m, H-14), 2.89 (3 H, s, H-13), 2.69 – 2.54 (2 H, m, H-15); δC (100 
MHz; CDCl3) 172.1 (C-12), 147.4 (C-6), 142.0 (C-4), 135.9 (C-7), 128.8 (CHAr), 128.7 
(CHAr), 128.63 (CHAr), 128.58 (CHAr), 121.0 (C-1), 120.1 (C-3), 101.8 (C-11), 47.2 (C-14), 
29.8 (C-13), 23.4 (C-15); Found (ESI): [MH]+ 279.1493; C18H19N2O requires [MH]
+ 
279.1492, 0.2 ppm. 
Lab-book No PD/9/30. 
 
Ethyl (2Z)-3-(benzylamino)-2-methyl-3-phenylprop-2-enoate (164) 
 
To a stirred solution of ethyl 2-methyl-3-oxo-3-phenylpropanoate (152a) (0.419 g, 2.03 
mmol) in toluene (10 mL) was added benzylamine (0.222 mL, 2.03 mmol) and p-TSA (0.042 
g, 0.221 mmol). The reaction mixture was stirred at 110 °C overnight with a Dean & Stark 
apparatus fitted on the reaction condenser. Then, the reaction mixture was allowed to cool 
to room temperature. Solvent was removed and the residue was purified by column 
chromatography (SiO2, Hexane/EtOAc, 19:1) to give the title compound 164 (0.191 g, 32%) 
as a colourless oil; Rf 0.42 (Hexane/EtOAc, 8:1); νmax (cm-1) 3266, 2937, 1737, 1686, 1646, 
1582, 1450, 1266, 1133, 777, 698; δH (400 MHz; CDCl3) 9.40 (1 H, br s, H-6), 7.40 – 7.34 
(3 H, m, HAr), 7.29 – 7.23 (2 H, m, H-2), 7.22 – 7.17 (1 H, m, H-1), 7.16 – 7.06 (4 H, m, 
HAr), 4.23 – 4.15 (2 H, m, H-15), 4.01 (2 H, d, J = 6.4 Hz, H-5), 1.49 (3 H, s, H-13), 1.30 (3 
H, t, J = 7.1 Hz, H-16); δC (100 MHz; CDCl3) 171.6 (C-14), 162.0 (C-7), 140.0 (C-4), 133.6 
(C-8), 128.8 (CHAr), 128.63 (CHAr), 128.57 (CHAr), 128.5 (CHAr), 128.3 (CHAr), 127.0 
(CHAr), 89.8 (C-12), 59.2 (C-15), 48.5 (C-5), 14.8 (C-16), 14.2 (C-13); Found (ESI): [MH]
+ 
296.1641; C19H22NO2 requires [MH]
+ 296.1645, 1.2 ppm. 
Lab-book No PD/10/28. 
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5-Methyl-2,4-diphenyl-1,3-oxazole (167) 
 
To a stirred solution of ethyl (2Z)-3-(benzylamino)-2-methyl-3-phenylprop-2-enoate (164) 
(0.044 g, 0.148 mmol) in mesitylene (4 mL) was added Cu(2-ethylhexanoate)2 (0.054 g, 
0.154 mmol). The reaction mixture was stirred at 170 °C for 1 h and allowed to cool to room 
temperature. NH4OH (5 mL) was added, the aqueous phase was extracted with EtOAc (2 × 
5 mL). The combined organic phases were washed with water (5 mL) and brine (5 mL), 
dried (MgSO4), filtered, and concentrated in vacuo. The residue was purified by column 
chromatography (SiO2, Hexane/EtOAc, 19:1) to give the title compound 167 (0.013 g, 37%) 
as a yellow oil; Rf 0.46 (Hexane/EtOAc, 6:1); δH (400 MHz; CDCl3) 8.12 – 8.05 (2 H, m, 
HAr), 7.77 – 7.71 (2 H, m, HAr), 7.50 – 7.40 (5 H, m, HAr), 7.36 – 7.27 (1 H, m, HAr), 2.61 (3 
H, s, H-7). 
Data are consistent with literature values.72 
Lab-book No PD/10/30. 
 
Ethyl (2Z)-3-phenyl-3-(phenylamino)prop-2-enoate78 (172a) 
 
To a solution of ethyl benzoylacetate (0.495 mL, 2.86 mmol) in toluene (15 mL) was added 
aniline (0.261 mL, 2.86 mmol) and p-TSA (0.055 g, 0.290 mmol). The flask was fitted with 
a Dean & Stark apparatus, and stirred overnight at 110 °C. The reaction mixture was allowed 
to cool to room temperature. Solvent was removed in vacuo and the residue was purified by 
column chromatography (SiO2, Hexane/EtOAc, 49:1) to give the title compound 172a 
(0.151 g, 20%) as a colourless solid; mp. 52-54 °C (Lit.153 67-68 °C); Rf 0.62 
(Hexane/EtOAc, 4:1); δH (400 MHz; CDCl3) 10.29 (1 H, br s, H-5), 7.36 – 7.26 (5 H, m, 
HAr), 7.13 – 7.02 (2 H, m, H-2), 6.90 (1 H, t, J = 7.4 Hz, H-1), 6.65 (2 H, J = 7.7 Hz, H-3), 
4.99 (1 H, s, H-12), 4.20 (2 H, q, J = 7.1 Hz, H-14), 1.31 (3 H, t, J = 7.1 Hz, H-15). 
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Data is consistent with literature values.78, 153 
Lab-book No PD/10/20. 
 
Ethyl (2Z)-3-[(2,4-dimethoxyphenyl)amino]-3-phenylprop-2-enoate (172b) 
 
Ethyl benzoylacetate (0.283 g, 1.47 mmol), 2,4-dimethoxyaniline (0.227 g, 1.48 mmol), and 
p-TSA (0.028 g, 0.147 mmol) in toluene (10 mL) were subjected to general procedure K. 
The residue was purified by column chromatography (SiO2, Hexane/EtOAc, 8:1) to give the 
title compound 172b (0.091 g, 19%) as a yellow oil; Rf 0.32 (Hexane/EtOAc, 4:1); νmax (cm-
1) 3263, 2976, 2836, 1653, 1609, 1587, 1573, 1516, 1463, 1439, 1418, 1329, 1277, 1207, 
1157, 1098, 1037, 911, 794, 774, 699; δH (400 MHz; CDCl3) 10.07 (1 H, br s, H-9), 7.32 – 
7.22 (5 H, m, HAr), 6.39 (1 H, d, J = 2.7 Hz, H-7), 6.22 (1 H, d, J = 8.7 Hz, H-3), 6.06 (1 H, 
dd, J = 8.7, 2.7 Hz, H-2), 4.91 (1 H, s, H-16), 4.19 (2 H, q, J = 7.1 Hz, H-18), 3.81 (3 H, s, 
H-6 or H-8), 3.67 (3 H, s, H-6 or H-8), 1.29 (3 H, t, J = 7.1 Hz, H-19); δC (100 MHz; CDCl3) 
170.3 (C-17), 159.7 (C-10), 156.6 (C-1 or C-5), 152.4 (C-1 or C-5), 136.6 (C-11), 129.2 (C-
14), 128.3 (C-12 or C-13), 128.2 (C-12 or C-13), 123.9 (C-3), 123.0 (C-4), 103.3 (C-2), 98.9 
(C-7), 89.7 (C-15), 59.2 (C-18), 55.8 (C-6 or C-8), 55.5 (C-6 or C-8), 14.7 (C-19); Found 
(ESI): [MNa]+ 350.1363; C19H21NNaO4 requires [MNa]
+ 350.1363, 0.1 ppm. 
Lab-book No PD/11/62. 
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Ethyl (2Z)-3-(4-methylphenyl)-3-(phenylamino)prop-2-enoate (172c) 
 
Ethyl 3-(4-methylphenyl)-3-oxopropanoate (0.275 g, 1.33 mmol), aniline (0.122 mL, 1.33 
mmol), and p-TSA (0.029 g, 0.152 mmol) in toluene (5 mL) were subjected to general 
procedure K. The residue was purified by column chromatography (SiO2, Hexane/EtOAc, 
19:1) to give the title compound 172c (0.045 g, 12%) as a colourless oil; Rf 0.70 
(Hexane/EtOAc, 4:1); νmax (cm-1) 3252, 2978, 1655, 1615, 1585, 1596, 1285, 1165, 1102, 
1037, 828, 794, 692; δH (400 MHz; CDCl3) 10.28 (1 H, br s, H-5), 7.26 – 7.21 (2 H, m, H-
8), 7.12 – 7.02 (4 H, m, H-2, and H-9), 6.90 (1 H, t, J = 7.4 Hz, H-1), 6.67 (2 H, d, J = 7.5 
Hz, H-3), 4.98 (1 H, s, H-13), 4.20 (2 H, q, J = 7.1 Hz, H-15), 2.32 (3 H, s, H-11), 1.31 (3 
H, t, J = 7.1 Hz, H-16); δC (100 MHz; CDCl3) 170.3 (C-14), 159.3 (C-6), 140.7 (C-4), 139.7 
(C-10), 133.1 (C-7), 129.2 (CHAr), 128.7 (CHAr), 128.2 (CHAr), 122.9 (C-1), 122.3 (C-3), 
90.9 (C-13), 59.3 (C-15), 21.4 (C-11), 14.6 (C-16); Found (ESI): [MH]+ 282.1489; 
C18H20NO2 requires [MH]
+ 282.1489, 0.1 ppm. 
Lab-book No PD/11/9. 
 
Ethyl (2Z)-3-(4-chlorophenyl)-3-(phenylamino)prop-2-enoate (172d) 
 
Ethyl 3-(4-chlorophenyl)-3-oxopropanoate (0.188 g, 0.829 mmol), aniline (0.076 mL, 0.829 
mmol), and p-TSA (0.018 g, 0.096 mmol) in toluene (5 mL) were subjected to general 
procedure K. The residue was purified by column chromatography (SiO2, Hexane/EtOAc, 
19:1) to give the title compound 172d (0.039 g, 16%) as a colourless oil; Rf 0.58 
(Hexane/EtOAc, 4:1); νmax (cm-1) 3253, 2979, 1656, 1612, 1597, 1584, 1564, 1500, 1478, 
1441, 1362, 1280, 1165, 1090, 1035, 837, 796, 748; δH (400 MHz; CDCl3) 10.24 (1 H, br s, 
H-5), 7.54 – 7.16 (4 H, m, H-8 and H-9), 7.19 – 7.00 (2 H, m, H-2), 6.92 (1 H, t, J = 7.4 Hz, 
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H-1), 6.65 (2 H, d, J = 7.5 Hz, H-3), 4.96 (1 H, s, H-12), 4.20 (2 H, q, J = 7.2 Hz, H-14), 
1.30 (3 H, t, J = 7.2 Hz, H-15); δC (100 MHz; CDCl3) 170.0 (C-13), 157.8 (C-6), 140.2 (C-
4), 135.5 (C-7 or C-10), 134.5 (C-7 or C-10), 129.6 (CHAr), 128.9 (CHAr), 128.8 (CHAr), 
123.3 (C-1), 122.5 (C-3), 91.6 (C-11), 59.5 (C-14), 14.6 (C-15); Found (ESI): [MNa]+ 
324.0759; C17H16ClNNaO2 requires [MNa]
+ 324.0762, 0.8 ppm. 
Lab-book No PD/11/6. 
 
Ethyl (2Z)-3-(phenylamino)-3-(thiophen-2-yl)prop-2-enoate (172e) 
 
Ethyl 3-oxo-3-(thiophen-2-yl)propanoate (0.257 g, 1.30 mmol), aniline (0.118 mL, 1.30 
mmol), and p-TSA (0.025 g, 0.131 mmol) in toluene (5 mL) were subjected to general 
procedure K. The residue was purified by column chromatography (SiO2, Hexane/EtOAc, 
19:1) to give the title compound 172e (0.019 g, 5%) as a colourless oil; Rf 0.48 
(Hexane/EtOAc, 4:1); νmax (cm-1) 3250, 2979, 1735, 1656, 1595, 1498, 1484, 1428, 1364, 
1270, 1220, 1167, 1043, 696; δH (400 MHz; CDCl3) 10.10 (1 H, br s, H-5), 7.29 (1 H, dd, J 
= 5.0, 1.2 Hz, H-10), 7.18 – 7.11 (2 H, m, H-2), 7.02 (1 H, dd, J = 3.7, 1.2 Hz, H-8), 6.98 (1 
H, t, J = 7.4 Hz, H-1), 6.91 (1 H, dd, J = 5.0, 3.7 Hz, H-9), 6.81 (2 H, d, J = 7.5 Hz, H-3), 
5.18 (1 H, s, H-12), 4.19 (2 H, q, J = 7.1 Hz, H-14), 1.30 (3 H, t, J = 7.1 Hz, H-15); δC (100 
MHz; CDCl3) 170.0 (C-13), 152.1 (C-6), 140.7 (C-4), 137.7 (C-7), 128.9 (C-8), 128.8 (C-
2), 127.7 (C-10), 127.3 (C-9), 123.7 (C-1), 123.1 (C-3), 91.3 (C-11), 59.5 (C-14), 14.6 (C-
15); Found (ESI): [MH]+ 274.0890; C15H16NO2S requires [MH]
+ 274.0896, 2.2 ppm. 
Lab-book No PD/11/12. 
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Ethyl 3-oxo-3-(pyridin-4-yl)propanoate154 
 
4-Ethyl picolinate (0.750 mL, 5.00 mmol), ethyl acetate (3.43 mL, 35.0 mmol), LHMDS (1 
M in THF, 10.0 mL, 10.0 mmol) in THF (10 mL) were subjected to general procedure I. The 
residue was purified by column chromatography (SiO2, Hexane/EtOAc, 1:1) to give the title 
compound (0.795 g, 82%) as a colourless crystalline solid in a 1:3 keto-enol mixture; mp. 
46-48 °C (Lit.155 57.5-58 °C); Rf 0.42 (Hexane/EtOAc, 1:2); δH (400 MHz; CDCl3, Keto) 
8.91 – 8.79 (2 H, m, H-1), 7.80 – 7.64 (2 H, m, H-2), 4.21 (2 H, q, J = 7.1 Hz, H-7), 3.98 (2 
H, s, H-5), 1.25 (3 H, t, J = 7.1 Hz, H-8); δH (400 MHz; CDCl3, Enol) 12.43 (1 H, s, OH), 
8.70 (2 H, dd, J = 4.7, 1.5 Hz, H-1), 7.60 (2 H, dd, J = 4.6, 1.5 Hz, H-2), 5.76 (1 H, s, H-5), 
4.28 (2 H, q, J = 7.2 Hz, H-7), 1.34 (3 H, t, J = 7.2 Hz, H-8). 
Data is consistent with literature values.155 
Lab-book No PD/11/49. 
 
Ethyl (2Z)-3-(phenylamino)-3-(pyridin-4-yl)prop-2-enoate (172f) 
 
Ethyl 3-oxo-3-(pyridin-4-yl)propanoate (0.234 g, 1.21 mmol), aniline (0.110 mL, 1.21 
mmol), and p-TSA (0.023 g, 0.121 mmol) in toluene (10 mL) were subjected to general 
procedure K. The residue was purified by column chromatography (SiO2, Hexane/EtOAc, 
2:1) to give the title compound 172f (0.115 g, 35%) as a yellow oil; Rf 0.40 (Hexane/EtOAc, 
1:1); νmax (cm-1) 3260, 2979, 1659, 1615, 1583, 1547, 1501, 1481, 1441, 1408, 1279, 1168, 
1034, 834, 795, 748, 693; δH (400 MHz; CDCl3) 10.19 (1 H, br s, H-5), 8.53 (2 H, d, J = 6.0 
Hz, H-9), 7.21 (2 H, d, J = 6.0 Hz, H-8), 7.09 (2 H, t, J = 7.8 Hz, H-2), 6.94 (1 H, t, J = 7.4 
Hz, H-1), 6.65 (2 H, d, J = 7.9 Hz, H-3), 5.02 (1 H, s, H-11), 4.20 (2 H, q, J = 7.1 Hz, H-13), 
1.30 (3 H, t, J = 7.1 Hz, H-14); δC (100 MHz; CDCl3) 169.8 (C-12), 156.1 (C-6), 150.2 (C-
9), 144.0 (C-7), 139.7 (C-4), 128.9 (C-2), 123.7 (C-1), 122.6 (C-3 or C-8), 122.5 (C-3 or C-
8), 92.7 (C-10), 59.7 (C-13), 14.5 (C-14); Found (ESI): [MH]+ 269.1288; C16H17N2O2 
requires [MH]+ 269.1285, 1.4 ppm. 
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Lab-book No PD/11/51. 
 
6.3.7 General procedure M: Cu(II)-mediated cyclisation to 1H-indoles 
 
Ethyl 2-phenyl-1H-indole-3-carboxylate (173a) 
 
To a stirred solution of ethyl (2Z)-3-phenyl-3-(phenylamino)prop-2-enoate (172a) (0.016 g, 
0.059 mmol) in mesitylene (2 mL) was added Cu(OAc)2·H2O (0.012 g, 0.058 mmol). The 
reaction mixture was stirred at 170 °C for 2 h and allowed to cool to room temperature. 
NH4OH (5 mL) was added and the aqueous phase was extracted with EtOAc (2 × 5 mL). 
The combined organic phases were washed with brine, dried (MgSO4), filtered, and 
concentrated in vacuo. The crude residue was purified by column chromatography (SiO2, 
Hexane/EtOAc, 8:1) and afforded the title compound 173a (0.011 g, 69%) as a colourless 
solid; mp. 134-136 °C (Lit.156 150-152 °C); Rf 0.26 (Hexane/EtOAc, 4:1); δH (400 MHz; 
CDCl3) 8.50 (1 H, br s, H-5), 8.39 – 8.09 (1 H, m, HAr), 7.78 – 7.57 (2 H, m, HAr), 7.47 – 
7.43 (3 H, m, HAr), 7.41 – 7.36 (1 H, m, HAr), 7.29 – 7.25 (2 H, m, HAr), 4.30 (2 H, q, J = 7.1 
Hz, H-15), 1.31 (3 H, t, J = 7.1 Hz, H-16); δC (100 MHz; CDCl3) 165.4 (C-14), 144.5 (CAr), 
135.2 (CAr), 132.2 (CAr), 129.7 (CHAr), 129.3 (CHAr), 128.2 (CHAr), 127.7 (CAr), 123.3 
(CHAr), 122.3 (CHAr), 122.2 (CHAr), 111.0 (CHAr), 104.9 (C-7), 59.8 (C-15), 14.4 (C-16). 
Data are consistent with literature values.78, 155 
Lab-book No PD/11/7. 
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Ethyl 5,7-dimethoxy-2-phenyl-1H-indole-3-carboxylate (173b) 
 
Ethyl (2Z)-3-[(2,4-dimethoxyphenyl)amino]-3-phenylprop-2-enoate (172b) (0.061 g, 0.185 
mmol), Cu(OAc)2·H2O (0.037 g, 0.185 mmol) in mesitylene (2 mL) were subjected to 
general procedure M at 170 °C for 2 h. Purification by column chromatography (SiO2, 
Hexane/EtOAc, 8:1) afforded the title compound 173b (0.020 g, 34%) as a yellow oil; Rf 
0.42 (Hexane/EtOAc, 2:1); νmax (cm-1) 3276, 2938, 2836, 1683, 1595, 1528, 1485, 1454, 
1420, 1291, 1202, 1155, 1044, 829, 697; δH (400 MHz; CDCl3) 8.56 (1 H, br s, H-5), 7.65 – 
7.62 (2 H, m, HAr), 7.45 – 7.41 (3 H, m, HAr), 7.29 (1 H, d, J = 2.1 Hz, H-9), 6.39 (1 H, d, J 
= 2.1 Hz, H-2), 4.28 (2 H, q, J = 7.1 Hz, H-17), 3.91 (3 H, s, H-10 or H-11), 3.89 (3 H, s, H-
10 or H-11), 1.27 (3 H, t, J = 7.1 Hz, H-18); δC (100 MHz; CDCl3) 165.6 (C-16), 156.8 (C-
1 or C-3), 146.3 (C-1 or C-3), 143.8 (C-6 or C-12), 132.4 (C-6 or C-12), 129.7 (C-13 or C-
14), 129.2 (C-15), 128.2 (C-13 or C-14), 127.1 (C-8), 121.1 (C-4), 105.1 (C-7), 95.4 (C-2 or 
C-9), 95.1 (C-2 or C-9), 59.7 (C-17), 55.9 (C-10 or C-11), 55.6 (C-10 or C-11), 14.4 (C-18); 
Found (ESI): [MNa]+ 348.1209; C19H19NNaO4 requires [MNa]
+ 348.1206, 0.9 ppm. 
Lab-book No PD/11/64. 
 
Ethyl 2-(4-methylphenyl)-1H-indole-3-carboxylate (173c) 
 
Ethyl (2Z)-3-(4-methylphenyl)-3-(phenylamino)prop-2-enoate (172c) (0.039 g, 0.138 
mmol), Cu(OAc)2·H2O (0.036 g, 0.142 mmol) in mesitylene (2 mL) were subjected to 
general procedure M at 170 °C for 2 h. Purification by column chromatography (SiO2, 
Hexane/EtOAc, 9:1) afforded the title compound 173c (0.019 g, 50%) as a colourless solid; 
mp. 144-146 °C (Lit.156 165-167 °C); Rf 0.30 (Hexane/EtOAc, 4:1); δH (400 MHz; CDCl3) 
8.53 (1 H, br s, H-5), 8.28 – 8.12 (1 H, m, HAr), 7.54 (2 H, d, J = 8.1 Hz, HAr), 7.37 – 7.34 
(1 H, m, HAr), 7.27 – 7.22 (4 H, m, HAr), 4.30 (2 H, q, J = 7.1 Hz, H-16), 2.39 (3 H, s, H-14), 
1.33 (3 H, t, J = 7.1 Hz, H-17); δC (100 MHz; CDCl3) 165.5 (C-15), 144.8 (C-6), 139.4 (C-
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13), 135.1 (CAr), 129.5 (C-11 or C-12), 129.1 (CAr), 128.9 (C-11 or C-12), 127.8 (CAr), 123.1 
(CHAr), 122.2 (CHAr), 122.1 (CHAr), 111.0 (CHAr), 104.6 (C-7), 59.8 (C-16), 21.5 (C-14), 
14.5 (C-17). Anal. Calcd. for C18H17NO2: C, 77.40; H, 6.13; N, 5.01. Found: C, 76.96; H, 
6.20; N, 4.81. 
Data are consistent with literature values.156 
Lab-book No PD/11/39. 
 
Ethyl 2-(4-chlorophenyl)-1H-indole-3-carboxylate (173d) 
 
Ethyl (2Z)-3-(4-chlorophenyl)-3-(phenylamino)prop-2-enoate (172d) (0.033 g, 0.109 
mmol), Cu(OAc)2·H2O (0.028 g, 0.110 mmol) in mesitylene (2 mL) were subjected to 
general procedure M at 170 °C for 2 h. Purification by column chromatography (SiO2, 
Hexane/EtOAc, 9:1) afforded the title compound 173d (0.015 g, 47%) as a colourless solid; 
mp. 135-137 °C; Rf 0.35 (Hexane/EtOAc, 4:1); νmax (cm-1) 3281, 2980, 1667, 1484, 1439, 
1278, 1213, 1128, 1091, 1045, 1015, 841, 830, 790, 726, 753; δH (400 MHz; CDCl3) 8.56 (1 
H, br s, H-5), 8.25 – 8.11 (1 H, m, HAr), 7.62 – 7.56 (2 H, m, H-11 or H-12), 7.43 – 7.39 (2 
H, m, H-11 or H-12), 7.39 – 7.34 (1 H, m, HAr), 7.31 – 7.26 (2 H, m, HAr), 4.31 (2 H, q, J = 
7.1 Hz, H-15), 1.33 (3 H, t, J = 7.1 Hz, H-16); δC (100 MHz; CDCl3) 165.3 (C-14), 143.2 
(CAr), 135.5 (CAr), 135.3 (CAr), 131.1 (C-11 or C-12), 130.5 (CAr), 128.6 (C-11 or C-12), 
127.6 (CAr), 123.6 (CHAr), 122.42 (CHAr), 122.41 (CHAr), 111.1 (CHAr), 105.3 (C-7), 60.0 
(C-15), 14.5 (C-16); Found (ESI): [MNa]+ 322.0596; C17H14ClNNaO2 requires [MNa]
+ 
322.0605, 2.8 ppm. 
Lab-book No PD/11/37. 
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Ethyl 2-(thiophen-2-yl)-1H-indole-3-carboxylate (173e) 
 
Ethyl (2Z)-3-(phenylamino)-3-(thiophen-2-yl)prop-2-enoate (172e) (0.014 g, 0.050 mmol), 
Cu(OAc)2·H2O (0.013 g, 0.050 mmol) in mesitylene (2 mL) were subjected to general 
procedure M at 170 °C for 2 h. Purification by column chromatography (SiO2, 
Hexane/EtOAc, 8:1) afforded the title compound 173e (0.009 g, 63%) as a yellow oil; Rf 
0.30 (Hexane/EtOAc, 4:1); νmax (cm-1) 3292, 2936, 1668, 1490, 1455, 1439, 1419, 1341, 
1274, 1203, 1121, 1110, 854, 788, 752, 703; δH (400 MHz; CDCl3) 8.57 (1 H, br s, H-5), 
8.25 – 8.15 (1 H, m, HAr), 7.73 (1 H, dd, J = 3.8, 1.3 Hz, H-11), 7.48 (1 H, dd, J = 5.2, 1.3 
Hz, H-13), 7.38 (1 H, dd, J = 6.2, 2.9 Hz, HAr), 7.29 – 7.26 (2 H, m, HAr), 7.15 (1 H, dd, J = 
5.2, 3.8 Hz, H-12), 4.42 (2 H, q, J = 7.1 Hz, H-15), 1.44 (3 H, t, J = 7.1 Hz, H-16); δC (100 
MHz; CDCl3) 165.4 (C-14), 137.3 (CAr), 135.2 (CAr), 132.7 (CAr), 129.6 (C-11), 128.1 (C-
13), 127.8 (CAr), 127.6 (C-12), 123.8 (CHAr), 122.5 (CHAr), 122.4 (CHAr), 111.0 (CHAr), 
105.2 (C-7), 60.2 (C-15), 14.7 (C-16); Found (ESI): [MH]+ 272.0731; C15H14NO2S requires 
[MH]+ 272.0740, 3.2 ppm. 
Lab-book No PD/11/53. 
 
Ethyl 2-(pyridin-4-yl)-1H-indole-3-carboxylate (173f) 
 
Ethyl (2Z)-3-(phenylamino)-3-(pyridin-4-yl)prop-2-enoate (172f) (0.049 g, 0.181 mmol), 
Cu(OAc)2·H2O (0.045 g, 0.181 mmol) in mesitylene (2 mL) were subjected to general 
procedure M at 170 °C for 2 h. Purification by column chromatography (SiO2, 
Hexane/EtOAc, 1:2) afforded the title compound 173f (0.027 g, 56%) as an orange solid; 
mp. 181-183 °C; Rf 0.08 (Hexane/EtOAc, 1:1); νmax (cm-1) 3273, 2978, 2928, 1697, 1605, 
1490, 1444, 1332, 1276, 1211, 1131, 1048, 788, 753; δH (400 MHz; CDCl3) 10.12 (1 H, br 
s, H-5), 8.63 (2 H, br s, H-12), 8.23 (1 H, dd, J = 6.4, 2.9 Hz, HAr), 7.61 (2 H, d, J = 3.3 Hz, 
H-11), 7.47 – 7.42 (1 H, m, HAr), 7.32 – 7.28 (2 H, m, HAr), 4.34 (2 H, q, J = 7.1 Hz, H-14), 
1.35 (3 H, t, J = 7.1 Hz, H-15); δC (100 MHz; CDCl3) 165.2 (C-13), 149.3 (CAr), 140.9 (CAr), 
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135.94 (CAr), 135.93 (CAr), 129.3 (CHAr), 127.4 (CHAr), 124.1 (CHAr), 122.54 (CHAr), 122.53 
(CHAr), 111.6 (CHAr), 106.2 (C-7), 60.2 (C-14), 14.4 (C-15); Found (ESI): [MH]
+ 267.1131; 
C16H15N2O2 requires [MH]
+ 267.1128, 1.2 ppm; Anal. Calcd. for C16H14N2O2: C, 72.17; H, 
5.30; N, 10.52. Found: C, 71.85; H, 5.58; N, 10.10. 
Lab-book No PD/11/54. 
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6.4 Studies towards the total synthesis of rankinidine 
 
6.4.1 Model studies for spirocyclic oxindole formation 
 
6.4.1.1 General procedure N: One-step MMC/amide coupling route 
 
N-Benzyl-2-oxo-N-phenylcyclopentane-1-carboxamide (102d) 
 
Cyclopentanone (0.290 g, 2.26 mmol) was added to a solution of methyl magnesium 
carbonate (2.0 M in DMF, 9.04 mL, 18.1 mmol). The reaction mixture was stirred for 6 h at 
130 °C. The reaction was allowed to cool to room temperature and an aq. sol. of HCl (10%, 
10 mL) was added slowly until the pH media became acidic. The aqueous layer was extracted 
with Et2O (3 × 10 mL). The combined organic phases were washed with water (4 × 10 mL) 
and brine (20 mL), dried (MgSO4), filtered and concentrated in vacuo to give a mixture of 
mono- and bis-acids. To a stirred solution of the crude acid mixture in CH2Cl2 (17 mL) was 
added N-benzylaniline (0.154 mL, 0.831 mmol), 2-chloro-1-methylpyridinium iodide (0.255 
g, 0.997 mmol) and Et3N (0.462 mL, 3.32 mmol) at 0 °C. The reaction mixture was allowed 
to warm to room temperature and stirred overnight. HCl (10% solution in water, 10 mL) was 
added to the reaction mixture and the aqueous phase was extracted with CH2Cl2 (2 × 10 
mL). The combined organic phases were washed with water (20 mL) and brine (20 mL), 
dried (MgSO4), filtered and concentrated in vacuo to give a mixture of mono- and bis-
anilides. Purification by column chromatography (SiO2, Hexane/EtOAc, 4:1) afforded the 
title compound 102d (0.043 g, 15%) as a colourless solid; mp. 97-99 °C; Rf 0.27 
(Hexane/EtOAc, 1:2); νmax (cm-1) 2966, 1739, 1644, 1595, 1495, 1405, 700; δH (400 MHz; 
CDCl3) 7.32 – 7.27 (3 H, m, HAr), 7.27 – 7.23 (3 H, m, HAr), 7.23 – 7.18 (2 H, m, HAr), 7.13 
(2 H, br s, HAr), 5.01 (1 H, d, J = 14.4 Hz, H-11a), 4.82 (1 H, d, J = 14.4 Hz, H-11b), 3.08 
(1 H, dd, J = 10.2, 9.2 Hz, H-6), 2.48 – 2.36 (1 H, m, H-10a), 2.35 – 2.16 (2 H, m, H-8a, H-
9a), 2.14 – 2.03 (2 H, m, H-8b, H-10b), 1.77 – 1.58 (1 H, m, H-9b); δC (100 MHz; CDCl3) 
214.8 (C-7), 170.1 (C-5), 142.1 (CAr), 137.1 (CAr), 129.6 (CHAr), 128.7 (2 × CHAr), 128.5 
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(CHAr), 128.3 (CHAr), 127.4 (CHAr), 53.3 (C-11), 52.9 (C-6), 38.6 (C-8), 28.4 (C-10), 21.1 
(C-9); Found (ESI): [MNa]+ 316.1297; C19H19NNaO2 requires [MNa]
+ 316.1308, 3.4 ppm. 
Lab-book No PD/9/22. 
 
N-Methyl-2-oxo-N-phenylcyclohexane-1-carboximide (102a) 
 
Cyclohexanone (0.210 mL, 2.04 mmol) and methyl magnesium carbonate (2.0 M in DMF, 
8.15 mL, 16.3 mmol) were subjected to general procedure N. The mixture of crude mono- 
and bis-acids was subsequently treated with N-methylaniline (0.254 mL, 2.34 mmol), 2-
chloro-1-methylpyridinium iodide (0.720 g, 2.82 mmol) and Et3N (1.31 mL, 9.38 mmol) 
following general procedure N. Purification by column chromatography (SiO2, 
Hexane/EtOAc, 3:1 to Hexane/EtOAc, 1:4) afforded the monoanilide product 102a (0.065 
g, 30%) as a yellow oil; Rf 0.52 (Hexane/EtOAc, 1:4); νmax (cm-1) 2941, 2865, 1710, 1652, 
1595, 1495, 1450, 1421, 1382, 1126, 775, 702; δH (400 MHz; CDCl3) 7.37 – 7.35 (2 H, m, 
H-2), 7.34 – 7.31 (1 H, m, H-1), 7.15 (2 H, dd, J = 8.2, 1.3 Hz, H-3), 3.28 (3 H, s, H-12), 
3.21 (1 H, dd, J = 11.7, 5.9 Hz, H-6), 2.44 – 2.37 (1 H, m, H-8a), 2.16 (1 H, ddd, J = 15.4, 
12.9, 3.6 Hz, H-11a), 2.04 – 1.94 (2 H, m, H-8b, H-11b), 1.94 – 1.83 (2 H, m, H-9a, H-10a), 
1.78 – 1.64 (1 H, m, H-9b), 1.51 – 1.37 (1 H, m, H-10b); δC (100 MHz; CDCl3) 207.5 (C-7), 
169.7 (C-5), 143.8 (C-4), 129.9 (C-2), 128.2 (C-1), 127.3 (C-3), 55.3 (C-6), 41.7 (C-8), 37.5 
(C-12), 30.5 (C-11), 26.9 (C-9), 23.8 (C-10); Found (ESI): [MNa]+ 254.1149; C14H17NNaO2 
requires [MNa]+ 254.1151, 0.8 ppm. 
Lab-book No PD/9/20/2a. 
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N-Methyl-2-oxo-N-phenylcycloheptane-1-carboxamide (102c) 
 
Cycloheptanone (0.190 g, 1.70 mmol) and methyl magnesium carbonate (2.0 M in DMF, 
6.80 mL, 13.6 mmol) were subjected to general procedure N. The mixture of crude mono- 
and bis-acids was subsequently treated with N-methylaniline (0.240 mL, 2.19 mmol), 2-
chloro-1-methylpyridinium iodide (0.668 g, 2.62 mmol) and Et3N (1.22 mL, 8.75 mmol) 
following general procedure N. Purification by column chromatography (SiO2, 
Hexane/EtOAc, 6:1) gave the title compound 102c (0.073 g, 34%) as a colourless oil; Rf 
0.23 (Hexane/EtOAc, 6:1); νmax (cm-1) 2884, 1678, 1624, 1570, 1472, 1359, 1097; δH (400 
MHz; CDCl3) 7.45 – 7.29 (3 H, m, H-1, H-2), 7.22 – 7.16 (2 H, m, H-3), 3.45 (1 H, dd, J = 
10.6, 3.9 Hz, H-6), 3.25 (3 H, s, H-13), 2.55 (1 H, ddd, J = 14.6, 11.6, 3.3 Hz, H-8a), 2.14 – 
2.04 (1 H, m, H-8b), 2.02 – 1.92 (1 H, m, H-11a), 1.92 – 1.81 (2 H, m, H-12), 1.80 – 1.71 (2 
H, m, H-9a, H-10a), 1.40 – 1.03 (3 H, m, H-9b, H-10b, H-11b); δC (100 MHz; CDCl3) 210.9 
(C-7), 170.6 (C-5), 143.6 (C-4), 129.9 (C-2), 128.2 (C-1), 128.0 (C-3), 56.6 (C-6), 43.3 (C-
8), 37.6 (C-13), 29.6 (C-10), 28.6 (C-12), 28.4 (C-11), 24.6 (C-9); Found (ESI): [MH]+ 
246.1497; C15H20NO2 requires [MH]
+ 246.1489, 3.2 ppm. 
Lab-book No PD/9/25. 
 
6.4.1.2 General procedure O: Copper(II)-mediated cyclisation to spirocyclic oxindoles 
 
1’-Benzyl-1’,2’-dihydrospiro[cyclopentane-1,3’-indole]-2’,5-dione (212) 
 
To a stirred solution of N-benzyl-2-oxo-N-phenylcyclopentane-1-carboxamide (102d) 
(0.011 g, 0.039 mmol) in toluene (2 mL) was added Cu(OAc)2·H2O (0.010 g, 0.052 mmol). 
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The reaction was stirred and heated at 110 °C for 1.5 h. The reaction mixture was allowed 
to cool to room temperature. NH4OH (10 mL) was added, the aqueous phase was extracted 
twice with EtOAc (2 × 5 mL). The combined organic extracts were washed with water (5 
mL) and brine (5 mL), dried (MgSO4), filtered and concentrated in vacuo. The residue was 
purified by flash chromatography (SiO2, Hexane/EtOAc, 6:1) to give the title compound 212 
(0.006 g, 56%) as a colourless oil; Rf 0.19 (Hexane/EtOAc, 4:1); νmax (cm-1) 2969, 1747, 
1702, 1611, 1489, 1466, 1360, 1183, 1107, 754, 697; δH (400 MHz; CDCl3) 7.34 – 7.24 (5 
H, m, HAr), 7.16 (1 H, td, J = 7.7, 1.3 Hz, H-2), 7.09 (1 H, dd, J = 7.2, 1.2 Hz, H-8), 7.00 (1 
H, td, J = 7.6, 1.0 Hz, H-1), 6.69 (1 H, d, J = 7.9 Hz, H-3), 5.00 (1 H, d, J = 15.8 Hz, H-13a), 
4.80 (1 H, d, J = 15.8 Hz, H-13b), 2.79 – 2.70 (1 H, m, CH2), 2.70 – 2.61 (1 H, m, CH2), 
2.60 – 2.48 (2 H, m, CH2), 2.46 – 2.37 (1 H, m, CH2), 2.32 – 2.19 (1 H, m, CH2); δC (100 
MHz; CDCl3) 212.7 (C-9), 175.4 (C-5), 143.5 (C-4), 135.4 (C-14), 130.5 (C-7), 128.9 
(CHAr), 128.7 (C-2), 127.7 (CHAr), 127.1 (CHAr), 123.0 (C-1), 122.6 (C-8), 109.6 (C-3), 63.1 
(C-6), 43.9 (C-13), 38.4 (CH2), 34.2 (CH2), 20.4 (CH2); Found (ESI): [MNa]
+ 314.1154; 
C19H17NNaO2 requires [MNa]
+ 314.1151, 0.8 ppm. 
Lab-book No PD/11/11. 
 
1’-Methyl-1’-2’-dihydrospiro[cyclohexane-1,3’-indole]-2’,6-dione (213) 
 
N-Methyl-2-oxo-N-phenylcyclohexane-1-carboximide (102a) (0.016 g, 0.068 mmol), 
Cu(OAc)2·H2O (0.014 g, 0.071 mmol) in toluene (2 mL) were subjected to general procedure 
O at 110 °C for 3 h. The residue was purified by flash chromatography (SiO2, 
Hexane/EtOAc, 6:1) to give the title compound 213 (0.010 g, 65%) as a colourless oil; Rf 
0.38 (Hexane/EtOAc, 2:1); νmax (cm-1) 2940, 2867, 1730, 1697, 1613, 1494, 1471, 1373, 
1348, 1127, 754; δH (400 MHz; CDCl3) 7.30 (1 H, td, J = 7.6, 1.1 Hz, H-2), 7.28 (1 H, d, J 
= 7.3 Hz, H-8), 7.09 (1 H, td, J = 7.5, 0.9 Hz, H-1), 6.83 (1 H, d, J = 7.8 Hz, H-3), 3.19 (3 
H, s, H-14), 3.05 (1 H, ddd, J = 14.2, 10.5, 5.5 Hz, CH2), 2.58 (1 H, dt, J = 14.2, 5.5 Hz, 
CH2), 2.41 (1 H, dtt, J = 14.2, 10.5, 4.0 Hz, CH2), 2.27 – 2.13 (2 H, m, CH2), 2.08 (1 H, ddd, 
J = 14.2, 10.5, 4.0 Hz, CH2), 2.03 – 1.92 (1 H, m, CH2), 1.90 – 1.81 (1 H, m, CH2); δC (100 
MHz; CDCl3) 205.4 (C-9), 174.4 (C-5), 143.3 (C-4), 129.5 (C-7), 128.8 (C-2), 124.7 (C-8), 
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122.8 (C-1), 108.5 (C-3), 63.8 (C-6), 39.9 (CH2), 37.4 (CH2), 27.0 (CH2), 26.6 (C-14), 20.4 
(CH2); Found (ESI): [MNa]
+ 252.0998; C14H15NNaO2 requires [MNa]
+ 252.0995, 1.1 ppm. 
Lab-book No PD/11/10. 
 
1'-Methyl-1’,2’-dihydrospiro[cycloheptane-1,3’-indole]-2’,7-dione (214) 
 
N-Methyl-2-oxo-N-phenylcycloheptane-1-carboxamide (102c) (0.037 g, 0.152 mmol), 
Cu(OAc)2·H2O (0.030 g, 0.152 mmol) in toluene (4 mL) were subjected to general procedure 
O at 110 °C for 1.5 h. Purification by column chromatography (SiO2, Hexane/EtOAc, 4:1) 
gave the title compound 214 (0.024 g, 66%) as a colourless oil; Rf 0.34 (Hexane/EtOAc, 
3:1); νmax (cm-1) 2889, 1703, 1668, 1585, 1471, 1447, 1352, 1325; δH (400 MHz; CDCl3) 
7.29 (1 H, td, J = 7.7, 1.2 Hz, H-2), 7.25 (1 H, ddd, J = 7.7, 1.2, 0.5 Hz, H-8), 7.06 (1 H, td, 
J = 7.7, 1.2 Hz, H-1), 6.83 (1 H, d, J = 7.7 Hz, H-3), 3.19 (3 H, s, H-15), 3.09–3.01 (1 H, m, 
H-10a), 2.78–2.67 (1 H, m, H-10b), 2.31 (1 H, dd, J = 14.8, 9.1 Hz, H-14a), 2.17 – 2.09 (1 
H, m, H-12a), 2.07 – 1.95 (1 H, m, H-14b), 1.94 – 1.84 (1 H, m, H-11a), 1.84 – 1.73 (4 H, 
m, H-13, H-12b, H-11b); δC (100 MHz; CDCl3) 207.6 (C-9), 175.3 (C-5), 143.5 (C-4), 130.8 
(C-7), 128.7 (C-2), 123.6 (C-8), 122.7 (C-1), 108.6 (C-3), 65.6 (C-6), 42.3 (C-10), 34.8 (C-
14), 30.9 (C-13), 26.8 (C-11), 26.5 (C-15), 25.4 (C-12); Found (ESI): [MH]+ 244.1334; 
C15H18NO2 requires [MH]
+ 244.1332, 0.8 ppm. 
Lab-book No PD/4/7. 
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6.4.2 Studies towards the formation of the N-methoxyoxindole scaffold 
 
N-Methoxy-4-nitrobenzamide157 (225) 
 
To a stirred solution of methoxylamine hydrochloride (0.232 g, 2.78 mmol) in a mixture of 
water:toluene (1:1, 20 mL) was added KHCO3 (0.470 g, 2.53 mmol). The reaction was 
cooled to 0 °C and 4-nitrobenzoyl chloride (0.698 g, 5.06 mmol) was added. The reaction 
mixture was stirred for 1 h, then allowed to warm to room temperature. The solution was 
stirred for 18 h at room temperature. The layers were separated and the aqueous phase was 
extracted with EtOAc (2 × 20 mL). The combined organic phases were washed with water 
(2 × 20 mL) and brine (2 × 20 mL), dried (MgSO4), filtered and concentrated in vacuo to 
give the title compound 225 (0.288 g, 53%) as a colourless powder; mp. 165-167 °C (Lit.157 
176–177 °C); Rf 0.21 (Petrol/EtOAc, 1:1); δH (400 MHz, DMSO-d6) 12.06 (1 H, s, H-6), 
8.28 (2 H, d, J = 8.9 Hz, H-2), 7.95 (2 H, d, J = 8.9 Hz, H-3), 3.71 (3 H, s, H-7). 
Analytical data are consistent with literature values.157 
Lab-book No PD/4/97. 
 
N-Methoxy-4-nitro-N-phenylbenzamide105 (226) 
 
A Schlenk tube was charged with hydroxamate 225 (0.400 g, 2.04 mmol), Cu2O (0.031 g, 
0.214 mmol), K2CO3 (0.563 g, 4.08 mmol) and flushed with argon. Then, iodobenzene 
(0.343 mL, 3.06 mmol), DMEDA (0.040 mL, 0.372 mmol) and toluene (15 mL) were added. 
The reaction mixture was stirred at 80 °C overnight and allowed to cool to room temperature. 
The solvent was removed in vacuo and the residue was dissolved in EtOAc (10 mL). A sat. 
aq. solution of NH4Cl (10 mL) was added and the aqueous phase was extracted with EtOAc 
(2 × 10 mL). The combined organic layers were washed with brine (2 × 10 mL) and water 
(2 × 10 mL), dried (MgSO4), filtered and concentrated in vacuo. The residue was purified 
by column chromatography (SiO2, Petrol/EtOAc, 4:1) to give the title compound 226 (0.218 
203 
g, 40%) as a yellow oil; Rf 0.63 (Petrol/EtOAc, 1:1); δH (400 MHz; CDCl3) 8.23 (2 H, d, J 
= 8.7 Hz, H-8), 7.69 (2 H, d, J = 8.7 Hz, H-7), 7.41 (1 H, t, J = 7.8 Hz, H-1), 7.35 – 7.29 (2 
H, m, H-3), 7.10 (2 H, t, J = 7.8 Hz, H-2), 3.66 (3 H, br s, H-10). 
Analytical data are consistent with literature values.105 
Lab-book No PD/4/99. 
 
O-Methyl-N-phenylhydroxylamine105 (223) 
 
The N-methoxyanilide 226 (0.086 g, 0.316 mmol) was treated with hydrazine hydrate (0.223 
mL, 4.59 mmol) in THF (9 mL). The reaction mixture was stirred at room temperature until 
the reaction was complete. n-Hexane (9 mL) was added and the solution concentrated using 
a steam of nitrogen. Solid by-products were removed by filtration, washed with Et2O (9 mL) 
and concentrated in vacuo to give 223 (0.016 g, 41%) as a yellow oil. The product was 
sufficiently pure to use in the next step without purification; Rf 0.65 (Petrol/EtOAc, 3:1); δH 
(400 MHz; CDCl3) δ 7.32 – 7.23 (2 H, m, HAr), 7.03 (1 H, br s, H-5), 6.99 – 6.90 (3 H, m, 
HAr), 3.77 (3 H, s, H-6). 
Analytical data are consistent with literature values.105 
Lab-book No PD/5/3. 
 
Ethyl 3-(methoxyamino)-2-methyl-3-oxopropanoate (228) 
 
To a stirred solution of 3-ethoxy-2-methyl-3-oxopropanoic acid (109) (1.11 g, 7.55 mmol) 
in CH2Cl2 (20 mL) was added oxalyl chloride (0.99 mL, 11.3 mmol) and a drop of DMF at 
0 °C. The reaction mixture was stirred at 0 °C for 2 h and allowed to warm to room 
temperature. The solvent was removed in vacuo and the crude acid chloride 230 was used in 
the next step without further purification. Acid chloride 230 was dissolved in CH2Cl2 (30 
204 
mL) and added at 0 °C, via a syringe pump (10 mL/h), to a stirred solution of Et3N (3.55 
mL, 25.5 mmol) and methoxylamine (1.41 g, 16.9 mmol) in CH2Cl2 (10 mL). The reaction 
mixture was stirred at 0 °C for a further 10 min and then quenched with sat. aq. NH4Cl (10 
mL). The organic layer was separated, and the aqueous was extracted with EtOAc (2 × 40 
mL). The combined organic layers were washed with water (2 × 40 mL) and brine (2 × 40 
mL), dried (MgSO4), filtered and concentrated in vacuo. The residue was purified by column 
chromatography (SiO2, Petrol/EtOAc, 1:1) to give the title compound 228 (0.512 g, 51%) as 
a colourless oil; Rf 0.21 (Petrol/EtOAc, 1:1); νmax (cm-1) 3202, 1662, 1739, 1455, 1187, 1092, 
1033, 932; δH (400 MHz; CDCl3) 9.27 (1 H, br s, H-2), 4.18 (1 H, q, J = 7.1, H-6a), 4.18 (1 
H, q, J = 7.1, H-6b), 3.76 (3 H, br s, H-1), 3.24 (1 H, q, J = 7.0 Hz, H-4), 1.44 (3 H, d, J = 
7.0 Hz, H-8), 1.26 (3 H, t, J = 7.1, H-7); δC (100 MHz; CDCl3) 172.2 (C-5), 170.6 (C-3), 
64.4 (C-1), 61.9 (C-6), 45.0 (C-4), 15.5 (C-8), 14.1 (C-7); Found (ESI): [MNa]+ 198.0732; 
C7H13NNaO4 requires [MNa]
+ 198.0737, 2.3 ppm. 
Lab-book No PD/5/32. 
 
 
Ethyl 3-(methoxy(phenyl)amino)-2-methyl-3-oxopropanoate (222) 
 
To a stirred solution of hydroxamate 228 (0.144 g, 0.819 mmol) in toluene (5 mL) was added 
Cu2O (0.020 g, 0.137 mmol), N,N’-dimethylethylenediamine (0.021 mL, 0.200 mmol), 
iodobenzene (0.076 mL, 0.675 mmol) and K2CO3 (0.234 g, 1.70 mmol). The reaction 
mixture was heated at 80 °C and held for 16 h. The resulting brown suspension was filtered 
through Celite®, washed with EtOAc (10 mL), and concentrated in vacuo. The residue was 
then purified by column chromatography (SiO2, Petrol/EtOAc, 8:1) to give the title 
compound 222 (0.068 g, 33%) as a colourless oil; Rf 0.42 (Petrol/EtOAc, 3:1); νmax (cm-1) 
1711, 1660, 1569, 1467, 1433, 1343, 1292, 1254, 1190, 1161, 1062, 1044, 1016, 746, 683; 
δH (400 MHz; CDCl3) 7.47 (2 H, d, J = 7.8 Hz, H-3), 7.40 (2 H, t, J = 7.8 Hz, H-2), 7.27 – 
7.23 (1 H, m, H-1), 4.30 – 4.10 (2 H, m, H-8), 3.85 (1 H, br s, H-6), 3.69 (3 H, s, H-10), 1.46 
(3 H, d, J = 7.0 Hz, H-11), 1.27 (3 H, t, J = 7.1 Hz, H-9); δC (100 MHz; CDCl3) 172.2 (C-
7), 170.8 (C-5), 137.9 (C-4), 129.0 (C-2), 126.8 (C-1), 123.1 (C-3), 61.9 (C-10), 61.3 (C-8), 
44.7 (C-6), 14.3 (C-11), 13.6 (C-9); Found (ESI): [MNa]+ 274.1044; C13H17NNaO4 requires 
[MNa]+ 274.1050, 2.1 ppm. 
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Lab-book No PD/5/31. 
 
Ethyl 1-methoxy-3-methyl-2-oxoindoline-3-carboxylate (221) 
 
To a stirred solution of ethyl 3-(methoxy(phenyl)amino)-2-methyl-3-oxopropanoate (222) 
(0.024 g, 0.097 mmol) in toluene (5 mL) was added Cu(2-ethylhexanoate)2 (0.068 g, 0.194 
mmol) and Hünig’s base (0.084 mL, 0.485 mmol). The reaction mixture was stirred at 110 
°C for 2 h, and allowed to cool to room temperature. NH4OH (5 mL) was added and the 
aqueous phase was extracted with EtOAc (2 × 5 mL). The combined organic extracts were 
washed with water (2 × 5 mL), brine (2 × 5 mL), dried (MgSO4), filtered and concentrated 
in vacuo. The residue was then purified by column chromatography (SiO2, Petrol/EtOAc, 
8:1) to give the title compound 221 (0.004 g, 17%) as a colourless oil; Rf 0.64 (Petrol/EtOAc, 
3:1); νmax (cm-1) 1746, 1733, 1615, 1466, 1324, 1240, 1112, 1039, 751; δH (400 MHz; 
CDCl3) 7.34 (1 H, td, J = 7.6, 1.2 Hz, H-2), 7.25 (1 H, ddd, J = 7.6, 1.2, 0.6 Hz, H-8), 7.09 
(1 H, td, J = 7.6, 1.2 Hz, H-1), 7.01 (1 H, dd, J = 7.6, 1.2 Hz, H-3), 4.17 (1 H, dq, J = 10.8, 
7.1 Hz, H-12a), 4.08 (1 H, dq, J = 10.8, 7.1 Hz, H-12b), 4.04 (3 H, s, H-9), 1.68 (3 H, s, H-
10), 1.15 (3 H, t, J = 7.1 Hz, H-13); Found (ESI): [MH]+ 250.1073; C13H16NO4 requires 
[MH]+ 250.1074, 0.5 ppm. 
Lab-book No PD/5/39. 
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N-(2,4-Dimethoxybenzyl)aniline111 (239) 
 
A solution of aniline (3.00 mL, 32.9 mmol) and 2,4-dimethoxybenzaldehyde (5.58 g, 33.6 
mmol) in toluene (40 mL) was stirred at 165 °C for 18 h under a Dean & Stark apparatus. 
After cooling to room temperature, the solvent was removed under reduced pressure and the 
crude imine (8.15 g, quant) was used in the next step without further purification. 
The crude imine was dissolved in CH2Cl2/EtOH (40 mL, 1:1) and cooled to 0 °C. Sodium 
borohydride (2.15 g, 56.8 mmol) was added portionwise to the solution and the reaction 
mixture then allowed to stir at room temperature for 12 h. The reaction mixture was then 
poured into ice. An aq. sol. of HCl (0.1 M, 2 mL) was added. The layers were separated, the 
aqueous phase was extracted with CH2Cl2 (2 × 50 mL). The combined organic fractions 
were dried (MgSO4), filtered and concentrated in vacuo to give the title compound 239 (7.91 
g, 96%) as a colourless solid; mp. 76-78 °C (Lit.111 99-100 °C); Rf 0.5 (Petrol/EtOAc, 4:1); 
δH (400 MHz; CDCl3) 7.19 (1 H, d, J = 8.2 Hz, H-14), 7.16 (2 H, dd, J = 8.6, 7.3 Hz, H-2), 
6.70 (1 H, dt, J = 7.3, 1.0 Hz, H-1), 6.65 (2 H, dd, J = 8.6, 1.0 Hz, H-3), 6.47 (1 H, d, J = 2.4 
Hz, H-10), 6.42 (1 H, dd, J = 8.2, 2.4 Hz, H-13), 4.24 (2 H, s, H-6), 3.82 (3 H, s, H-9 or H-
12), 3.79 (3 H, s, H-9 or H-12). 
Analytical data are consistent with literature values.111 
Lab-book No PD/6/16. 
 
Ethyl 3-((2,4-dimethoxybenzyl)(phenyl)amino)-2-methyl-3-oxopropanoate (235) 
 
To a stirred solution of 3-ethoxy-2-methyl-3-oxopropanoic acid (109) (0.322 g, 2.18 mmol) 
in CH2Cl2 (10 mL) at 0 °C was added N-(2,4-dimethoxybenzyl)aniline (239) (0.564 g, 2.29 
mmol), 2-chloro-1-methylpyridinium iodide (0.843 g, 3.27 mmol) and Et3N (1.52 mL, 10.9 
mmol). The reaction mixture was allowed to warm to room temperature, stirred for 1 h, and 
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then quenched with sat. aq. NH4Cl (10 mL). The aqueous layer was extracted with CH2Cl2 
(2 × 10 mL). The combined organic phases were washed with water (2 × 10 mL) and brine 
(2 × 10 mL), dried (MgSO4), filtered and concentrated in vacuo. Purification by flash 
chromatography (SiO2, Petrol/EtOAc, 5:1) gave the title compound 235 (0.661 g, 82%) as a 
clear oil; Rf 0.20 (Petrol/EtOAc, 3:1); νmax (cm-1) 1740, 1656,1613, 1594, 1507, 1495, 1455, 
1399, 1207, 1182, 701; δH (400 MHz; CDCl3) 7.32 – 7.23 (5 H, m, H-1, H-2 and H-3), 7.03 
(1 H, dd, J = 8.2, 2.4 Hz, H-19), 6.41 (1 H, dd, J = 8.2, 2.4 Hz, H-18), 6.30 (1 H, d, J = 2.4 
Hz, H-15), 4.95 (1 H, J = 14.4 Hz, H-11a), 4.82 (1 H, J = 14.4 Hz, H-11b), 4.09 (2 H, q, J = 
7.1 Hz, H-8), 3.77 (3 H, s, H-14 or H-17), 3.50 (3 H, s, H-14 or H-17), 3.35 (1 H, q, J = 7.1 
Hz, H-6), 1.31 (3 H, d, J = 7.1 Hz, H-10), 1.22 (3 H, t, J = 7.1 Hz, H-9); δC (100 MHz; 
CDCl3) 171.0 (C-7), 170.0 (C-5), 160.3 (C-13 or C-16), 158.5 (C-13 or C-16), 142.2 (C-4), 
131.0 (C-1), 129.3 (C-2), 128.7 (C-3), 128.1 (C-19), 117.9 (C-12), 104.2 (C-18), 98.2 (C-
15), 61.2 (C-8), 55.4 (C-14 or C-17), 55.1 (C-14 or C-17), 47.1 (C-11), 44.0 (C-6), 14.3 (C-
10), 14.2 (C-9); Found (ESI): [MH]+ 372.1800; C21H26NO5 requires [MH]
+ 372.1805, 1.5 
ppm. 
Lab-book No PD/5/92. 
 
Ethyl 1-(2,4-dimethoxybenzyl)-3-methyl-2-oxoindoline-3-carboxylate (234) 
 
To a stirred solution of ethyl 3-((2,4-dimethoxybenzyl)(phenyl)amino)-2-methyl-3-
oxopropanoate (235) (0.560 g, 1.50 mmol) in toluene (30 mL) at room temperature was 
added Cu(OAc)2∙H2O (0.300 g, 1.50 mmol). The reaction mixture was heated at reflux and 
held for 18 h. The solvent was removed in vacuo. The brown residue was diluted with EtOAc 
(50 mL), filtered through Celite® and washed with EtOAc (2 × 50 mL). The residue was 
purified by column chromatography (SiO2, Petrol/EtOAc, 6:1) to give the title compound 
234 (0.300 g, 54%) as a thick yellow oil; Rf 0.42 (Petrol/EtOAc, 3:1); νmax (cm-1) 1738, 1713, 
1610, 1508, 1466, 1262, 1208, 1121, 1034, 751; δH (400 MHz; CDCl3) 7.23 (1 H, ddd, J = 
7.8, 1.3, 0.5 Hz, H-8), 7.19 (1 H, td, J = 7.8, 1.3 Hz, H-2), 7.07 (1 H, d, J = 8.4 Hz, H-17), 
7.00 (1 H, td, J = 7.8, 1.3 Hz, H-1), 6.78 (1 H, d, J = 7.8 Hz, H-3), 6.46 (1 H, d, J = 2.4 Hz, 
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H-13), 6.35 (1 H, dd, J = 8.4, 2.4 Hz, H-16), 4.98 (1 H, d, J = 16.6 Hz, H-9a), 4.81 (1 H, d, 
J = 16.6 Hz, H-9b), 4.18 (1 H, dq, J = 10.8, 7.1 Hz, H-20a), 4.08 (1 H, dq, J = 10.8, 7.1 Hz, 
H-20b), 3.87 (3 H, s, H-12 or H-15), 3.76 (3 H, s, H-12 or H-15), 1.70 (3 H, s, H-18), 1.16 
(3 H, t, J = 7.1 Hz, H-21); δC (100 MHz; CDCl3) 175.6 (C-19), 170.0 (C-5), 160.4 (C-11 or 
C-14), 158.1 (C-11 or C-14), 143.1 (C-4), 130.3 (C-7), 129.0 (C-2), 128.8 (C-17), 122.8 (C-
8), 122.7 (C-1), 116.0 (C-10), 109.7 (C-3), 104.4 (C-16), 98.4 (C-13), 62.0 (C-20), 55.5 (C-
12 or C-15), 55.4 (C-12 or C-15), 55.2 (C-6), 38.0 (C-9), 20.0 (C-18), 14.0 (C-21); Found 
(ESI): [MNa]+ 392.1471; C21H23NNaO5 requires [MNa]
+ 392.1468, 0.7 ppm. 
Lab-book No PD/5/96. 
 
Ethyl 3-methyl-2-oxoindoline-3-carboxylate (233) 
 
To a solution of oxindole 234 (0.253 g, 0.685 mmol) in CH2Cl2:water (22 mL, 10:1) was 
added DDQ (0.784 g, 3.42 mmol) and trifluoroacetic acid (0.166 mL, 2.04 mmol) at room 
temperature. The reaction was then heated at reflux for 2 d. The reaction mixture was poured 
into sat. aq. NaHCO3 (50 mL) and extracted with CH2Cl2 (3 × 15 mL). The combined 
organic layers were dried (MgSO4), filtered, and concentrated in vacuo. The residue was 
purified by flash chromatography (SiO2, Petrol/EtOAc, 5:1 to Petrol/EtOAc, 3:1) to give the 
title compound 233 (0.237 g, quant.) as a colourless solid; mp. 73-75 °C; Rf 0.22 
(Petrol/EtOAc, 3:1); νmax (cm-1) 1675, 1599, 1579, 1503, 1460, 1423, 1262, 1213, 1028, 829; 
δH (400 MHz; CDCl3) 9.34 (1 H, br s, H-9), 7.23 (2 H, d, J = 7.8 Hz, H-2, H-8), 7.03 (1 H, 
td, J = 7.8, 1.0 Hz, H-1), 6.96 (1 H, dd, J = 7.8, 1.0 Hz, H-3), 4.14 (2 H, dq, J = 10.8, 7.1 
Hz, H-12), 1.69 (3 H, s, H-10), 1.15 (3 H, t, J = 7.1 Hz, H-13); δC (100 MHz; CDCl3) 178.1 
(C-11), 169.8 (C-5), 141.1 (C-4), 130.9 (C-7), 129.1 (C-2), 123.3 (C-8), 122.9 (C-1), 110.5 
(C-3), 62.1 (C-12), 55.8 (C-6), 20.2 (C-10), 14.0 (C-13); Found (ESI): [MH]+ 220.0958; 
C12H14NO3 requires [MH]
+ 220.0968, 4.4 ppm. Anal. Calcd. for C12H14NO3: C, 65.74; H, 
5.98; N, 6.39. Found: C, 65.56; H, 5.91; N, 6.22. 
Lab-book No PD/5/98. 
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6.4.2.1 Preparation of DMDO (241) 
 
A three necked 2 L round-bottomed flask (RBF) was equipped with an air condenser, and 
connected to a 2 necked 100 mL RBF cooled to –78 °C, with the latter connected to vacuum. 
The 2 L RBF was charged with NaHCO3 (48 g), water (40 mL), and acetone (25 mL). In a 
dropping funnel (attached to the 3 necked RBF) was introduced water (30 mL) and acetone 
(30 mL). Then, oxone (4 × 22.5 g) was added in 4 portions. Vigorous stirring was continued 
for 1 h while a slight vacuum is applied to the 2 necked RBF. A yellow solution of 
dimethyldioxirane in acetone was collected in the receiving flask. The DMDO was allowed 
to reach 0 °C, dried with anhydrous K2CO3, and the solution was flushed with Ar and stored 
in the freezer. The concentration of DMDO was determined by titration as follows: 25 mL 
of 0.02 M aq. sol. of Na2S2O3 (0.496 g of Na2S2O3·5H2O in 100 mL of H2O) was placed in 
a 25 mL burette. A 100 mL Erlenmeyer flask was charged with water (20 mL), glacial acetic 
acid (1 mL), a freshly prepared solution of sodium iodide (10 mL, 10 g of NaI in 50 mL of 
water) and then the solution of DMDO (2 mL) was added. The resulting dark yellow solution 
was titrated with the 0.02 M aq. sol. of Na2S2O3 until it turned colourless. The concentration 
was calculated according to the following equation [(molarity of titrant) × (mL of 
titrant)]/[(mL of DMDO solution) × 2] and the concentration was included between 0.05 
and 0.07 M. 
Lab-book No PD/2/88. 
 
Ethyl 1-methoxy-3-methyl-2-oxoindoline-3-carboxylate (221) 
 
To a stirred suspension of NaH (60% in mineral oil, 0.002 g, 0.070 mmol) in THF (1 mL) at 
0 °C was added oxindole 233 (0.008 g, 0.042 mmol) as a solution in THF (1 mL). The 
reaction mixture was stirred for 10 min and then DMDO (0.05-0.07 M in acetone, 1.85 mL) 
was added at 0 °C. The reaction mixture was allowed to warm to room temperature and 
stirred for 18 h. A solution of sat. aq. NH4Cl (2 mL) was added. The aqueous portion was 
extracted with EtOAc (2 mL), washed with brine (2 × 2 mL), dried (MgSO4), filtered, and 
concentrated in vacuo. The residue was purified by column chromatography (SiO2, 
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Petrol/EtOAc, 6:1) to give an inseparable 1:1 mixture of starting material 233, and the title 
compound 221 (0.006 g, 70%); Rf 0.64 (Petrol/EtOAc, 3:1); νmax (cm-1) 1746, 1733, 1615, 
1466, 1324, 1240, 1112, 1039, 751; δH (400 MHz; CDCl3) 7.34 (1 H, td, J = 7.6, 1.2 Hz, H-
2), 7.25 (1 H, ddd, J = 7.6, 1.2, 0.6 Hz, H-8), 7.09 (1 H, td, J = 7.6, 1.2 Hz, H-1), 7.01 (1 H, 
dd, J = 7.6, 1.2 Hz, H-3), 4.17 (1 H, dq, J = 10.8, 7.1 Hz, H-12a), 4.08 (1 H, dq, J = 10.8, 
7.1 Hz, H-12b), 4.04 (3 H, s, H-9), 1.68 (3 H, s, H-10), 1.15 (3 H, t, J = 7.1 Hz, H-13); Found 
(ESI): [MH]+ 250.1073; C13H16NO4 requires [MH]
+ 250.1074, 0.5 ppm. 
Lab-book No PD/6/6. 
 
3,4-Dihydronaphthalen-1(2H)-one oxime116 (251) 
 
To a stirred solution of NH2OH∙HCl (3.50 g, 50.4 mmol) in water (21 mL) was added a 
solution of NaOH (10% in water, 14 mL). Then, α-tetralone (3.51 g, 23.9 mmol) in EtOH (7 
mL) was added and the reaction mixture was heated at reflux for 2 h. The reaction mixture 
was allowed to cool to room temperature. Water (30 mL) was added and the aqueous phase 
was extracted with EtOAc (2 × 30 mL). The combined organic portions were washed with 
water (30 mL) and brine (30 mL), dried (MgSO4), filtered, and concentrated in vacuo to give 
the crude oxime 251 (3.58 g, 93%) as a pale yellow solid, which was used in the next step 
without further purification; Rf 0.32 (Petrol/EtOAc, 9:1); δH (400 MHz; CDCl3) 8.70 (1 H, 
br s, H-11), 7.88 (1 H, dd, J = 7.4, 1.5 Hz, HAr), 7.27 (1 H, dt, J = 7.4, 1.5 Hz, HAr), 7.21 (1 
H, td, J = 7.4, 1.5 Hz, HAr), 7.15 (1 H, dd, J = 7.4, 1.5 Hz, HAr), 2.83 (2 H, t, J = 6.2 Hz, H-
7), 2.76 (2 H, t, J = 6.2 Hz, H-5), 1.88 (2 H, pent, J = 6.2 Hz, H-6). 
Analytical data are consistent with literature values.116 
Lab-book No PD/6/28. 
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4,5-Dihydro-1H-benzo[b]azepin-2(3H)-one116 (252) 
 
A mixture of oxime 251 (3.58 g, 22.2 mmol) was placed in a 100 mL flask with 
polyphosphoric acid (≥83% phosphate (as P2O5) basis, 52.4 g). The reaction mixture was 
stirred and heated at 120 °C. The viscosity of the mixture decreased as the temperature 
reached 120 °C. The reaction was heated for 1 h and allowed to return to room temperature. 
The mixture was poured onto ice, then the aqueous phase was extracted with EtOAc (50 
mL). The organic phase was washed with NaOH (2.0 M in water, 50 mL). The combined 
organic portions were dried (MgSO4), filtered, and concentrated in vacuo to give the lactam 
252 (2.98 g, 83%). The crude solid was used in the next step without further purification; Rf 
0.21 (CH2Cl2/EtOAc, 9:1); mp. 110-112 °C (Lit.
116 142-143 °C); δH (400 MHz; CDCl3) 7.88 
(1 H, br s, H-9), 7.24 – 7.20 (2 H, m, HAr), 7.13 (1 H, td, J = 7.6, 1.3 Hz, HAr), 6.98 (1 H, d, 
J = 7.6 Hz, HAr), 2.80 (2 H, t, J = 7.2 Hz, H-5), 2.35 (2 H, t, J = 7.2 Hz, H-7), 2.23 (2 H, 
pent, J = 7.2 Hz, H-6). 
Analytical data are consistent with literature values.116 
Lab-book No PD/6/29. 
 
1-Methoxy-4,5-dihydro-1H-benzo[b]azepin-2(3H)-one157a (253) 
 
To a stirred solution of NaH (60% in mineral oil, 0.007 g, 0.172 mmol) in THF (1 mL) at 0 
°C was added 4,5-dihydro-1H-benzo[b]azepin-2(3H)-one (252) (0.020 g, 0.121 mmol) as a 
solution in THF (1 mL). The reaction mixture was stirred for 10 min then DMDO (0.055 M 
in acetone, 3.20 mL, 0.180 mmol) was added at 0 °C. The reaction mixture was allowed to 
warm to room temperature and stirred for 18 h. A solution of sat. aq. NH4Cl (5 mL) was 
added. The aqueous phase was extracted with EtOAc (5 mL), and the organic layer washed 
with brine (2 × 3 mL), dried (MgSO4), filtered, and concentrated in vacuo. The resulting 
separable mixture was purified by column chromatography (SiO2, CH2Cl2/EtOAc, 9:1) to 
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give the starting material 252 (11.8 mg, 59%) as a colourless solid, and the title compound 
253 (0.004 g, 18%), as a colourless oil; Rf 0.41 (EtOAc/Petrol, 3:1); δH (400 MHz, CDCl3) 
δ 7.44 (1 H, d, J = 8.2 Hz, H-10), 7.34 (1 H, ddd, J = 8.2, 5.2, 3.9 Hz, H-1), 7.21 (1 H, dd, J 
= 3.9, 1.2 Hz, H-2 or H-3), 7.22 (1 H, dd, J = 5.2, 1.2 Hz, H-2 or H-3), 3.79 (3 H, s, H-11), 
2.78 (2 H, t, J = 7.1 Hz, H-5), 2.29 (1 H, td, J = 7.1, 1.1 Hz, H-7), 2.20 (2 H, td, J = 7.1, 1.1 
Hz, H-6).  
Analytical data are consistent with literature values.157a 
Lab-book No PD/6/30. 
 
(E)-2-Ethoxy-4,5-dihydro-3H-benzo[b]azepine119 (254) 
 
To a stirred solution of 4,5-dihydro-1H-benzo[b]azepin-2(3H)-one (252) (0.073 g, 0.462 
mmol) in CH2Cl2 (5 mL) was added dropwise triethyloxonium tetrafluoroborate (0.091 g, 
0.478 mmol) as a solution in CH2Cl2 (1 mL). The reaction mixture was stirred for 2 d at 
room temperature. A sat. aq. solution of NaHCO3 (5 mL) was added and the mixture was 
stirred for 30 min. The aqueous phase was separated and extracted with CH2Cl2 (2 × 5 mL). 
The combined organic portions were washed with water (2 × 5 mL), and brine (2 × 5 mL), 
dried (MgSO4), filtered, and concentrated in vacuo to afford the crude product 254 (0.071 g, 
83%) as an oil, which was used in the next step without further purification; Rf 0.31 
(CH2Cl2/EtOAc, 4:1); δH (400 MHz; CDCl3) 7.24 – 7.18 (2 H, m, HAr), 7.16 – 7.10 (1 H, m, 
HAr), 6.98 – 6.94 (1 H, m, HAr), 4.30 (2 H, q, J = 7.1 Hz, H-11), 2.59 – 2.53 (2 H, m, CH2), 
2.40 – 2.34 (2 H, m, CH2), 2.28 – 2.18 (2 H, m, CH2), 1.37 (3 H, t, J = 7.1 Hz, H-12). 
Analytical data are consistent with literature values.119 
Lab-book No PD/6/46. 
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Ethyl 4-(2-nitrophenyl)butanoate (258) 
 
To a stirred solution of imino ether 254 (0.034 g, 0.159 mmol) in acetone (1 mL) was added 
at 0 °C, DMDO (0.07 M, 3.2 mL, 0.224 mmol) in solution in acetone. The reaction mixture 
was allowed to warm to room temperature and stirred overnight. Acetone was removed 
under vacuum. The residue was purified by column chromatography (SiO2, CH2Cl2/EtOAc, 
6:1) to give the title compound 258 (0.013 g, 33%), along with 4,5-dihydro-1H-
benzo[b]azepin-2(3H)-one (252) (0.012 g, 47%). Ethyl 4-(2-nitrophenyl)butanoate (258) 
was isolated as an orange oil; Rf 0.91 (CH2Cl2/EtOAc, 4:1); νmax (cm-1) 2983, 1729, 1524, 
1345, 1248, 1181, 1155, 1024, 857, 786, 741; δH (400 MHz; CDCl3) 7.88 (1 H, d, J = 8.1 
Hz, H-2), 7.51 (1 H, t, J = 7.5 Hz, H-4), 7.35 (2 H, m, H-3 and H-5), 4.12 (2 H, q, J = 7.1 
Hz, H-11), 2.91 (2 H, t, J = 7.3 Hz, H-7), 2.37 (2 H, t, J = 7.3 Hz, H-9), 1.98 (2 H, pent, J = 
7.3 Hz, H-8), 1.25 (3 H, t, J = 7.1 Hz, H-12); δC (100 MHz; CDCl3) 173.1 (C-10), 149.4 (C-
1), 136.5 (C-6), 132.9 (C-2), 132.0 (C-4), 127.2 (C-5), 124.7 (C-3), 60.4 (C-11), 33.8 (C-9), 
32.1 (C-7), 25.8 (C-8), 14.2 (C-12); Found (ESI): [MNa]+ 260.0892; C12H15NNaO4 requires 
[MNa]+ 260.0893, 0.6 ppm. 
Lab-book No PD/6/47. 
 
6.4.3 Progress towards the total synthesis of rankinidine (49) 
 
tert-Butyl(2-iodoethoxy)dimethylsilane158 (272) 
 
To a suspension of NaH (60% in mineral oil, 1.22 g, 30.5 mmol) in THF (60 mL) at 0 °C 
was added ethylene glycol (1.70 mL, 30.5 mmol). The reaction mixture was stirred for 2 h 
at room temperature. Then, tert-butyldimethylsilyl chloride (4.60 g, 30.5 mmol) was added 
at 0 °C. The resulting mixture was warmed to room temperature and stirred for 2 h. The 
reaction was quenched with a sat. aq. solution of NH4Cl (60 mL). The aqueous layer was 
extracted with EtOAc (2 × 30 mL). The combined organic portions were washed with water 
(2 × 30 mL) and brine (2 × 30 mL), dried (MgSO4), filtered, and concentrated in vacuo to 
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give the mono-protected alcohol (5.29 g, 98%) as a clear oil. The residue was used in the 
next step without further purification. 
To a solution of the alcohol (5.29 g, 30.0 mmol), imidazole (3.09 g, 45.4 mmol) and PPh3 
(10.2 g, 38.9 mmol) in THF (150 mL) was added iodine (9.14 g, 36.0 mmol) at 0 °C, over 
20 min. The resulting dark mixture was stirred for 40 min at room temperature. The reaction 
was quenched with a mixture of sat. aq. Na2S2O3:NH4Cl (1:1, 150 mL), and the aqueous 
layer was extracted with EtOAc (2 × 75 mL). The triphenylphosphine oxide by-product was 
precipitated out using Et2O (75 mL) and hexane (75 mL), then filtered off. Concentration 
and column chromatography (SiO2, 100% petrol) gave the title compound 272 (6.31 g, 73%) 
as a clear oil; Rf 0.90 (Petrol/EtOAc, 4:1); δH (400 MHz; CDCl3) 3.83 (2 H, t, J = 7.0 Hz, H-
2), 3.20 (2 H, t, J = 7.0 Hz, H-1), 0.90 (9 H, s, H-5), 0.08 (6 H, s, H-3). 
Analytical data are consistent with literature values.158 
Lab-book No PD/5/2. 
 
Ethyl 3-(benzyl(phenyl)amino)-3-oxopropanoate159 (270) 
 
To a solution of N-benzylaniline (3.46 mL, 20.0 mmol) in CH2Cl2 (100 mL) was added 
successively monoethyl malonate (2.64 g, 20.0 mmol) and DCC (4.13 g, 20.0 mmol). The 
reaction mixture was stirred at room temperature for 1 h. The mixture was filtered through 
a short pad of silica and the filtrate was concentrated in vacuo. The residue was treated with 
NaHCO3 (50 mL) and extracted with EtOAc (3 × 50 mL). The combined organic layers 
were dried (MgSO4), filtered and concentrated in vacuo. Purification by column 
chromatography (SiO2, Petrol/EtOAc, 6:1) gave the title compound 270 (4.32 g, 73%) as a 
thick and colourless oil; Rf 0.44 (Petrol/EtOAc, 1:1); δH (400 MHz; CDCl3) 7.35 – 7.19 (8 
H, m, HAr), 7.05 – 6.97 (2 H, m, HAr), 4.91 (2 H, s, H-10), 4.12 (2 H, q, J = 7.2 Hz, H-8), 
3.21 (2 H, s, H-6), 1.23 (3 H, t, J = 7.2 Hz, H-9). 
Analytical data are consistent with literature values.159 
Lab-book No PD/5/4.  
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6.4.3.1 General procedure P: alkylation of β-amido esters 
 
Ethyl 2-(benzyl(phenyl)carbamoyl)-4-(tert-butyldimethylsilyloxy)butanoate (271) 
 
To a stirred solution of NaH (60% in mineral oil, 0.142 g, 3.36 mmol) in DMF (50 mL) was 
added anilide 270 (1.00 g, 3.36 mmol) at 0 °C. The reaction mixture was stirred for 15 min 
and alkyl iodide 272 (0.963 g, 3.35 mmol) was added slowly. The resulting light green 
solution was stirred for 30 min and then allowed to warm to room temperature where it 
slowly turned yellow. The reaction mixture was stirred overnight and quenched with sat. aq. 
NH4Cl (50 mL). The aqueous layer was extracted with EtOAc (2 × 50 mL). The combined 
organic phases were washed with water (5 × 50 mL) and brine (2 × 50 mL), dried (MgSO4), 
filtered and concentrated in vacuo. The crude pale yellow oil was then purified by column 
chromatography (SiO2, Petrol/EtOAc, 9:1) to give the title compound 271 (1.06 g, 69%) as 
a yellow oil; Rf 0.62 (Petrol/EtOAc, 3:1); νmax (cm-1) 2910, 1714, 1636, 1473, 1378, 1237, 
1080, 823, 765, 689; δH (400 MHz; CDCl3) 7.31 – 7.18 (8 H, m, HAr), 7.05 – 7.00 (2 H, m, 
HAr), 5.05 (1 H, d, J = 14.3 Hz, H-10a), 4.76 (1 H, d, J = 14.3 Hz, H-10b), 4.09 (2 H, q, J = 
7.1 Hz, H-8), 3.59 (2 H, t, J = 5.7 Hz, H-16), 3.57 (1 H, t, J = 6.8 Hz, H-6), 2.08 (2 H, dt, J 
= 6.8, 5.7 Hz, H-15), 1.20 (3 H, t, J = 7.1 Hz, H-9), 0.78 (9 H, s, H-19), −0.05 (3 H, s, H-
17a), −0.08 (3 H, s, H-17b); δC (100 MHz; CDCl3) 170.3 (C-7), 169.1 (C-5), 141.8 (C-11 or 
C-4), 137.4 (C-11 or C-4), 129.6 (CHAr), 128.8 (2 × CHAr), 128.4 (CHAr), 128.3 (CHAr), 
127.5 (CHAr), 61.2 (C-8), 60.5 (C-16), 53.4 (C-10), 45.8 (C-6), 32.6 (C-15), 26.0 (C-19), 
18.3 (C-18), 14.1 (C-9), −5.3 (C-17); Found (ESI): [MH]+ 456.2541; C26H38NO4Si requires 
[MH]+ 456.2565, 4.8 ppm. 
Lab-book No PD/5/5. 
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Ethyl 1-benzyl-3-(2-(tert-butyldimethylsilyloxy)ethyl)-2-oxoindoline-3-carboxylate (273) 
 
To a stirred solution of anilide 271 (0.510 g, 1.12 mmol) in toluene (50 mL) at room 
temperature was added Cu(OAc)2∙H2O (0.022 g, 0.112 mmol). The reaction mixture was 
heated at reflux and held for 22 h. The solvent was removed in vacuo. The brown residue 
was diluted with EtOAc (50 mL), filtered through Celite® and washed with EtOAc (2 × 50 
mL). The filtrate was concentrated in vacuo and the crude product was then purified by 
column chromatography (SiO2, Petrol/EtOAc, 9:1) to give the title compound 273 (0.312 g, 
62%) as a pink oil; Rf 0.61 (Petrol/EtOAc, 3:1); νmax (cm-1) 2910, 1715, 1694, 1585, 1466, 
1445, 1340, 1201, 1086, 823; δH (400 MHz; CDCl3) 7.36 – 7.26 (5 H, m, HAr), 7.23 (1 H, 
dd, J = 7.6 Hz, H-8), 7.17 (1 H, td, J = 7.6, 0.8 Hz, H-2), 7.00 (1 H, td, J = 7.6, 0.8 Hz, H-
1), 6.67 (1 H, d, J = 7.6 Hz, H-3), 5.20 (1 H, d, J = 15.9 Hz, H-9a), 4.65 (1 H, d, J = 15.9 
Hz, H-9b), 4.17 (1 H, dq, J = 10.8, 7.1 Hz, H-20a), 4.07 (1 H, dq, J = 10.8, 7.1 Hz, H-20b), 
3.49 (2 H, ddd, J = 13.3, 6.7, 3.3 Hz, H-15), 2.63 (1 H, dt, J = 13.9, 7.5 Hz, H-14a), 2.53 (1 
H, ddd, J = 13.9, 6.7, 5.4 Hz, H-14b), 1.16 (3 H, t, J = 7.1 Hz, H-21), 0.77 (9 H, s, H-18), 
−0.11 (3 H, s, H-16a), −0.12 (3 H, s, H-16b); δC (100 MHz; CDCl3) 174.4 (C-19), 169.5 (C-
5), 143.4 (C-4), 135.8 (C-10), 128.9 (C-2), 128.7 (C-12), 127.8 (C-7), 127.6 (C-13), 127.3 
(C-11), 123.6 (C-8), 122.7 (C-1), 109.4 (C-3), 62.1 (C-20), 59.0 (C-15), 57.8 (C-6), 43.9 (C-
9), 36.1 (C-14), 25.9 (C-18), 18.3 (C-17), 13.9 (C-21), −5.50 (C-16); Found (ESI): [MH]+ 
454.2391; C26H36NO4Si requires [MH]
+ 454.2408, 1.7 ppm. 
Lab-book No PD/5/6. 
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1-Benzyl-3-(2-(tert-butyldimethylsilyloxy)ethyl)-1H-indole (277) 
 
To a stirred solution of oxindole 273 (0.098 g, 0.216 mmol) in Et2O (5 mL) was added 
DIBAL-H (1.0 M in hexanes, 0.240 mL, 0.237 mmol) at −78 °C. The reaction mixture was 
stirred for 1 h at −78 °C, then warmed to room temperature and stirred for a further 2 h. 
MeOH (1 mL), followed by water (1 mL) was added slowly to the reaction mixture. The 
aqueous layer was extracted with Et2O (2 × 5 mL). The combined organic phases were 
washed with water (10 mL) and brine (10 mL), dried (MgSO4), filtered, and concentrated in 
vacuo. The crude product was purified by column chromatography (SiO2, Petrol/EtOAc, 
50:1) to give the title compound 277 (0.008 g, 11%) as a colourless oil; Rf 0.71 
(Petrol/EtOAc, 9:1); δH (400 MHz; CDCl3) 7.61 (1 H, ddd, J = 7.7, 1.2 Hz, HAr), 7.31 – 7.23 
(2 H, m, HAr), 7.28 (2 H, d, J = 7.1 Hz, HAr), 7.16 (1 H, t, J = 7.7 Hz, HAr), 7.12 – 7.07 (1 H, 
m, HAr), 7.11 (2 H, d, J = 7.7 Hz, HAr), 6.96 (1 H, s, H-14), 5.27 (2 H, s, H-9), 3.87 (2 H, t, 
J = 7.4 Hz, H-16), 2.99 (2 H, t, J = 7.4 Hz, H-15), 0.89 (9 H, s, H-19), 0.02 (6 H, s, H-17). 
Analytical data are consistent with literature values.124 
Lab-book No PD/5/10. 
 
Methyl 3-oxohept-6-enoate160 (279) 
 
To a suspension of NaH (60% in mineral oil, 1.10 g, 27.5 mmol) in THF (100 mL) at 0 °C 
was added methyl acetoacetate (2.80 mL, 26.1 mmol). The reaction mixture was stirred for 
30 min and n-BuLi (24.4 mL, 39.1 mmol) was slowly added. After 10 min, allyl bromide 
(3.46 mL, 28.7 mmol) was added at 0 °C. The reaction mixture was allowed to warm to room 
temperature, stirred for 3 h, and then quenched with sat. aq. NH4Cl (100 mL). The aqueous 
layer was extracted with EtOAc (2 × 100 mL). The combined organic layers were washed 
with brine (2 × 100 mL). The resulting solution was dried (MgSO4), filtered and 
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concentrated in vacuo. The residue was purified by column chromatography (SiO2, 
Petrol/EtOAc, 99:1 to Petrol/EtOAc, 20:1) to give the title compound 279 (2.61 g, 65%) as 
a colourless oil; Rf 0.82 (Petrol/EtOAc, 1:1); δH (400 MHz; CDCl3) 5.79 (1 H, ddt, J = 16.7, 
10.2, 6.5 Hz, H-2), 5.09 – 4.95 (2 H, m, H-1), 3.73 (3 H, s, H-8), 3.45 (2 H, s, H-6), 2.64 (2 
H, t, J = 7.0 Hz, H-4), 2.34 (2 H, td, J = 7.0, 6.5 Hz, H-3). 
Analytical data are consistent with literature values.160 
Lab-book No PD/5/59. 
 
3-Oxohept-6-enoic acid161 (280) 
 
To a stirred solution of the ester 279 (2.06 g, 13.2 mmol) in MeOH (50 mL) at room 
temperature was added a solution of KOH (1.0 M in water, 13.2 mmol). The reaction mixture 
was stirred at room temperature for 2 h. After removal of MeOH, the reaction was acidified 
with 10% aq. HCl (30 mL) to pH 3 and extracted with EtOAc. The organic portion was 
washed with sat. aq. NH4Cl (2 × 50 mL) and brine (2 × 50 mL), dried (MgSO4), filtered, 
and concentrated in vacuo to give the acid 280 (1.53 g, 63%) as a colourless oil. The crude 
acid 280 was used in the next step without further purification; δH (400 MHz; CDCl3) 11.79 
(1 H, br s, H-8), 5.79 (1 H, ddt, J = 16.8, 10.2, 6.5 Hz, H-2), 5.09 – 4.98 (2 H, m, H-1), 3.51 
(2 H, s, H-6), 2.67 (2 H, t, J = 7.3 Hz, H-4), 2.42 – 2.30 (2 H, m, H-3). 
Analytical data are consistent with literature values.161 
Lab-book No PD/5/60. 
 
N-Benzyl-3-oxo-N-phenylhept-6-enamide (281) 
 
To a stirred solution of acid 280 (1.53 g, 10.8 mmol) in CH2Cl2 (50 mL) at 0 °C was added 
N-benzylaniline (1.95 mL, 11.3 mmol), 2-chloro-1-methylpyridinium iodide (4.13 g, 16.2 
mmol) and Et3N (7.50 mL, 54.0 mmol). The reaction mixture was allowed to warm to room 
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temperature, stirred for 4 h, and then quenched with sat. aq. NH4Cl (50 mL). The aqueous 
layer was extracted with EtOAc (2 × 50 mL). The combined organic phases were washed 
with water (2 × 50 mL) and brine (2 × 50 mL). The resulting solution was dried (MgSO4), 
filtered and concentrated in vacuo. The residue was purified by column chromatography 
(SiO2, Petrol/EtOAc, 3:1) to give the title compound 281 (3.02 g, 81%) as an orange oil; Rf 
0.35 (Petrol/EtOAc, 3:1); νmax (cm-1) 1720, 1651, 1594, 1495, 1393, 1273, 914, 730, 697; δH 
(400 MHz; CDCl3) 7.33 – 7.21 (8 H, m, HAr), 6.97 (2 H, dd, J = 6.5, 3.0 Hz, HAr), 5.70 (1 
H, ddt, J = 16.8, 10.4, 6.4 Hz, H-10), 4.98 – 4.92 (2 H, m, H-11), 4.91 (2 H, s, H-12), 3.30 
(2 H, s, H-6), 2.42 (2 H, t, J = 7.0 Hz, H-8), 2.22 (2 H, td, J = 7.0, 6.4 Hz, H-9); δC (100 
MHz; CDCl3) 203.7 (C-7), 141.9 (C-5), 137.0 (CAr), 136.8 (C-10), 129.8 (CAr), 129.6 (CHAr), 
128.9 (CHAr), 128.6 (CHAr), 128.52 (CHAr), 128.48 (CHAr), 127.6 (CHAr), 115.5 (C-11), 53.1 
(C-12), 49.5 (C-6), 42.3 (C-8), 27.5 (C-9); Found (ESI): [MH]+ 308.1642; C20H22NO2 
requires [MH]+ 308.1645, 0.9 ppm. 
Lab-book No PD/5/62. 
 
N-Benzyl-2-(2-(tert-butyldimethylsilyloxy)ethyl)-3-oxo-N-phenylhept-6-enamide (282) 
 
N-Benzyl-3-oxo-N-phenylhept-6-enamide (281) (0.484 g, 1.58 mmol), NaH (0.072 g, 1.73 
mmol), tert-Butyl(2-iodoethoxy)dimethylsilane (0.480 g, 1.66 mmol) in DMF (15 mL) were 
subjected to general procedure P at 0 °C for 18 h. The residue was purified by column 
chromatography (SiO2, Petrol/EtOAc, 6:1) to give the title compound 282 (0.436 g, 60%) as 
a colourless oil; Rf 0.57 (Petrol/EtOAc, 3:1); νmax (cm-1) 1692, 1633, 1473, 1372, 1236, 1080, 
823, 690; δH (400 MHz; CDCl3) 7.32 – 7.28 (3 H, m, HAr), 7.27 – 7.23 (3 H, m, HAr), 7.21 – 
7.17 (2 H, m, HAr), 6.96 – 6.92 (2 H, m, HAr), 5.66 (1 H, ddt, J = 16.9, 10.3, 6.5 Hz, H-10), 
4.95 – 4.91 (2 H, m, H-11), 4.90 (2 H, s, H-12), 3.67 (1 H, dd, J = 8.2, 5.4 Hz, H-6), 3.63 – 
3.50 (2 H, m, H-18), 2.36 (1 H, ddd, J = 17.0, 8.4, 5.7 Hz, H-8a), 2.18 – 2.09 (3 H, m, H-9, 
H-17a), 2.03 (1 H, ddd, J = 17.0, 8.4, 5.7 Hz, H-8b), 1.90 (1 H, ddt, J = 13.4, 8.2, 5.4 Hz, H-
17b), 0.81 (9 H, s, H-21), −0.02 (3 H, s, H-19a), −0.04 (3 H, s, H-19b); δC (100 MHz; CDCl3) 
205.9 (C-7), 169.1 (C-5), 141.6 (CAr), 137.4 (CAr), 137.0 (C-10), 129.7 (CHAr), 129.1 (CHAr), 
128.9 (CHAr), 128.53 (CHAr), 128.48 (CHAr), 127.5 (CHAr), 115.3 (C-11), 60.7 (C-18), 53.42 
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(C-6), 53.39 (C-12), 40.3 (C-8), 32.4 (C-17), 27.5 (C-9), 26.0 (C-21), 18.3 (C-20), −5.3 (C-
19a), −5.3 (C-19b); Found (ESI): [MH]+ 466.2773; C28H40NO3Si requires [MH]+ 466.2772, 
0.2 ppm. 
Lab-book No PD/5/65. 
 
1-Benzyl-3-(2-(tert-butyldimethylsilyloxy)ethyl)-3-pent-4-enoylindolin-2-one (283) 
 
N-Benzyl-2-(2-(tert-butyldimethylsilyloxy)ethyl)-3-oxo-N-phenylhept-6-enamide (282) 
(0.035 g, 0.080 mmol), Cu(OAc)2·H2O (0.015 g, 0.080 mmol) in toluene (3 mL) were 
subjected to general procedure O at 110 °C for 18 h. The residue was purified by column 
chromatography (SiO2, Petrol/EtOAc, 8:1) to give the title compound 283 (0.018 g, 49%) as 
a colourless oil; Rf 0.41 (Petrol/EtOAc, 3:1); νmax (cm-1) 1718, 1681, 1583, 1463, 1443, 1336, 
822, 687; δH (400 MHz; CDCl3) 7.37 – 7.26 (5 H, m, HAr), 7.22 (1 H, td, J = 7.6, 1.3 Hz, H-
2), 7.12 (1 H, ddd, J = 7.6, 1.3, 0.5 Hz, H-8), 7.03 (1 H, td, J = 7.6, 1.3 Hz, H-1), 6.82 (1 H, 
d, J = 7.6 Hz, H-3), 5.58 (1 H, ddt, J = 12.4, 10.4, 4.6 Hz, H-22), 5.08 (1 H, d, J = 15.4 Hz, 
H-9a), 4.79 (1 H, d, J = 15.4 Hz, H-9b), 4.88 – 4.83 (2 H, m, H-23), 3.43 (2 H, t, J = 6.9 Hz, 
H-15), 2.55 – 2.44 (3 H, m, H-14, H-20a), 2.24 – 2.09 (3 H, m, H-20b, H-21), 0.77 (9 H, s, 
H-18), −0.11 (3 H, s, H-16a), −0.12 (3 H, s, H-16b); δC (100 MHz; CDCl3) 202.1 (C-19), 
175.1 (C-5), 143.5 (C-4), 136.7 (C-22), 135.8 (C-10), 129.01 (C-2), 128.95 (C-11), 127.9 
(C-13), 127.7 (C-12), 127.1 (C-7), 124.3 (C-8), 123.0 (C-1), 115.3 (C-23), 109.5 (C-3), 64.6 
(C-6), 59.2 (C-15), 44.3 (C-9), 37.7 (C-20), 35.8 (C-14), 27.4 (C-21), 25.9 (C-18), 18.3 (C-
17), −5.5 (C-16a), −5.5 (C-16b); Found (ESI): [MNa]+ 486.2440; C28H37NNaO3Si requires 
[MNa]+ 486.2435, 1.0 ppm. 
Lab-book No PD/5/43 
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2-(1-Benzyl-3-hydroxy-2-oxoindolin-3-yl)ethyl pent-4-enoate (286) 
 
To a stirred solution of oxindole 283 (0.075 g, 0.162 mmol) in THF (8 mL) at 0 °C was 
added TBAF (1.0 M in THF, 0.18 mL, 0.178 mmol). The reaction mixture was stirred for 
10 min and allowed to warm to room temperature. After 1 h, the reaction was complete by 
TLC. The solvent was removed under vacuum and the residue was purified by column 
chromatography (SiO2, Petrol/EtOAc, 3:1) to give the title compound 286 (0.053 g, 90%) as 
a crystalline solid; mp. 57-59 °C; Rf 0.5 (Petrol/EtOAc, 1:1); νmax (cm-1) 3369, 1705, 1614, 
1467, 1356, 1172, 1103, 1079, 752, 697; δH (400 MHz; CDCl3) 7.39 (1 H, dd, J = 7.6, 1.0 
Hz, H-8), 7.35 – 7.26 (5 H, m, HAr), 7.21 (1 H, td, J = 7.6, 1.0 Hz, H-2), 7.07 (1 H, td, J = 
7.6, 1.0 Hz, H-1), 6.71 (1 H, d, J = 7.6 Hz, H-3), 5.73 (1 H, ddt, J = 16.5, 10.3, 6.1 Hz, H-
20), 5.02 – 4.94 (2 H, m, H-21), 4.93 (1 H, d, J = 15.7 Hz, H-9a), 4.83 (1 H, d, J = 15.7 Hz, 
H-9b), 4.23 (1 H, dt, J = 11.5, 6.4 Hz, H-16a), 4.05 (1 H, dt, J = 11.5, 6.4 Hz, H-16b), 2.39 
(2 H, t, J = 6.4 Hz, H-15), 2.27 – 2.12 (4 H, m, H-18, H-19); δC (100 MHz; CDCl3) 177.6 
(C-5), 172.8 (C-17), 142.6 (C-4), 136.7 (C-20), 135.4 (C-10), 130.0 (C-2), 129.5 (C-7), 129.0 
(C-11), 127.9 (C-13), 127.3 (C-12), 124.2 (C-8), 123.4 (C-1), 115.6 (C-21), 109.8 (C-3), 
75.2 (C-6), 59.8 (C-16), 44.0 (C-9), 37.1 (C-15), 33.2 (C-18), 28.7 (C-19); Found (ESI): 
[MNa]+ 388.1520; C22H23NNaO4 requires [MNa]
+ 388.1523, 0.7 ppm. CCDC 1049570 
contains the supplementary crystallographic data for this compound. These data can be 
obtained free of charge from The Cambridge Crystallographic Data Centre via 
www.ccdc.cam.ac.uk/data_request/cif. 
Crystals suitable for X-ray diffraction were obtained by slow evaporation from hexane in 
which a few drops of dichloromethane were added. 
Lab-book No PD/5/69. 
  
222 
N-Benzyl-2-(2-nitroethyl)-3-oxo-N-phenylhept-6-enamide (293) 
 
To a stirred solution of anilide 281 (0.971 g, 3.16 mmol) in CH2Cl2 (40 mL) at room 
temperature was added freshly distilled nitroethylene (0.227 mL, 3.32 mmol) and Ni(acac)2 
(0.008 g, 0.030 mmol). The reaction mixture was stirred at room temperature overnight. The 
solvent was removed in vacuo and the residue was purified by column chromatography 
(SiO2, Petrol/EtOAc, 6:1) to give the title compound 293 (0.740 g, 62%) as a pale yellow 
oil; Rf 0.30 (Petrol/EtOAc, 3:1); νmax (cm-1) 1720, 1652, 1595, 1551, 1495, 1399, 701; δH 
(400 MHz; CDCl3) 7.37 – 7.34 (3 H, m, HAr), 7.30 – 7.24 (3 H, m, HAr), 7.18 (2 H, dd, J = 
7.2, 2.4 Hz, HAr), 6.95 – 6.91 (2 H, m, HAr), 5.66 (1 H, ddt, J = 17.5, 9.8, 6.4 Hz, H-10), 4.97 
– 4.90 (2 H, m, H-11), 4.97 (1 H, d, J = 14.0 Hz, H-12a), 4.82 (1 H, d, J = 14.0 Hz, H-12b), 
4.50 (1 H, ddd, J = 13.3, 7.2, 6.0 Hz, H-18a), 4.42 (1 H, ddd, J = 13.3, 7.2, 6.0 Hz, H-18b), 
3.50 (1 H, t, J = 6.6 Hz, H-6), 2.41 (2 H, ddd, J = 7.2, 6.6 Hz, H-17), 2.31 (1 H, dd, J = 10.2, 
7.6 Hz, H-8a), 2.21 – 2.13 (3 H, m, H-8b, H-9); δC (100 MHz; CDCl3) δ 203.9 (C-7), 172.1 
(C-5), 168.0 (CAr), 141.0 (CAr), 136.8 (C-10), 136.5 (CHAr), 130.2 (CHAr), 128.7 (CHAr), 
129.0 (CHAr), 128.8 (CHAr), 127.8 (CHAr), 115.7 (C-11), 73.3 (C-18), 53.5 (C-12), 53.3 (C-
6), 40.5 (C-8), 27.4 (C-9), 26.1 (C-17); Found (ESI): [MH]+ 381.1795; C22H25N2O4 requires 
[MH]+ 381.1809, 3.7 ppm. 
Lab-book No PD/5/76. 
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1-Benzyl-3-(2-nitroethyl)-3-pent-4-enoylindolin-2-one (292) 
 
N-Benzyl-2-(2-nitroethyl)-3-oxo-N-phenylhept-6-enamide (293) (0.079 g, 0.208 mmol), 
Cu(OAc)2·H2O (0.005 g, 0.021 mmol) in toluene (4 mL) were subjected to general procedure 
O at 110 °C for 18 h. The residue was purified by column chromatography (SiO2, 
Petrol/EtOAc, 8:1) to give the title compound 292 (0.026 g, 40%) as a pale yellow oil; Rf 
0.40 (Petrol/EtOAc, 3:1); νmax (cm-1) 1722, 1704, 1609, 1552, 1487, 1381, 1361, 1171, 753, 
699; δH (400 MHz; CDCl3) 7.37 – 7.31 (4 H, m, HAr), 7.32 – 7.26 (2 H, m, HAr), 7.10 – 7.04 
(2 H, m, HAr), 6.90 (1 H, d, J = 7.9 Hz, H-3), 5.54 (1 H, ddt, J = 17.1, 10.3, 6.3 Hz, H-19), 
5.05 (1 H, d, J = 15.4 Hz, H-9a), 4.86 (1 H, d, J = 15.4 Hz, H-9b), 4.85 (1 H, dq, J = 10.3, 
1.5 Hz, H-20a), 4.82 (1 H, dq, J = 17.1, 1.5 Hz, H-20b), 4.36 (1 H, dd, J = 8.6, 6.5 Hz, H-
15a), 4.36 (1 H, dd, J = 8.6, 6.5 Hz, H-15b), 2.98 (1 H, ddd, J = 14.4, 8.6, 6.5 Hz, H-14a), 
2.73 (1 H, ddd, J = 14.4, 8.6, 6.5 Hz, H-14b), 2.42 (1 H, ddd, J = 17.5, 8.0, 6.0 Hz, H-17a), 
2.26 – 2.17 (1 H, m, H-18a), 2.17 – 2.10 (1 H, m, H-18b), 2.06 (1 H, ddd, J = 17.5, 8.0, 6.0 
Hz, H-17b); δC (100 MHz; CDCl3) 200.7 (C-16), 173.9 (C-5), 143.1 (C-4), 136.1 (C-19), 
135.2 (C-10), 130.1 (C-2), 129.0 (C-11), 128.2 (C-13), 127.6 (C-12), 125.8 (C-7), 123.81 
(C-8), 123.76 (C-1), 115.5 (C-20), 110.1 (C-3), 70.7 (C-15), 63.3 (C-6), 44.4 (C-9), 37.6 (C-
17), 29.8 (C-14), 27.1 (C-18); Found (ESI): [MH]+ 379.1650; C22H23N2O4 requires [MH]
+ 
379.1652, 0.5 ppm. 
Lab-book No PD/5/79. 
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Methyl 2-(2-nitroethyl)-3-oxohept-6-enoate (298) 
 
To a stirred solution of methyl 3-oxohept-6-enoate 279 (0.205 g, 1.31 mmol) in CH2Cl2 (10 
mL) was added freshly distilled nitroethylene (106 mbar, 140-150 °C (oil bath temperature)) 
and Ni(acac)2 (0.006 g, 0.020 mmol). The reaction mixture was stirred at room temperature 
and held for 18 h. The solvent was removed in vacuo and the residue was purified by column 
chromatography (SiO2, Petrol/EtOAc, 8:1) to give the title compound 298 (0.160 g, 53%) as 
a colourless oil; Rf 0.41 (Petrol/EtOAc, 4:1); νmax (cm-1) 1743, 1715, 1554, 1436, 1383, 1363, 
1247, 1174, 1000, 918; δH (400 MHz; CDCl3) 5.77 (1 H, ddt, J = 16.8, 10.2, 6.5 Hz, H-2), 
5.03 (1 H, dd, J = 16.8, 1.2 Hz, H-1a), 4.99 (1 H, dd, J = 10.2, 1.2 Hz, H-1b), 4.43 (2 H, dt, 
J = 13.9, 7.1 Hz, H-10), 3.75 (3 H, s, H-8), 3.69 (1 H, t, J = 7.1 Hz, H-6), 2.76 (1 H, dt, J = 
17.7, 7.4 Hz, H-4a), 2.63 (1 H, dt, J = 17.7, 7.1 Hz, H-4b), 2.56 – 2.40 (2 H, m, H-9), 2.34 
(2 H, ddd, J = 7.1, 7.4, 6.5 Hz, H-3); δC (100 MHz; CDCl3) 202.9 (C-5), 168.8 (C-7), 136.4 
(C-2), 115.9 (C-1), 72.9 (C-10), 54.8 (C-6), 53.0 (C-8), 41.8 (C-4), 27.5 (C-3), 25.0 (C-9); 
Found (ESI): [MNa]+ 252.0837; C10H15NNaO5 requires [MNa]
+ 252.0842, 2.2 ppm. 
Lab-book No PD/6/45. 
 
1-Benzyl-3-(2-nitroethyl)-3-(3-(oxiran-2-yl)propanoyl)indolin-2-one (301) 
 
To a stirred solution of oxindole 292 (0.019 g, 0.050 mmol) in acetone (1 mL) at 0 °C was 
added DMDO (0.06 M solution in acetone, 3.30 mL, 0.202 mmol). The reaction mixture was 
stirred at 0 °C for 30 min, allowed to warm to room temperature and stirred for 30 min. The 
solvent was removed in vacuo and the residue was purified by column chromatography 
(SiO2, Petrol/EtOAc, 3:1) to give the title compound 301 (0.018 g, 93%) as a colourless oil 
and inseparable mixture of diastereoisomers in a 1:1 ratio; Rf 0.2 (Petrol/EtOAc, 4:1); νmax 
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(cm-1) 1723, 1702, 1608, 1553, 1486, 1381, 1349, 1172, 755, 700; δH (400 MHz; CDCl3) 
7.38 – 7.28 (6 H, m, HAr, H-8), 7.13 – 7.07 (2 H, m, H-1, H-2), 6.92 (1 H, d, J = 7.8 Hz, H-
3), 5.04 (0.5 H, d, J = 15.4 Hz, H-9a), 5.04 (0.5 H, d, J = 15.4 Hz, H-9a’), 4.93 (0.5 H, d, J 
= 15.4 Hz, H-9b), 4.91 (0.5 H, d, J = 15.4 Hz, H-9b’), 4.36 (2 H, t, J = 7.6 Hz, H-15), 2.98 
(1 H, ddd, J = 15.2, 7.6 Hz, H-14a), 2.80 – 2.69 (2 H, m, H-19, H-14b), 2.63 (1 H, dd, J = 
6.3, 4.8 Hz, H-20a), 2.47 (1 H, ddt, J = 18.2, 8.0, 6.2 Hz, H-17a), 2.31 (1 H, dd, J = 4.8, 2.7 
Hz, H-20b), 2.14 (1 H, ddd, J = 18.2, 8.0, 6.2 Hz, H-17b), 1.96 – 1.78 (1 H, m, H-18a), 1.65 
– 1.43 (1 H, m, H-18b); δC (100 MHz; CDCl3) 200.92 and 200.91 (C-16), 173.93 and 173.88 
(C-5), 143.23 and 143.21 (C-4), 135.20 and 135.19 (C-10), 130.3 (C-8), 129.2 (C-12), 128.3 
(C-13), 127.73 and 127.72 (C-11), 125.84 and 125.82 (C-7), 124.0 (C-2), 123.87 and 123.86 
(C-1), 110.3 (C-3), 70.7 (C-15), 63.4 and 63.3 (C-6), 51.0 and 50.8 (C-19), 47.1 and 46.9 
(C-20), 44.5 (C-9), 34.9 and 34.4 (C-17), 29.93 and 29.88 (C-14), 26.1 and 25.9 (C-18); 
Found (ESI): [MNa]+ 417.1423; C22H22N2NaO5 requires [MNa]
+ 417.1421, 0.5 ppm. 
Lab-book No PD/6/3. 
 
(Z)-1-Benzyl-3-(5-(hydroxymethyl)dihydrofuran-2(3H)-ylidene)indolin-2-one (303) 
 
To a stirred solution of oxindole 301 (0.014 g, 0.040 mmol) in toluene (1 mL) was added 
DBU (0.007 mL, 0.050 mmol). The reaction mixture was stirred overnight at room 
temperature. The toluene was removed under vacuum and the residue was treated with water 
(1 mL) and extracted with EtOAc (2 × 2 mL). The combined organic portions were washed 
with brine (2 × 2 mL), dried (MgSO4), filtered, and concentrated in vacuo. The residue was 
purified by column chromatography (SiO2, EtOAc/Petrol, 4:1) to give the title compound 
303 (0.006 g, 89%) as a colourless oil; Rf 0.40 (EtOAc); νmax (cm-1) 3405, 1722, 1681, 1611, 
1467, 1349, 1244, 1185, 1140, 1098, 961, 751, 735, 698; δH (400 MHz; CDCl3) 7.66 (1 H, 
dd, J = 7.6, 1.2 Hz, H-8), 7.32 – 7.24 (4 H, m, HAr), 7.22 (1 H, dd, J = 8.3, 4.2 Hz, HAr), 7.06 
(1 H, td, J = 7.6, 1.2 Hz, H-2), 6.99 (1 H, td, J = 7.6, 1.2 Hz, H-1), 6.71 (1 H, d, J = 7.6 Hz, 
H-3), 4.98 (2 H, s, H-9), 4.87 (1 H, tdd, J = 7.3, 5.2, 3.1 Hz, H-17), 4.02 (1 H, ddd, J = 12.6, 
6.0, 3.1 Hz, H-18a), 3.79 (1 H, ddd, J = 12.6, 6.0, 5.2 Hz, H-18b), 3.64 (1 H, ddd, J = 19.1, 
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9.5, 4.9 Hz, H-15a), 3.33 (1 H, ddd, J = 19.1, 9.5, 8.1 Hz, H-15b), 2.29 (1 H, dddd, J = 12.6, 
9.5, 7.3, 4.9 Hz, H-16a), 2.11 (1 H, dddd, J = 12.6, 9.5, 8.0, 7.3 Hz, H-16b), 1.94 (1 H, br t, 
J = 6.0 Hz, H-19); δC (100 MHz; CDCl3) 171.7 (C-14), 169.1 (C-5), 139.3 (C-4), 137.0 (C-
10), 128.7 (CHAr), 127.4 (CHAr), 127.3 (CHAr), 125.9 (C-2), 122.6 (C-7), 122.1 (C-8), 121.7 
(C-1), 108.2 (C-3), 100.3 (C-6), 86.3 (C-17), 64.3 (C-18), 43.4 (C-9), 31.1 (C-16), 24.5 (C-
15); Found (ESI): [MNa]+ 344.1245; C20H19NNaO3 requires [MNa]
+ 344.1263, 4.4 ppm. 
Lab-book No PD/6/7. 
 
1-Benzyl-3-(2-nitroethyl)indolin-2-one (305) 
 
To a stirred solution of oxindole 292 (0.017 g, 0.045 mmol) in CH2Cl2:EtOH (2 mL, 1:1) at 
0 °C was added NaBH4 (0.003 g, 0.067 mmol). After 30 min the ice bath was removed and 
the reaction mixture was allowed to warm to room temperature and stirred overnight. The 
mixture was poured into ice, extracted with EtOAc (2 × 2 mL), washed with water (2 mL) 
and brine (2 mL). The combined organic phases were dried (MgSO4), filtered, and 
concentrated in vacuo. The residue was purified by column chromatography (SiO2, 
Petrol/EtOAc, 6:1) to give the title compound 305 (0.010 g, 77%) as a colorless oil; Rf 0.45 
(Petrol/EtOAc, 4:1); νmax (cm-1) 1703, 1613, 1550, 1489, 1467, 1382, 1362, 1169, 752, 698; 
δH (400 MHz; CDCl3) 7.35 – 7.26 (6 H, m, HAr, H-8), 7.21 (1 H, t, J = 7.8 Hz, H-2), 7.05 (1 
H, t, J = 7.8 Hz, H-1), 6.76 (1 H, d, J = 7.8 Hz, H-3), 4.90 (2 H, s, H-9), 4.76 (1 H, ddd, J = 
14.2, 7.7, 6.0 Hz, H-15a), 4.62 (1 H, ddd, J = 14.2, 7.7, 6.0 Hz, H-15b), 3.63 (1 H, dd, J = 
8.4, 5.3 Hz, H-6), 2.75 (1 H, dtd, J = 14.2, 7.7, 5.3 Hz, H-14a), 2.50 (1 H, ddt, J = 14.2, 8.4, 
6.0 Hz, H-14b); δC (100 MHz; CDCl3) 176.7 (C-5), 143.5 (C-4), 135.7 (C-10), 129.3 (CHAr), 
129.0 (C-8), 128.1 (C-2), 127.4 (CHAr), 127.0 (CHAr), 124.0 (C-7), 123.0 (C-1), 109.5 (C-
3), 72.5 (C-6), 44.4 (C-9), 42.3 (C-15), 28.9 (C-14); Found (ESI): [MNa]+ 319.1052; 
C17H16N2NaO3 requires [MNa]
+ 319.1053, 0.4 ppm. 
Lab-book No PD/6/17. 
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2-Allyl-N-benzyl-3-oxo-N-phenylhept-6-enamide (314) 
 
N-Benzyl-3-oxo-N-phenylhept-6-enamide (281) (0.242 g, 0.790 mmol), NaH (0.035 g, 
0.870 mmol), allyl bromide (0.072 mL, 0.830 mmol) in DMF (8 mL) were subjected to 
general procedure P at 0 °C for 2 h. The residue was purified by column chromatography 
(SiO2, Petrol/EtOAc, 6:1) to give the title compound 314 (0.227 g, 83%) as a colourless oil; 
Rf 0.45 (Petrol/EtOAc, 3:1); νmax (cm-1) 1717, 1650, 1594, 1495, 1392, 1255, 914, 699; δH 
(400 MHz; CDCl3) 7.36 – 7.30 (3 H, m, HAr), 7.28 – 7.23 (3 H, m, HAr), 7.21 – 7.17 (2 H, 
m, HAr), 6.95 – 6.91 (2 H, m, HAr), 5.77 – 5.59 (2 H, m, H-10, H-18), 5.07 – 4.90 (4 H, m, 
H-11, H-19), 4.89 (2 H, s, H-12) 3.39 (1 H, dd, J = 8.4, 5.9 Hz, H-6), 2.66 (1 H, dddt, J = 
15.4, 8.4, 7.1, 1.2 Hz, H-17a), 2.48 (1 H, dddt, J = 15.4, 7.1, 5.9, 1.2 Hz, H-17b), 2.44 – 2.37 
(1 H, m, H-8a), 2.30 – 2.21 (1 H, m, H-8b), 2.24 – 2.09 (2 H, m, H-9); δC (100 MHz; CDCl3) 
204.9 (C-7), 168.8 (C-5), 141.6 (CAr), 137.2 (CAr), 137.0 (C-10), 135.0 (C-18), 129.8 (CHAr), 
129.1 (CHAr), 129.0 (CHAr), 128.6 (CHAr), 128.5 (CHAr), 127.6 (CHAr), 117.4 (C-19), 115.3 
(C-11), 56.9 (C-6), 53.4 (C-12), 40.3 (C-8), 33.6 (C-17), 27.4 (C-9); Found (ESI): [MH]+ 
348.1967; C23H26NO2 requires [MH]
+ 348.1958, 2.5 ppm. 
Lab-book No PD/5/64. 
 
3-Allyl-1-benzyl-3-pent-4-enoylindolin-2-one (313) 
 
2-Allyl-N-benzyl-3-oxo-N-phenylhept-6-enamide (314) (0.356 g, 1.03 mmol), 
Cu(OAc)2·H2O (0.208 g, 1.03 mmol) in toluene (20 mL) were subjected to general procedure 
O at 110 °C for 18 h. The residue was purified by column chromatography (SiO2, 
Petrol/EtOAc, 8:1) to give the title compound 313 (0.090 g, 45%) as a colourless oil; Rf 0.50 
(Petrol/EtOAc, 5:1); νmax (cm-1) 1723, 1707, 1609, 1486, 1466, 1349, 1173, 752, 699; δH 
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(400 MHz; CDCl3) 7.36 – 7.27 (5 H, m, HAr), 7.22 (1 H, td, J = 7.5, 1.3 Hz, H-2), 7.15 (1 H, 
ddd, J = 7.5, 1.3, 0.5 Hz, H-8), 7.04 (1 H, td, J = 7.5, 1.3 Hz, H-1), 6.79 (1 H, d, J = 7.5 Hz, 
H-3), 5.66 – 5.55 (1 H, m, H-20), 5.30 (1 H, dddd, J = 16.5, 10.1, 8.2, 6.4 Hz, H-15), 5.04 
(1 H, ddd, J = 16.5, 3.1, 1.2 Hz, H-16a), 4.99 (1 H, d, J = 15.6 Hz, H-9a), 4.92 (1 H, d, J = 
15.6 Hz, H-9b), 4.91 – 4.82 (3 H, m, H-16b, H-21), 3.02 (1 H, ddt, J = 13.8, 6.4, 1.2 Hz, H-
14a), 2.92 (1 H, dd, J = 13.8, 8.2 Hz, H-14b), 2.56 – 2.46 (1 H, m, H-18a), 2.28 – 2.12 (3 H, 
m, H-18b, H-19); δC (100 MHz; CDCl3) 202.0 (C-17), 174.7 (C-5), 143.5 (C-4), 136.6 (C-
20), 135.6 (C-10), 131.6 (C-15), 129.2 (C-2), 128.9 (C-11), 127.9 (C-13), 127.7 (C-12), 
127.0 (C-7), 124.2 (C-8), 123.2 (C-1), 119.6 (C-16), 115.4 (C-21), 109.6 (C-3), 66.2 (C-6), 
44.2 (C-9), 38.2 (C-18), 37.7 (C-14), 27.3 (C-19); Found (ESI): [MNa]+ 368.1673; 
C23H23NNaO2 requires [MNa]
+ 368.1621, 1.7 ppm. 
Lab-book No PD/5/73. 
 
6.4.3.2 General procedure Q: Ring-closing metathesis to 7-membered ring systems 
 
(Z)-1'-Benzylspiro[cyclohept[3]ene-1,3'-indoline]-2',7-dione (312) 
 
To a degassed solution of 313 (0.090 g, 0.220 mmol) (purged three times with nitrogen and 
vacuum) in CH2Cl2 (50 mL) was added Grubbs 2
nd generation catalyst (0.022 g, 0.030 mmol) 
then, the reaction was heated at 45 °C. After 5 h, the reaction mixture was complete by TLC 
and was allowed to cool to room temperature. The solvent was removed under vacuum and 
the residue was purified by column chromatography (SiO2, Petrol/EtOAc, 6:1) to give the 
title compound 312 (0.050 g, 61%) as a clear oil; Rf 0.25 (Petrol/EtOAc, 6:1); νmax (cm-1) 
1716, 1669, 1586, 1464, 1443, 1328, 1172, 753, 699; δH (400 MHz; CDCl3) 7.34 – 7.21 (6 
H, m, HAr, H-8), 7.18 (1 H, td, J = 7.6, 1.0 Hz, H-2), 7.00 (1 H, td, J = 7.6, 1.0 Hz, H-1), 
6.70 (1 H, d, J = 7.6 Hz, H-3), 5.97 – 5.80 (2 H, m, H-17, H-18), 4.95 (1 H, d, J = 15.9 Hz, 
H-9a), 4.84 (1 H, d, J = 15.9 Hz, H-9b), 3.66 – 3.58 (1 H, m, H-15a), 3.43 (1 H, ddd, J = 
15.4, 4.4, 1.8 Hz, H-19a), 2.78 – 2.67 (2 H, m, H-15b, H-16a), 2.65 – 2.50 (1 H, m, H-16b), 
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2.38 (1 H, dd, J = 15.4, 7.5 Hz, H-19b); δC (100 MHz; CDCl3) 206.5 (C-14), 174.2 (C-5), 
142.8 (C-4), 135.5 (C-10), 131.0 (C-17), 128.92 (C-11), 128.89 (C-7), 128.8 (C-2), 127.7 
(C-12), 127.1 (C-13), 125.6 (C-18), 124.2 (C-8), 122.9 (C-1), 109.6 (C-3), 67.8 (C-6), 43.9 
(C-9), 39.0 (C-15), 31.4 (C-19), 27.7 (C-16); Found (ESI): [MH]+ 318.1488; C21H20NO2 
requires [MH]+ 318.1489, 0.3 ppm. 
Lab-book No PD/5/74. 
 
5-(1-Hydroxypent-4-enylidene)-2,2-dimethyl-1,3-dioxane-4,6-dione (316) 
 
A solution of DCC (4.74 g, 23.0 mmol) in CH2Cl2 (10 mL) was added slowly to a stirred 
solution of Meldrum’s acid (3.01 g, 20.9 mmol), 4-pentenoic acid (2.13 mL, 20.9 mmol), 
and 4-(dimethylamino)pyridine (2.81 g, 23.0 mmol) in CH2Cl2 (30 mL) at 0 °C. The reaction 
mixture was allowed to warm to room temperature and stirred for 16 h. The suspension was 
filtered through Celite®, and then washed with CH2Cl2 (50 mL). The filtrate was washed 
subsequently with 10% aq. HCl (50 mL). The aqueous phase was extracted twice with 
CH2Cl2 (2  × 20 mL). The combined organic phases were washed with water (2 × 30 mL) 
and brine (2 × 30 mL), dried (MgSO4), filtered, and concentrated in vacuo. The residue was 
purified by column chromatography (SiO2, EtOAc) to give the title compound 316 (3.32 g, 
70%) as a yellow oil; Rf 0.21 (EtOAc/Petrol, 4:1); νmax (cm-1) 1739, 1665, 1574, 1408, 1282, 
1154, 1031, 919; δH (400 MHz; CDCl3) 5.84 (1 H, ddt, J = 16.9, 10.2, 6.6 Hz, H-2), 5.08 (1 
H, dtd, J = 16.9, 1.4, 1.3 Hz, H-1a), 5.02 (1 H, dtd, J = 10.2, 1.4, 1.3 Hz, H-1b), 3.19 (2 H, 
dd, J = 7.7, 6.6 Hz, H-4), 2.48 (1 H, ddd, J = 6.6, 6.6, 1.4 Hz, H-3a), 2.45 (1 H, ddd, J = 7.7, 
6.6, 1.4 Hz, H-3b), 1.72 (6 H, s, H-9); δC (100 MHz; CDCl3) 197.2 (C-5), 170.6 (C-10), 
160.3 (C-7), 136.1 (C-2), 116.3 (C-1), 105.0 (C-8), 91.7 (C-6), 35.1 (C-4), 29.9 (C-3), 26.9 
(C-9); Found (ESI): [MNa]+ 249.0742; C11H14NaO5 requires [MNa]
+ 249.0733, 3.6 ppm. 
Lab-book No PD/7/1. 
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N-(4-Methoxybenzyl)-3-oxo-N-phenylhept-6-enamide (317) 
 
To a stirred solution of masked β-keto acid 316 (2.16 g, 9.55 mmol) in 1,4-dioxane (14 mL) 
was added N-(4-methoxybenzyl)aniline (2.04 g, 9.55 mmol). The reaction mixture was 
stirred for 4 h at 110 °C, then the solvent was removed in vacuo and the residual oil was 
purified by column chromatography (SiO2, Petrol/EtOAc, 5:1) to give the title compound 
317 (2.81 g, 87%) as a yellow oil; Rf 0.31 (Petrol/EtOAc, 4:1); νmax (cm-1) 1720, 1651, 1594, 
1512, 1395, 1244, 1175, 1033, 821, 701; δH (400 MHz; CDCl3) 7.32 – 7.28 (3 H, m, H-1, 
H-2), 7.12 (2 H, d, J = 8.7 Hz, H-14), 6.94 (2 H, dd, J = 6.5, 3.1 Hz, H-3), 6.78 (2 H, d, J = 
8.7 Hz, H-15), 5.70 (1 H, ddt, J = 16.8, 10.2, 6.6 Hz, H-10), 4.94 (1 H, dd, J = 16.8, 1.5 Hz, 
H-11a), 4.91 (1 H, dd, J = 10.2, 1.5 Hz, H-11b), 4.83 (2 H, s, H-12), 3.76 (3 H, s, H-17), 
3.27 (2 H, s, H-6), 2.41 (2 H, t, J = 7.1 Hz, H-8), 2.21 (2 H, td, J = 7.1, 6.6 Hz, H-9); δC (100 
MHz; CDCl3) 203.7 (C-7), 166.7 (C-5), 159.0 (C-16), 141.9 (C-13), 136.8 (C-10), 130.3 (C-
14), 129.7 (C-2), 129.2 (C-4), 128.6 (C-3), 128.5 (C-1), 115.4 (C-11), 113.8 (C-15), 55.3 (C-
17), 52.5 (C-12), 49.5 (C-6), 42.3 (C-8), 27.5 (C-9); Found (ESI): [MNa]+ 360.1561; 
C21H23NNaO3 requires [MNa]
+ 360.1570, 2.6 ppm. 
Lab-book No PD/7/2. 
 
N-(4-Methoxybenzyl)-2-(2-methylallyl)-3-oxo-N-phenylhept-6-enamide (318) 
 
N-(4-Methoxybenzyl)-3-oxo-N-phenylhept-6-enamide (317) (2.58 g, 7.65 mmol), NaH 
(0.336 g, 8.41 mmol), allyl bromide (0.695 mL, 8.03 mmol) in DMF (100 mL) were 
subjected to general procedure P at 0 °C for 18 h. Purification by column chromatography 
(SiO2, Petrol/EtOAc, 6:1) gave the title compound 318 (3.21 g, quant.) as a light yellow oil; 
Rf 0.43 (Petrol/EtOAc, 4:1); νmax (cm-1) 1717, 1650, 1613, 1594, 1512, 1394, 1302, 1245, 
1176, 1033, 916, 702; δH (400 MHz; CDCl3) 7.34 – 7.29 (3 H, m, H-1, H-2), 7.09 (2 H, d, J 
= 8.6 Hz, H-14), 6.90 (2 H, dd, J = 6.6, 3.1 Hz, H-3), 6.77 (2 H, d, J = 8.6 Hz, H-15), 5.75 – 
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5.58 (2 H, m, H-10, H-19), 5.05 – 4.90 (4 H, m, H-11, H-20), 4.82 (2 H, s, H-12), 3.77 (3 H, 
s, H-17), 3.35 (1 H, dd, J = 8.4, 5.9 Hz, H-6), 2.64 (1 H, ddd, J = 15.3, 8.4, 7.2 Hz, H-18a), 
2.47 (1 H, ddd, J = 15.3, 7.2, 5.9 Hz, H-18b), 2.42 – 2.35 (1 H, m, H-8a), 2.29 – 2.21 (1 H, 
m, H-8b), 2.22 – 2.14 (2 H, m, H-9); δC (100 MHz; CDCl3) 204.9 (C-7), 168.7 (C-5), 159.1 
(C-16), 141.5 (C-13), 137.0 (C-10), 135.1 (C-19), 130.4 (C-14), 129.8 (C-2), 129.4 (C-4), 
129.2 (C-3), 128.5 (C-1), 117.3 (C-20), 115.3 (C-11), 113.8 (C-15), 56.9 (C-6), 55.3 (C-17), 
52.8 (C-12), 40.3 (C-8), 33.6 (C-18), 27.4 (C-9); Found (ESI): [MNa]+ 400.1878; 
C24H27NNaO3 requires [MNa]
+ 400.1883, 1.4 ppm. 
Lab-book No PD/7/11. 
 
(Z)-N-(4-Methoxybenzyl)-7-oxo-N-phenylcyclohept-3-enecarboxamide (319) 
 
N-(4-Methoxybenzyl)-2-(2-methylallyl)-3-oxo-N-phenylhept-6-enamide (318) (0.493 g, 
1.33 mmol), Grubbs 2nd generation catalyst (0.052 g, 0.067 mmol), in CH2Cl2 (100 mL) were 
subjected to general procedure Q at 45 °C for 1 h. The residue was purified by column 
chromatography (SiO2, Petrol/EtOAc, 5:1 to Petrol/EtOAc, 2:1) to give the title compound 
319 (0.264 g, 57%) as a colourless oil; Rf 0.42 (Petrol/EtOAc, 4:1); νmax (cm-1) 1709, 1661, 
1648, 1594, 1512, 1396, 1244, 1176, 1033, 702; δH (400 MHz; CDCl3) 7.30 – 7.26 (3 H, m, 
H-1, H-2), 7.12 (2 H, d, J = 8.7 Hz, H-15), 6.94 (2 H, dd, J = 5.8, 3.8 Hz, H-3), 6.77 (2 H, 
d, J = 8.7 Hz, H-16), 5.68 – 5.56 (2 H, m, H-10, H-11), 4.88 (1 H, d, J = 14.2 Hz, H-13a), 
4.77 (1 H, d, J = 14.2 Hz, H-13b), 3.80 (1 H, dd, J = 11.9, 3.9 Hz, H-6), 3.75 (3 H, s, H-18), 
2.79 – 2.71 (1 H, m, H-12a), 2.67 (1 H, dd, J = 14.9, 7.3 Hz, H-8a), 2.43 – 2.34 (1 H, m, H-
12b), 2.08 – 2.02 (2 H, m, H-9), 2.01 – 1.93 (1 H, m, H-8b); δC (100 MHz; CDCl3) 209.2 
(C-7), 169.5 (C-5), 159.0 (C-17), 141.6 (C-4), 130.2 (C-15), 129.6 (CHAr), 129.4 (C-14), 
129.2 (CHAr), 129.1 (CHAr), 128.4 (C-10 or C-11), 128.2 (C-10 or C-11), 113.8 (C-16), 55.3 
(C-6 or C-18), 55.2 (C-6 or C-18), 52.5 (C-13), 42.2 (C-8), 28.4 (C-12), 23.9 (C-9); Found 
(ESI): [MNa]+ 372.1573; C22H23NNaO3 requires [MNa]
+ 372.1570, 0.7 ppm. 
Lab-book No PD/7/13. 
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N-(4-Methoxybenzyl)-4-oxo-N-phenyl-8-oxabicyclo[5.1.0]octane-3-carboxamide (320) 
 
To a stirred solution of (Z)-N-(4-methoxybenzyl)-7-oxo-N-phenylcyclohept-3-
enecarboxamide (319) (0.122 g, 0.348 mmol) in acetone (2 mL) at 0 °C was added a solution 
of DMDO (0.06 M in acetone, 11.05 mL, 0.696 mmol). The reaction mixture was stirred at 
0 °C for 1 h and allowed to warm to room temperature for a further 1 h. The solvent was 
removed in vacuo. The residue was purified by column chromatography (SiO2, EtOAc/Petrol 
2:1) to give the title compound 320 (0.108 g, 85%) as a colourless oil and inseparable mixture 
of 1:1.5 diastereoisomers 320:320’; Rf 0.11 (Petrol/EtOAc, 2:1); νmax (cm-1) 1710, 1657, 
1594, 1594, 1512, 1396, 1244, 1176, 1031, 730, 702; δH (400 MHz; CDCl3) 7.31 – 7.26 (3 
H, m, H-1, H-2), 7.14 – 7.06 (2 H, m, H-15), 6.92 – 6.84 (2 H, m, H-3), 6.80– 6.74 (2 H, m, 
H-16), 4.84 (1 H, d, J = 14.3 Hz, H-13a, H-13a’), 4.77 (0.4 H, d, J = 14.3 Hz, H-13b), 4.75 
(0.6 H, d, J = 14.3 Hz, H-13b’), 3.75 (3 H, s, H-18), 3.66 – 3.58 (1 H, m, H-6), 3.17 (1 H, 
td, J = 4.6, 1.7 Hz, H-11), 3.06 – 3.01 (1 H, m, H-10), 2.54 – 2.34 (2 H, m, H-12), 2.09 (0.6 
H, ddd, J = 12.1, 7.5, 4.4 Hz, H-8a’), 2.01 – 1.93 (2 H, m, H-9), 1.82 (1.4 H, ddd, J = 12.1, 
9.8, 4.4 Hz, H-8a, H-8b, H-8b’); δC (100 MHz; CDCl3) 209.3 and 207.4 (C-7), 168.9 and 
168.7 (C-5), 159.0 (C-17), 141.3 and 141.2 (C-4), 130.2 and 130.1 (C-15), 129.74 and 
129.70 (C-2), 129.4 (C-1), 129.31 and 129.26 (C-14), 128.5 (C-3), 113.8 (C-16), 55.3 (C-
18), 54.4 (C-11), 54.0 and 53.3 (C-10), 52.6 and 52.5 (C-13), 51.7 and 51.4 (C-6), 38.0 and 
36.3 (C-8), 28.6 and 27.3 (C-12), 24.0 and 22.7 (C-9); Found (ESI): [MNa]+ 388.1504; 
C22H23NNaO4 requires [MNa]
+ 388.1519, 3.9 ppm. 
Lab-book No PD/7/14. 
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(Z)-1'-(4-Methoxybenzyl)spiro[cyclohept[3]ene-1,3'-indoline]-2',7-dione (321) 
 
(Z)-N-(4-Methoxybenzyl)-7-oxo-N-phenylcyclohept-3-enecarboxamide (319) (0.023 g, 
0.067 mmol), Cu(OAc)2·H2O (0.018 g, 0.094 mmol) in toluene (2 mL) were subjected to 
general procedure O at 100 °C for 1.5 h. The residue was purified by column 
chromatography (SiO2, Petrol/EtOAc 6:1) to give the title compound 321 (0.013 g, 55%) as 
a colourless solid; mp. 125-127 °C; Rf 0.27 (Petrol/EtOAc, 4:1); νmax (cm-1) 1697, 1610, 
1514, 1487, 1466, 1352, 1248, 1178, 1033, 750; δH (400 MHz; CDCl3) 7.28 (1 H, dd, J = 
7.6, 1.0 Hz, H-8), 7.20 (2 H, d, J = 8.7 Hz, H-11), 7.17 (1 H, td, J = 7.6, 1.0 Hz, H-2), 6.99 
(1 H, td, J = 7.6, 1.0 Hz, H-1), 6.83 (2 H, d, J = 8.7 Hz, H-12), 6.72 (1 H, d, J = 7.6 Hz, H-
3), 5.95 – 5.80 (2 H, m, H-18, H-19), 4.88 (1 H, d, J = 15.5 Hz, H-9a), 4.77 (1 H, d, J = 15.5 
Hz, H-9b), 3.76 (3 H, s, H-14), 3.60 (1 H, dd, J = 14.2, 8.1 Hz, H-16a), 3.41 (1 H, ddd, J = 
15.4, 4.7, 2.2 Hz, H-20a), 2.76 – 2.65 (2 H, m, H-16b, H-17a), 2.63 – 2.50 (1 H, m, H-17b), 
2.35 (1 H, dd, J = 15.4, 7.4 Hz, H-20b); δC (100 MHz; CDCl3) 206.6 (C-15), 174.2 (C-5), 
159.1 (C-13), 142.9 (C-4), 131.0 (C-18 or C-19), 130.6 (C-7), 128.8 (C-2), 128.5 (C-11), 
127.5 (C-10), 125.6 (C-18 or C-19), 124.2 (C-8), 122.8 (C-1), 114.3 (C-12), 109.6 (C-3), 
67.8 (C-6), 55.3 (C-14), 43.4 (C-9), 39.0 (C-16), 31.4 (C-20), 27.7 (C-17); Found (ESI): 
[MNa]+ 370.1410; C22H21NNaO3 requires [MNa]
+ 370.1414, 1.1 ppm. 
Lab-book No PD/7/17. 
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1'-(4-Methoxybenzyl)-8-oxaspiro[bicyclo[5.1.0]octane-3,3'-indoline]-2',4-dione (322) 
 
N-(4-Methoxybenzyl)-4-oxo-N-phenyl-8-oxabicyclo[5.1.0]octane-3-carboxamide (320) 
(0.024 g, 0.067 mmol), Cu(OAc)2·H2O (0.016 g, 0.085 mmol) in toluene (2 mL) were 
subjected to general procedure O at 100 °C for 1.5 h. The residue was purified by column 
chromatography (SiO2, Petrol/EtOAc, 3:1) to give the title compound 322 (0.015 g, 62%) as 
a slightly yellow oil and inseparable mixture of diastereoisomers in a 1:3 ratio of 322:322’; 
Rf 0.48 (Petrol/EtOAc, 1:1); νmax (cm-1) 1698, 1611, 1514, 1488, 1466, 1362, 1248, 1178, 
1033, 751; δH (400 MHz; CDCl3) 7.55 (1 H, dd, J = 7.6, 1.0 Hz, H-8), 7.20 (1 H, td, J = 7.6, 
1.0 Hz, H-2), 7.17 (2 H, d, J = 8.8 Hz, H-11), 7.08 (0.75 H, td, J = 7.6, 1.0 Hz, H-1’), 7.02 
(0.25 H, td, J = 7.6, 1.0 Hz, H-1), 6.83 (2 H, d, J = 8.8 Hz, H-12), 6.73 (1 H, d, J = 7.6 Hz, 
H-3), 4.94 – 4.74 (1 H, m, H-9a, H-9a’), 4.76 (0.75 H, d, J = 15.6 Hz, H-9b’), 4.76 (0.25 H, 
d, J = 15.6 Hz, H-9b), 3.75 (3 H, s, H-14), 3.43 (1 H, ddd, J = 6.9, 3.9, 2.4 Hz, H-19), 3.31 
(1 H, dt, J = 3.9, 2.8 Hz, H-18), 3.19 (1 H, dd, J = 8.4, 3.0 Hz, H-16a), 3.13 (1 H, dd, J = 
15.7, 2.4 Hz, H-20a), 2.54 – 2.47 (3 H, m, H-16b, H-17), 2.41 (1 H, dd, J = 15.7, 6.9 Hz, H-
20b); δC (100 MHz; CDCl3) 204.0 (C-15), 173.9 (C-5), 159.2 (C-13), 142.9 (C-4), 130.3 (C-
7), 129.2 and 128.8 (C-2), 128.53 and 128.45 (C-11), 127.4 (C-10), 125.6 and 123.9 (C-8), 
123.4 and 122.9 (C-1), 114.3 (C-12), 110.1 and 109.5 (C-3), 64.8 and 63.8 (C-6), 55.3 (C-
14), 55.2 and 53.9 (C-18), 54.3 and 53.5 (C-19), 43.54 and 43.46 (C-9), 36.5 and 35.8 (C-
16), 33.1 and 32.8 (C-20), 25.9 and 24.9 (C-17); Found (ESI): [MNa]+ 386.1369; 
C22H21NNaO4 requires [MNa]
+ 386.1363, 1.6 ppm. 
Lab-book No PD/7/16. 
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2-((tert-Butyldimethylsilyloxy)methyl)prop-2-en-1-ol136a (330) 
 
To a stirred solution of paraformaldehyde (1.50 g, 50.0 mmol) and methyl acrylate (13.5 
mL, 150 mmol) in a mixture of 1,4-dioxane:water (25 mL, 1:1) was added DABCO (5.21 g, 
50.0 mmol). The reaction mixture was stirred overnight at room temperature. Water (20 mL) 
and Et2O (20 mL) were added to the mixture. The aqueous phase was separated and extracted 
with Et2O (2  × 20 mL). The combined organics were washed with brine (20 mL), dried 
(MgSO4), filtered, and concentrated in vacuo. 
To a stirred solution of methyl 2-(hydroxymethyl)acrylate (4.55 g, 35.0 mmol) in dry CH2Cl2 
(100 mL) was added imidazole (5.99 g, 88.0 mmol) and tert-butyldimethylsilyl chloride 
(6.33 g, 42.0 mmol). The reaction mixture was stirred at room temperature for 2 h and 
subsequently quenched with a solution of sat. aq. NaHCO3 (100 mL). The organic layer was 
separated by extraction with CH2Cl2 (2  × 50 mL). The organic layers were combined, 
washed with brine (2  × 50 mL), dried (MgSO4), filtered, and concentrated in vacuo to afford 
a colourless oil which was purified by column chromatography (SiO2, Petrol/EtOAc, 99:1) 
to give the ester (5.13 g, 64%) as a colourless oil. (Lab-book No PD/6/59) 
To a stirred solution of ester (5.13 g, 22.3 mmol) in Et2O (180 mL) at −78 °C was added a 
solution of diisobutylaluminum hydride (1.0 M in hexanes, 67.0 mL, 67.0 mmol) dropwise. 
After 2 h, the reaction mixture was quenched with sat. aq. Rochelle’s salt (100 mL). The 
reaction mixture was diluted with EtOAc (100 mL) and allowed to warm to room 
temperature. After stirring overnight, the organic layer was separated, and the aqueous phase 
was extracted with EtOAc (3  × 50 mL). The combined organic layers were dried (MgSO4), 
filtered, and concentrated in vacuo to afford the title compound 330 (4.18 g, 94%) as a clear 
oil which was used in the next step without further purification; Rf 0.11 (Petrol/EtOAc, 9:1); 
5.08 (1 H, dd, J = 2.0, 1.2 Hz, H-4a), 5.07 (1 H, dd, J = 2.0, 1.2 Hz, H-4b), 4.23 (2 H, s, H-
5), 4.15 (2 H, s, H-2), 0.90 (9 H, s, H-8), 0.07 (6 H, s, H-6). 
Analytical data are consistent with literature values.136a 
Lab-book No PD/6/60 
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(2-(Bromomethyl)allyloxy)tert-butyldimethylsilane162 (326) 
 
To a stirred solution of allylic alcohol 330 (1.02 g, 4.94 mmol) in CH2Cl2 (15 mL) at 0 °C 
was added tetrabromomethane (3.28 g, 9.88 mmol) and PPh3 (2.59 g, 9.88 mmol). The 
reaction mixture was stirred for 30 min and allowed to warm to room temperature, then 
stirred for a further 2 h, and subsequently quenched with a sat. aq. solution of NH4Cl (20 
mL). The aqueous layer was separated, and extracted with CH2Cl2 (2  × 20 mL). The organic 
layers were combined, washed with brine (2  × 20 mL), dried (MgSO4), filtered, and 
concentrated in vacuo to afford a colourless oil which was purified by column 
chromatography (SiO2, Petrol/EtOAc, 99:1) to give the title compound 326 (0.420 g, 32%) 
as a colourless oil; Rf 0.80 (Petrol/EtOAc, 9:1); δH (400 MHz; CDCl3) 5.25 (1 H, dq, J = 2.0, 
1.2 Hz, H-3a), 5.20 (1 H, dq, J = 2.0, 1.2 Hz, H-3b), 4.26 (2 H, t, J = 1.2 Hz, H-4), 4.00 (2 
H, s, H-1), 0.91 (9 H, s, H-7), 0.09 (6 H, s, H-5). 
Analytical data are consistent with literature values.162 
Lab-book No PD/6/68. 
 
Ethyl 6-((tert-butyldimethylsilyloxy)methyl)-3-oxohept-6-enoate (331) 
 
To a stirred solution of diisopropylamine (0.420 mL, 3.02 mmol) in THF (5 mL) was added 
n-BuLi (1.6 M in hexanes, 1.97 mL, 3.16 mmol) at 0 °C. The pale yellow solution was held 
at 0 °C for 20 min and cooled to −78 °C, then ethyl acetoacetate (0.180 mL, 1.44 mmol) was 
added and the reaction was stirred at −78 °C for 15 min before the subsequent addition of 
(2-(bromomethyl)allyloxy)tert-butyldimethylsilane (326) (0.400 g, 1.51 mmol) as a solution 
in THF (1 mL). The reaction mixture was stirred for 1 h at −78 °C, warmed to room 
temperature, and stirred for 4 h. An aq. sat. sol. of NH4Cl (5 mL) was added. The aqueous 
layer was extracted with EtOAc (2 × 5 mL). The combined organic extracts were washed 
with water (10 mL) and brine (10 mL), dried (MgSO4), filtered, and concentrated in vacuo. 
The crude residue was purified by column chromatography (SiO2, Petrol/EtOAc, 20:1) to 
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give the title compound 331 (0.107 g, 24%) as a colourless oil; Rf 0.40 (Petrol/EtOAc, 9:1); 
νmax (cm-1) 2955, 2930, 2857, 1472, 1463, 1252, 1084, 834, 775, 669; δH (400 MHz; CDCl3) 
5.04 (1 H, dd, J = 2.6, 1.2 Hz, H-1a), 4.79 (1 H, dd, J = 2.6, 1.2 Hz, H-1b), 4.19 (2 H, q, J = 
7.0 Hz, H-8), 4.06 (2 H, s, H-10), 3.44 (2 H, s, H-6), 2.73 (2 H, t, J = 8.2 Hz, H-4), 2.30 (2 
H, t, J = 8.2 Hz, H-3), 1.27 (3 H t, J = 7.0 Hz, H-9), 0.90 (9 H, s, H-13), 0.05 (6 H, s, H-11); 
δC (100 MHz; CDCl3) 203.1 (C-5), 167.3 (C-7), 147.0 (C-2), 109.3 (C-1), 66.1 (C-10), 61.5 
(C-8), 49.4 (C-6), 41.4 (C-4), 26.2 (C-3), 26.0 (C-13), 18.4 (C-12), 14.2 (C-9), −5.3 (C-11); 
Found (ESI): [MNa]+ 337.1803; C16H30NaO4Si requires [MNa]
+ 337.1806, 0.7 ppm. 
Lab-book No PD/6/70. 
 
Ethyl 2-allyl-6-[(tert-butyldimethylsilyloxy)methyl]-3-oxohept-6-enoate (332) 
 
Ethyl 6-[(tert-butyldimethylsilyloxy)methyl]-3-oxohept-6-enoate (331) (0.089 g, 0.280 
mmol), NaH (0.012 g, 0.310 mmol), allyl bromide (0.026 g, 0.300 mmol) in DMF (8 mL) 
were subjected to general procedure P at 0 °C for 2 h. The crude pale yellow oil was then 
purified by column chromatography (SiO2, Petrol/EtOAc, 40:1) to give the title compound 
332 (0.045 g, 46%) as a colourless oil in a 1.5:1 mixture of keto-enol tautomers, respectively; 
Rf 0.38 (Petrol/EtOAc, 20:1); νmax (cm-1) 2956, 2930, 2857, 1743, 1716, 1472, 1253, 1112, 
837, 777; δH (400 MHz; CDCl3, Keto) 5.72 (1 H, ddt, J = 17.0, 10.2, 6.9 Hz, H-11), 5.11 – 
5.04 (2 H, m, H-12), 5.04 – 5.03 (1 H, m, H-1a), 4.77 (1 H, dd, J = 2.7, 1.3 Hz, H-1b), 4.17 
(2 H, dq, J = 10.8, 7.1 Hz, H-8), 4.05 (2 H, s, H-13), 3.53 (1 H, t, J = 7.4 Hz, H-6), 2.74 (1 
H, t, J = 7.6 Hz, H-4a), 2.68 (1 H, t, J = 7.6 Hz, H-4b), 2.58 (2 H, dd, J = 7.4, 6.9 Hz, H-10), 
2.27 (2 H, t, J = 7.6 Hz, H-3), 1.25 (3 H, t, J = 7.1 Hz, H-9), 0.89 (9 H, s, H-16), 0.05 (6 H, 
s, H-14); δC (100 MHz; CDCl3, Keto) 204.0 (C-5), 169.3 (C-7), 147.2 (C-2), 134.4 (C-11), 
117.6 (C-12), 109.2 (C-1), 66.1 (C-13), 61.5 (C-8), 58.6 (C-6), 40.6 (C-4), 32.3 (C-10), 26.1 
(C-3), 26.0 (C-16), 18.4 (C-15), 14.2 (C-9), −5.3 (C-14); δH (400 MHz; CDCl3, Enol) 5.60 
(1 H, ddt, J = 16.6, 10.4, 7.3 Hz, H-11), 5.17 (1 H, dd, J = 2.6, 1.2 Hz, H-1a), 5.07 – 5.04 (2 
H, m, H-12), 4.82 (1 H, dd, J = 2.6, 1.2 Hz, H-1b), 4.17 (2 H, dq, J = 10.8, 7.1 Hz, H-8), 
3.93 (2 H, s, H-13), 2.76 – 2.58 (6 H, m, H-3, H-4, H-10), 1.25 (3 H, t, J = 7.1 Hz, H-9), 
0.88 (9 H, s, H-16), 0.03 (6 H, s, H-14); δC (100 MHz; CDCl3, Enol) 204.5 (C-5), 171.9 (C-
7), 143.7 (C-2), 132.6 (C-11), 119.1 (C-12), 113.3 (C-1), 66.1 (C-13), 63.2 (C-6), 61.5 (C-
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8), 40.6 (C-4), 36.4 (C-10), 34.3 (C-3), 26.0 (C-16), 18.4 (C-15), 14.1 (C-9), −5.3 (C-14); 
Found (ESI): [MNa]+ 377.2107; C19H34NaO4Si requires [MNa]
+ 377.2119, 3.1 ppm. 
Lab-book No PD/6/72. 
 
Ethyl 4-{[(tert-butyldimethylsilyl)oxy]methyl}-7-oxocyclohept-3-ene-1-carboxylate (324) 
 
To a stirred and degassed solution of diene 332 (0.043 g, 0.120 mmol) in CH2Cl2 (20 mL) 
was added 2nd generation Grubbs catalyst (0.011 g, 0.012 mmol). The reaction mixture was 
stirred for 1 h at reflux during which a colour change from light red to brown was observed. 
The reaction was allowed to cool to room temperature, then the solvent was removed under 
vacuum and the crude residue was purified by column chromatography (SiO2, Petrol/EtOAc, 
20:1) to give the title compound 324 (0.035 g, 90%) as a colourless oil and as a respective 
1.3:1 mixture of keto-enol tautomers, respectively; Rf 0.32 (Petrol/EtOAc, 9:1); νmax (cm-1) 
2955, 2930, 2857, 1745, 1714, 1464, 1362, 1252, 1153, 1096, 1069, 836, 777; δH (400 MHz; 
CDCl3, Keto) 5.77 (1 H, t, J = 6.5 Hz, H-1), 4.25 (2 H, q, J = 7.1 Hz, H-13), 4.03 (2 H, s, 
H-8), 3.74 (1 H, dd, J = 10.6, 3.8 Hz, H-3), 3.13 (1 H, dd, J = 15.7, 6.5 Hz, H-5a), 2.95 – 
2.90 (2 H, m, H-6), 2.76 (1 H, dd, J = 15.7, 6.5 Hz, H-5b), 2.30 – 2.24 (2 H, m, H-2), 1.25 
(3 H, t, J = 7.1 Hz, H-14), 0.88 (9 H, s, H-11), 0.04 (6 H, s, H-9); δC (100 MHz; CDCl3, 
Keto) 207.5 (C-4), 169.9 (C-12), 141.4 (C-7), 121.3 (C-1), 67.6 (C-8), 61.7 (C-13), 57.6 (C-
3), 41.9 (C-5), 39.0 (C-6), 26.5 (C-2), 25.9 (C-11), 18.4 (C-10), 14.2 (C-14), −5.3 (C-9); δH 
(400 MHz; CDCl3, Enol) 5.41 (1 H, td, J = 5.7, 2.1 Hz, H-1), 4.19 (2 H, q, J = 7.1 Hz, H-
13), 4.13 (2 H, s, H-8), 2.95 – 2.92 (1 H, m, H-5a), 2.88 – 2.86 (2 H, m, H-6), 2.75 – 2.69 (1 
H, m, H-5b), 2.16 (2 H, s, H-2), 1.28 (3 H, t, J = 7.1 Hz, H-14), 0.88 (9 H, s, H-11), 0.04 (6 
H, s, H-9); δC (100 MHz; CDCl3, Enol) 202.9 (C-4), 172.9 (C-12), 141.6 (C-7), 121.3 (C-
1), 65.8 (C-3), 61.7 (C-13), 61.2 (C-8), 41.9 (C-5), 38.9 (C-6), 25.9 (C-11), 24.5 (C-2), 18.4 
(C-10), 14.1 (C-14), −5.3 (C-9); Found (ESI): [MNa]+ 349.1800; C17H30NaO4Si requires 
[MNa]+ 349.1806, 1.6 ppm. 
Lab-book No PD/6/73. 
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1H NMR spectrum of spirocyclic bis-oxindole trans-91a (400 MHz; CDCl3) 
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13C NMR spectrum of spirocyclic bis-oxindole trans-91a (100 MHz; CDCl3) 
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1H NMR spectrum of bis-oxindole dl-116a (400 MHz; CDCl3) 
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13C NMR spectrum of bis-oxindole dl-116a (100 MHz; CDCl3) 
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1H NMR spectrum of bis-oxindole meso-116a (400 MHz; CDCl3) 
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13C NMR spectrum of bis-oxindole meso-116a (100 MHz; CDCl3) 
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1H NMR spectrum of 3H-indole 148a (400 MHz; CDCl3) 
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13C NMR spectrum of 3H-indole 148a (100 MHz; CDCl3) 
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1H NMR spectrum of spirooxindole 214 (400 MHz; CDCl3) 
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13C NMR spectrum of spirooxindole 214 (100 MHz; CDCl3) 
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Compound 92a (CCDC 1013303) 
 
Identification code  rjkt1410   
Empirical formula  C21H22N2O3   
Formula weight  350.40   
Temperature/K  110.05(10)   
Crystal system  monoclinic   
Space group  P21/n   
a/Å  8.75713(16)  α = 90° 
b/Å  15.9322(2)  β = 108.2987(19)° 
c/Å  13.1649(2)  γ = 90° 
Volume/Å3  1743.89(5)   
Z  4   
ρcalcg/cm3  1.335   
μ/mm-1  0.090   
F(000)  744.0   
Crystal size/mm3  0.1835 × 0.16 × 0.1458   
Radiation  MoKα (λ = 0.71073)   
2Θ range for data collection/°  6.058 to 59.996   
Index ranges  -11 ≤ h ≤ 12, -22 ≤ k ≤ 22, -18 ≤ l ≤ 18   
Reflections collected  20689   
Independent reflections  5098 [Rint = 0.0289, Rsigma = 0.0227]   
Data/restraints/parameters  5098/0/237   
Goodness-of-fit on F2  1.044   
Final R indexes [I>=2σ (I)]  R1 = 0.0496, wR2 = 0.1284   
Final R indexes [all data]  R1 = 0.0570, wR2 = 0.1340   
Largest diff. peak/hole / e Å-3  0.53/-0.42   
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Compound 91a (CCDC 1004040) 
 
Identification code  rjkt1403  
Empirical formula  C21H18N2O3  
Formula weight  346.37  
Temperature/K  110.05(10)  
Crystal system  monoclinic  
Space group  P21/c  
a/Å  15.1668(10)  
b/Å  13.0868(3)  
c/Å  18.4536(8)  
α/°  90  
β/°  114.242(7)  
γ/°  90  
Volume/Å3  3339.8(3)  
Z  8  
ρcalcmg/mm3  1.378  
m/mm-1  0.093  
F(000)  1456.0  
Crystal size/mm3  0.4761 × 0.2122 × 0.0636  
Radiation  MoKα (λ = 0.7107)  
2Θ range for data collection  5.888 to 60.218°  
Index ranges  -12 ≤ h ≤ 20, -18 ≤ k ≤ 10, -25 ≤ l ≤ 25  
Reflections collected  10277  
Independent reflections  6553 [Rint = 0.0282, Rsigma = 0.0483]  
Data/restraints/parameters  6553/0/473  
Goodness-of-fit on F2  1.070  
Final R indexes [I>=2σ (I)]  R1 = 0.0478, wR2 = 0.1092  
Final R indexes [all data]  R1 = 0.0716, wR2 = 0.1228  
Largest diff. peak/hole / e Å-3  0.27/-0.21  
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Compound dl-116a (CCDC 1004039) 
 
Identification code  rjkt1231   
Empirical formula  C21H20N2O3   
Formula weight  348.39   
Temperature/K  110.00(10)   
Crystal system  orthorhombic   
Space group  Pna21   
a/Å  27.4231(9)   α = 90° 
b/Å  7.8100(2)   β = 90° 
c/Å  16.1403(4)   γ = 90° 
Volume/Å3  3456.85(16)   
Z  8   
ρcalcmg/mm3  1.339   
m/mm-1  0.090   
F(000)  1472.0   
Crystal size/mm3  0.1696 × 0.093 × 0.0709   
2Θ range for data collection  5.8 to 55.12°   
Index ranges  -35 ≤ h ≤ 32, -8 ≤ k ≤ 10, -21 ≤ l ≤ 20   
Reflections collected  12994   
Independent reflections  7464[R(int) = 0.0267]   
Data/restraints/parameters  7464/1/477   
Goodness-of-fit on F2  1.073   
Final R indexes [I>=2σ (I)]  R1 = 0.0497, wR2 = 0.1151   
Final R indexes [all data]  R1 = 0.0583, wR2 = 0.1201   
Largest diff. peak/hole / e Å-3  0.35/-0.27   
Flack parameter -0.7(9)  
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Compound trans-116b (CCDC 1016758) 
 
Identification code  rjkt1404   
Empirical formula  C22H22N2O3   
Formula weight  362.41   
Temperature/K  110.05(10)   
Crystal system  monoclinic   
Space group  P21/c   
a/Å  7.7526(3)  α = 90° 
b/Å  16.2826(7)  β = 96.448(5)° 
c/Å  14.5413(8)  γ = 90° 
Volume/Å3  1823.97(15)   
Z  4   
ρcalcg/cm3  1.320   
μ/mm-1  0.088   
F(000)  768.0   
Crystal size/mm3  0.1956 × 0.0941 × 0.0393   
Radiation  MoKα (λ = 0.71073)   
2Θ range for data collection/°  5.638 to 60.7   
Index ranges  -10 ≤ h ≤ 10, -22 ≤ k ≤ 22, -20 ≤ l ≤ 18   
Reflections collected  14503   
Independent reflections  4976 [Rint = 0.0592, Rsigma = 0.0632]   
Data/restraints/parameters  4976/43/314   
Goodness-of-fit on F2  1.057   
Final R indexes [I>=2σ (I)]  R1 = 0.0928, wR2 = 0.2206   
Final R indexes [all data]  R1 = 0.1533, wR2 = 0.2563   
Largest diff. peak/hole / e Å-3  0.31/-0.29   
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Compound cis-116b (CCDC 1004041) 
 
Identification code  rjkt1405   
Empirical formula  C22H22N2O3   
Formula weight  362.41   
Temperature/K  110.05(10)   
Crystal system  orthorhombic   
Space group  Pbca   
a/Å  9.00239(19)   α = 90° 
b/Å  14.4646(3)   β = 90° 
c/Å  27.9468(6)   γ = 90° 
Volume/Å3  3639.13(13)   
Z  8   
ρcalcmg/mm3  1.323   
m/mm-1  0.089   
F(000)  1536.0   
Crystal size/mm3  0.257 × 0.2069 × 0.1358   
Radiation  MoKα (λ = 0.71073)   
2Θ range for data collection  5.812 to 52.682°   
Index ranges  -11 ≤ h ≤ 11, -18 ≤ k ≤ 18, -34 ≤ l ≤ 34  
Reflections collected  24004   
Independent reflections  3719 [Rint = 0.0296, Rsigma = 0.0142]   
Data/restraints/parameters  3719/0/248   
Goodness-of-fit on F2  1.132   
Final R indexes [I>=2σ (I)]  R1 = 0.0519, wR2 = 0.1370   
Final R indexes [all data]  R1 = 0.0547, wR2 = 0.1392   
Largest diff. peak/hole / e Å-3  0.42/-0.30   
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Compound 148h (CCDC 1033699) 
 
Identification code  rjkt1416   
Empirical formula  C19H19NO2   
Formula weight  293.35   
Temperature/K  109.9(2)   
Crystal system  triclinic   
Space group  P-1   
a/Å  8.6704(8)   α = 82.390(6)° 
b/Å  8.8590(6)   β = 67.841(8)° 
c/Å  11.4799(8)   γ = 72.612(7)° 
Volume/Å3  779.15(11)   
Z  2   
ρcalcg/cm3  1.250   
μ/mm-1  0.642   
F(000)  312.0   
Crystal size/mm3  0.1685 × 0.1242 × 0.0297   
Radiation  CuKα (λ = 1.54184)   
2Θ range for data collection/°  8.318 to 134.148   
Index ranges  -10 ≤ h ≤ 10, -10 ≤ k ≤ 10, -13 ≤ l ≤ 13   
Reflections collected  9975   
Independent reflections  2788 [Rint = 0.0319, Rsigma = 0.0283]   
Data/restraints/parameters  2788/0/202   
Goodness-of-fit on F2  1.032   
Final R indexes [I>=2σ (I)]  R1 = 0.0392, wR2 = 0.0991   
Final R indexes [all data]  R1 = 0.0479, wR2 = 0.1055   
Largest diff. peak/hole / e Å-3  0.25/-0.23   
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Compound 286 (CCDC 1049570) 
 
Identification code  rjkt1308   
Empirical formula  C22H23NO4   
Formula weight  365.41   
Temperature/K  110   
Crystal system  monoclinic   
Space group  P21/c   
a/Å  11.5049(4)  α = 90° 
b/Å  8.7499(3)  β = 97.701(3)° 
c/Å  18.8298(7)  γ = 90° 
Volume/Å3  1878.44(11)   
Z  4   
ρcalcmg/mm3  1.292   
m/mm-1  0.089   
F(000)  776.0   
Crystal size/mm3  0.1482 × 0.0609 × 0.032   
2Θ range for data collection  6 to 55.9°   
Index ranges  -12 ≤ h ≤ 14, -11 ≤ k ≤ 9, -14 ≤ l ≤ 22   
Reflections collected  5931   
Independent reflections  3705[R(int) = 0.0270]   
Data/restraints/parameters  3705/3/258   
Goodness-of-fit on F2  1.079   
Final R indexes [I>=2σ (I)]  R1 = 0.0571, wR2 = 0.1079   
Final R indexes [all data]  R1 = 0.0891, wR2 = 0.1254   
Largest diff. peak/hole / e Å-3  0.22/-0.23   
Appendix III – Org. Lett. 2014, 16, 4900-4903 
 
256 
Appendix III: Org. Lett. 2014, 16, 4900-4903 
 
  
Appendix III – Org. Lett. 2014, 16, 4900-4903 
 
257 
 
 
  
Appendix III – Org. Lett. 2014, 16, 4900-4903 
 
258 
 
 
  
Appendix III – Org. Lett. 2014, 16, 4900-4903 
 
259 
 
 
 
Appendix IV – Tetrahedron 2015, doi: 10.1016/j.tet.2015.02.060 
 
260 
Appendix IV: Tetrahedron 2015, doi: 10.1016/j.tet.2015.02.060 
 
  
Appendix IV – Tetrahedron 2015, doi: 10.1016/j.tet.2015.02.060 
 
261 
 
 
  
Appendix IV – Tetrahedron 2015, doi: 10.1016/j.tet.2015.02.060 
 
262 
 
 
  
Appendix IV – Tetrahedron 2015, doi: 10.1016/j.tet.2015.02.060 
 
263 
 
 
  
Appendix IV – Tetrahedron 2015, doi: 10.1016/j.tet.2015.02.060 
 
264 
 
 
  
Appendix IV – Tetrahedron 2015, doi: 10.1016/j.tet.2015.02.060 
 
265 
 
 
  
Appendix IV – Tetrahedron 2015, doi: 10.1016/j.tet.2015.02.060 
 
266 
 
 
  
Appendix IV – Tetrahedron 2015, doi: 10.1016/j.tet.2015.02.060 
 
267 
 
 
  
Appendix IV – Tetrahedron 2015, doi: 10.1016/j.tet.2015.02.060 
 
268 
 
 
  
Appendix IV – Tetrahedron 2015, doi: 10.1016/j.tet.2015.02.060 
 
269 
 
 
  
Appendix IV – Tetrahedron 2015, doi: 10.1016/j.tet.2015.02.060 
 
270 
 
 
  
Appendix IV – Tetrahedron 2015, doi: 10.1016/j.tet.2015.02.060 
 
271 
 
 
  
Appendix IV – Tetrahedron 2015, doi: 10.1016/j.tet.2015.02.060 
 
272 
 
 
 
Appendix V – Eur. J. Org. Chem. 2015, 2333-2336 
 
273 
Appendix V: Eur. J. Org. Chem. 2015, 2333-2336 
 
 
  
Appendix V – Eur. J. Org. Chem. 2015, 2333-2336 
 
274 
 
  
Appendix V – Eur. J. Org. Chem. 2015, 2333-2336 
 
275 
 
 
  
Appendix V – Eur. J. Org. Chem. 2015, 2333-2336 
 
276 
 
 
 
 277 
Abbreviations 
 
1,10-phen 1,10-phenanthroline 
9-BBN 9-borabicyclo[3.3.1]nonane 
acac acetylacetone 
Ac acetyl 
Ac2O acetic anhydride 
AChe acetylcholinesterase 
Ar aryl 
AIBN 2,2-azobisisobutyronitrile 
aq aqueous 
atm atmosphere 
BINAP 2,2’-bis(diphenylphosphino)-1,1’-binaphthyl 
Bn benzyl 
Boc tert-butoxycarbonyl 
BuChe butyrylcholinesterase 
Bz benzoyl 
cat catalytic 
m-CPBA meta-chloroperbenzoic acid 
cod cyclooctadiene 
CDC cross-dehydrogenative coupling 
CDI 1,1′-carbonyldiimidazole 
CDK cyclin dependent kinases 
COSY correlation spectroscopy 
CSA camphor-10-sulfonic acid 
 chemical shift 
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DABCO 1,4-diazabicyclo[2.2.2]octane 
dba dibenzylideneacetone 
DBU 1,8-diazabicyclo[5.4.0]undec-7-ene 
DCC N,N′-dicyclohexylcarbodiimide 
DCE 1,2-dichloroethane 
DCM dichloromethane 
DDQ 2,3-dichloro-5,6-dicyano-p-benzoquinone 
DEAD diethyl azodicarboxylate 
DIBAL-H diisobutylaluminium hydride 
DIPEA N,N’-diisopropylethylamine 
DMA N,N’-dimethylacetamide 
DMAP 4-(dimethylamino)pyridine 
DMB 2,4-dimethoxybenzyl 
DMDO dimethyldioxirane 
DMEDA N,N’-dimethylethylenediamine 
DMF N,N’-dimethylformamide 
DMPU N,N′-dimethylpropylene urea 
DMSO dimethyl sulfoxide 
DPPF 1,1′-bis(diphenylphosphino)ferrocene 
dr diastereomeric ratio 
ee enantiomeric excess 
eq equivalent(s) 
er enantiomeric ratio 
ESI-HRMS electrospray ionisation-high resolution mass spectrometry 
Et ethyl 
EWG electron withdrawing group 
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g gram(s) 
h hour(s) 
hal halogenated 
HMBC heteronuclear multiple bond correlation 
HMDS hexamethyldisilazane 
HSQC heteronuclear single quantum correlation 
Hz Hertz(s) 
imid imidazole 
INOC Intramolecular Nitrile oxide-Olefin Cycloaddition 
IR infrared 
J coupling constant in Hz 
L litre(s) 
LAH lithium aluminium hydride 
LDA lithium diisopropylamide 
LHMDS lithium hexamethyldisilazane (or LiHMDS) 
m meter(s) 
m/z  mass to charge ratio 
M molar 
MCR multicomponent reactions 
Me methyl 
MMC methyl magnesium carbonate 
MS mass spectrometry or molecular sieves 
MTBE methyl tert-butyl ether 
NMP N-methylpyrrolidone 
NMR nuclear magnetic resonance 
p-TSA para-toluenesulfonic acid 
 280 
Petrol petroleum ether (fraction which boils at 40-60 °C) 
PG protecting groups 
Ph phenyl 
Phth phthaloyl 
PIG 1,1,2,3,3-pentaisopropylguanidine 
PMB para-methoxybenzyl 
PPA polyphosphoric acid 
PPTS pyridinium para-toluenesulfonate 
py pyridine 
quant. quantitative 
R alkyl group (undefined) 
RBF round-bottomed flask 
RCM ring-closing metathesis 
Red-Al sodium bis(2-methoxyethoxy)aluminum hydride 
Rf retention factor 
rt room temperature 
sat saturated 
SET single-electron transfer 
T3P propane phosphonic acid anhydride 
TBAF tetrabutylammonium fluoride 
TBHP tert-butyl hydroperoxide 
TBS tert-butyldimethylsilyl (or TBDMS) 
TEMPO 2,2,6,6-tetramethyl-1-piperidinyloxy 
Tf trifluoromethanesulfonyl 
TFA trifluoroacetic acid 
THF tetrahydrofuran 
 281 
TIPS triisopropylsilyl 
TLC thin layer chromatography 
TMS trimethylsilyl 
TMTU tetramethylthiourea 
TPD Tryptophan decarboxylase 
TPH Tryptophan hydroxylase 
Troc 2,2,2-trichloroethoxycarbonyl 
Ts para-toluenesulfonyl 
UV ultraviolet 
Xantphos 4,5-bis(diphenylphosphino)-9,9-dimethylxanthene 
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